Product version
Guoqian Jiang
Jane Bane
Junguk Hur
Yu Lin
Abra Guo
Rebecca Racz
Yongqun "Oliver" He (YH)
2016-05-16
ODNAE is an extension of OAE with a focus on drug-associated neuropathy adverse events.
OWL-DL
An ontology for the annotation of the adverse event domain.
ODNAE: Ontology of Drug Neuropathy Adverse Events
Vision Release; 1.0.13
Relates an entity in the ontology to the name of the variable that is used to represent it in the code that generates the BFO OWL file from the lispy specification.
Really of interest to developers only
BFO OWL specification label
BFO OWL specification label
Relates an entity in the ontology to the term that is used to represent it in the the CLIF specification of BFO2
Person:Alan Ruttenberg
Really of interest to developers only
BFO CLIF specification label
BFO CLIF specification label
editor preferred label
editor preferred term
The concise, meaningful, and human-friendly name for a class or property preferred by the ontology developers. (US-English)
PERSON:Daniel Schober
GROUP:OBI:<http://purl.obolibrary.org/obo/obi>
editor preferred label
editor preferred term
editor preferred term
example
example of usage
A phrase describing how a class name should be used. May also include other kinds of examples that facilitate immediate understanding of a class semantics, such as widely known prototypical subclasses or instances of the class. Although essential for high level terms, examples for low level terms (e.g., Affymetrix HU133 array) are not
PERSON:Daniel Schober
GROUP:OBI:<http://purl.obolibrary.org/obo/obi>
example of usage
example of usage
has curation status
PERSON:Alan Ruttenberg
PERSON:Bill Bug
PERSON:Melanie Courtot
OBI_0000281
has curation status
has curation status
definition
definition
The official OBI definition, explaining the meaning of a class or property. Shall be Aristotelian, formalized and normalized. Can be augmented with colloquial definitions.
The official definition, explaining the meaning of a class or property. Shall be Aristotelian, formalized and normalized. Can be augmented with colloquial definitions.
PERSON:Daniel Schober
GROUP:OBI:<http://purl.obolibrary.org/obo/obi>
definition
definition
textual definition
editor note
An administrative note intended for its editor. It may not be included in the publication version of the ontology, so it should contain nothing necessary for end users to understand the ontology.
PERSON:Daniel Schober
GROUP:OBI:<http://purl.obfoundry.org/obo/obi>
IAO:0000116
uberon
editor_note
1
editor_note
editor note
editor note
definition editor
term editor
Name of editor entering the definition in the file. The definition editor is a point of contact for information regarding the term. The definition editor may be, but is not always, the author of the definition, which may have been worked upon by several people
Name of editor entering the term in the file. The term editor is a point of contact for information regarding the term. The term editor may be, but is not always, the author of the definition, which may have been worked upon by several people
20110707, MC: label update to term editor and definition modified accordingly. See http://code.google.com/p/information-artifact-ontology/issues/detail?id=115.
PERSON:Daniel Schober
GROUP:OBI:<http://purl.obolibrary.org/obo/obi>
definition editor
definition editor
term editor
term editor
alternative term
An alternative name for a class or property which means the same thing as the preferred name (semantically equivalent)
PERSON:Daniel Schober
GROUP:OBI:<http://purl.obolibrary.org/obo/obi>
alternative term
alternative term
definition source
formal citation, e.g. identifier in external database to indicate / attribute source(s) for the definition. Free text indicate / attribute source(s) for the definition. EXAMPLE: Author Name, URI, MeSH Term C04, PUBMED ID, Wiki uri on 31.01.2007
PERSON:Daniel Schober
Discussion on obo-discuss mailing-list, see http://bit.ly/hgm99w
GROUP:OBI:<http://purl.obolibrary.org/obo/obi>
definition source
definition source
curator note
An administrative note of use for a curator but of no use for a user
PERSON:Alan Ruttenberg
IAO:0000232
uberon
curator_notes
1
curator_notes
curator note
curator note
curator notes
imported from
For external terms/classes, the ontology from which the term was imported
PERSON:Alan Ruttenberg
PERSON:Melanie Courtot
GROUP:OBI:<http://purl.obolibrary.org/obo/obi>
imported from
imported from
expand expression to
elucidation
elucidation
has associated axiom(nl)
has associated axiom(nl)
has associated axiom(fol)
has associated axiom(fol)
YH, JX
a chinese translation represents a chinese translation of the existing term.
Chinese translation
An assertion that holds between an OWL Object Property and a temporal interpretation that elucidates how OWL Class Axioms that use this property are to be interpreted in a temporal context.
temporal interpretation
https://code.google.com/p/obo-relations/wiki/ROAndTime
logical macro assertion on an object property
An alternate textual definition for a class taken unmodified from an external source. This definition may have been used to derive a generalized definition for the new class.
UBPROP:0000001
uberon
external_definition
1
external_definition
This annotation property may be replaced with an annotation property from an external ontology such as IAO
external_definition
A textual description of an axiom loss in this ontology compared to an external ontology.
UBPROP:0000002
uberon
axiom_lost_from_external_ontology
1
axiom_lost_from_external_ontology
This annotation property may be replaced with an annotation property from an external ontology such as IAO
axiom_lost_from_external_ontology
Notes on the homology status of this class.
UBPROP:0000003
uberon
homology_notes
1
homology_notes
This annotation property may be replaced with an annotation property from an external ontology such as IAO
homology_notes
Used to connect a class to an adjectival form of its label. For example, a class with label 'intestine' may have a relational adjective 'intestinal'.
UBPROP:0000007
uberon
has_relational_adjective
1
has_relational_adjective
has_relational_adjective
Notes on the how instances of this class vary across species.
UBPROP:0000008
uberon
taxon_notes
1
taxon_notes
taxon_notes
Notes on the structure, composition or histology of instances of this class.
This annotation property may be replaced with an annotation property from an external ontology such as IAO
UBPROP:0000010
uberon
structure_notes
1
structure_notes
structure_notes
Notes on how similar or equivalent classes are represented in other ontologies.
This annotation property may be replaced with an annotation property from an external ontology such as IAO
UBPROP:0000012
uberon
external_ontology_notes
1
external_ontology_notes
external_ontology_notes
has_RxCUI
CUMBO
A class which has a weakened disjointness axiom, to avoid inconsistency. These are kept separately in the uberon_disjoint_from_strict ontology.
A class that represents an early developmental structure, like a blastocyst. This part of the ontology is undergoing review to remove inappropriate grouping classes.
EFO slim
functional_classification
Subset consisting of classes creating for grouping purposes
classes that have some inconsistency with FMA
somewhat fuzzy grouping for analysis purposes, currently composed of something like: liver, heart, skeletal, kidney, bladder, brain, skin, mouth, esophagus, stomach, small intestine, large intestines, trachea nose, lungs, brain, spinal cord, peripheral nerves, kidneys, ureters, bladder, urethra, gonads
organs, excluding individual muscles and skeletal elements
Uberon slim - somewhat arbitrary subset that excludes obscure terms and deep compositional terms
abstract upper-level terms not directly useful for analysis
core classes typically found across vertebrates. one purpose is to create a rough set of terms that could be used to start a new vertebrate AO
abstract upper-level terms not directly useful for analysis
subset_property
has_alternative_id
has_broad_synonym
database_cross_reference
has_exact_synonym
has_narrow_synonym
has_obo_namespace
has_related_synonym
in_subset
shorthand
label
uberon
foaf-depicted_by
1
foaf-depicted_by
depicted_by
BFO:0000050
uberon
part_of
part_of
part of
part_of
BFO:0000067
uberon
contains_process
contains_process
contains process
contains process
has-s-dep_st
[copied from inverse property 'specifically depends on at some time'] A pain s-depends_on the organism that is experiencing the pain
[copied from inverse property 'specifically depends on at some time'] a gait s-depends_on the walking object. (All at some specific time.)
[copied from inverse property 'specifically depends on at some time'] a shape s-depends_on the shaped object
[copied from inverse property 'specifically depends on at some time'] one-sided s-dependence of a dependent continuant on an independent continuant: an instance of headache s-depends_on some head
[copied from inverse property 'specifically depends on at some time'] one-sided s-dependence of a dependent continuant on an independent continuant: an instance of temperature s-depends_on some organism
[copied from inverse property 'specifically depends on at some time'] one-sided s-dependence of a process on something: a process of cell death s-depends_on a cell
[copied from inverse property 'specifically depends on at some time'] one-sided s-dependence of a process on something: an instance of seeing (a relational process) s-depends_on some organism and on some seen entity, which may be an occurrent or a continuant
[copied from inverse property 'specifically depends on at some time'] one-sided s-dependence of one occurrent on another: a process of answering a question is dependent on a prior process of asking a question
[copied from inverse property 'specifically depends on at some time'] one-sided s-dependence of one occurrent on another: a process of obeying a command is dependent on a prior process of issuing a command
[copied from inverse property 'specifically depends on at some time'] one-sided s-dependence of one occurrent on multiple independent continuants: a relational process of hitting a ball with a cricket bat
[copied from inverse property 'specifically depends on at some time'] one-sided s-dependence of one occurrent on multiple independent continuants: a relational process of paying cash to a merchant in exchange for a bag of figs
[copied from inverse property 'specifically depends on at some time'] reciprocal s-dependence between occurrents: a process of buying and the associated process of selling
[copied from inverse property 'specifically depends on at some time'] reciprocal s-dependence between occurrents: a process of increasing the volume of a portion of gas while temperature remains constant and the associated process of decreasing the pressure exerted by the gas
[copied from inverse property 'specifically depends on at some time'] reciprocal s-dependence between occurrents: in a game of chess the process of playing with the white pieces is mutually dependent on the process of playing with the black pieces
[copied from inverse property 'specifically depends on at some time'] the one-sided dependence of an occurrent on an independent continuant: football match on the players, the ground, the ball
[copied from inverse property 'specifically depends on at some time'] the one-sided dependence of an occurrent on an independent continuant: handwave on a hand
[copied from inverse property 'specifically depends on at some time'] the three-sided reciprocal s-dependence of the hue, saturation and brightness of a color [45
[copied from inverse property 'specifically depends on at some time'] the three-sided reciprocal s-dependence of the pitch, timbre and volume of a tone [45
[copied from inverse property 'specifically depends on at some time'] the two-sided reciprocal s-dependence of the roles of husband and wife [20
[copied from inverse property 'specifically depends on at some time'] Alan Ruttenberg: This is a binary version of a ternary time-indexed, instance level, relation. The BFO reading of the binary relation 'specifically depends on at some time@en' is: exists t, exists_at(x,t) & exists_at(y,t) & 'specifically depends on@en'(x,y,t)
[copied from inverse property 'specifically depends on at some time'] BFO 2 Reference: An entity – for example an act of communication or a game of football – can s-depends_on more than one entity. Complex phenomena for example in the psychological and social realms (such as inferring, commanding and requesting) or in the realm of multi-organismal biological processes (such as infection and resistance), will involve multiple families of dependence relations, involving both continuants and occurrents [1, 4, 28
[copied from inverse property 'specifically depends on at some time'] BFO 2 Reference: S-dependence is just one type of dependence among many; it is what, in the literature, is referred to as ‘existential dependence’ [87, 46, 65, 20
[copied from inverse property 'specifically depends on at some time'] BFO 2 Reference: the relation of s-depends_on does not in every case require simultaneous existence of its relata. Note the difference between such cases and the cases of continuant universals defined historically: the act of answering depends existentially on the prior act of questioning; the human being who was baptized or who answered a question does not himself depend existentially on the prior act of baptism or answering. He would still exist even if these acts had never taken place.
[copied from inverse property 'specifically depends on at some time'] BFO2 Reference: specifically dependent continuant\; process; process boundary
[copied from inverse property 'specifically depends on at some time'] To say that b s-depends_on a at t is to say that b and c do not share common parts & b is of its nature such that it cannot exist unless c exists & b is not a boundary of c and b is not a site of which c is the host [64
has specific dependent at some time
has_specified_input
see is_input_of example_of_usage
A relation between a planned process and a continuant participating in that process that is not created during the process. The presence of the continuant during the process is explicitly specified in the plan specification which the process realizes the concretization of.
8/17/09: specified inputs of one process are not necessarily specified inputs of a larger process that it is part of. This is in contrast to how 'has participant' works.
PERSON: Alan Ruttenberg
PERSON: Bjoern Peters
PERSON: Larry Hunter
PERSON: Melanie Coutot
has_specified_input
has_specified_output
A relation between a planned process and a continuant participating in that process. The presence of the continuant at the end of the process is explicitly specified in the objective specification which the process realizes the concretization of.
PERSON: Alan Ruttenberg
PERSON: Bjoern Peters
PERSON: Larry Hunter
PERSON: Melanie Courtot
has_specified_output
RO:0000052
inheres_in
inheres in
bearer of
this apple is bearer of this red color
this vase is bearer of this fragility
a relation between an independent continuant (the bearer) and a specifically dependent continuant (the dependent), in which the dependent specifically depends on the bearer for its existence
A bearer can have many dependents, and its dependents can exist for different periods of time, but none of its dependents can exist when the bearer does not exist.
bearer_of
is bearer of
RO:0000053
uberon
bearer_of
bearer_of
bearer of
bearer of
role of
RO:0001015
uberon
location_of
location_of
location of
location_of
RO:0001025
uberon
located_in
located_in
located in
located_in
The relationships between a boundary (a 2D immaterial entity) and the material entity that it delimits.
RO:0002000
boundary_of
boundary of
FMA:85999
dbprop:nerve
RO:0002005
nerve supply
uberon
innervated_by
innervated_by
http://code.google.com/p/obo-relations/issues/detail?id=6
innervated_by
innervated_by
RO:0002081
before_or_simultaneous_with
before_or_simultaneous_with
RO:0002086
ends_after
ends_after
RO:0002090
immediately_precedes
immediately_precedes
starts_during
happens_during
A overlaps B if they share some part in common.
x overlaps y if and only if there exists some z such that x has part z and z part of y
x overlaps y iff they have some part in common.
BFO_0000051 some (BFO_0000050 some ?Y)
RO:0002131
uberon
overlaps
overlaps
overlaps
overlaps
RO:0002134
uberon
innervates
innervates
http://code.google.com/p/obo-relations/issues/detail?id=6
innervates
innervates
X continuous_with Y if and only if X and Y share a fiat boundary.
RO:0002150
uberon
continuous_with
continuous_with
continuous with
continuous_with
Binary relationship: x connected_to y if and only if there exists some z such that z connects x and y in a ternary connected_to(x,y,z) relationship.
RO:0002170
uberon
connected_to
connected_to
Connection does not imply overlaps.
connected to
connected to
Binary relationship: z connects x if and only if there exists some y such that z connects x and y in a ternary connected_to(x,y,z) relationship.
this is currently used for both structural relationships (such as between a valve and the chamber it connects) and abstract relationships (anatomical lines and the entities they connect)
RO:0002176
uberon
connects
connects
connects
connects
a is attached to part of b if a is attached to b, or a is attached to some p, where p is part of b.
RO:0002177
uberon
attaches_to_part_of
attached_to_part_of
attaches_to_part_of
attached to part of
attaches_to_part_of
Relation between an arterial structure and another structure, where the arterial structure acts as a conduit channeling fluid, substance or energy.
relation between an artery and the structure is supplies with blood.
FMA:86003
RO:0002178
arterial supply of
uberon
supplies
supplies
source: FMA
supplies
supplies
x develops from y if and only if either (a) x directly develops from y or (b) there exists some z such that x directly develops from z and z develops from y
RO:0002202
uberon
develops_from
develops_from
develops from
develops_from
Candidate definition: x directly_develops from y if and only if there exists some developmental process (GO:0032502) p such that x and y both participates in p, and x is the output of p and y is the input of p, and a substantial portion of the matter of y comes from x, and the start of x is coincident with or after the end of y
RO:0002207
uberon
directly_develops_from
directly_develops_from
directly develops from
directly_develops_from
RO:0002222
temporally_related_to
temporally related to
x ends with y if and only if x has part y and the time point at which x ends is equivalent to the time point at which y ends. Formally: α(y) > α(x) ∧ ω(y) = ω(x), where α is a function that maps a process to a start point, and ω is a function that maps a process to an end point.
RO:0002230
ends_with
ends with
x has developmental contribution from y iff x has some part z such that z develops from y
RO:0002254
uberon
has_developmental_contribution_from
has_developmental_contribution_from
has developmental contribution from
has developmental contribution from
t1 developmentally_induced_by t2 if there is a process of organ induction (GO:0001759) with t1 and t2 as interacting participants. t2 causes t1 to change its fate from a precursor tissue type T to T', where T' develops_from T.
t1 induced_by t2 if there is a process of developmental induction (GO:0031128) with t1 and t2 as interacting participants. t2 causes t1 to change its fate from a precursor anatomical structure type T to T', where T' develops_from T
RO:0002256
uberon
developmentally_induced_by
developmentally_induced_by
sources for developmentally_induced_by relationships in Uberon: Developmental Biology, Gilbert, 8th edition, figure 6.5(F)
developmentally induced by
developmentally_induced_by
Candidate definition: x developmentally related to y if and only if there exists some developmental process (GO:0032502) p such that x and y both participates in p, and x is the output of p and y is the input of p
RO:0002258
uberon
developmentally_preceded_by
developmentally_preceded_by
developmentally preceded by
developmentally preceded by
q inheres in part of w if and only if there exists some p such that q inheres in p and p part of w.
RO:0002314
inheres_in_part_of
inheres in part of
A relationship that holds via some environmental process
RO:0002320
evolutionarily_related_to
evolutionarily related to
A mereological relationship or a topological relationship
RO:0002323
mereotopologically_related_to
mereotopologically related to
A relationship that holds via some developmental process (GO:0032502)
RO:0002324
developmentally_related_to
developmentally related to
RO:0002328
uberon
functionally_related_to
functionally_related_to
functionally related to
functionally related to
FMA:85990
RO:0002371
uberon
attaches_to
attached_to
attaches_to
attached to
attaches_to
RO:0002375
in_branching_relationship_with
in branching relationship with
x is a branching part of y if and only if x is part of y and x is a branch_of the main stem of y
we need to check if FMA branch_of implies part_of. the relation we intend to use here should - for example, see vestibulocochlear nerve
FMA:85994
RO:0002380
uberon
branching_part_of
branching_part_of
branching part of
branching_part_of
x has developmental potential involving y iff x is capable of a developmental process with output y. y may be the successor of x, or may be a different structure in the vicinity (as for example in the case of developmental induction).
RO:0002384
has_developmental_potential_involving
has developmental potential involving
RO:0002487
relation_between_structure_and_stage
relation between structure and stage
Relation between continuant c and occurrent s, such that every instance of c comes into existing during some s.
c existence starts during s iff start_of(c) part_of s
BFO:0000068
RO:0002488
begins_to_exist_during
uberon
existence_starts_during
existence_starts_during
existence starts during
RO:0002490
existence_overlaps
existence overlaps
x transformation of y if x is the immediate transformation of y, or is linked to y through a chain of transformation relationships
RO:0002494
transforms from
uberon
transformation_of
transformation_of
transformation of
RO:0002502
depends_on
depends on
RO:0002507
uberon
has_material_contribution_from
has_material_contribution_from
has material contribution from
a produces b if some process that occurs_in a has_output b, where a and b are material entities. Examples: hybridoma cell line produces monoclonal antibody reagent; chondroblast produces avascular GAG-rich matrix.
RO:0003000
uberon
produces
produces
produces
produces
RO:0003001
uberon
produced_by
produced_by
produced by
produced_by
uberon
transitively_connected_to
transitively_connected to
NDF-RT:N0000000065
Physiochemical Activity
N0000000065
989958
C1372991
C308
Physiochemical Activity [MoA]
NDF-RT:N0000000066
Small Ion Transport Pump Interactions
N0000000066
986087
C1373107
C310
Small Ion Transport Pump Interactions [MoA]
NDF-RT:N0000000067
HER Receptor Family Interactions
N0000000067
986672
EGFR Family Interactions
Epidermal Growth Factor Receptor Family Interactions
HER Family Interactions
Human Epidermal Growth Factor Receptor Family Interactions
C2916814
C312
HER Receptor Family Interactions [MoA]
NDF-RT:N0000000069
Calcium Channel Antagonists
D002121
Calcium Channel Blockers
N0000000069
986242
Calcium Channel Blocker
C2757014
C316
Calcium Channel Antagonists [MoA]
NDF-RT:N0000000070
Angiotensin 2 Receptor Antagonists
N0000000070
984935
Angiotensin II Receptor Antagonists
Angiotensin II Receptor Blockers
C2757003
C318
Angiotensin 2 Receptor Antagonists [MoA]
NDF-RT:N0000000072
Active Transporter Interactions
N0000000072
1031287
C1373104
C322
Active Transporter Interactions [MoA]
NDF-RT:N0000000076
Protease Inhibitors
D011480
Protease Inhibitors
N0000000076
992709
C2756997
C330
Protease Inhibitors [MoA]
NDF-RT:N0000000082
Immunologic Factors
D007155
Immunologic Factors
N0000000082
993127
C2757006
C342
Immunologic Factors [MoA]
NDF-RT:N0000000083
Leukotriene Receptor Antagonists
N0000000083
992724
C2757015
C344
Leukotriene Receptor Antagonists [MoA]
NDF-RT:N0000000084
Sex Hormone Receptor Antagonists
N0000000084
985639
C1373000
C346
Sex Hormone Receptor Antagonists [MoA]
NDF-RT:N0000000085
Receptor Interactions
N0000000085
988560
C1372999
C348
Receptor Interactions [MoA]
NDF-RT:N0000000087
Chelating Activity
D002614
Chelating Activity
N0000000087
1025213
C1527256
C352
Chelating Activity [MoA]
NDF-RT:N0000000092
Adrenergic Antagonists
D018674
Adrenergic Antagonists
N0000000092
993129
C2757018
C362
Adrenergic Antagonists [MoA]
NDF-RT:N0000000097
Cholinergic Muscarinic Receptor Interactions
N0000000097
986244
C1373009
C372
Cholinergic Muscarinic Receptor Interactions [MoA]
NDF-RT:N0000000098
Thymidylate Synthetase Inhibitors
N0000000098
993154
C2756988
C374
Thymidylate Synthetase Inhibitors [MoA]
NDF-RT:N0000000099
Adrenergic alpha-Antagonists
D000317
Adrenergic alpha-Antagonists
N0000000099
1023426
Alpha-adrenergic Blocker
alpha-Adrenergic Antagonists
C2756989
C376
Adrenergic alpha-Antagonists [MoA]
NDF-RT:N0000000102
Norepinephrine Uptake Inhibitors
D018759
Adrenergic Uptake Inhibitors
N0000000102
989028
C2757023
C382
Norepinephrine Uptake Inhibitors [MoA]
NDF-RT:N0000000103
Reverse Transcriptase Inhibitors
D018894
Reverse Transcriptase Inhibitors
N0000000103
993157
C2757067
C384
Reverse Transcriptase Inhibitors [MoA]
NDF-RT:N0000000104
Cholinergic Muscarinic Agonists
N0000000104
990721
C2757026
C386
Cholinergic Muscarinic Agonists [MoA]
NDF-RT:N0000000105
Neurotransmitter Transporter Interactions
N0000000105
985066
C1373006
C388
Neurotransmitter Transporter Interactions [MoA]
NDF-RT:N0000000109
Serotonin Uptake Inhibitors
D017367
Serotonin Uptake Inhibitors
N0000000109
992711
C2757053
C396
Serotonin Uptake Inhibitors [MoA]
NDF-RT:N0000000111
Folic Acid Metabolism Inhibitors
D005493
Folic Acid Antagonists
N0000000111
1029786
Folic Acid Antagonists
Folic Acid Metabolic Inhibitors
C2916820
C400
Folic Acid Metabolism Inhibitors [MoA]
NDF-RT:N0000000114
Dopamine Uptake Inhibitors
D018765
Dopamine Uptake Inhibitors
N0000000114
1028789
C2757017
C406
Dopamine Uptake Inhibitors [MoA]
NDF-RT:N0000000117
Dopamine Agonists
D018491
Dopamine Agonists
N0000000117
992714
Dopaminergic Agonist
C2757007
C412
Dopamine Agonists [MoA]
NDF-RT:N0000000118
GABA A Modulators
N0000000118
990722
GABA A Receptor Modulators
C1373017
C414
GABA A Modulators [MoA]
NDF-RT:N0000000121
Hydroxymethylglutaryl-CoA Reductase Inhibitors
D019161
Hydroxymethylglutaryl-CoA Reductase Inhibitors
N0000000121
993150
HMG-CoA Reductase Inhibitor
HMG-CoA Reductase Inhibitors
C2756999
C420
Hydroxymethylglutaryl-CoA Reductase Inhibitors [MoA]
NDF-RT:N0000000122
Adrenergic Agonists
D000322
Adrenergic Agonists
N0000000122
1029285
C2757025
C422
Adrenergic Agonists [MoA]
NDF-RT:N0000000124
Leukotriene Receptor Interactions
N0000000124
987670
C1373014
C426
Leukotriene Receptor Interactions [MoA]
NDF-RT:N0000000128
Phosphodiesterase Inhibitors
D010726
Phosphodiesterase Inhibitors
N0000000128
993167
C1656262
C434
Phosphodiesterase Inhibitors [MoA]
NDF-RT:N0000000130
Serotonin Antagonists
D012702
Serotonin Antagonists
N0000000130
993156
C2757052
C438
Serotonin Antagonists [MoA]
NDF-RT:N0000000132
Organic Anion Transporter Interactions
N0000000132
987411
C1373100
C442
Organic Anion Transporter Interactions [MoA]
NDF-RT:N0000000133
Enzyme Inhibitors
D004791
Enzyme Inhibitors
N0000000133
1032544
C2756995
C444
Enzyme Inhibitors [MoA]
NDF-RT:N0000000134
Lipoxygenase Inhibitors
D016859
Lipoxygenase Inhibitors
N0000000134
1031400
C2757064
C446
Lipoxygenase Inhibitors [MoA]
NDF-RT:N0000000135
Immunologic Adjuvants
D000276
Adjuvants, Immunologic
N0000000135
989878
Adjuvants, Immunologic
C1383096
C448
Immunologic Adjuvants [MoA]
NDF-RT:N0000000138
GABA A Receptor Interactions
N0000000138
988922
C1373022
C454
GABA A Receptor Interactions [MoA]
NDF-RT:N0000000140
Calcium Channel Interactions
N0000000140
990245
C1373020
C458
Calcium Channel Interactions [MoA]
NDF-RT:N0000000144
Iron Chelating Activity
D007502
Iron Chelating Activity
N0000000144
985781
C2757050
C466
Iron Chelating Activity [MoA]
NDF-RT:N0000000145
Estrogen Receptor Antagonists
N0000000145
984514
Estrogen Receptor Inhibitor
C1373098
C468
Estrogen Receptor Antagonists [MoA]
NDF-RT:N0000000147
Proton Pump Inhibitors
N0000000147
986356
C1384478
C472
Proton Pump Inhibitors [MoA]
NDF-RT:N0000000149
Hormone Receptor Agonists
N0000000149
985200
C1373095
C476
Hormone Receptor Agonists [MoA]
NDF-RT:N0000000150
Protein Synthesis Inhibitors
D011500
Protein Synthesis Inhibitors
N0000000150
993158
C2757051
C478
Protein Synthesis Inhibitors [MoA]
NDF-RT:N0000000152
G-Protein-linked Receptor Interactions
N0000000152
984725
G-Protein-linked Receptor-Effector Interactions
C2916797
C482
G-Protein-linked Receptor Interactions [MoA]
NDF-RT:N0000000153
Adrenergic Receptor Interactions
N0000000153
987972
C1373072
C484
Adrenergic Receptor Interactions [MoA]
NDF-RT:N0000000155
Uncouplers
N0000000155
986674
C1373071
C488
Uncouplers [MoA]
NDF-RT:N0000000156
Chloride Channel Interactions
N0000000156
987326
C1373070
C490
Chloride Channel Interactions [MoA]
NDF-RT:N0000000159
Glucocorticoid Receptor Agonists
N0000000159
989879
C1373068
C496
Glucocorticoid Receptor Agonists [MoA]
NDF-RT:N0000000160
Cyclooxygenase Inhibitors
D016861
Cyclooxygenase Inhibitors
N0000000160
992710
C2756982
C498
Cyclooxygenase Inhibitors [MoA]
NDF-RT:N0000000161
Adrenergic beta-Antagonists
D000319
Adrenergic beta-Antagonists
N0000000161
993131
Beta-adrenergic Blocker
Beta-adrenergic Receptor Inhibitor
beta-Adrenergic Antagonists
beta-Adrenergic Blocker
beta-Adrenergic Receptor Inhibitor
C2757061
C500
Adrenergic beta-Antagonists [MoA]
NDF-RT:N0000000162
Steroid Receptor Antagonists
N0000000162
987973
C1373067
C502
Steroid Receptor Antagonists [MoA]
NDF-RT:N0000000167
Serotonin Transporter Interactions
N0000000167
987204
C1373063
C512
Serotonin Transporter Interactions [MoA]
NDF-RT:N0000000168
Selective Estrogen Receptor Modulators
D020845
Selective Estrogen Receptor Modulators
N0000000168
993164
C2757056
C514
Selective Estrogen Receptor Modulators [MoA]
NDF-RT:N0000000172
Steroid Receptor Modulators
N0000000172
987671
C1373061
C522
Steroid Receptor Modulators [MoA]
NDF-RT:N0000000174
Opioid Agonists
N0000000174
985466
C1373059
C526
Opioid Agonists [MoA]
NDF-RT:N0000000175
Cytokine Receptor Superfamily Interactions
N0000000175
984937
C1373058
C528
Cytokine Receptor Superfamily Interactions [MoA]
NDF-RT:N0000000176
Topoisomerase Inhibitors
N0000000176
989757
DNA Gyrase Inhibitors
Topoisomerase Inhibitor
C1384454
C530
Topoisomerase Inhibitors [MoA]
NDF-RT:N0000000177
Cholinesterase Inhibitors
D002800
Cholinesterase Inhibitors
N0000000177
992680
C2757012
C532
Cholinesterase Inhibitors [MoA]
NDF-RT:N0000000180
Sodium Channel Interactions
N0000000180
987802
C1373055
C538
Sodium Channel Interactions [MoA]
NDF-RT:N0000000181
Angiotensin-converting Enzyme Inhibitors
D000806
Angiotensin-Converting Enzyme Inhibitors
N0000000181
992731
Angiotensin Converting Enzyme Inhibitor
C2757044
C540
Angiotensin-converting Enzyme Inhibitors [MoA]
NDF-RT:N0000000182
Steroid Hormone Receptor Agonists
N0000000182
990907
C1373054
C542
Steroid Hormone Receptor Agonists [MoA]
NDF-RT:N0000000183
Acetyl Aldehyde Dehydrogenase Inhibitors
N0000000183
986817
C1373053
C544
Acetyl Aldehyde Dehydrogenase Inhibitors [MoA]
NDF-RT:N0000000184
Monoamine Oxidase Inhibitors
D008996
Monoamine Oxidase Inhibitors
N0000000184
992698
MAOI
C2756978
C546
Monoamine Oxidase Inhibitors [MoA]
NDF-RT:N0000000185
Progestational Hormone Receptor Agonists
N0000000185
986818
C1373052
C548
Progestational Hormone Receptor Agonists [MoA]
NDF-RT:N0000000190
Histamine H1 Receptor Antagonists
D006634
Histamine H1 Antagonists
N0000000190
992695
H1 Receptor Antagonists
H1 Receptor Blockers
Histamine H1 Antagonists
Histamine H1 Blockers
C2757048
C558
Histamine H1 Receptor Antagonists [MoA]
NDF-RT:N0000000191
Dihydrofolate Reductase Inhibitors
N0000000191
441741
C1373048
C560
Dihydrofolate Reductase Inhibitors [MoA]
NDF-RT:N0000000193
Ion Channel Interactions
N0000000193
988382
C1373047
C564
Ion Channel Interactions [MoA]
NDF-RT:N0000000198
Serotonin Receptor Interactions
N0000000198
988082
C1373043
C574
Serotonin Receptor Interactions [MoA]
NDF-RT:N0000000200
Opioid Receptor Interactions
N0000000200
989758
C1373041
C578
Opioid Receptor Interactions [MoA]
NDF-RT:N0000000203
Dopamine Receptor Interactions
N0000000203
985948
C1373039
C584
Dopamine Receptor Interactions [MoA]
NDF-RT:N0000000205
Radiopharmaceutical Activity
D019275
Radiopharmaceuticals
N0000000205
987975
C2757000
C588
Radiopharmaceutical Activity [MoA]
NDF-RT:N0000000206
Xanthine Oxidase Inhibitors
N0000000206
984728
C1384464
C590
Xanthine Oxidase Inhibitors [MoA]
NDF-RT:N0000000207
Histamine Receptor Antagonists
D006633
Histamine Antagonists
N0000000207
989667
Histamine Antagonists
C1383092
C592
Histamine Receptor Antagonists [MoA]
NDF-RT:N0000000209
Adrenergic alpha-Agonists
D000316
Adrenergic alpha-Agonists
N0000000209
1029039
alpha-Adrenergic Agonists
C2757042
C596
Adrenergic alpha-Agonists [MoA]
NDF-RT:N0000000211
Potassium Channel Interactions
N0000000211
989960
C1373036
C600
Potassium Channel Interactions [MoA]
NDF-RT:N0000000212
Ribonucleotide Reductase Inhibitors
N0000000212
441728
C1373035
C602
Ribonucleotide Reductase Inhibitors [MoA]
NDF-RT:N0000000213
Receptor Protein Kinase Interactions
N0000000213
986538
C1373034
C604
Receptor Protein Kinase Interactions [MoA]
NDF-RT:N0000000214
Sex Hormone Receptor Agonists
N0000000214
990080
C1373033
C606
Sex Hormone Receptor Agonists [MoA]
NDF-RT:N0000000216
Histamine Receptor Interactions
N0000000216
989394
C1373031
C610
Histamine Receptor Interactions [MoA]
NDF-RT:N0000000219
Dopamine Transporter Interactions
N0000000219
984515
C1373028
C616
Dopamine Transporter Interactions [MoA]
NDF-RT:N0000000221
Hormone Receptor Antagonists
N0000000221
990790
C1373026
C620
Hormone Receptor Antagonists [MoA]
NDF-RT:N0000000225
Insulin Receptor Agonists
N0000000225
986676
C1373092
C628
Insulin Receptor Agonists [MoA]
NDF-RT:N0000000230
Dopamine Antagonists
D018492
Dopamine Antagonists
N0000000230
1032050
C2757008
C638
Dopamine Antagonists [MoA]
NDF-RT:N0000000233
Nucleic Acid Synthesis Inhibitors
D019384
Nucleic Acid Synthesis Inhibitors
N0000000233
993166
C2757009
C644
Nucleic Acid Synthesis Inhibitors [MoA]
NDF-RT:N0000000234
Norepinephrine Transporter Interactions
N0000000234
988817
C2267223
C646
Norepinephrine Transporter Interactions [MoA]
NDF-RT:N0000000236
Alkylating Activity
D000477
Alkylating Activity
N0000000236
1031878
C2756975
C650
Alkylating Activity [MoA]
NDF-RT:N0000000240
Insulin Receptor Interactions
N0000000240
987414
C1373083
C658
Insulin Receptor Interactions [MoA]
NDF-RT:N0000000242
Transcription Factor Activity
N0000000242
1028825
C1148759
C662
Transcription Factor Activity [MoA]
NDF-RT:N0000000243
Androgen Receptor Antagonists
N0000000243
989356
Androgen Receptor Inhibitor
C1373082
C664
Androgen Receptor Antagonists [MoA]
NDF-RT:N0000000246
HIV Protease Inhibitors
D017320
HIV Protease Inhibitors
N0000000246
993149
Human Immunodeficiency Virus Protease Inhibitors
C2756991
C670
HIV Protease Inhibitors [MoA]
NDF-RT:N0000000247
Biological Response Modifiers
D015545
Biological Response Modifiers
N0000000247
993132
C2757019
C672
Biological Response Modifiers [MoA]
NDF-RT:N0000000254
Immunologic and Biological Factors
D007151
Immunologic and Biological Factors
N0000000254
1032698
C0021048
C686
Immunologic and Biological Factors [MoA]
NDF-RT:N0000000255
Hormone Receptor Modulators
N0000000255
989214
C1373075
C688
Hormone Receptor Modulators [MoA]
NDF-RT:N0000000256
Serotonin Agonists
D017366
Serotonin Agonists
N0000000256
1022850
C2756998
C690
Serotonin Agonists [MoA]
NDF-RT:N0000000257
Hormone Receptor Interactions
N0000000257
986361
C1373074
C692
Hormone Receptor Interactions [MoA]
NDF-RT:N0000008288
Cyclooxygenase 2 Inhibitors
N0000008288
993136
COX-2 Inhibitors
Cyclooxygenase II Inhibitors
C2757001
C26942
Cyclooxygenase 2 Inhibitors [MoA]
NDF-RT:N0000009918
Adrenergic alpha2-Agonists
N0000009918
1035126
Adrenergic alpha-2 Agonists
alpha-2 Adrenergic Agonists
C1373110
C30202
Adrenergic alpha2-Agonists [MoA]
NDF-RT:N0000009923
Adrenergic beta1-Antagonists
N0000009923
986189
Adrenergic beta-1 Antagonists
beta-1 Adrenergic Antagonists
C1373134
C30212
Adrenergic beta1-Antagonists [MoA]
NDF-RT:N0000009924
Adrenergic beta2-Antagonists
N0000009924
987660
Adrenergic beta-2 Antagonists
beta-2 Adrenergic Antagonists
C1373133
C30214
Adrenergic beta2-Antagonists [MoA]
NDF-RT:N0000009946
Para-Aminobenzoic Acid Inhibitors
N0000009946
984916
PABA Inhibitor
C2916799
C30260
Para-Aminobenzoic Acid Inhibitors [MoA]
NDF-RT:N0000009948
Non-Nucleoside Reverse Transcriptase Inhibitors
N0000009948
989597
C1373120
C30264
Non-Nucleoside Reverse Transcriptase Inhibitors [MoA]
NDF-RT:N0000009949
Antibody-Receptor Interactions
N0000009949
985716
C2267208
C30266
Antibody-Receptor Interactions [MoA]
NDF-RT:N0000009950
Tumor Necrosis Factor Receptor Interactions
N0000009950
984657
TNF Receptor Interactions
C1373118
C30268
Tumor Necrosis Factor Receptor Interactions [MoA]
NDF-RT:N0000009956
Sterol Synthesis Inhibitors
N0000009956
988794
C1373112
C30280
Sterol Synthesis Inhibitors [MoA]
NDF-RT:N0000009958
Bone Surface Interactions
N0000009958
985507
C1373129
C30284
Bone Surface Interactions [MoA]
NDF-RT:N0000010215
Transpeptidase Inhibitors
N0000010215
984931
PBP inhibitors
Transpepsidase Inhibitors
penicillin binding protein Inhibitors
C1373138
C31788
Transpeptidase Inhibitors [MoA]
NDF-RT:N0000010226
Antibody Interactions
N0000010226
987958
C2916825
C31810
Antibody Interactions [MoA]
NDF-RT:N0000010255
Cellular Structure Molecule Interactions
N0000010255
989808
C1373148
C31868
Cellular Structure Molecule Interactions [MoA]
NDF-RT:N0000010256
Tubulin Interactions
N0000010256
1023254
C1373147
C31870
Tubulin Interactions [MoA]
NDF-RT:N0000010260
beta Tubulin Interactions
N0000010260
986466
C1373143
C31878
beta Tubulin Interactions [MoA]
NDF-RT:N0000010261
Neurokinin 1 Receptor Interactions
N0000010261
984193
NK 1 Receptor Interactions
Substance P Receptor Interactions
C1373142
C31880
Neurokinin 1 Receptor Interactions [MoA]
NDF-RT:N0000010262
Neurokinin 1 Antagonists
N0000010262
988216
NK 1 Receptor Antagonists
Substance P Receptor Antagonists
C2916827
C31882
Neurokinin 1 Antagonists [MoA]
NDF-RT:N0000010278
Interleukin 2 Receptor Interactions
N0000010278
984934
IL2 Receptor Interactions
C1373153
C31914
Interleukin 2 Receptor Interactions [MoA]
NDF-RT:N0000010279
Interleukin 2 Receptor Antagonists
N0000010279
986467
IL2 Receptor Antagonists
IL2 Receptor Blockers
IL2 Receptor Inhibitors
Interleukin 2 Receptor Blockers
Interleukin 2 Receptor Inhibitors
C1373152
C31916
Interleukin 2 Receptor Antagonists [MoA]
NDF-RT:N0000019992
Hypothalmic Hormone Interactions
N0000019992
985094
C2267109
C300377
Hypothalmic Hormone Interactions [MoA]
NDF-RT:N0000019993
Hypothalamic Hormone Receptor Agonists
N0000019993
989569
C2916835
C300378
Hypothalamic Hormone Receptor Agonists [MoA]
NDF-RT:N0000020000
Receptor Tyrosine Kinase Inhibitors
N0000020000
987029
C2267115
C300385
Receptor Tyrosine Kinase Inhibitors [MoA]
NDF-RT:N0000020001
Tyrosine Kinase Inhibitors
N0000020001
1028392
C2757011
C300386
Tyrosine Kinase Inhibitors [MoA]
NDF-RT:N0000020006
HER Receptor Family Antagonists
N0000020006
990667
EGFR Family Antagonists
EGFR Family Inhibitors
Epidermal Growth Factor Receptor Family Antagonists
Epidermal Growth Factor Receptor Family Inhibitors
HER Antagonists
HER Family Antagonists
HER Family Inhibitors
HER Inhibitors
HER Receptor Family Inhibitors
Human Epidermal Growth Factor Receptor Family Antagonists
Human Epidermal Growth Factor Receptor Family Inhibitors
C2916840
C300391
HER Receptor Family Antagonists [MoA]
NDF-RT:N0000020008
HER2/Neu/cerbB2 Antagonists
N0000020008
984590
HER-2 Antagonists
HER-2 Inhibitors
HER-2/Neu/cerbB2 Antagonists
HER-2/Neu/cerbB2 Inhibitors
HER2 Antagonists
HER2 Inhibitors
HER2/Neu/cerbB2 Inhibitors
C2916795
C300393
HER2/Neu/cerbB2 Antagonists [MoA]
NDF-RT:N0000020009
Bcr-Abl Tyrosine Kinase Inhibitors
N0000020009
984994
Bcr-Abl Tyrosine Kinase Inhibitor
C2267122
C300394
Bcr-Abl Tyrosine Kinase Inhibitors [MoA]
NDF-RT:N0000020010
HER1 Antagonists
N0000020010
989266
EGFR Antagonists
EGFR Inhibitors
Epidermal Growth Factor Receptor Antagonists
Epidermal Growth Factor Receptor Inhibitors
HER-1 Antagonists
HER-1 Inhibitors
HER1 Inhibitors
C2916831
C300395
HER1 Antagonists [MoA]
NDF-RT:N0000020018
Glucosyl Transferase Inhibitors
N0000020018
988136
C2267130
C300403
Glucosyl Transferase Inhibitors [MoA]
NDF-RT:N0000020019
Glucosylceramide Synthase Inhibitors
N0000020019
989376
C2267131
C300404
Glucosylceramide Synthase Inhibitors [MoA]
NDF-RT:N0000020025
14-alpha Demethylase Inhibitors
N0000020025
989952
C2267137
C300411
14-alpha Demethylase Inhibitors [MoA]
NDF-RT:N0000020026
Phosphodiesterase 5 Inhibitors
N0000020026
985515
Phosphodiesterase V Inhibitor
Phosphodiesterase V Inhibitors
C2267138
C300412
Phosphodiesterase 5 Inhibitors [MoA]
NDF-RT:N0000020065
L-Calcium Channel Receptor Antagonists
N0000020065
989377
C2916833
C300455
L-Calcium Channel Receptor Antagonists [MoA]
NDF-RT:N0000020084
Ubiquitin Ligase Inhibitors
N0000020084
986156
C1661195
C300474
Ubiquitin Ligase Inhibitors [MoA]
NDF-RT:N0000020089
Viral Envelope Interactions
N0000020089
989812
C2267190
C300479
Viral Envelope Interactions [MoA]
NDF-RT:N0000175074
Nucleoside Synthesis Inhibitors
N0000175074
987332
C2266855
C634436
Nucleoside Synthesis Inhibitors [MoA]
NDF-RT:N0000175075
Proteasome Inhibitors
N0000175075
988088
Proteasome Inhibitor
Proteosome Inhibitors
C2266856
C634437
Proteasome Inhibitors [MoA]
NDF-RT:N0000175076
Protein Kinase Inhibitors
N0000175076
993161
C2757016
C634438
Protein Kinase Inhibitors [MoA]
NDF-RT:N0000175082
Kinase Inhibitors
N0000175082
1025684
C1152564
C634444
Kinase Inhibitors [MoA]
NDF-RT:N0000175355
Binding Activity
N0000175355
990338
C2266866
C634738
Binding Activity [MoA]
NDF-RT:N0000175368
Cholinergic Interactions
N0000175368
987379
C2266879
C634751
Cholinergic Interactions [MoA]
NDF-RT:N0000175369
Cholinergic Agonists
N0000175369
1033063
C2757066
C634752
Cholinergic Agonists [MoA]
NDF-RT:N0000175446
Tumor Necrosis Factor alpha Receptor Blocking Activity
N0000175446
988325
TNF-a Receptor Blocking Activity
TNF-alpha Receptor Blocking Activity
C2267209
C30270
Tumor Necrosis Factor alpha Receptor Blocking Activity [MoA]
NDF-RT:N0000175450
Corticosteroid Hormone Receptor Agonists
N0000175450
988660
C2266939
C634830
Corticosteroid Hormone Receptor Agonists [MoA]
NDF-RT:N0000175451
Tumor Necrosis Factor Receptor Blocking Activity
N0000175451
984952
TNF Blocker
TNF Receptor Blocking Activity
C2266940
C634831
Tumor Necrosis Factor Receptor Blocking Activity [MoA]
NDF-RT:N0000175472
Metal Chelating Activity
N0000175472
986481
C1154714
C634853
Metal Chelating Activity [MoA]
NDF-RT:N0000175919
Cholesterol Synthesis Inhibitors
N0000175919
991925
C2917205
C635357
Cholesterol Synthesis Inhibitors [MoA]
BFO:0000001
entity
Entity
Julius Caesar
Verdi’s Requiem
the Second World War
your body mass index
BFO 2 Reference: In all areas of empirical inquiry we encounter general terms of two sorts. First are general terms which refer to universals or types:animaltuberculosissurgical procedurediseaseSecond, are general terms used to refer to groups of entities which instantiate a given universal but do not correspond to the extension of any subuniversal of that universal because there is nothing intrinsic to the entities in question by virtue of which they – and only they – are counted as belonging to the given group. Examples are: animal purchased by the Emperortuberculosis diagnosed on a Wednesdaysurgical procedure performed on a patient from Stockholmperson identified as candidate for clinical trial #2056-555person who is signatory of Form 656-PPVpainting by Leonardo da VinciSuch terms, which represent what are called ‘specializations’ in [81
Entity doesn't have a closure axiom because the subclasses don't necessarily exhaust all possibilites. For example Werner Ceusters 'portions of reality' include 4 sorts, entities (as BFO construes them), universals, configurations, and relations. It is an open question as to whether entities as construed in BFO will at some point also include these other portions of reality. See, for example, 'How to track absolutely everything' at http://www.referent-tracking.com/_RTU/papers/CeustersICbookRevised.pdf
An entity is anything that exists or has existed or will exist. (axiom label in BFO2 Reference: [001-001])
entity
BFO:0000002
continuant
Continuant
BFO 2 Reference: Continuant entities are entities which can be sliced to yield parts only along the spatial dimension, yielding for example the parts of your table which we call its legs, its top, its nails. ‘My desk stretches from the window to the door. It has spatial parts, and can be sliced (in space) in two. With respect to time, however, a thing is a continuant.’ [60, p. 240
Continuant doesn't have a closure axiom because the subclasses don't necessarily exhaust all possibilites. For example, in an expansion involving bringing in some of Ceuster's other portions of reality, questions are raised as to whether universals are continuants
A continuant is an entity that persists, endures, or continues to exist through time while maintaining its identity. (axiom label in BFO2 Reference: [008-002])
if b is a continuant and if, for some t, c has_continuant_part b at t, then c is a continuant. (axiom label in BFO2 Reference: [126-001])
if b is a continuant and if, for some t, cis continuant_part of b at t, then c is a continuant. (axiom label in BFO2 Reference: [009-002])
if b is a material entity, then there is some temporal interval (referred to below as a one-dimensional temporal region) during which b exists. (axiom label in BFO2 Reference: [011-002])
(forall (x y) (if (and (Continuant x) (exists (t) (continuantPartOfAt y x t))) (Continuant y))) // axiom label in BFO2 CLIF: [009-002]
(forall (x y) (if (and (Continuant x) (exists (t) (hasContinuantPartOfAt y x t))) (Continuant y))) // axiom label in BFO2 CLIF: [126-001]
(forall (x) (if (Continuant x) (Entity x))) // axiom label in BFO2 CLIF: [008-002]
(forall (x) (if (Material Entity x) (exists (t) (and (TemporalRegion t) (existsAt x t))))) // axiom label in BFO2 CLIF: [011-002]
continuant
BFO:0000003
occurrent
Occurrent
BFO 2 Reference: every occurrent that is not a temporal or spatiotemporal region is s-dependent on some independent continuant that is not a spatial region
BFO 2 Reference: s-dependence obtains between every process and its participants in the sense that, as a matter of necessity, this process could not have existed unless these or those participants existed also. A process may have a succession of participants at different phases of its unfolding. Thus there may be different players on the field at different times during the course of a football game; but the process which is the entire game s-depends_on all of these players nonetheless. Some temporal parts of this process will s-depend_on on only some of the players.
Occurrent doesn't have a closure axiom because the subclasses don't necessarily exhaust all possibilites. An example would be the sum of a process and the process boundary of another process.
Simons uses different terminology for relations of occurrents to regions: Denote the spatio-temporal location of a given occurrent e by 'spn[e]' and call this region its span. We may say an occurrent is at its span, in any larger region, and covers any smaller region. Now suppose we have fixed a frame of reference so that we can speak not merely of spatio-temporal but also of spatial regions (places) and temporal regions (times). The spread of an occurrent, (relative to a frame of reference) is the space it exactly occupies, and its spell is likewise the time it exactly occupies. We write 'spr[e]' and `spl[e]' respectively for the spread and spell of e, omitting mention of the frame.
An occurrent is an entity that unfolds itself in time or it is the instantaneous boundary of such an entity (for example a beginning or an ending) or it is a temporal or spatiotemporal region which such an entity occupies_temporal_region or occupies_spatiotemporal_region. (axiom label in BFO2 Reference: [077-002])
Every occurrent occupies_spatiotemporal_region some spatiotemporal region. (axiom label in BFO2 Reference: [108-001])
b is an occurrent entity iff b is an entity that has temporal parts. (axiom label in BFO2 Reference: [079-001])
(forall (x) (if (Occurrent x) (exists (r) (and (SpatioTemporalRegion r) (occupiesSpatioTemporalRegion x r))))) // axiom label in BFO2 CLIF: [108-001]
(forall (x) (iff (Occurrent x) (and (Entity x) (exists (y) (temporalPartOf y x))))) // axiom label in BFO2 CLIF: [079-001]
occurrent
BFO:0000004
ic
IndependentContinuant
a chair
a heart
a leg
a molecule
a spatial region
an atom
an orchestra.
an organism
the bottom right portion of a human torso
the interior of your mouth
b is an independent continuant = Def. b is a continuant which is such that there is no c and no t such that b s-depends_on c at t. (axiom label in BFO2 Reference: [017-002])
For any independent continuant b and any time t there is some spatial region r such that b is located_in r at t. (axiom label in BFO2 Reference: [134-001])
For every independent continuant b and time t during the region of time spanned by its life, there are entities which s-depends_on b during t. (axiom label in BFO2 Reference: [018-002])
(forall (x t) (if (IndependentContinuant x) (exists (r) (and (SpatialRegion r) (locatedInAt x r t))))) // axiom label in BFO2 CLIF: [134-001]
(forall (x t) (if (and (IndependentContinuant x) (existsAt x t)) (exists (y) (and (Entity y) (specificallyDependsOnAt y x t))))) // axiom label in BFO2 CLIF: [018-002]
(iff (IndependentContinuant a) (and (Continuant a) (not (exists (b t) (specificallyDependsOnAt a b t))))) // axiom label in BFO2 CLIF: [017-002]
independent continuant
BFO:0000015
process
Process
a process of cell-division, \ a beating of the heart
a process of meiosis
a process of sleeping
the course of a disease
the flight of a bird
the life of an organism
your process of aging.
p is a process = Def. p is an occurrent that has temporal proper parts and for some time t, p s-depends_on some material entity at t. (axiom label in BFO2 Reference: [083-003])
BFO 2 Reference: The realm of occurrents is less pervasively marked by the presence of natural units than is the case in the realm of independent continuants. Thus there is here no counterpart of ‘object’. In BFO 1.0 ‘process’ served as such a counterpart. In BFO 2.0 ‘process’ is, rather, the occurrent counterpart of ‘material entity’. Those natural – as contrasted with engineered, which here means: deliberately executed – units which do exist in the realm of occurrents are typically either parasitic on the existence of natural units on the continuant side, or they are fiat in nature. Thus we can count lives; we can count football games; we can count chemical reactions performed in experiments or in chemical manufacturing. We cannot count the processes taking place, for instance, in an episode of insect mating behavior.Even where natural units are identifiable, for example cycles in a cyclical process such as the beating of a heart or an organism’s sleep/wake cycle, the processes in question form a sequence with no discontinuities (temporal gaps) of the sort that we find for instance where billiard balls or zebrafish or planets are separated by clear spatial gaps. Lives of organisms are process units, but they too unfold in a continuous series from other, prior processes such as fertilization, and they unfold in turn in continuous series of post-life processes such as post-mortem decay. Clear examples of boundaries of processes are almost always of the fiat sort (midnight, a time of death as declared in an operating theater or on a death certificate, the initiation of a state of war)
(iff (Process a) (and (Occurrent a) (exists (b) (properTemporalPartOf b a)) (exists (c t) (and (MaterialEntity c) (specificallyDependsOnAt a c t))))) // axiom label in BFO2 CLIF: [083-003]
process
BFO:0000016
disposition
Disposition
an atom of element X has the disposition to decay to an atom of element Y
certain people have a predisposition to colon cancer
children are innately disposed to categorize objects in certain ways.
the cell wall is disposed to filter chemicals in endocytosis and exocytosis
BFO 2 Reference: Dispositions exist along a strength continuum. Weaker forms of disposition are realized in only a fraction of triggering cases. These forms occur in a significant number of cases of a similar type.
b is a disposition means: b is a realizable entity & b’s bearer is some material entity & b is such that if it ceases to exist, then its bearer is physically changed, & b’s realization occurs when and because this bearer is in some special physical circumstances, & this realization occurs in virtue of the bearer’s physical make-up. (axiom label in BFO2 Reference: [062-002])
If b is a realizable entity then for all t at which b exists, b s-depends_on some material entity at t. (axiom label in BFO2 Reference: [063-002])
(forall (x t) (if (and (RealizableEntity x) (existsAt x t)) (exists (y) (and (MaterialEntity y) (specificallyDepends x y t))))) // axiom label in BFO2 CLIF: [063-002]
(forall (x) (if (Disposition x) (and (RealizableEntity x) (exists (y) (and (MaterialEntity y) (bearerOfAt x y t)))))) // axiom label in BFO2 CLIF: [062-002]
disposition
BFO:0000017
realizable
RealizableEntity
the disposition of this piece of metal to conduct electricity.
the disposition of your blood to coagulate
the function of your reproductive organs
the role of being a doctor
the role of this boundary to delineate where Utah and Colorado meet
To say that b is a realizable entity is to say that b is a specifically dependent continuant that inheres in some independent continuant which is not a spatial region and is of a type instances of which are realized in processes of a correlated type. (axiom label in BFO2 Reference: [058-002])
All realizable dependent continuants have independent continuants that are not spatial regions as their bearers. (axiom label in BFO2 Reference: [060-002])
(forall (x t) (if (RealizableEntity x) (exists (y) (and (IndependentContinuant y) (not (SpatialRegion y)) (bearerOfAt y x t))))) // axiom label in BFO2 CLIF: [060-002]
(forall (x) (if (RealizableEntity x) (and (SpecificallyDependentContinuant x) (exists (y) (and (IndependentContinuant y) (not (SpatialRegion y)) (inheresIn x y)))))) // axiom label in BFO2 CLIF: [058-002]
realizable entity
BFO:0000019
quality
Quality
the ambient temperature of this portion of air
the color of a tomato
the length of the circumference of your waist
the mass of this piece of gold.
the shape of your nose
the shape of your nostril
a quality is a specifically dependent continuant that, in contrast to roles and dispositions, does not require any further process in order to be realized. (axiom label in BFO2 Reference: [055-001])
If an entity is a quality at any time that it exists, then it is a quality at every time that it exists. (axiom label in BFO2 Reference: [105-001])
(forall (x) (if (Quality x) (SpecificallyDependentContinuant x))) // axiom label in BFO2 CLIF: [055-001]
(forall (x) (if (exists (t) (and (existsAt x t) (Quality x))) (forall (t_1) (if (existsAt x t_1) (Quality x))))) // axiom label in BFO2 CLIF: [105-001]
quality
BFO:0000020
sdc
SpecificallyDependentContinuant
Reciprocal specifically dependent continuants: the function of this key to open this lock and the mutually dependent disposition of this lock: to be opened by this key
of one-sided specifically dependent continuants: the mass of this tomato
of relational dependent continuants (multiple bearers): John’s love for Mary, the ownership relation between John and this statue, the relation of authority between John and his subordinates.
the disposition of this fish to decay
the function of this heart: to pump blood
the mutual dependence of proton donors and acceptors in chemical reactions [79
the mutual dependence of the role predator and the role prey as played by two organisms in a given interaction
the pink color of a medium rare piece of grilled filet mignon at its center
the role of being a doctor
the shape of this hole.
the smell of this portion of mozzarella
b is a relational specifically dependent continuant = Def. b is a specifically dependent continuant and there are n > 1 independent continuants c1, … cn which are not spatial regions are such that for all 1 i < j n, ci and cj share no common parts, are such that for each 1 i n, b s-depends_on ci at every time t during the course of b’s existence (axiom label in BFO2 Reference: [131-004])
b is a specifically dependent continuant = Def. b is a continuant & there is some independent continuant c which is not a spatial region and which is such that b s-depends_on c at every time t during the course of b’s existence. (axiom label in BFO2 Reference: [050-003])
Specifically dependent continuant doesn't have a closure axiom because the subclasses don't necessarily exhaust all possibilites. We're not sure what else will develop here, but for example there are questions such as what are promises, obligation, etc.
(iff (RelationalSpecificallyDependentContinuant a) (and (SpecificallyDependentContinuant a) (forall (t) (exists (b c) (and (not (SpatialRegion b)) (not (SpatialRegion c)) (not (= b c)) (not (exists (d) (and (continuantPartOfAt d b t) (continuantPartOfAt d c t)))) (specificallyDependsOnAt a b t) (specificallyDependsOnAt a c t)))))) // axiom label in BFO2 CLIF: [131-004]
(iff (SpecificallyDependentContinuant a) (and (Continuant a) (forall (t) (if (existsAt a t) (exists (b) (and (IndependentContinuant b) (not (SpatialRegion b)) (specificallyDependsOnAt a b t))))))) // axiom label in BFO2 CLIF: [050-003]
specifically dependent continuant
BFO:0000023
role
Role
John’s role of husband to Mary is dependent on Mary’s role of wife to John, and both are dependent on the object aggregate comprising John and Mary as member parts joined together through the relational quality of being married.
the priest role
the role of a boundary to demarcate two neighboring administrative territories
the role of a building in serving as a military target
the role of a stone in marking a property boundary
the role of subject in a clinical trial
the student role
BFO 2 Reference: One major family of examples of non-rigid universals involves roles, and ontologies developed for corresponding administrative purposes may consist entirely of representatives of entities of this sort. Thus ‘professor’, defined as follows,b instance_of professor at t =Def. there is some c, c instance_of professor role & c inheres_in b at t.denotes a non-rigid universal and so also do ‘nurse’, ‘student’, ‘colonel’, ‘taxpayer’, and so forth. (These terms are all, in the jargon of philosophy, phase sortals.) By using role terms in definitions, we can create a BFO conformant treatment of such entities drawing on the fact that, while an instance of professor may be simultaneously an instance of trade union member, no instance of the type professor role is also (at any time) an instance of the type trade union member role (any more than any instance of the type color is at any time an instance of the type length).If an ontology of employment positions should be defined in terms of roles following the above pattern, this enables the ontology to do justice to the fact that individuals instantiate the corresponding universals – professor, sergeant, nurse – only during certain phases in their lives.
b is a role means: b is a realizable entity & b exists because there is some single bearer that is in some special physical, social, or institutional set of circumstances in which this bearer does not have to be& b is not such that, if it ceases to exist, then the physical make-up of the bearer is thereby changed. (axiom label in BFO2 Reference: [061-001])
(forall (x) (if (Role x) (RealizableEntity x))) // axiom label in BFO2 CLIF: [061-001]
role
BFO:0000030
object
Object
atom
cell
cells and organisms
engineered artifacts
grain of sand
molecule
organelle
organism
planet
solid portions of matter
star
BFO 2 Reference: BFO rests on the presupposition that at multiple micro-, meso- and macroscopic scales reality exhibits certain stable, spatially separated or separable material units, combined or combinable into aggregates of various sorts (for example organisms into what are called ‘populations’). Such units play a central role in almost all domains of natural science from particle physics to cosmology. Many scientific laws govern the units in question, employing general terms (such as ‘molecule’ or ‘planet’) referring to the types and subtypes of units, and also to the types and subtypes of the processes through which such units develop and interact. The division of reality into such natural units is at the heart of biological science, as also is the fact that these units may form higher-level units (as cells form multicellular organisms) and that they may also form aggregates of units, for example as cells form portions of tissue and organs form families, herds, breeds, species, and so on. At the same time, the division of certain portions of reality into engineered units (manufactured artifacts) is the basis of modern industrial technology, which rests on the distributed mass production of engineered parts through division of labor and on their assembly into larger, compound units such as cars and laptops. The division of portions of reality into units is one starting point for the phenomenon of counting.
BFO 2 Reference: Each object is such that there are entities of which we can assert unproblematically that they lie in its interior, and other entities of which we can assert unproblematically that they lie in its exterior. This may not be so for entities lying at or near the boundary between the interior and exterior. This means that two objects – for example the two cells depicted in Figure 3 – may be such that there are material entities crossing their boundaries which belong determinately to neither cell. Something similar obtains in certain cases of conjoined twins (see below).
BFO 2 Reference: To say that b is causally unified means: b is a material entity which is such that its material parts are tied together in such a way that, in environments typical for entities of the type in question,if c, a continuant part of b that is in the interior of b at t, is larger than a certain threshold size (which will be determined differently from case to case, depending on factors such as porosity of external cover) and is moved in space to be at t at a location on the exterior of the spatial region that had been occupied by b at t, then either b’s other parts will be moved in coordinated fashion or b will be damaged (be affected, for example, by breakage or tearing) in the interval between t and t.causal changes in one part of b can have consequences for other parts of b without the mediation of any entity that lies on the exterior of b. Material entities with no proper material parts would satisfy these conditions trivially. Candidate examples of types of causal unity for material entities of more complex sorts are as follows (this is not intended to be an exhaustive list):CU1: Causal unity via physical coveringHere the parts in the interior of the unified entity are combined together causally through a common membrane or other physical covering\. The latter points outwards toward and may serve a protective function in relation to what lies on the exterior of the entity [13, 47
BFO 2 Reference: an object is a maximal causally unified material entity
BFO 2 Reference: ‘objects’ are sometimes referred to as ‘grains’ [74
b is an object means: b is a material entity which manifests causal unity of one or other of the types CUn listed above & is of a type (a material universal) instances of which are maximal relative to this criterion of causal unity. (axiom label in BFO2 Reference: [024-001])
object
object
BFO:0000031
gdc
GenericallyDependentContinuant
The entries in your database are patterns instantiated as quality instances in your hard drive. The database itself is an aggregate of such patterns. When you create the database you create a particular instance of the generically dependent continuant type database. Each entry in the database is an instance of the generically dependent continuant type IAO: information content entity.
the pdf file on your laptop, the pdf file that is a copy thereof on my laptop
the sequence of this protein molecule; the sequence that is a copy thereof in that protein molecule.
b is a generically dependent continuant = Def. b is a continuant that g-depends_on one or more other entities. (axiom label in BFO2 Reference: [074-001])
(iff (GenericallyDependentContinuant a) (and (Continuant a) (exists (b t) (genericallyDependsOnAt a b t)))) // axiom label in BFO2 CLIF: [074-001]
generically dependent continuant
BFO:0000040
material
MaterialEntity
a flame
a forest fire
a human being
a hurricane
a photon
a puff of smoke
a sea wave
a tornado
an aggregate of human beings.
an energy wave
an epidemic
the undetached arm of a human being
BFO 2 Reference: Material entities (continuants) can preserve their identity even while gaining and losing material parts. Continuants are contrasted with occurrents, which unfold themselves in successive temporal parts or phases [60
BFO 2 Reference: Object, Fiat Object Part and Object Aggregate are not intended to be exhaustive of Material Entity. Users are invited to propose new subcategories of Material Entity.
BFO 2 Reference: ‘Matter’ is intended to encompass both mass and energy (we will address the ontological treatment of portions of energy in a later version of BFO). A portion of matter is anything that includes elementary particles among its proper or improper parts: quarks and leptons, including electrons, as the smallest particles thus far discovered; baryons (including protons and neutrons) at a higher level of granularity; atoms and molecules at still higher levels, forming the cells, organs, organisms and other material entities studied by biologists, the portions of rock studied by geologists, the fossils studied by paleontologists, and so on.Material entities are three-dimensional entities (entities extended in three spatial dimensions), as contrasted with the processes in which they participate, which are four-dimensional entities (entities extended also along the dimension of time).According to the FMA, material entities may have immaterial entities as parts – including the entities identified below as sites; for example the interior (or ‘lumen’) of your small intestine is a part of your body. BFO 2.0 embodies a decision to follow the FMA here.
A material entity is an independent continuant that has some portion of matter as proper or improper continuant part. (axiom label in BFO2 Reference: [019-002])
Every entity which has a material entity as continuant part is a material entity. (axiom label in BFO2 Reference: [020-002])
every entity of which a material entity is continuant part is also a material entity. (axiom label in BFO2 Reference: [021-002])
(forall (x) (if (MaterialEntity x) (IndependentContinuant x))) // axiom label in BFO2 CLIF: [019-002]
(forall (x) (if (and (Entity x) (exists (y t) (and (MaterialEntity y) (continuantPartOfAt x y t)))) (MaterialEntity x))) // axiom label in BFO2 CLIF: [021-002]
(forall (x) (if (and (Entity x) (exists (y t) (and (MaterialEntity y) (continuantPartOfAt y x t)))) (MaterialEntity x))) // axiom label in BFO2 CLIF: [020-002]
material entity
material entity
A triazole-based antifungal agent used for the treatment of esophageal candidiasis, invasive pulmonary aspergillosis, and serious fungal infections caused by Scedosporium apiospermum and Fusarium spp.
121243
CHEBI:127308
Beilstein:7694998
ChEMBL:127308
ChemIDplus:137234-62-9
DrugBank:137234-62-9
DrugBank:DB00582
KEGG COMPOUND:137234-62-9
KEGG COMPOUND:C07622
KEGG DRUG:137234-62-9
KEGG DRUG:D00578
Patent:EP440372
Patent:US5278175
Wikipedia:Voriconazole
(2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol
(R-(R*,S*))-alpha-(2,4-difluorophenyl)-5-fluoro-beta-methyl-alpha-(1H-1,2,4-triazol-1-ylmethyl)-4-pyrimidineethanol
(alphaR,betaS)-alpha-(2,4-difluorophenyl)-5-fluoro-beta-methyl-alpha(1H-1,2,4-triazol-1-ylmethyl)-4-pyrimidineethanol
C16H14F3N5O
C[C@@H](c1ncncc1F)[C@](O)(Cn1cncn1)c1ccc(F)cc1F
InChI=1S/C16H14F3N5O/c1-10(15-14(19)5-20-7-22-15)16(25,6-24-9-21-8-23-24)12-3-2-11(17)4-13(12)18/h2-5,7-10,25H,6H2,1H3/t10-,16+/m0/s1
InChIKey=BCEHBSKCWLPMDN-MGPLVRAMSA-N
VCZ
Vfend
voriconazole
CHEBI:10023
voriconazole
CHEBI:10023
Quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.
2551
CHEBI:102718
CHEBI:3717
CHEBI:41638
Beilstein:3568352
ChEMBL:100241
ChEMBL:102718
ChEMBL:10397494
ChEMBL:10737746
ChemIDplus:85721-33-1
DrugBank:DB00537
KEGG COMPOUND:85721-33-1
KEGG DRUG:D00186
Patent:DE3142854
Patent:US4670444
Wikipedia:Ciprofloxacin
1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid
Ciprofloxacin
ciprofloxacin
1-CYCLOPROPYL-6-FLUORO-4-OXO-7-PIPERAZIN-1-YL-1,4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID
1-Cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydro-quinoline-3-carboxylic acid
1-Cyclopropyl-6-fluoro-7-(4-methyl-piperazin-1-yl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid
1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid
1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid
1-cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydroquinoline-3-carboxylic acid
1-cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid
1-cyclopropyl-6-fluoro-7-hexahydro-1-pyrazinyl-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid
C17H18FN3O3
InChI=1S/C17H18FN3O3/c18-13-7-11-14(8-15(13)20-5-3-19-4-6-20)21(10-1-2-10)9-12(16(11)22)17(23)24/h7-10,19H,1-6H2,(H,23,24)
InChIKey=MYSWGUAQZAJSOK-UHFFFAOYSA-N
OC(=O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O
ciprofloxacin
ciprofloxacine
ciprofloxacino
ciprofloxacinum
CHEBI:100241
Ciprofloxacin
ciprofloxacin
CHEBI:100241
A synthetic fluoroquinolone with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase.
7517
CHEBI:7629
Beilstein:567897
ChEMBL:100246
ChemIDplus:70458-96-7
CiteXplore:3317294
CiteXplore:3908074
CiteXplore:6211142
CiteXplore:6224685
CiteXplore:6234465
CiteXplore:6454381
CiteXplore:6461606
DrugBank:DB01059
Gmelin:1576626
KEGG COMPOUND:70458-96-7
KEGG COMPOUND:C06687
KEGG DRUG:D00210
Patent:BE863429
Patent:DE2840910
Patent:US4146719
Patent:US4292317
Wikipedia:Norfloxacin
1-ethyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid
1,4-Dihydro-1-ethyl-6-fluoro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid
1-Ethyl-6-fluor-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-chinolincarbonsaeure
1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid
C16H18FN3O3
CCn1cc(C(O)=O)c(=O)c2cc(F)c(cc12)N1CCNCC1
InChI=1S/C16H18FN3O3/c1-2-19-9-11(16(22)23)15(21)10-7-12(17)14(8-13(10)19)20-5-3-18-4-6-20/h7-9,18H,2-6H2,1H3,(H,22,23)
InChIKey=OGJPXUAPXNRGGI-UHFFFAOYSA-N
NFLX
norfloxacin
norfloxacine
norfloxacino
norfloxacinum
CHEBI:100246
Norfloxacin
norfloxacin
CHEBI:100246
An indole that has formula C31H33N3O6S.
114970
Beilstein:3641829
ChemIDplus:107753-78-6
DrugBank:DB00549
KEGG COMPOUND:107753-78-6
KEGG COMPOUND:C07206
KEGG DRUG:D00411
Wikipedia:Zafirlukast
cyclopentyl 3-[2-methoxy-4-(2-methylphenylsulfonylcarbamoyl)benzyl]-1-methyl-1H-indol-5-ylcarbamate
4-(5-cyclopentyloxycarbonylamino-1-methyl-1H-indol-3-ylmethyl)-3-methoxy-N-o-tolylsulfonylbenzamide
Accolate
C31H33N3O6S
COc1cc(ccc1Cc1cn(C)c2ccc(NC(=O)OC3CCCC3)cc12)C(=O)NS(=O)(=O)c1ccccc1C
InChI=1S/C31H33N3O6S/c1-20-8-4-7-11-29(20)41(37,38)33-30(35)22-13-12-21(28(17-22)39-3)16-23-19-34(2)27-15-14-24(18-26(23)27)32-31(36)40-25-9-5-6-10-25/h4,7-8,11-15,17-19,25H,5-6,9-10,16H2,1-3H3,(H,32,36)(H,33,35)
InChIKey=YEEZWCHGZNKEEK-UHFFFAOYSA-N
cyclopentyl 3-(2-methoxy-4-((o-tolylsulfonyl)carbamoyl)benzyl)-1-methylindole-5-carbamate
zafirlukast
CHEBI:10100
zafirlukast
CHEBI:10100
A pyrazolo[1,5-a]pyrimidine having a nitrile group at position 3 and a 3-(N-ethylacetamido)phenyl substituent at the 7-position.
74667
Beilstein:8153844
ChemIDplus:151319-34-5
DrugBank:151319-34-5
DrugBank:DB00962
KEGG COMPOUND:151319-34-5
KEGG COMPOUND:C07484
KEGG DRUG:151319-34-5
KEGG DRUG:D00530
NIST Chemistry WebBook:151319-34-5
Patent:US4626538
Wikipedia:Zaleplon
N-[3-(3-cyanopyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-N-ethylacetamide
3'-(3-Cyanopyrazolo(1,5-a)pyrimidin-7-yl)-N-ethylacetanilide
C17H15N5O
CCN(C(C)=O)c1cccc(c1)-c1ccnc2c(cnn12)C#N
InChI=1S/C17H15N5O/c1-3-21(12(2)23)15-6-4-5-13(9-15)16-7-8-19-17-14(10-18)11-20-22(16)17/h4-9,11H,3H2,1-2H3
InChIKey=HUNXMJYCHXQEGX-UHFFFAOYSA-N
zaleplon
CHEBI:10102
zaleplon
CHEBI:10102
A pyrimidine 2',3'-dideoxyribonucleoside compound having a 3'-azido substituent and thymine as the nucleobase.
11413
CHEBI:619601
Beilstein:763034
ChEMBL:19112024
ChEMBL:619601
ChemIDplus:30516-87-1
DrugBank:30516-87-1
DrugBank:DB00495
KEGG COMPOUND:30516-87-1
KEGG COMPOUND:C07210
KEGG DRUG:30516-87-1
KEGG DRUG:D00413
Patent:US4724232
Wikipedia:Zidovudine
3'-azido-3'-deoxythymidine
AZT
Azidothymidine
C10H13N5O4
Cc1cn([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)c(=O)[nH]c1=O
InChI=1S/C10H13N5O4/c1-5-3-15(10(18)12-9(5)17)8-2-6(13-14-11)7(4-16)19-8/h3,6-8,16H,2,4H2,1H3,(H,12,17,18)/t6-,7+,8+/m0/s1
InChIKey=HBOMLICNUCNMMY-XLPZGREQSA-N
Zidovudin
Zidovudinum
zidovudine
CHEBI:10110
Zidovudine
zidovudine
CHEBI:10110
A piperazine compound having 1,2-benzothiazol-3-yl- and 2-(6-chloro-1,3-dihydro-2-oxindol-5-yl)ethyl substituents attached to the nitrogen atoms.
115698
Beilstein:6669199
ChemIDplus:146939-27-7
DrugBank:146939-27-7
DrugBank:DB00246
KEGG COMPOUND:C07568
KEGG DRUG:146939-27-7
KEGG DRUG:D08687
Patent:EP281309
Patent:US4831031
Wikipedia:Ziprasidone
5-{2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl}-6-chloro-1,3-dihydro-2H-indol-2-one
Ziprasidone
C21H21ClN4OS
Clc1cc2NC(=O)Cc2cc1CCN1CCN(CC1)c1nsc2ccccc12
InChI=1S/C21H21ClN4OS/c22-17-13-18-15(12-20(27)23-18)11-14(17)5-6-25-7-9-26(10-8-25)21-16-3-1-2-4-19(16)28-24-21/h1-4,11,13H,5-10,12H2,(H,23,27)
InChIKey=MVWVFYHBGMAFLY-UHFFFAOYSA-N
ziprasidona
ziprasidone
ziprasidonum
CHEBI:10119
ziprasidone
CHEBI:10119
An imidazo[1,2-a]pyridine compound having a 4-tolyl group at the 2-position, an N,N-dimethylcarbamoylmethyl group at the 3-position and a methyl substituent at the 6-position.
39993
Beilstein:4355785
ChemIDplus:82626-48-0
DrugBank:82626-48-0
DrugBank:DB00425
KEGG COMPOUND:82626-48-0
KEGG COMPOUND:C07219
KEGG DRUG:82626-48-0
KEGG DRUG:D08690
NIST Chemistry WebBook:82626-48-0
Patent:EP50563
Patent:US4382938
Wikipedia:Zolpidem
N,N-dimethyl-2-[6-methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridin-3-yl]acetamide
C19H21N3O
CN(C)C(=O)Cc1c(nc2ccc(C)cn12)-c1ccc(C)cc1
InChI=1S/C19H21N3O/c1-13-5-8-15(9-6-13)19-16(11-18(23)21(3)4)22-12-14(2)7-10-17(22)20-19/h5-10,12H,11H2,1-4H3
InChIKey=ZAFYATHCZYHLPB-UHFFFAOYSA-N
N,N,6-Trimethyl-2-(4-methylphenyl)imidazo(1,2-a)pyridine-3-acetamide
zolpidem
zolpidemum
CHEBI:10125
zolpidem
CHEBI:10125
A 1,2-benzoxazole compound having a sulfamoylmethyl substituent at the 3-position.
39998
CHEBI:139857
Beilstein:1077076
ChEMBL:139857
ChemIDplus:68291-97-4
DrugBank:68291-97-4
DrugBank:DB00909
KEGG COMPOUND:68291-97-4
KEGG COMPOUND:C07504
KEGG DRUG:68291-97-4
KEGG DRUG:D00538
Patent:JP7877057
Patent:US4172896
Wikipedia:Zonisamide
1-(1,2-benzisoxazol-3-yl)methanesulfonamide
1,2-Benzisoxazole-3-methanesulfonamide
3-(Sulfamoylmethyl)-1,2-benzisoxazole
Benzo[d]isoxazol-3-yl-methanesulfonamide
C8H8N2O3S
InChI=1S/C8H8N2O3S/c9-14(11,12)5-7-6-3-1-2-4-8(6)13-10-7/h1-4H,5H2,(H2,9,11,12)
InChIKey=UBQNRHZMVUUOMG-UHFFFAOYSA-N
NS(=O)(=O)Cc1noc2ccccc12
zonisamida
zonisamide
zonisamidum
CHEBI:10127
zonisamide
CHEBI:10127
The (S,S)-diastereoisomer of 2,3-dihydro-1,5-benzothiazepin-4(5H)-one in which positions 2 and 3 are substituted by 4-methoxyphenyl and acetoxy, respectively, while the hydrogen attached to the nitrogen is substituted by a 2-(dimethylamino)ethyl group. A calcium-channel blocker and vasodilator, it is used as the hydrochloride in the management of angina pectoris and hypertension.
3443
CHEBI:4602
Beilstein:3573079
ChEMBL:101278
ChemIDplus:42399-41-7
DrugBank:DB00343
KEGG COMPOUND:42399-41-7
KEGG COMPOUND:C06958
KEGG DRUG:D07845
NIST Chemistry WebBook:42399-41-7
Patent:DE1805714
Patent:DE3415035
Patent:US3562257
Patent:US4552695
Wikipedia:Diltiazem
(2S,3S)-5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate
DILTIAZEM
Diltiazem
(+)-cis-5-[2-(dimethylamino)ethyl]-2,3-dihydro-3-hydroxy-2-(p-methoxyphenyl)-1,5-benzothiazepin-4(5H)-one acetate ester
(2S,3S)-5-(2-(dimethylamino)ethyl)-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepin-3-yl acetate
(2S-cis)-3-(acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3-dihydro-2-(4-methoxyphenyl)-1,5-benzothiazepin-4(5H)-one
Acetic acid (2S,3S)-5-(2-dimethylamino-ethyl)-2-(4-methoxy-phenyl)-4-oxo-2,3,4,5-tetrahydro-benzo[b][1,4]thiazepin-3-yl ester
C22H26N2O4S
COc1ccc(cc1)[C@@H]1Sc2ccccc2N(CCN(C)C)C(=O)[C@@H]1OC(C)=O
InChI=1S/C22H26N2O4S/c1-15(25)28-20-21(16-9-11-17(27-4)12-10-16)29-19-8-6-5-7-18(19)24(22(20)26)14-13-23(2)3/h5-12,20-21H,13-14H2,1-4H3/t20-,21+/m1/s1
InChIKey=HSUGRBWQSSZJOP-RTWAWAEBSA-N
diltiazem
diltiazemum
CHEBI:101278
Diltiazem
diltiazem
CHEBI:101278
Barbituric acid in which the hydrogens at position 5 are substituted by an allyl group and an isobutyl group. Frequently combined with other medicines, such as aspirin, paracetamol and codeine, it is used for treatment of pain and headache.
19860
Beilstein:202119
ChEMBL:102524
ChEMBL:6864729
ChemIDplus:77-26-9
DrugBank:DB00241
KEGG DRUG:D03182
NIST Chemistry WebBook:77-26-9
Wikipedia:Butalbital
5-(2-methylpropyl)-5-(prop-2-en-1-yl)pyrimidine-2,4,6(1H,3H,5H)-trione
5-(2-methylpropyl)-5-prop-2-enyl-1,3-diazinane-2,4,6-trione
5-Allyl-5-isobutyl-pyrimidine-2,4,6-trione
5-allyl-5-(2'-methyl-n-propyl) barbituric acid
5-allyl-5-(2-methylpropyl)barbituric acid
5-allyl-5-isobutyl-2,4,6(1H,3H,5H)-pyrimidinetrione
5-allyl-5-isobutylbarbituric acid
5-isobutyl-5-allylbarbituric acid
C11H16N2O3
CC(C)CC1(CC=C)C(=O)NC(=O)NC1=O
InChI=1S/C11H16N2O3/c1-4-5-11(6-7(2)3)8(14)12-10(16)13-9(11)15/h4,7H,1,5-6H2,2-3H3,(H2,12,13,14,15,16)
InChIKey=UZVHFVZFNXBMQJ-UHFFFAOYSA-N
allylbarbital
allylbarbitone
allylbarbituric acid
butalbarbital
butalbital
butalbitalum
iso-butylallylbarbituric acid
itobarbital
tetrallobarbital
CHEBI:102524
butalbital
CHEBI:102524
A sulfonamide that consists of N,N-dimethyltryptamine bearing an additional (N-methylsulfamoyl)methyl substituent at position 5. Selective agonist for a vascular 5-HT1 receptor subtype (probably a member of the 5-HT1D family).
37418
Beilstein:5346011
ChemIDplus:103628-46-2
CiteXplore:11045888
CiteXplore:11401410
CiteXplore:12172708
CiteXplore:12856385
CiteXplore:12917936
CiteXplore:15652399
CiteXplore:16120224
CiteXplore:16142613
CiteXplore:17557349
CiteXplore:18442019
CiteXplore:19619527
CiteXplore:19825906
CiteXplore:22106962
CiteXplore:22150557
CiteXplore:22272067
CiteXplore:22302025
CiteXplore:22336849
CiteXplore:22336867
CiteXplore:22336868
CiteXplore:22435741
DrugBank:DB00669
HMDB:HMDB05037
KEGG COMPOUND:103628-46-2
KEGG COMPOUND:C07319
KEGG DRUG:D00451
NIST Chemistry WebBook:103628-46-2
Reaxys:5346011
Wikipedia:Sumatriptan
1-{3-[2-(dimethylamino)ethyl]-1H-indol-5-yl}-N-methylmethanesulfonamide
(3-[2-(dimethylamino)ethyl]-1H-indol-5-yl)-N-methylmethanesulfonamide
1-[3-(2-dimethylaminoethyl)-1H-indol-5-yl]-N-methyl-methanesulfonamide
3-(2-(dimethylamino)ethyl)-N-methyl-1H-indole-5-methanesulfonamide
3-[2-(dimethylamino)ethyl]-N-methylindole-5-methanesulfonamide
C14H21N3O2S
CNS(=O)(=O)Cc1ccc2[nH]cc(CCN(C)C)c2c1
Imigran
Imitrex
InChI=1S/C14H21N3O2S/c1-15-20(18,19)10-11-4-5-14-13(8-11)12(9-16-14)6-7-17(2)3/h4-5,8-9,15-16H,6-7,10H2,1-3H3
InChIKey=KQKPFRSPSRPDEB-UHFFFAOYSA-N
Sumatran
Sumax
sumatriptan
sumatriptanum
CHEBI:10650
Sumatriptan
sumatriptan
CHEBI:10650
The carboxamide resulting from the formal condensation of the aryl amino group of N-phenyl-1-(2-phenylethyl)piperidin-4-amine with propanoic acid.
4337
CHEBI:310077
CHEBI:5012
ChEMBL:10669565
ChEMBL:10987438
ChEMBL:11585443
ChEMBL:119915
ChEMBL:14698188
ChEMBL:310077
ChemIDplus:437-38-7
CiteXplore:16621415
DrugBank:DB00813
KEGG DRUG:437-38-7
KEGG DRUG:D00320
Patent:FR1344366
Patent:US3164600
Reaxys:494484
Wikipedia:Fentanyl
FENTANYL
N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide
1-phenethyl-4-(N-phenylpropionamido)piperidine
1-phenethyl-4-N-propionylanilinopiperidine
C22H28N2O
CCC(=O)N(C1CCN(CC1)CCc1ccccc1)c1ccccc1
InChI=1S/C22H28N2O/c1-2-22(25)24(20-11-7-4-8-12-20)21-14-17-23(18-15-21)16-13-19-9-5-3-6-10-19/h3-12,21H,2,13-18H2,1H3
InChIKey=PJMPHNIQZUBGLI-UHFFFAOYSA-N
N-(1-Phenethyl-piperidin-4-yl)-N-phenyl-propionamide
N-(1-phenethyl-4-piperidinyl)-N-phenylpropionamide
N-(1-phenethyl-4-piperidyl)propionanilide
N-(1-phenethylpiperidin-4-yl)-N-phenylpropionamide
N-phenethyl-4-(N-propionylanilino)piperidine
N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide
fentanila
fentanyl
fentanylum
CHEBI:119915
Fentanyl
fentanyl
CHEBI:119915
Phosphoric acid in which one of the hydroxy groups is replaced by a carboxylic acid group. It is used as the trisodium salt as an antiviral agent in the treatment of cytomegalovirus retinitis (CMV retinitis, an inflamation of the retina that can lead to blindness) and as an alternative to ganciclovir for AIDS patients who require concurrent antiretroviral therapy but are unable to tolerate ganciclovir due to haematological toxicity.
33562
CHEBI:45085
CHEBI:8158
ChEMBL:127780
ChemIDplus:4428-95-9
CiteXplore:11576919
CiteXplore:15182735
CiteXplore:16858125
CiteXplore:19213941
CiteXplore:19288498
CiteXplore:21056575
CiteXplore:21566148
DrugBank:DB00529
KEGG COMPOUND:4428-95-9
KEGG COMPOUND:C06456
PDBeChem:PPF
Reaxys:1756501
Wikipedia:Foscarnet
PHOSPHONOFORMIC ACID
dihydroxyphosphanecarboxylic acid oxide
CH3O5P
FOSCARNET
Foscarmet
InChI=1S/CH3O5P/c2-1(3)7(4,5)6/h(H,2,3)(H2,4,5,6)
InChIKey=ZJAOAACCNHFJAH-UHFFFAOYSA-N
OC(=O)P(O)(O)=O
carboxyphosphonic acid
foscarnet
phosphonomethanoic acid
CHEBI:127780
Foscarnet
phosphonoformic acid
CHEBI:127780
Any amide of aniline.
CiteXplore:6205897
KEGG COMPOUND:C01402
anilide
C7H6NOR
N-phenyl amide
N-phenyl amides
[*]C(=O)Nc1ccccc1
CHEBI:13248
anilide
CHEBI:13248
Benzoic acid carrying an acetoxy group at the 2-position.
1191
CHEBI:22188
CHEBI:22203
CHEBI:2890
CHEBI:40705
Beilstein:779271
ChemIDplus:50-78-2
CiteXplore:11402787
CiteXplore:11597554
CiteXplore:11733186
CiteXplore:12852484
CiteXplore:14753751
CiteXplore:15542410
CiteXplore:15590729
CiteXplore:1650428
CiteXplore:18226435
CiteXplore:18335236
CiteXplore:19386367
CiteXplore:19706045
CiteXplore:21699808
CiteXplore:445303
DrugBank:DB00945
Gmelin:218864
KEGG COMPOUND:50-78-2
KEGG COMPOUND:C01405
KEGG DRUG:D00109
NIST Chemistry WebBook:50-78-2
PDBeChem:AIN
Reaxys:779271
Wikipedia:Aspirin
2-(acetyloxy)benzoic acid
Acetylsalicylic acid
2-(ACETYLOXY)BENZOIC ACID
2-Acetoxybenzenecarboxylic acid
2-acetoxybenzoic acid
ASA
Acetylsalicylate
Acetylsalicylsaeure
Aspirin
Azetylsalizylsaeure
C9H8O4
CC(=O)Oc1ccccc1C(O)=O
Easprin
InChI=1S/C9H8O4/c1-6(10)13-8-5-3-2-4-7(8)9(11)12/h2-5H,1H3,(H,11,12)
InChIKey=BSYNRYMUTXBXSQ-UHFFFAOYSA-N
O-acetylsalicylic acid
acide 2-(acetyloxy)benzoique
acide acetylsalicylique
acido acetilsalicilico
acidum acetylsalicylicum
o-acetoxybenzoic acid
o-carboxyphenyl acetate
salicylic acid acetate
CHEBI:15365
Aspirin
acetylsalicylic acid
CHEBI:15365
An optically active form of dopa having L-configuration.
6375
CHEBI:11693
CHEBI:13098
CHEBI:1377
CHEBI:19825
CHEBI:41871
CHEBI:49933
Beilstein:2215169
Beilstein:6060047
COMe:MOL000169
ChemIDplus:59-92-7
CiteXplore:8301021
DrugBank:DB01235
Gmelin:365846
KEGG COMPOUND:59-92-7
KEGG COMPOUND:C00355
KEGG DRUG:D00059
NIST Chemistry WebBook:59-92-7
PDBeChem:DAH_LFOH
Reaxys:2215169
Wikipedia:Levodopa
(2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid
L-DOPA
L-Dopa
L-dopa
(-)-3-(3,4-dihydroxyphenyl)-L-alanine
(-)-dopa
3,4-DIHYDROXYPHENYLALANINE
3,4-Dihydroxy-L-phenylalanine
3-Hydroxy-L-tyrosine
C9H11NO4
Dihydroxy-L-phenylalanine
Dopar
InChI=1S/C9H11NO4/c10-6(9(13)14)3-5-1-2-7(11)8(12)4-5/h1-2,4,6,11-12H,3,10H2,(H,13,14)/t6-/m0/s1
InChIKey=WTDRDQBEARUVNC-LURJTMIESA-N
L-beta-(3,4-Dihydroxyphenyl)alanine
N[C@@H](Cc1ccc(O)c(O)c1)C(O)=O
beta-(3,4-dihydroxyphenyl)-L-alanine
beta-(3,4-dihydroxyphenyl)alanine
levodopa
levodopum
CHEBI:15765
L-dopa
Levodopa
CHEBI:15765
Compounds having the structure RSR (R =/= H). Such compounds were once called thioethers.
CHEBI:13694
CHEBI:26960
CHEBI:9340
KEGG COMPOUND:C00297
sulfides
RSR
SR2
Sulfide
Thioether
organic sulfides
thioether
thioethers
CHEBI:16385
organic sulfide
CHEBI:16385
Amide derived from two or more amino carboxylic acid molecules (the same or different) by formation of a covalent bond from the carbonyl carbon of one to the nitrogen atom of another with formal loss of water. The term is usually applied to structures formed from alpha-amino acids, but it includes those derived from any amino carboxylic acid.
CHEBI:14753
CHEBI:25906
CHEBI:7990
KEGG COMPOUND:C00012
Peptide
peptides
C2H4NO2R(C2H2NOR)n
Peptid
peptido
peptidos
CHEBI:16670
peptide
CHEBI:16670
Codeine is an alkaloid found in the opium poppy, Papaver somniferum var. album; has analgesic, anti-tussive and anti-diarrhoeal properties.
2670
CHEBI:14006
CHEBI:23348
CHEBI:3803
Beilstein:5303198
Beilstein:5768734
Beilstein:94996
ChemIDplus:76-57-3
CiteXplore:2215478
DrugBank:DB00318
Gmelin:232454
KEGG COMPOUND:76-57-3
KEGG COMPOUND:C06174
NIST Chemistry WebBook:76-57-3
Wikipedia:Codeine
3-methoxy-17-methyl-7,8-didehydro-4,5alpha-epoxymorphinan-6alpha-ol
Codeine
(5alpha,6alpha)-7,8-Didehydro-4,5-epoxy-3-methoxy-17-methylmorphinan-6-ol
7,8-didehydro-4,5alpha-epoxy-3-methoxy-17-methylmorphinan-6alpha-ol
C18H21NO3
Codein
Codicept
Coducept
InChI=1S/C18H21NO3/c1-19-8-7-18-11-4-5-13(20)17(18)22-16-14(21-2)6-3-10(15(16)18)9-12(11)19/h3-6,11-13,17,20H,7-9H2,1-2H3/t11-,12+,13-,17-,18-/m0/s1
InChIKey=OROGSEYTTFOCAN-DNJOTXNNSA-N
O(3)-methylmorphine
[H][C@]12C=C[C@H](O)[C@@H]3Oc4c(OC)ccc5C[C@H]1N(C)CC[C@@]23c45
codeina
codeine
codeine anhydrous
l-codeine
methylmorphine
morphine 3-methyl ether
morphine monomethyl ether
morphine-3-methyl ether
CHEBI:16714
Codeine
codeine
CHEBI:16714
CHEBI:13431
CHEBI:8749
KEGG COMPOUND:C00375
CH4NR
NC[*]
RCH2NH2
primary aliphatic amines
CHEBI:17062
primary aliphatic amine
CHEBI:17062
A amino cyclitol glycoside that consists of streptidine having a disaccharyl moiety attached at the 4-position. The parent of the streptomycin class
10109
CHEBI:15119
CHEBI:26784
CHEBI:45745
CHEBI:9284
Beilstein:74498
ChemIDplus:57-92-1
CiteXplore:11228320
CiteXplore:11905029
CiteXplore:12118520
CiteXplore:13030054
CiteXplore:13116094
CiteXplore:13136149
CiteXplore:13596285
CiteXplore:13691614
CiteXplore:13985260
CiteXplore:13990247
CiteXplore:14623118
CiteXplore:14828344
CiteXplore:14852338
CiteXplore:14939639
CiteXplore:15081082
CiteXplore:15137533
CiteXplore:15207172
CiteXplore:15686853
CiteXplore:15736038
CiteXplore:16904706
CiteXplore:17105735
CiteXplore:17238915
CiteXplore:17429930
CiteXplore:18173084
CiteXplore:18916143
CiteXplore:19052412
CiteXplore:19335957
CiteXplore:21350946
CiteXplore:21362244
CiteXplore:21593257
CiteXplore:21937264
DrugBank:DB01082
KEGG COMPOUND:57-92-1
KEGG COMPOUND:C00413
KEGG DRUG:D08531
PDBeChem:SRY
Reaxys:74498
Wikipedia:Streptomycin
N,N'''-[(1R,2R,3S,4R,5R,6S)-4-{5-deoxy-2-O-[2-deoxy-2-(methylamino)-alpha-L-glucopyranosyl]-3-C-formyl-alpha-L-lyxofuranosyloxy}-2,5,6-trihydroxycyclohexane-1,3-diyl]diguanidine
STREPTOMYCIN
2,4-Diguanidino-3,5,6-trihydroxycyclohexyl 5-deoxy-2-O-(2-deoxy-2-methylamino-alpha-L-glucopyranosyl)-3-C-formyl-beta-L-lyxopentanofuranoside
C21H39N7O12
CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@H]1[C@@H](O[C@@H](C)[C@]1(O)C=O)O[C@H]1[C@H](O)[C@@H](O)[C@H](NC(N)=N)[C@@H](O)[C@@H]1NC(N)=N
InChI=1S/C21H39N7O12/c1-5-21(36,4-30)16(40-17-9(26-2)13(34)10(31)6(3-29)38-17)18(37-5)39-15-8(28-20(24)25)11(32)7(27-19(22)23)12(33)14(15)35/h4-18,26,29,31-36H,3H2,1-2H3,(H4,22,23,27)(H4,24,25,28)/t5-,6-,7+,8-,9-,10-,11+,12-,13-,14+,15+,16-,17-,18-,21+/m0/s1
InChIKey=UCSJYZPVAKXKNQ-HZYVHMACSA-N
Kantrex
SM
[2-deoxy-2-(dimethylamino)-alpha-L-glucopyranosyl]-(1->2)-[5-deoxy-3-C-formyl-alpha-L-lyxofuranosyl]-(1->4)-{N',N'''-[(1,3,5/2,4,6)-2,4,5,6-tetrahydroxycyclohexane-1,3-diyl]diguanidine}
streptomycin
CHEBI:17076
Streptomycin
streptomycin
CHEBI:17076
A compound in which a carbonyl group is bonded to two carbon atoms: R2C=O (neither R may be H).
CHEBI:13427
CHEBI:24974
CHEBI:6127
CHEBI:8742
KEGG COMPOUND:C00709
KEGG COMPOUND:C01450
Ketone
ketones
COR2
Keton
R-CO-R'
[*]C([*])=O
cetone
ketones
CHEBI:17087
ketone
CHEBI:17087
Any member of the group of substituted penams containing two methyl substituents at position 2, a carboxylate substituent at position 3 and a carboxamido group at position 6.
CHEBI:14742
CHEBI:25869
CHEBI:7961
CiteXplore:12833570
CiteXplore:1502708
CiteXplore:16033609
CiteXplore:7798534
KEGG COMPOUND:C00395
Penicillin
penicillin
penicillins
C9H11N2O4SR
[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC([*])=O)C(O)=O
penicillins
CHEBI:17334
penicillin
CHEBI:17334
A 2'-deoxycytidine having geminal fluoro substituents in the 2'-position. Gemcitabine is used in various carcinomas: non-small cell lung cancer, pancreatic cancer, bladder cancer and breast cancer.
12574
CHEBI:42752
CHEBI:5295
Beilstein:5382060
ChEMBL:11356111
ChEMBL:17101674
ChEMBL:175901
ChEMBL:17602464
ChEMBL:17887663
ChEMBL:17939651
ChEMBL:18186604
ChEMBL:18257544
ChemIDplus:95058-81-4
CiteXplore:11034044
CiteXplore:11061612
CiteXplore:11088063
CiteXplore:11122828
CiteXplore:11132538
CiteXplore:11142482
CiteXplore:11221019
CiteXplore:11374818
CiteXplore:11489002
CiteXplore:11504793
CiteXplore:11510027
CiteXplore:11585734
CiteXplore:11595724
CiteXplore:11807603
CiteXplore:11859947
CiteXplore:11901308
CiteXplore:12057041
CiteXplore:12057046
CiteXplore:12057157
CiteXplore:12115355
CiteXplore:12142097
CiteXplore:12571808
CiteXplore:12722678
CiteXplore:12722691
CiteXplore:12743987
CiteXplore:12761494
CiteXplore:12798170
CiteXplore:12917815
CiteXplore:12954073
CiteXplore:14606642
CiteXplore:14653877
CiteXplore:14720338
CiteXplore:15131028
CiteXplore:15160243
CiteXplore:15221904
CiteXplore:15282439
CiteXplore:15297392
CiteXplore:15542781
CiteXplore:15637766
CiteXplore:15744590
CiteXplore:16001951
CiteXplore:16041610
CiteXplore:16080557
CiteXplore:16143373
CiteXplore:16149285
CiteXplore:16317298
CiteXplore:16500746
CiteXplore:16555971
CiteXplore:16584929
CiteXplore:16807461
CiteXplore:16807463
CiteXplore:16894289
CiteXplore:16905983
CiteXplore:17296311
CiteXplore:17296587
CiteXplore:17347561
CiteXplore:17429628
CiteXplore:17460420
CiteXplore:17639396
CiteXplore:17941128
CiteXplore:17987263
CiteXplore:18035967
CiteXplore:18050344
CiteXplore:18086345
CiteXplore:18166944
CiteXplore:18348652
CiteXplore:18773046
CiteXplore:18789834
CiteXplore:18819792
CiteXplore:18981552
CiteXplore:19034448
CiteXplore:19177022
CiteXplore:19399788
CiteXplore:19839926
CiteXplore:19879060
DrugBank:95058-81-4
DrugBank:DB00441
KEGG COMPOUND:95058-81-4
KEGG COMPOUND:C07650
KEGG DRUG:95058-81-4
KEGG DRUG:D02368
PDBeChem:GEO
Patent:EP1939198
Patent:EP2108368
Patent:EP2275135
Patent:GB2136425
Patent:US2009124797
Patent:US2010111852
Patent:US4808614
Reaxys:5382060
Wikipedia:Gemcitabine
2'-deoxy-2',2'-difluorocytidine
2',2'-Difluorodeoxycytidine
2'-Deoxy-2',2'-difluorocytidine
4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
C9H11F2N3O4
InChI=1S/C9H11F2N3O4/c10-9(11)6(16)4(3-15)18-7(9)14-2-1-5(12)13-8(14)17/h1-2,4,6-7,15-16H,3H2,(H2,12,13,17)/t4-,6-,7-/m1/s1
InChIKey=SDUQYLNIPVEERB-QPPQHZFASA-N
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
gemcitabina
gemcitabine
gemcitabinum
CHEBI:175901
gemcitabine
CHEBI:175901
Cortisol is a corticosteroid hormone or glucocorticoid produced by zona fasciculata of the adrenal cortex, which is a part of the adrenal gland. It is usually referred to as the "stress hormone" as it is involved in response to stress and anxiety, controlled by corticotropin-releasing hormone (CRH). It increases blood pressure and blood sugar, and reduces immune responses
5492
CHEBI:14023
CHEBI:24633
CHEBI:3893
CHEBI:58221
Beilstein:1354819
ChemIDplus:50-23-7
CiteXplore:10438974
DrugBank:DB00741
KEGG COMPOUND:50-23-7
KEGG COMPOUND:C00735
KEGG DRUG:D00088
LIPID MAPS:LMST02030001
NIST Chemistry WebBook:50-23-7
Patent:US2602769
Wikipedia:Hydrocortisone
11beta,17,21-trihydroxypregn-4-ene-3,20-dione
Cortisol
cortisol
(11beta)-11,17,21-trihydroxypregn-4-ene-3,20-dione
11beta,17alpha,21-Trihydroxy-4-pregnene-3,20-dione
11beta,17alpha,21-trihydroxy-4-pregnene-3,20-dione
11beta-hydrocortisone
17-hydroxycorticosterone
4-pregnen-11beta,17alpha,21-triol-3,20-dione
C21H30O5
Hydrocortisone
InChI=1S/C21H30O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h9,14-16,18,22,24,26H,3-8,10-11H2,1-2H3/t14-,15-,16-,18+,19-,20-,21-/m0/s1
InChIKey=JYGXADMDTFJGBT-VWUMJDOOSA-N
Kendall's compound F
Reichstein's substance M
[H][C@@]12CCC3=CC(=O)CC[C@]3(C)[C@@]1([H])[C@@H](O)C[C@@]1(C)[C@@]2([H])CC[C@]1(O)C(=O)CO
hidrocortisona
hydrocortisone
hydrocortisonum
CHEBI:17650
Hydrocortisone
cortisol
CHEBI:17650
Any of a group of aminoglycoside antibiotics produced by fermentation of some Micromonospora spp.
142438
CHEBI:14293
CHEBI:24206
CHEBI:24212
CHEBI:5306
KEGG COMPOUND:1403-66-3
KEGG COMPOUND:C00505
4,6-diamino-3-[3-deoxy-4-C-methyl-3-(methylamino)pentopyranosyloxy]-2-hydroxycyclohexyl 2-amino-2,3,4,6,7-pentadeoxy-6-(methylamino)heptopyranoside
Gentamicin
gentamicin
gentamycins
CHEBI:17833
Gentamicin Sulfate (USP)
gentamycin
CHEBI:17833
'Lipids' is a loosely defined term for substances of biological origin that are soluble in nonpolar solvents. They consist of saponifiable lipids, such as glycerides (fats and oils) and phospholipids, as well as nonsaponifiable lipids, principally steroids.
CHEBI:14517
CHEBI:25054
CHEBI:6486
KEGG COMPOUND:C01356
Lipid
lipid
lipids
CHEBI:18059
lipid
CHEBI:18059
A penicillin in which the substituent at position 6 of the penam ring is a phenylacetamido group.
7980
CHEBI:14743
CHEBI:25866
CHEBI:45073
CHEBI:7962
Beilstein:44740
ChemIDplus:61-33-6
CiteXplore:10930630
CiteXplore:11431418
CiteXplore:11906332
CiteXplore:12569987
CiteXplore:12850488
CiteXplore:1384868
CiteXplore:16033609
CiteXplore:1709917
CiteXplore:2083978
CiteXplore:6161899
CiteXplore:7602118
CiteXplore:7716788
DrugBank:DB01053
Gmelin:781913
KEGG COMPOUND:61-33-6
KEGG COMPOUND:C05551
KEGG DRUG:D02336
PDBeChem:PNN
Patent:US3024169
Reaxys:44740
Wikipedia:Penicillin_G
2,2-dimethyl-6beta-(phenylacetamido)penam-3alpha-carboxylic acid
Benzylpenicillin
(2S,5R,6R)-3,3-dimethyl-7-oxo-6-(phenylacetamido)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
6-(2-phenylacetamido)penicillanic acid
C16H18N2O4S
InChI=1S/C16H18N2O4S/c1-16(2)12(15(21)22)18-13(20)11(14(18)23-16)17-10(19)8-9-6-4-3-5-7-9/h3-7,11-12,14H,8H2,1-2H3,(H,17,19)(H,21,22)/t11-,12+,14-/m1/s1
InChIKey=JGSARLDLIJGVTE-MBNYWOFBSA-N
PENICILLIN G
PG
Penicillin G
[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)Cc1ccccc1)C(O)=O
bencilpenicilina
benzylpenicillin
benzylpenicilline
benzylpenicillinic acid
benzylpenicillinum
free penicillin II
CHEBI:18208
Penicillin G
benzylpenicillin
CHEBI:18208
CHEBI:1083
CHEBI:11394
CHEBI:11567
CHEBI:11568
CHEBI:19259
CHEBI:19560
CHEBI:4421
KEGG COMPOUND:C02269
KEGG COMPOUND:C03216
2'-Deoxynucleoside
2'-deoxynucleoside
2'-deoxyribonucleosides
2-Deoxy-D-ribosyl-base
Deoxynucleoside
CHEBI:18274
2'-deoxyribonucleoside
CHEBI:18274
A compound having the structure RC#N; thus a C-substituted derivative of hydrocyanic acid, HC#N. In systematic nomenclature, the suffix nitrile denotes the triply bound #N atom, not the carbon atom attached to it.
CHEBI:13212
CHEBI:13426
CHEBI:13660
CHEBI:25547
CHEBI:7584
KEGG COMPOUND:C00726
Nitrile
nitrile
nitriles
CNR
Nitril
R-CN
[*]C#N
nitrilos
CHEBI:18379
nitrile
CHEBI:18379
delta-lactone
1,5-lactone
1,5-lactones
delta-lactona
delta-lactonas
delta-lactones
CHEBI:18946
delta-lactone
CHEBI:18946
17-keto steroids
17-ketosteroids
17-oxo steroids
CHEBI:19168
17-oxo steroid
CHEBI:19168
purine 2'-deoxyribonucleosides
CHEBI:19254
purine 2'-deoxyribonucleoside
CHEBI:19254
pyrimidine 2'-deoxyribonucleosides
CHEBI:19255
pyrimidine 2'-deoxyribonucleoside
CHEBI:19255
Any aminopurine having the amino substituent at the 2-position.
2-aminopurines
CHEBI:20702
2-aminopurines
CHEBI:20702
A glycosyl compound arising formally from the elimination of water from a glycosidic hydroxy group and an H atom bound to a nitrogen atom, thus creating a C-N bond.
glycosylamine
N-glycoside
N-glycosides
N-glycosyl compounds
glycosylamines
CHEBI:21731
N-glycosyl compound
CHEBI:21731
Any of basic nitrogen compounds (mostly heterocyclic) occurring mostly in the plant kingdom (but not excluding those of animal origin). Amino acids, peptides, proteins, nucleotides, nucleic acids, amino sugars and antibiotics are not normally regarded as alkaloids. By extension, certain neutral compounds biogenetically related to basic alkaloids are included.
Alkaloid
alkaloids
Alkaloide
alcaloide
alcaloides
CHEBI:22315
alkaloid
CHEBI:22315
CHEBI:22327
alkyl sulfide
CHEBI:22327
An alcohol containing an amino functional group in addition to the alcohol-defining hydroxy group.
amino alcohols
aminoalcohol
aminoalcohols
CHEBI:22478
amino alcohol
CHEBI:22478
amino cyclitol glycoside
amino cyclitol glycosides
CHEBI:22479
amino cyclitol glycoside
CHEBI:22479
aminoglycoside antibiotics
CHEBI:22507
aminoglycoside antibiotic
CHEBI:22507
Any purine having at least one amino substituent.
aminopurines
CHEBI:22527
aminopurine
CHEBI:22527
anthracenequinones
anthraquinones
CHEBI:22580
anthraquinone
CHEBI:22580
Compounds containing the group -N3, and salts of hydrazoic acid, HN3.
azides
CHEBI:22680
azides
CHEBI:22680
Any member of the wide class of molecules that share the core azobenzene structure, comprising two phenyl rings linked by a N=N double bond, which may have different functional groups extending from the rings.
azobenzenes
CHEBI:22682
azobenzenes
CHEBI:22682
Pyrimidine-2,4,6(1H,3H,5H)-trione (barbituric acid) and derivatives. Largest group of the synthetic sedative/hypnotics, sharing a characteristic six-membered ring structure.
barbiturates
barbituric acids
CHEBI:22693
barbiturates
CHEBI:22693
CHEBI:22712
benzenes
CHEBI:22712
An organic heterocyclic compound containing a benzene ring fused to an imidazole ring.
CHEBI:22715
benzimidazoles
CHEBI:22715
CHEBI:22723
benzoic acids
CHEBI:22723
benzopyrroles
CHEBI:22728
benzopyrrole
CHEBI:22728
beta-D-glucoside
beta-D-glucosides
CHEBI:22798
beta-D-glucoside
CHEBI:22798
Benzenoid aromatic compounds containing two phenyl or substituted-phenyl groups which are joined together by a single bond.
CHEBI:22888
biphenyls
CHEBI:22888
An ester of carbamic acid.
carbamate esters
carbamates
CHEBI:23003
carbamate ester
CHEBI:23003
CHEBI:23007
carbohydrate-containing antibiotic
CHEBI:23007
A class of beta-lactam antibiotics differing from the penicillins in having a 6-membered, rather than a 5-membered, side ring.
CHEBI:3538
CiteXplore:12833570
CiteXplore:6762896
KEGG COMPOUND:C00875
Cephalosporin
C7H5NO3SR2
[H][C@]12SCC([*])=C(N1C(=O)[C@H]2[*])C(O)=O
cephalosporins
CHEBI:23066
cephalosporin
CHEBI:23066
CHEBI:23117
chlorine molecular entity
CHEBI:23117
A carbotricyclic compound comprising 5,6,7,9-tetrahydrobenzo[a]heptalene having four methoxy substituents at the 1-, 2-, 3- and 10-positions as well as an oxo group at the 9-position and an acetamido group at the 7-position.
2683
Beilstein:2228812
CiteXplore:9819133
NIST Chemistry WebBook:54192-66-4
Reaxys:2228812
N-(1,2,3,10-tetramethoxy-9-oxo-5,6,7,9-tetrahydrobenzo[a]heptalen-7-yl)acetamide
C22H25NO6
COc1cc2CCC(NC(C)=O)c3cc(=O)c(OC)ccc3-c2c(OC)c1OC
InChI=1S/C22H25NO6/c1-12(24)23-16-8-6-13-10-19(27-3)21(28-4)22(29-5)20(13)14-7-9-18(26-2)17(25)11-15(14)16/h7,9-11,16H,6,8H2,1-5H3,(H,23,24)
InChIKey=IAKHMKGGTNLKSZ-UHFFFAOYSA-N
CHEBI:23359
Colchicine
colchicine
CHEBI:23359
Any constitutionally or isotopically distinct atom, molecule, ion, ion pair, radical, radical ion, complex, conformer etc., identifiable as a separately distinguishable entity.
molecular entity
entidad molecular
entidades moleculares
entite moleculaire
molecular entities
molekulare Entitaet
CHEBI:23367
molecular entity
CHEBI:23367
Salts and C-organyl derivatives of hydrogen cyanide, HC#N.
cyanides
CHEBI:23424
cyanides
CHEBI:23424
cyclic amide
cyclic amides
CHEBI:23443
cyclic amide
CHEBI:23443
Cyclopeptid
Zyklopeptid
cyclic peptides
peptide cyclique
peptido ciclico
CHEBI:23449
cyclic peptide
CHEBI:23449
A polyol consisting of a cycloalkane containing at least three hydroxy groups, each attached to a different ring carbon atom.
cyclitols
CHEBI:23451
cyclitol
CHEBI:23451
CHEBI:23480
cyclohexanols
CHEBI:23480
deoxyribonucleosides
CHEBI:23636
deoxyribonucleoside
CHEBI:23636
diamines
CHEBI:23666
diamine
CHEBI:23666
Either one of a pair of heterocyclic organic compounds comprising three carbon atoms and two nitrogen atoms arranged in a ring.
diazoles
CHEBI:23677
diazole
CHEBI:23677
quinolones
CHEBI:23765
quinolone
CHEBI:23765
Any terpenoid having a C20 skeleton, derived from geranylgeranyl phosphate.
LIPID MAPS:LMPR0104
diterpenoids
C20 isoprenoids
diterpenoides
CHEBI:23849
diterpenoid
CHEBI:23849
ethanolamine
CHEBI:23981
ethanolamines
CHEBI:23981
fluorine molecular entity
fluorine compounds
fluorine molecular entities
CHEBI:24062
fluorine molecular entity
CHEBI:24062
Compounds containing at least one furan ring.
oxacyclopenta-2,4-dienes
CHEBI:24129
furans
CHEBI:24129
Glucocorticoids are a class of steroid hormones that regulate a variety of physiological processes, in particular control of the concentration of glucose in blood.
glucocorticoids
CHEBI:24261
glucocorticoid
CHEBI:24261
glucosides
CHEBI:24278
glucoside
CHEBI:24278
A glycosyl compound resulting from the attachment of a glycosyl group to a non-acyl group RO-, which itself may be derived from a saccharide and chalcogen replacements thereof (RS-, RSe-). The bond between the glycosyl group and the OR group is called a glycosidic bond. By extension, the terms N-glycosides and C-glycosides are used as class names for glycosylamines and for compounds having a glycosyl group attached to a hydrocarbyl group respectively. These terms are misnomers and should not be used. The preferred terms are glycosylamines and C-glycosyl compounds, respectively.
glycosides
O-glycoside
O-glycosides
glycosides
CHEBI:24400
glycoside
CHEBI:24400
A chemical entity is a physical entity of interest in chemistry including molecular entities, parts thereof, and chemical substances.
CHEBI:24431
chemical entity
CHEBI:24431
CHEBI:24436
guanidines
CHEBI:24436
halogen molecular entity
halogen compounds
halogen molecular entities
CHEBI:24471
halogen molecular entity
CHEBI:24471
CHEBI:24531
heterocyclic antibiotic
CHEBI:24531
A cyclic compound having as ring members atoms of carbon and at least of one other element.
organic heterocycle
organic heterocyclic compounds
CHEBI:24532
organic heterocyclic compound
CHEBI:24532
A homodetic cyclic peptide is a cyclic peptide in which the ring consists solely of amino-acid residues in peptide linkages.
homodetic cyclic peptide
homodetic cyclic peptides
peptide cyclique homodetique
peptido ciclico homodetico
CHEBI:24613
homodetic cyclic peptide
CHEBI:24613
CHEBI:24628
imidazolidine-2,4-dione
CHEBI:24628
Hydroxides are chemical compounds containing a hydroxy group or salts containing hydroxide (OH(-)).
CHEBI:24651
hydroxides
CHEBI:24651
CHEBI:24662
hydroxy-amino acid
CHEBI:24662
hydroxy carboxylic acids
CHEBI:24669
hydroxy carboxylic acid
CHEBI:24669
CHEBI:24734
hydroxyphenylalanine
CHEBI:24734
A five-membered organic heterocycle containing two nitrogen atoms at positions 1 and 3, or any of its derivatives; compounds containing an imidazole skeleton.
CHEBI:24780
imidazoles
CHEBI:24780
CHEBI:24803
indole-3-acetic acids
CHEBI:24803
indol-3-yl carboxylic acids
CHEBI:24810
indol-3-yl carboxylic acid
CHEBI:24810
Any compound containing an indole skeleton.
CHEBI:24828
indoles
CHEBI:24828
CHEBI:24829
indolones
CHEBI:24829
A compound which contains oxygen, at least one other element, and at least one hydrogen bound to oxygen, and which produces a conjugate base by loss of positive hydrogen ion(s) (hydrons).
oxoacid
oxoacids
oxacids
oxiacids
oxo acid
oxy-acids
oxyacids
CHEBI:24833
oxoacid
CHEBI:24833
iodine molecular entity
iodine compounds
iodine molecular entities
CHEBI:24860
iodine molecular entity
CHEBI:24860
Any lipid formally derived from isoprene (2-methylbuta-1,3-diene), the skeleton of which can generally be discerned in repeated occurrence in the molecule. The skeleton of isoprenoids may differ from strict additivity of isoprene units by loss or shift of a fragment, commonly a methyl group. The class includes both hydrocarbons and oxygenated derivatives.
CiteXplore:12769708
CiteXplore:19219049
LIPID MAPS:LMPR01
isoprenoid
isoprenoids
isoprenoids
CHEBI:24913
isoprenoid
CHEBI:24913
isoquinoline alkaloids
CHEBI:24921
isoquinoline alkaloid
CHEBI:24921
A benzopyridine with the nitrogen of the pyridine moiety in position 2.
CHEBI:24922
isoquinolines
CHEBI:24922
Cyclic amides of amino carboxylic acids, having a 1-azacycloalkan-2-one structure, or analogues having unsaturation or heteroatoms replacing one or more carbon atoms of the ring.
lactam
lactams
Laktam
Laktame
lactams
CHEBI:24995
lactam
CHEBI:24995
Any cyclic carboxylic ester containing a 1-oxacycloalkan-2-one structure, or an analogue having unsaturation or heteroatoms replacing one or more carbon atoms of the ring.
lactone
lactones
Lacton
Lakton
Laktone
lactona
lactonas
CHEBI:25000
lactone
CHEBI:25000
methylxanthines
CHEBI:25348
methylxanthine
CHEBI:25348
CHEBI:25359
modified amino acid
CHEBI:25359
An oxoacid containing a single carboxy group.
monocarboxylic acid
monocarboxylic acids
CHEBI:25384
monocarboxylic acid
CHEBI:25384
CHEBI:25418
morphinane alkaloid
CHEBI:25418
organonitrogen heterocyclic antibiotics
CHEBI:25558
organonitrogen heterocyclic antibiotic
CHEBI:25558
Any molecule that contains a small number (usually 2 to 10) amino-acid residues connected by peptide linkages.
oligopeptides
Oligopeptid
oligopeptido
CHEBI:25676
oligopeptide
CHEBI:25676
organic heteromonocyclic compounds
CHEBI:25693
organic heteromonocyclic compound
CHEBI:25693
A compound ROR (where R is not H).
ether
ethers
OR2
[*]O[*]
ethers
CHEBI:25698
ether
CHEBI:25698
Any compound that has an aldehydic or ketonic group as well as a carboxylic acid group in the same molecule.
oxo carboxylic acids
oxo acids
oxo carboxylic acids
CHEBI:25754
oxo carboxylic acid
CHEBI:25754
oxygen molecular entity
oxygen molecular entities
CHEBI:25806
oxygen molecular entity
CHEBI:25806
oxopurines
CHEBI:25810
oxopurine
CHEBI:25810
CHEBI:25865
penicillanic acids
CHEBI:25865
CHEBI:25985
phenylalanine derivative
CHEBI:25985
HP(=O)(OH)2 (phosphonic acid) and its P-substituted derivatives.
phosphonic acids
CHEBI:26069
phosphonic acids
CHEBI:26069
phosphorus molecular entities
CHEBI:26082
phosphorus molecular entity
CHEBI:26082
CHEBI:26144
piperazines
CHEBI:26144
CHEBI:26151
piperidines
CHEBI:26151
An adamantane that has formula C10H17N.
620
Beilstein:2204333
ChemIDplus:768-94-5
DrugBank:DB00915
Gmelin:27066
KEGG COMPOUND:768-94-5
KEGG COMPOUND:C06818
KEGG DRUG:D07441
NIST Chemistry WebBook:768-94-5
Wikipedia:Amantadine
Amantadine
adamantan-1-ylamine
1-adamantanamine
1-adamantylamine
1-aminoadamantane
Amantidine
Aminoadamantane
C10H17N
InChI=1S/C10H17N/c11-10-4-7-1-8(5-10)3-9(2-7)6-10/h7-9H,1-6,11H2
InChIKey=DKNWSYNQZKUICI-UHFFFAOYSA-N
NC12CC3CC(CC(C3)C1)C2
Viregyt
Virosol
amantadina
amantadine
amantadinum
tricyclo[3.3.1.1(3,7)]decan-1-amine
tricyclo[3.3.1.1(3,7)]decan-1-ylamine
tricyclo[3.3.1.1(3,7)]decane-1-amine
CHEBI:2618
Amantadine
amantadine
CHEBI:2618
A compound that contains three or more hydroxyl groups.
polyols
CHEBI:26191
polyol
CHEBI:26191
CHEBI:26292
propanone
CHEBI:26292
Derivatives of oxoacids RnE(=O)OH in which the hydroxy group is replaced by an amino group and the oxo group is replaced by =NR. In organic chemistry an unspecified amidine is commonly a carboxamidine.
amidine
amidines
Amidines
amidines
CHEBI:2634
amidine
CHEBI:2634
CHEBI:26373
pteridines
CHEBI:26373
purine alkaloids
CHEBI:26385
purine alkaloid
CHEBI:26385
purine nucleoside
purine nucleosides
CHEBI:26394
purine nucleoside
CHEBI:26394
Any compound containing purine as part of its structure.
CHEBI:13678
CHEBI:26401
purines
CHEBI:26401
pyridinemonocarboxylic acids
CHEBI:26420
pyridinemonocarboxylic acid
CHEBI:26420
CHEBI:26421
pyridines
CHEBI:26421
pyrimidine nucleosides
CHEBI:26440
pyrimidine nucleoside
CHEBI:26440
CHEBI:26455
pyrroles
CHEBI:26455
quinolinemonocarboxylic acids
CHEBI:26512
quinolinemonocarboxylic acid
CHEBI:26512
A class of aromatic heterocyclic compounds each of which contains a benzene ring ortho fused to carbons 2 and 3 of a pyridine ring.
CHEBI:26513
quinolines
CHEBI:26513
A 1-benzofuran that has formula C25H29I2NO3.
703
Beilstein:1271711
ChemIDplus:1951-25-3
KEGG COMPOUND:1951-25-3
KEGG COMPOUND:C06823
Wikipedia:Amiodarone
(2-butyl-1-benzofuran-3-yl){4-[2-(diethylamino)ethoxy]-3,5-diiodophenyl}methanone
Amiodarone
2-Butyl-3-(3,5-diiodo-4-(2-diethylaminoethoxy)benzoyl)benzofuran
2-Butyl-3-benzofuranyl 4-(2-(diethylamino)ethoxy)-3,5-diiodophenyl ketone
2-n-Butyl-3',5'-diiodo-4'-N-diethylaminoethoxy-3-benzoylbenzofuran
C25H29I2NO3
CCCCc1oc2ccccc2c1C(=O)c1cc(I)c(OCCN(CC)CC)c(I)c1
InChI=1S/C25H29I2NO3/c1-4-7-11-22-23(18-10-8-9-12-21(18)31-22)24(29)17-15-19(26)25(20(27)16-17)30-14-13-28(5-2)6-3/h8-10,12,15-16H,4-7,11,13-14H2,1-3H3
InChIKey=IYIKLHRQXLHMJQ-UHFFFAOYSA-N
CHEBI:2663
Amiodarone
amiodarone
CHEBI:2663
A tricyclic antidepressant that has formula C20H23N.
704
Beilstein:2217885
ChemIDplus:50-48-6
KEGG COMPOUND:50-48-6
KEGG COMPOUND:C06824
NIST Chemistry WebBook:50-48-6
Wikipedia:Amitriptyline
3-(10,11-dihydro-5H-dibenzo[a,d][7]annulen-5-ylidene)-N,N-dimethylpropan-1-amine
Amitriptyline
10,11-dihydro-5-(gamma-dimethylaminopropylidene)-5H-dibenzo(a,d)cycloheptene
10,11-dihydro-N,N-dimethyl-5H-dibenzo(a,d)heptalene-Delta(5),gamma-propylamine
3-(10,11-dihydro-5H-dibenzo(a,d)cyclohepten-5-ylidene)-N,N-dimethyl-1-propanamine
3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N,N-dimethylpropan-1-amine
5-(3-dimethylaminopropylidene)-10,11-dihydro-5H-dibenzo(a,d)cycloheptatriene
5-(3-dimethylaminopropylidene)-10,11-dihydro-5H-dibenzo(a,d)cycloheptene
5-(gamma-dimethylaminopropylidene)-5H-dibenzo[a,d][1,4]cycloheptadiene
Amitriptylin
C20H23N
CN(C)CCC=C1c2ccccc2CCc2ccccc12
InChI=1S/C20H23N/c1-21(2)15-7-12-20-18-10-5-3-8-16(18)13-14-17-9-4-6-11-19(17)20/h3-6,8-12H,7,13-15H2,1-2H3
InChIKey=KRMDCWKBEZIMAB-UHFFFAOYSA-N
CHEBI:2666
Amitriptyline
amitriptyline
CHEBI:2666
A fully substituted dialkyl 1,4-dihydropyridine-3,5-dicarboxylate derivative, which is used for the treatment of hypertension, chronic stable angina and confirmed or suspected vasospastic angina.
17767
Beilstein:3570229
ChemIDplus:88150-42-9
DrugBank:88150-42-9
DrugBank:DB00381
KEGG COMPOUND:88150-42-9
KEGG COMPOUND:C06825
KEGG DRUG:88150-42-9
KEGG DRUG:D07450
Patent:EP89167
Patent:US4572909
Wikipedia:Amlodipine
3-ethyl 5-methyl 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate
3-Ethyl-5-methyl (+-)-2-(2-aminoethoxymethyl)-4-(o-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate
Amlodipine Free Base
C20H25ClN2O5
CCOC(=O)C1=C(COCCN)NC(C)=C(C1c1ccccc1Cl)C(=O)OC
InChI=1S/C20H25ClN2O5/c1-4-28-20(25)18-15(11-27-10-9-22)23-12(2)16(19(24)26-3)17(18)13-7-5-6-8-14(13)21/h5-8,17,23H,4,9-11,22H2,1-3H3
InChIKey=HTIQEAQVCYTUBX-UHFFFAOYSA-N
amlodipine
amlodipino
amlodipinum
CHEBI:2668
Amlodipine
amlodipine
CHEBI:2668
Any steroid that act as hormone.
Steroidhormon
Steroidhormone
hormona esteroide
hormonas esteroideas
hormone steroide
hormones steroides
steroid hormones
CHEBI:26764
steroid hormone
CHEBI:26764
CHEBI:26788
streptomycins
CHEBI:26788
CHEBI:26822
sulfide
CHEBI:26822
sulfur molecular entity
sulfur molecular entities
CHEBI:26835
sulfur molecular entity
CHEBI:26835
Any natural product or related compound formally derived from isoprene units. Terpenoids may contain oxygen in various functional groups. This class is subdivided according to the number of carbon atoms in the same manner as are terpenes. The skeleton of terpenoids may differ from strict additivity of isoprene units by the loss or shift of a fragment, generally a methyl group.
Terpenoid
terpenoids
terpenoide
terpenoides
CHEBI:26873
terpenoid
CHEBI:26873
A tertiary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has three other carbon atoms attached to it.
tertiary alcohol
C4H7OR3
OC(C[*])(C[*])C[*]
tertiary alcohols
CHEBI:26878
tertiary alcohol
CHEBI:26878
Any oxacycle having an oxolane (tetrahydrofuran) skeleton.
CHEBI:26912
oxolanes
CHEBI:26912
heterotricyclic compounds
organic heterotricyclic compounds
CHEBI:26979
organic heterotricyclic compound
CHEBI:26979
A 1,2,4-triazole compound having a 3,5-bis(2-cyano-2-propyl)benzyl group at the 1-position.
84857
Beilstein:8005958
ChemIDplus:120511-73-1
DrugBank:120511-73-1
DrugBank:DB01217
KEGG COMPOUND:120511-73-1
KEGG COMPOUND:C08159
KEGG DRUG:120511-73-1
KEGG DRUG:D00960
Patent:EP296749
Patent:US4935437
Wikipedia:Anastrozole
2,2'-[5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-phenylene]bis(2-methylpropanenitrile)
Anastrozol
C17H19N5
CC(C)(C#N)c1cc(Cn2cncn2)cc(c1)C(C)(C)C#N
InChI=1S/C17H19N5/c1-16(2,9-18)14-5-13(8-22-12-20-11-21-22)6-15(7-14)17(3,4)10-19/h5-7,11-12H,8H2,1-4H3
InChIKey=YBBLVLTVTVSKRW-UHFFFAOYSA-N
alpha,alpha,alpha',alpha'-Tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile
anastrozole
CHEBI:2704
anastrozole
CHEBI:2704
trimethylxanthines
CHEBI:27134
trimethylxanthine
CHEBI:27134
Tryptamine and its substitution derivatives.
CHEBI:27162
tryptamines
CHEBI:27162
heterobicyclic compounds
organic heterobicyclic compounds
CHEBI:27171
organic heterobicyclic compound
CHEBI:27171
CHEBI:27267
valine derivative
CHEBI:27267
A group of indole-indoline dimers which are alkaloids obtained from the Vinca genus of plants.
vinca alkaloid
vinca alkaloids
vincaleukoblastines
CHEBI:27288
vinca alkaloid
CHEBI:27288
A penicillin compound having a 6beta-(phenoxyacetyl)amino side chain.
7984
CHEBI:25868
CHEBI:44947
CHEBI:7966
Beilstein:96259
ChemIDplus:87-08-1
CiteXplore:10930630
CiteXplore:12569987
CiteXplore:14687482
CiteXplore:16033609
CiteXplore:8566082
KEGG COMPOUND:87-08-1
KEGG COMPOUND:C08126
KEGG DRUG:D05411
PDBeChem:PNV
Reaxys:96259
Wikipedia:Phenoxymethylpenicillin
2,2-dimethyl-6beta-[(phenoxyacetyl)amino]penam-3alpha-carboxylic acid
3,3-dimethyl-6beta-[(phenoxyacetyl)amino]penam-2alpha-carboxylic acid (PIN)
(2S,5R,6R)-3,3-DIMETHYL-7-OXO-6-(2-PHENOXYACETAMIDO)-4-THIA-1- AZABICYCLO(3.2.0)HEPTANE-2-CARBOXYLIC ACID
(2S,5R,6R)-3,3-dimethyl-7-oxo-6-[(phenoxyacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
6-phenoxyacetamidopenicillanic acid
C16H18N2O5S
Fenospen
InChI=1S/C16H18N2O5S/c1-16(2)12(15(21)22)18-13(20)11(14(18)24-16)17-10(19)8-23-9-6-4-3-5-7-9/h3-7,11-12,14H,8H2,1-2H3,(H,17,19)(H,21,22)/t11-,12+,14-/m1/s1
InChIKey=BPLBGHOLXOTWMN-MBNYWOFBSA-N
Oracillin
PV
Penicillin V
V-Cillin
[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)COc1ccccc1)C(O)=O
fenoximetilpenicilina
penicillin phenoxymethyl
phenoxomethylpenicillin
phenoxymethylenepenicillinic acid
phenoxymethylpenicillin
phenoxymethylpenicilline
phenoxymethylpenicillinum
CHEBI:27446
Penicillin V
phenoxymethylpenicillin
CHEBI:27446
A trimethylxanthine that has formula C8H10N4O2.
1886
CHEBI:22982
CHEBI:3295
CHEBI:41472
Beilstein:17705
ChemIDplus:58-08-2
DrugBank:DB00201
Gmelin:103040
KEGG COMPOUND:58-08-2
KEGG COMPOUND:C07481
KEGG DRUG:D00528
NIST Chemistry WebBook:58-08-2
PDBeChem:CFF
Wikipedia:Caffeine
1,3,7-trimethyl-3,7-dihydro-1H-purine-2,6-dione
CAFFEINE
Caffeine
1,3,7-trimethyl-2,6-dioxopurine
1,3,7-trimethylpurine-2,6-dione
1,3,7-trimethylxanthine
1-methyltheobromine
3,7-Dihydro-1,3,7-trimethyl-1H-purin-2,6-dion
7-methyltheophylline
C8H10N4O2
Cn1cnc2n(C)c(=O)n(C)c(=O)c12
Coffein
InChI=1S/C8H10N4O2/c1-10-4-9-6-5(10)7(13)12(3)8(14)11(6)2/h4H,1-3H3
InChIKey=RYYVLZVUVIJVGH-UHFFFAOYSA-N
Koffein
Thein
anhydrous caffeine
cafeina
cafeine
guaranine
mateina
methyltheobromine
teina
theine
CHEBI:27732
Caffeine
caffeine
CHEBI:27732
A platinum-containing anticancer drug that interacts with, and forms cross-links between, DNA and proteins. It is used as a neoplasm inhibitor to treat solid tumours, primarily of the testis and ovary.
2555
CHEBI:23314
CHEBI:3722
ChemIDplus:15663-27-1
DrugBank:DB00515
Gmelin:2519
KEGG COMPOUND:15663-27-1
KEGG COMPOUND:C06911
KEGG DRUG:D00275
MolBase:25
Patent:DE2318020
Patent:DE2329485
(SP-4-2)-diamminedichloridoplatinum
(SP-4-2)-diamminedichloroplatinum
Cisplatin
cis-diamminedichloridoplatinum(II)
cis-diamminedichloroplatinum(II)
Briplatin
Cismaplat
Cl2H6N2Pt
H6Cl2N2Pt
InChI=1S/2ClH.2H3N.Pt/h2*1H;2*1H3;/q;;;;+2/p-2
InChIKey=LXZZYRPGZAFOLE-UHFFFAOYSA-L
Lederplatin
Neoplatin
Peyrone's chloride
Peyrone's salt
Platamine
Platinex
Platinol
Randa
[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]
cis-DDP
cis-[PtCl2(NH3)2]
cis-diamminedichloroplatinum
cis-diammineplatinum(II) dichloride
cis-dichlorodiammineplatinum(II)
cisplatin
cisplatine
cisplatino
cisplatinum
CHEBI:27899
Cisplatin
cisplatin
CHEBI:27899
CHEBI:10427
CHEBI:22844
CHEBI:27933
beta-lactam antibiotic
CHEBI:27933
A amino cyclitol glycoside that is kanamycin B lacking the 3-hydroxy substituent from the 2,6-diaminoglucose ring.
10627
CHEBI:19849
CHEBI:45933
CHEBI:9610
ChemIDplus:32986-56-4
CiteXplore:11000679
CiteXplore:11072877
CiteXplore:11459219
CiteXplore:11478352
CiteXplore:14961139
CiteXplore:15813341
CiteXplore:16205136
CiteXplore:16239129
CiteXplore:16478137
CiteXplore:16650821
CiteXplore:17150225
CiteXplore:18331849
CiteXplore:19072156
CiteXplore:19220547
CiteXplore:19340717
CiteXplore:19465435
CiteXplore:20000576
CiteXplore:20884302
CiteXplore:20938669
CiteXplore:21275493
CiteXplore:21343445
CiteXplore:21357290
CiteXplore:21396748
CiteXplore:21414310
CiteXplore:21429824
CiteXplore:21438171
CiteXplore:21530479
CiteXplore:21592592
CiteXplore:21726492
CiteXplore:21756818
CiteXplore:21796931
CiteXplore:21815282
KEGG COMPOUND:32986-56-4
KEGG COMPOUND:C00397
KEGG DRUG:D00063
PDBeChem:TOY
Reaxys:1357507
Wikipedia:Tobramycin
(1S,2S,3R,4S,6R)-4,6-diamino-3-(2,6-diamino-2,3,6-trideoxy-alpha-D-ribo-hexopyranosyloxy)-2-hydroxycyclohexyl 3-amino-3-deoxy-alpha-D-glucopyranoside
Tobramycin
3'-Deoxykanamycin B
C18H37N5O9
InChI=1S/C18H37N5O9/c19-3-9-8(25)2-7(22)17(29-9)31-15-5(20)1-6(21)16(14(15)28)32-18-13(27)11(23)12(26)10(4-24)30-18/h5-18,24-28H,1-4,19-23H2/t5-,6+,7+,8-,9+,10+,11-,12+,13+,14-,15+,16-,17+,18+/m0/s1
InChIKey=NLVFBUXFDBBNBW-PBSUHMDJSA-N
NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)C[C@@H]1O
Nebramycin 6
Nebramycin factir 6
O-3-Amino-3-deoxy-alpha-D-glucopyranosyl-(1-4)-O-(2,6-diamino-2,3,6-trideoxy-alpha-D-ribohexopyranosyl-(1-4))-2-deoxy-D-streptamine
Tobracin (TN)
Tobrex (TN)
CHEBI:28864
Tobramycin
tobramycin
CHEBI:28864
CHEBI:13211
CHEBI:22207
CHEBI:25383
CHEBI:6977
monocarboxylic acid amide
monocarboxylic acid amides
CHEBI:29347
monocarboxylic acid amide
CHEBI:29347
A monocarboxylic acid amide derived from a fatty acid.
CHEBI:13247
CHEBI:22310
CHEBI:22330
CHEBI:2572
CHEBI:35749
CHEBI:38838
KEGG COMPOUND:C02244
LIPID MAPS:LMFA08
fatty amide
Aliphatic amide
CHNOR2
an aliphatic amide
fatty amides
CHEBI:29348
fatty amide
CHEBI:29348
3-Aminopropane-1,2-diol in which the hydrogen of the primary hydoxy is substituted by a 4-[2-(cyclopropylmethoxy)ethyl]phenyl group and one of the hydrogens attached to the amino group is substituted by isopropyl. It is a selective beta1-receptor blocker and is used in the treatment of glaucoma as well as hypertension, arrhythmias, and coronary heart disease. It is also used to reduce non-fatal cardiac events in patients with heart failure.
1520
CHEBI:101354
Beilstein:1991268
ChEMBL:101354
ChEMBL:10891117
ChEMBL:1361581
ChEMBL:14971904
ChEMBL:15993593
ChemIDplus:63659-18-7
DrugBank:DB00195
KEGG COMPOUND:63659-18-7
KEGG COMPOUND:C06849
KEGG DRUG:D07526
Patent:DE2649605
Patent:US4252984
Wikipedia:Betaxolol
1-{4-[2-(cyclopropylmethoxy)ethyl]phenoxy}-3-(propan-2-ylamino)propan-2-ol
1-(4-(2-(cyclopropylmethoxy)ethyl)phenoxy)-3-((1-methylethyl)amino)-2-propanol
1-(isopropylamino)-3-[p-(cyclopropylmethoxyethyl)phenoxy]-2-propanol
C18H29NO3
CC(C)NCC(O)COc1ccc(CCOCC2CC2)cc1
InChI=1S/C18H29NO3/c1-14(2)19-11-17(20)13-22-18-7-5-15(6-8-18)9-10-21-12-16-3-4-16/h5-8,14,16-17,19-20H,3-4,9-13H2,1-2H3
InChIKey=NWIUTZDMDHAVTP-UHFFFAOYSA-N
betaxolol
betaxololum
CHEBI:3082
Betaxolol
betaxolol
CHEBI:3082
A compound in which a hydroxy group, -OH, is attached to a saturated carbon atom.
CHEBI:13804
CHEBI:22288
CHEBI:2553
KEGG COMPOUND:C00069
Alcohol
alcohols
CHOR3
HOR
OC([*])([*])[*]
CHEBI:30879
alcohol
CHEBI:30879
A carboxamide that has formula C18H14F4N2O4S.
83008
Beilstein:5364666
ChemIDplus:90357-06-5
DrugBank:DB01128
KEGG COMPOUND:C08160
KEGG DRUG:D00961
Patent:EP100172
Patent:US4636505
Wikipedia:Bicalutamide
(2R)-N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide
C18H14F4N2O4S
C[C@](O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(c1)C(F)(F)F
Casodex
InChI=1S/C18H14F4N2O4S/c1-17(26,10-29(27,28)14-6-3-12(19)4-7-14)16(25)24-13-5-2-11(9-23)15(8-13)18(20,21)22/h2-8,26H,10H2,1H3,(H,24,25)/t17-/m0/s1
InChIKey=LKJPYSCBVHEWIU-KRWDZBQOSA-N
bicalutamida
bicalutamide
bicalutamidum
CHEBI:3090
bicalutamide
CHEBI:3090
A platinum coordination entity that has formula C6H12N2O4Pt.
40048
ChemIDplus:41575-94-4
Gmelin:1044703
Gmelin:51428
KEGG DRUG:41575-94-4
KEGG DRUG:D01363
(SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum
Carboplatin
C6H12N2O4Pt
C6H6O4Pt.2H3N
InChI=1S/C6H8O4.2H3N.Pt/c7-4(8)6(5(9)10)2-1-3-6;;;/h1-3H2,(H,7,8)(H,9,10);2*1H3;/q;;;+2/p-2
InChIKey=OLESAACUTLOWQZ-UHFFFAOYSA-L
Paraplatin
[H][N]([H])([H])[Pt]1(OC(=O)C2(CCC2)C(=O)O1)[N]([H])([H])[H]
cbdca
cis-(1,1-cyclobutanedicarboxylato)diammineplatinum(II)
cis-diammine(1,1-cyclobutanedicarboxylato)platinum
cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II)
CHEBI:31355
Carboplatin
carboplatin
CHEBI:31355
CHEBI:31577
ethylenediamine derivatives
CHEBI:31577
An indole alkaloid that has formula C32H40BrN5O5.
1760
Beilstein:741357
ChemIDplus:25614-03-3
DrugBank:DB01200
KEGG COMPOUND:25614-03-3
KEGG COMPOUND:C06856
KEGG DRUG:D03165
Patent:DE1926045
Patent:US3752814
Wikipedia:Bromocriptine
(5'alpha)-2-bromo-12'-hydroxy-5'-(2-methylpropyl)-2'-(propan-2-yl)-3',6',18-trioxoergotaman
Bromocriptine
(5'alpha)-2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-3',6',18-trioxoergotaman
(5'alpha)-2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)ergotaman-3',6',18-trione
(5'alpha)-2-bromo-12'-hydroxy-5'-isobutyl-2'-isopropyl-3',6',18-trioxoergotaman
2-bromo-alpha-ergocryptine
2-bromo-alpha-ergokryptin
2-bromo-alpha-ergokryptine
C32H40BrN5O5
InChI=1S/C32H40BrN5O5/c1-16(2)12-24-29(40)37-11-7-10-25(37)32(42)38(24)30(41)31(43-32,17(3)4)35-28(39)18-13-20-19-8-6-9-22-26(19)21(27(33)34-22)14-23(20)36(5)15-18/h6,8-9,13,16-18,23-25,34,42H,7,10-12,14-15H2,1-5H3,(H,35,39)/t18-,23-,24+,25+,31-,32+/m1/s1
InChIKey=OZVBMTJYIDMWIL-AYFBDAFISA-N
[H][C@@]12Cc3c(Br)[nH]c4cccc(C1=C[C@H](CN2C)C(=O)N[C@@]1(O[C@]2(O)N([C@@H](CC(C)C)C(=O)N5CCC[C@@]25[H])C1=O)C(C)C)c34
bromocriptine
bromocriptinum
bromocryptine
bromoergocriptine
CHEBI:3181
Bromocriptine
bromocriptine
CHEBI:3181
A platinum coordination entity that has formula C6H14N2.C2O4.Pt.
32592
ChemIDplus:63121-00-6
DrugBank:DB00526
Gmelin:1046012
Gmelin:28892
KEGG COMPOUND:61825-94-3
KEGG COMPOUND:C13258
KEGG DRUG:D01790
(SP-4-2)[(1R,2R)-cyclohexane-1,2-diamine-kappa(2)N,N'][ethanedioato(2-)-kappa(2)O(1),O(2)]platinum
Oxaliplatin
(SP-4-2-(1R-trans))-(1,2-cyclohexanediamine-N,N')(ethanedioato(2-)-O,O')platinum
C6H14N2.C2O4.Pt
C8H14N2O4Pt
Eloxatin
InChI=1S/C6H14N2.C2H2O4.Pt/c7-5-3-1-2-4-6(5)8;3-1(4)2(5)6;/h5-6H,1-4,7-8H2;(H,3,4)(H,5,6);/q;;+2/p-2/t5-,6-;;/m1../s1
InChIKey=ZROHGHOFXNOHSO-BNTLRKBRSA-L
[H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
oxalato(1,2-diaminocyclohexane)platinum(II)
oxaliplatin
oxaliplatine
oxaliplatino
oxaliplatinum
CHEBI:31941
oxaliplatin
CHEBI:31941
A propanone that has formula C13H18ClNO.
42347
ChemIDplus:2101062
ChemIDplus:34911-55-2
KEGG COMPOUND:34841-39-9
KEGG COMPOUND:C06860
Wikipedia:Bupropion
2-(tert-butylamino)-1-(3-chlorophenyl)propan-1-one
Bupropion
C13H18ClNO
CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1
InChI=1S/C13H18ClNO/c1-9(15-13(2,3)4)12(16)10-6-5-7-11(14)8-10/h5-9,15H,1-4H3
InChIKey=SNPPWIUOZRMYNY-UHFFFAOYSA-N
CHEBI:3219
Bupropion
bupropion
CHEBI:3219
An azaspiro compound that has formula C21H31N5O2.
1827
Beilstein:964904
ChemIDplus:36505-84-7
DrugBank:DB00490
KEGG COMPOUND:36505-84-7
KEGG COMPOUND:C06861
KEGG DRUG:D07593
Patent:DE2057845
Patent:US3717634
Wikipedia:Buspirone
8-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]-8-azaspiro[4.5]decane-7,9-dione
Buspirone
8-(4-(4-(2-Pyrimidinyl)-1-piperizinyl)butyl)-8-azaspiro(4,5)decane-7,9-dione
C21H31N5O2
InChI=1S/C21H31N5O2/c27-18-16-21(6-1-2-7-21)17-19(28)26(18)11-4-3-10-24-12-14-25(15-13-24)20-22-8-5-9-23-20/h5,8-9H,1-4,6-7,10-17H2
InChIKey=QWCRAEMEVRGPNT-UHFFFAOYSA-N
O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)c1ncccn1
buspirona
buspirone
buspironum
CHEBI:3223
Buspirone
buspirone
CHEBI:3223
A compound formally derived from ammonia by replacing three hydrogen atoms by hydrocarbyl groups.
CHEBI:26879
CHEBI:9458
KEGG COMPOUND:C02196
Tertiary amine
tertiary amines
NR3
R3N
[*]N([*])[*]
tertiaeres Amin
CHEBI:32876
tertiary amine
CHEBI:32876
A compound formally derived from ammonia by replacing one hydrogen atom by a hydrocarbyl group.
CHEBI:26263
CHEBI:26265
CHEBI:8407
CHEBI:8409
KEGG COMPOUND:C00893
KEGG COMPOUND:C02580
Primary amine
primary amines
H2NR
N[*]
Primary monoamine
R-NH2
primaeres Amin
CHEBI:32877
primary amine
CHEBI:32877
A compound formally derived from ammonia by replacing one, two or three hydrogen atoms by hydrocarbyl groups.
CHEBI:13814
CHEBI:22474
CHEBI:2641
KEGG COMPOUND:C00706
Amine
amines
Amin
an amine
CHEBI:32952
amine
CHEBI:32952
An amide is a derivative of an oxoacid RkE(=O)l(OH)m (l =/= 0) in which an acidic hydroxy group has been replaced by an amino or substituted amino group.
CHEBI:22473
CHEBI:2633
KEGG COMPOUND:C00241
Amide
amides
CHEBI:32988
amide
CHEBI:32988
An assembly consisting of a central atom (usually metallic) to which is attached a surrounding array of other groups of atoms (ligands).
coordination entities
coordination entity
coordination compounds
CHEBI:33240
coordination entity
CHEBI:33240
oxoacid derivatives
CHEBI:33241
oxoacid derivative
CHEBI:33241
A derivative of an oxoacid RkE(=O)l(OH)m (l =/= 0) in which an acidic hydroxy group has been replaced by an amino or substituted amino group.
primary amide
primary amides
CHEBI:33256
primary amide
CHEBI:33256
An organosulfur compound is a compound containing at least one carbon-sulfur bond.
CHEBI:23010
CHEBI:25714
Wikipedia:Organosulfur_compounds
organosulfur compound
organosulfur compounds
CHEBI:33261
organosulfur compound
CHEBI:33261
A heteroorganic entity is an organic molecular entity in which carbon atoms or organic groups are bonded directly to one or more heteroatoms.
heteroorganic entities
organoelement compounds
CHEBI:33285
heteroorganic entity
CHEBI:33285
pnictogen molecular entity
pnictogen molecular entities
CHEBI:33302
pnictogen molecular entity
CHEBI:33302
Any p-block molecular entity containing a chalcogen.
chalcogen molecular entity
chalcogen compounds
chalcogen molecular entities
CHEBI:33304
chalcogen molecular entity
CHEBI:33304
An ester of a carboxylic acid.
CHEBI:13204
CHEBI:23028
CHEBI:3408
KEGG COMPOUND:C02391
Carboxylic ester
carboxylic ester
carboxylic esters
CO2R2
carboxylic acid esters
CHEBI:33308
carboxylic ester
CHEBI:33308
sulfur oxoacid derivative
sulfur oxoacid derivatives
CHEBI:33424
sulfur oxoacid derivative
CHEBI:33424
A molecular entity containing one or more atoms of a transition element.
transition element molecular entities
transition metal molecular entity
CHEBI:33497
transition element molecular entity
CHEBI:33497
sulfonic acid derivative
derivatives of sulfonic acid
sulfonic acid derivatives
CHEBI:33552
sulfonic acid derivative
CHEBI:33552
An oxoacid acid carrying at least one -C(=O)OH group and having the structure RC(=O)OH, where R is any any monovalent functional group. Carboxylic acids are the most common type of organic acid.
CHEBI:13428
CHEBI:13627
CHEBI:23027
CiteXplore:17147560
CiteXplore:18433345
carboxylic acid
carboxylic acids
CHO2R
Carbonsaeure
Carbonsaeuren
Karbonsaeure
OC([*])=O
RC(=O)OH
acide carboxylique
acides carboxyliques
acido carboxilico
acidos carboxilicos
CHEBI:33575
carboxylic acid
CHEBI:33575
A molecular entity containing one or more atoms from any of groups 1, 2, 13, 14, 15, 16, 17, and 18 of the periodic table.
main group compounds
main group molecular entities
CHEBI:33579
main group molecular entity
CHEBI:33579
carbon group molecular entity
carbon group molecular entities
CHEBI:33582
carbon group molecular entity
CHEBI:33582
cyclic compounds
CHEBI:33595
cyclic compound
CHEBI:33595
A cyclic compound having as ring members atoms of the same element only.
homocyclic compound
homocyclic compounds
isocyclic compounds
CHEBI:33597
homocyclic compound
CHEBI:33597
A cyclic compound in which all of the ring members are carbon atoms.
carbocyclic compound
carbocyclic compounds
carbocycle
CHEBI:33598
carbocyclic compound
CHEBI:33598
A compound having one atom as the only common member of two rings.
spiro compound
spiro compounds
spiro-fused compounds
spirofused compounds
CHEBI:33599
spiro compound
CHEBI:33599
hydrogen compounds
hydrogen molecular entities
CHEBI:33608
hydrogen molecular entity
CHEBI:33608
polycyclic compounds
CHEBI:33635
polycyclic compound
CHEBI:33635
A molecule that features two fused rings.
bicyclic compounds
CHEBI:33636
bicyclic compound
CHEBI:33636
Any acyclic or cyclic, saturated or unsaturated carbon compound, excluding aromatic compounds.
aliphatic compounds
CHEBI:33653
aliphatic compound
CHEBI:33653
An aliphatic compound having a carbocyclic ring structure which may be saturated or unsaturated, but may not be a benzenoid or other aromatic system.
alicyclic compounds
CHEBI:33654
alicyclic compound
CHEBI:33654
A cyclically conjugated molecular entity with a stability (due to delocalization) significantly greater than that of a hypothetical localized structure (e.g. Kekule structure) is said to possess aromatic character.
aromatic compounds
aromatic molecular entity
aromatics
aromatische Verbindungen
CHEBI:33655
aromatic compound
CHEBI:33655
organic aromatic compounds
CHEBI:33659
organic aromatic compound
CHEBI:33659
monocyclic compounds
CHEBI:33661
monocyclic compound
CHEBI:33661
heteromonocyclic compound
heteromonocyclic compounds
CHEBI:33670
heteromonocyclic compound
CHEBI:33670
heteropolycyclic compounds
polyheterocyclic compounds
CHEBI:33671
heteropolycyclic compound
CHEBI:33671
A bicyclic compound in which at least one of the rings contains at least one skeletal heteroatom.
heterobicyclic compounds
CHEBI:33672
heterobicyclic compound
CHEBI:33672
An s-block molecular entity is a molecular entity containing one or more atoms of an s-block element.
s-block molecular entity
s-block compounds
s-block molecular entities
CHEBI:33674
s-block molecular entity
CHEBI:33674
A p-block molecular entity is a molecular entity containing one or more atoms of a p-block element.
p-block compounds
p-block molecular entities
p-block molecular entitiy
CHEBI:33675
p-block molecular entity
CHEBI:33675
A d-block molecular entity is a molecular entity containing one or more atoms of a d-block element.
d-block molecular entity
d-block compounds
d-block molecular entities
CHEBI:33676
d-block molecular entity
CHEBI:33676
A carboxylic acid containing one or more amino groups.
CHEBI:13815
CHEBI:22477
Aminocarbonsaeure
Aminokarbonsaeure
Aminosaeure
amino acids
CHEBI:33709
amino acid
CHEBI:33709
A capsaicinoid that has formula C18H27NO3.
1992
Beilstein:2816484
ChemIDplus:404-86-4
KEGG COMPOUND:404-86-4
KEGG COMPOUND:C06866
KEGG DRUG:D00250
Wikipedia:Capsaicin
(6E)-N-(4-hydroxy-3-methoxybenzyl)-8-methylnon-6-enamide
Capsaicin
(E)-8-Methyl-N-vanillyl-6-nonenamide
C18H27NO3
COc1cc(CNC(=O)CCCC\C=C\C(C)C)ccc1O
InChI=1S/C18H27NO3/c1-14(2)8-6-4-5-7-9-18(21)19-13-15-10-11-16(20)17(12-15)22-3/h6,8,10-12,14,20H,4-5,7,9,13H2,1-3H3,(H,19,21)/b8-6+
InChIKey=YKPUWZUDDOIDPM-SOFGYWHQSA-N
Isodecenoic acid vanillylamide
Zostrix
trans-8-Methyl-N-vanillyl-6-nonenamide
CHEBI:3374
Capsaicin
capsaicin
CHEBI:3374
copper group molecular entity
copper group molecular entities
CHEBI:33745
copper group molecular entity
CHEBI:33745
nickel group molecular entity
nickel group molecular entities
CHEBI:33747
nickel group molecular entity
CHEBI:33747
platinum molecular entity
platinum compounds
platinum molecular entities
CHEBI:33749
platinum molecular entity
CHEBI:33749
An organic compound having at least one hydroxy group attached to a carbon atom.
hydroxy compounds
organic hydroxy compounds
CHEBI:33822
organic hydroxy compound
CHEBI:33822
organic cyclic compounds
CHEBI:33832
organic cyclic compound
CHEBI:33832
A heterocyclic compound formally derived from an arene by replacement of one or more methine (-C=) and/or vinylene (-CH=CH-) groups by trivalent or divalent heteroatoms, respectively, in such a way as to maintain the continuous pi-electron system characteristic of aromatic systems and a number of out-of-plane pi-electrons corresponding to the Hueckel rule (4n+2).
heteroarenes
hetarenes
CHEBI:33833
heteroarene
CHEBI:33833
benzenoid aromatic compounds
benzenoid compound
CHEBI:33836
benzenoid aromatic compound
CHEBI:33836
Nucleosides are ribosyl or deoxyribosyl derivatives of the pyrimidine or purine bases adenine, guanine, xanthine, thymine, cytosine, and uracil.
CHEBI:13661
CHEBI:25611
CHEBI:7647
KEGG COMPOUND:C00801
Nucleoside
nucleoside
nucleosides
C5H9O4R
nucleosides
CHEBI:33838
nucleoside
CHEBI:33838
Compounds having one or more hydroxy groups attached to a benzene or other arene ring.
CHEBI:13664
CHEBI:13825
CHEBI:25969
CHEBI:2857
KEGG COMPOUND:C15584
MetaCyc:Aryl-Alcohol
phenols
Aryl alcohol
arenols
aryl alcohol
CHEBI:33853
phenols
CHEBI:33853
An amine in which the amino group is linked directly to an aromatic system.
CHEBI:22622
CHEBI:2834
aromatic amines
CHEBI:33860
aromatic amine
CHEBI:33860
transition element coordination entities
transition metal coordination compounds
transition metal coordination entities
CHEBI:33861
transition element coordination entity
CHEBI:33861
platinum coordination entity
platinum coordination compounds
platinum coordination entities
CHEBI:33862
platinum coordination entity
CHEBI:33862
gold molecular entity
gold compounds
gold molecular entities
CHEBI:33969
gold molecular entity
CHEBI:33969
gold coordination compounds
gold coordination entities
CHEBI:33971
gold coordination entity
CHEBI:33971
CHEBI:22721
CHEBI:35259
benzofurans
CHEBI:35259
A polyclic compound in which all of the ring members are carbon atoms.
carbopolycyclic compounds
CHEBI:35294
carbopolycyclic compound
CHEBI:35294
homopolycyclic compounds
CHEBI:35295
homopolycyclic compound
CHEBI:35295
hexoside
hexosides
CHEBI:35313
hexoside
CHEBI:35313
Any of naturally occurring compounds and synthetic analogues, based on the cyclopenta[a]phenanthrene carbon skeleton, partially or completely hydrogenated; there are usually methyl groups at C-10 and C-13, and often an alkyl group at C-17. By extension, one or more bond scissions, ring expansions and/or ring contractions of the skeleton may have occurred. Natural steroids are derived biogenetically from triterpenoids.
CHEBI:13687
CHEBI:26768
CHEBI:9263
KEGG COMPOUND:C00377
Steroid
steroids
a steroid
CHEBI:35341
steroid
CHEBI:35341
CHEBI:13585
CHEBI:19174
CHEBI:782
KEGG COMPOUND:C03336
17-alpha-Hydroxysteroid
17alpha-hydroxy steroids
a 17alpha-hydroxysteroid
CHEBI:35342
17alpha-hydroxy steroid
CHEBI:35342
CHEBI:1300
CHEBI:13596
CHEBI:19803
KEGG COMPOUND:C02506
21-Hydroxysteroid
21-hydroxy steroids
21-hydroxysteroids
a 21-hydroxysteroid
CHEBI:35344
21-hydroxy steroid
CHEBI:35344
CHEBI:13774
CHEBI:19134
CHEBI:738
KEGG COMPOUND:C01058
11beta-Hydroxysteroid
11beta-hydroxy steroids
11beta-hydroxysteroids
an 11beta-hydroxysteroid
CHEBI:35346
11beta-hydroxy steroid
CHEBI:35346
CHEBI:24748
CHEBI:5814
KEGG COMPOUND:C02159
Hydroxysteroid
hydroxy steroids
hydroxysteroids
CHEBI:35350
hydroxy steroid
CHEBI:35350
Any heteroorganic entity containing at least one carbon-nitrogen bond.
organonitrogen compounds
organonitrogens
CHEBI:35352
organonitrogen compound
CHEBI:35352
An amide of a sulfonic acid RS(=O)2NR'2.
CiteXplore:2434548
sulfonamides
NO2SR3
[*]S(=O)(=O)N([*])[*]
sulfonamides
CHEBI:35358
sulfonamide
CHEBI:35358
Compounds having the structure RC(=NR)NR2. The term is used as a suffix in systematic nomenclature to denote the -C(=NH)NH2 group including its carbon atom.
KEGG COMPOUND:C06060
carboxamidines
Amidines
carboxamidines
CHEBI:35359
carboxamidine
CHEBI:35359
Compounds derived from oxoacids RkE(=O)l(OH)m (l =/= 0) by replacing -OH by -NRNR2 (R groups are commonly H). (IUPAC).
hydrazides
hydrazides
CHEBI:35362
hydrazide
CHEBI:35362
A hydrazide consisting of hydrazine carrying one or more carboacyl groups.
carbohydrazides
carbohydrazides
CHEBI:35363
carbohydrazide
CHEBI:35363
CHEBI:21009
CHEBI:4173
KEGG COMPOUND:C01798
D-Glucoside
C6H11O6R
D-glucosides
CHEBI:35436
D-glucoside
CHEBI:35436
Compounds of structure RSSR in which R and R' are organic groups.
disulfides
S2R2
[*]SS[*]
organic disulfides
CHEBI:35489
organic disulfide
CHEBI:35489
An addition compound contains two or more simpler compounds that can be packed in a definite ratio into a crystal. The term covers donor-acceptor complexes (adducts) and a variety of lattice compounds.
addition compounds
CHEBI:35504
addition compound
CHEBI:35504
An addition compound that contains water in weak chemical combination with another compound.
Hydrat
hidrato
hidratos
hydrates
CHEBI:35505
hydrate
CHEBI:35505
propanolamine
propanolamines
CHEBI:35533
propanolamine
CHEBI:35533
CHEBI:35618
aromatic ether
CHEBI:35618
An azaspiro compound is a spiro compound in which at least one of the cyclic components is a nitrogen heterocyle.
azaspiro compound
azaspiro compounds
CHEBI:35624
azaspiro compound
CHEBI:35624
A beta-lactam is a lactam in which the amide bond is contained within a four-membered ring, which includes the amide nitrogen and the carbonyl carbon.
CHEBI:10426
CHEBI:22845
KEGG COMPOUND:C01866
beta-Lactam
beta-lactam
beta-lactams
CHEBI:35627
beta-lactam
CHEBI:35627
A secondary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has two other carbon atoms attached to it.
CHEBI:13425
CHEBI:13686
CHEBI:26617
CHEBI:58662
CHEBI:8741
CHEBI:9077
KEGG COMPOUND:C00432
KEGG COMPOUND:C01612
Secondary alcohol
secondary alcohol
C3H6OR2
R-CHOH-R'
[H]C(O)(C[*])C[*]
secondary alcohols
CHEBI:35681
secondary alcohol
CHEBI:35681
CHEBI:35689
tetrazoles
CHEBI:35689
An oxoacid containing two carboxy groups.
CHEBI:23692
CHEBI:4501
KEGG COMPOUND:C02028
Dicarboxylic acid
C2H2O4R
dicarboxylic acids
CHEBI:35692
dicarboxylic acid
CHEBI:35692
A compound formally derived from an oxoacid RkE(=O)l(OH)m (l > 0) and an alcohol, phenol, heteroarenol, or enol by linking with formal loss of water from an acidic hydroxy group of the former and a hydroxy group of the latter.
CHEBI:23960
CHEBI:4859
KEGG COMPOUND:C00287
Ester
esters
CHEBI:35701
ester
CHEBI:35701
A compound having the nitro group, -NO2 (free valence on nitrogen), which may be attached to carbon, nitrogen (as in nitramines), or oxygen (as in nitrates), among other elements (in the absence of specification, C-nitro compounds are usually implied).
nitro compounds
CHEBI:35715
nitro compound
CHEBI:35715
A compound having the nitro group (-NO2) attached to carbon atom.
C-nitro compounds
CHEBI:35716
C-nitro compound
CHEBI:35716
triazole compounds
CHEBI:35727
triazoles
CHEBI:35727
CHEBI:27315
CHEBI:35747
fatty acid esters
CHEBI:35748
fatty acid ester
CHEBI:35748
CHEBI:24979
CHEBI:25804
keto steroids
ketosteroids
oxo steroids
oxosteroids
CHEBI:35789
oxo steroid
CHEBI:35789
A compound based on a five-membered heterocyclic aromatic skeleton containing one N and one O atom.
oxazole
oxazoles
CHEBI:35790
oxazole
CHEBI:35790
Compounds having the structure R2S=O (R =/= H).
sulfoxide
sulfoxides
CHEBI:35813
sulfoxide
CHEBI:35813
Compounds having the structure RS(=O)2R (R =/= H).
sulfone
sulfones
CHEBI:35850
sulfone
CHEBI:35850
hydroxy acid
hydroxy monocarboxylic acids
CHEBI:35868
hydroxy monocarboxylic acid
CHEBI:35868
Any monocarboxylic acid having at least one additional oxo functional group.
oxo monocarboxylic acids
CHEBI:35871
oxo monocarboxylic acid
CHEBI:35871
imidazopyrimidines
CHEBI:35875
imidazopyrimidine
CHEBI:35875
dihydroxy monocarboxylic acids
CHEBI:35972
dihydroxy monocarboxylic acid
CHEBI:35972
Natural and synthetic antibiotics containing the 4-thia-1-azabicyclo[3.2.0]heptan-7-one structure, generally assumed to have the 5R configuration unless otherwise specified.
penams
CHEBI:35992
penams
CHEBI:35992
Compounds having a fully conjugated cyclic dione structure, such as that of benzoquinones, derived from aromatic compounds by conversion of an even number of -CH= groups into -C(=O)- groups with any necessary rearrangement of double bonds (polycyclic and heterocyclic analogues are included).
CHEBI:13684
CHEBI:26517
Wikipedia:Quinone
quinone
quinones
Chinon
a quinone
quinones
CHEBI:36141
quinone
CHEBI:36141
A monoester of a dicarboxylic acid.
dicarboxylic acid monoesters
CHEBI:36244
dicarboxylic acid monoester
CHEBI:36244
Any molecular entity consisting of more than one atom.
polyatomic entities
CHEBI:36357
polyatomic entity
CHEBI:36357
CHEBI:36360
phosphorus oxoacids and derivatives
CHEBI:36360
pseudoketone
pseudoketones
pseudoketones
CHEBI:36585
pseudoketone
CHEBI:36585
Any compound containing the carbonyl group, C=O. The term is commonly used in the restricted sense of aldehydes and ketones, although it actually includes carboxylic acids and derivatives.
carbonyl compounds
CHEBI:36586
carbonyl compound
CHEBI:36586
Organic compounds containing an oxygen atom, =O, doubly bonded to carbon or another element.
oxo compounds
organic oxo compounds
CHEBI:36587
organic oxo compound
CHEBI:36587
A cyclic compound in which a carbonyl group in a ring is bonded to one or two skeletal heteroatoms.
cyclic pseudoketones
CHEBI:36588
cyclic pseudoketone
CHEBI:36588
Compounds in which an acyclic carbonyl group is bonded to one or two acyclic skeletal heteroatoms, except nitrogen, halogen, or halogenoid atoms, or to a heteroatom of a ring or ring system.
acyclic pseudoketone
acyclic pseudoketones
acyclic pseudoketones
CHEBI:36589
acyclic pseudoketone
CHEBI:36589
An organochlorine compound is a compound containing at least one carbon-chlorine bond.
organochlorine compound
chloroorganic compounds
chlororganische Verbindungen
organochlorine compounds
CHEBI:36683
organochlorine compound
CHEBI:36683
A compound containing at least one carbon-halogen bond.
organohalogen compounds
CHEBI:36684
organohalogen compound
CHEBI:36684
heterotricyclic compound
heterotricyclic compounds
heterotricyclic compounds
CHEBI:36688
heterotricyclic compound
CHEBI:36688
Any of a class of steroid hormones that are produced in the adrenal cortex.
adrenal cortex hormones
corticosteroid hormones
CHEBI:36699
corticosteroid hormone
CHEBI:36699
aminoquinoline
aminoquinolines
CHEBI:36709
aminoquinoline
CHEBI:36709
A bicyclic compound in which all the ring atoms are carbon.
carbobicyclic compounds
CHEBI:36785
carbobicyclic compound
CHEBI:36785
antidepresivo triciclico
antidepresivos triciclicos
tricyclic antidepressant drugs
tricyclic antidepressants
tricyclic antidepressive agents
CHEBI:36809
tricyclic antidepressant
CHEBI:36809
CHEBI:36815
5-methoxyvalerophenone O-(2-aminoethyl)oxime
CHEBI:36815
O-organyl oximes R2C=NOR' (R' =/= H).
oxime O-ether
oxime O-ethers
CNOR3
O-substituted oximes
[*]O\N=C(/[*])[*]
oxime O-ethers
CHEBI:36816
oxime O-ether
CHEBI:36816
Two or more cyclic systems (single rings or fused systems) which are directly joined to each other by double or single bonds are named ring assemblies when the number of such direct ring junctions is one less than the number of cyclic systems involved.
ring assemblies
ring assembly
CHEBI:36820
ring assembly
CHEBI:36820
17-hydroxy steroids
CHEBI:36838
17-hydroxy steroid
CHEBI:36838
11-hydroxy steroids
CHEBI:36841
11-hydroxy steroid
CHEBI:36841
20-oxo steroids
CHEBI:36885
20-oxo steroid
CHEBI:36885
An organochalcogen compound is a compound containing at least one carbon-chalcogen bond.
organochalcogen compound
organochalcogen compounds
CHEBI:36962
organochalcogen compound
CHEBI:36962
An organochalcogen compound containing at least one carbon-oxygen bond.
CiteXplore:17586126
organooxygen compound
organooxygen compounds
CHEBI:36963
organooxygen compound
CHEBI:36963
An organoiodine compound is a compound containing at least one carbon-iodine bond.
organoiodine compound
organoiodine compounds
CHEBI:37142
organoiodine compound
CHEBI:37142
An organofluorine compound is a compound containing at least one carbon-fluorine bond.
organofluorine compound
fluoroorganic compound
fluoroorganic compounds
fluoroorganics
fluororganische Verbindungen
organofluorine compounds
CHEBI:37143
organofluorine compound
CHEBI:37143
An anthraquinone substituted with one or more hydroxy groups.
CHEBI:13829
CHEBI:24672
an hydroxyanthraquinone
CHEBI:37485
hydroxyanthraquinones
CHEBI:37485
Derivatives of diazene with the general structure R-N=N-R'.
azo compounds
azo compounds
CHEBI:37533
azo compound
CHEBI:37533
A molecular entity consisting of two or more chemical elements.
chemical compound
heteroatomic molecular entities
CHEBI:37577
heteroatomic molecular entity
CHEBI:37577
CHEBI:37578
halide
CHEBI:37578
Compounds having two beta-haloalkyl groups bound to a nitrogen atom, as in (X-C2H2-C2H2)2NR.
nitrogen mustards
nitrogen mustards
CHEBI:37598
nitrogen mustard
CHEBI:37598
An amide of a carboxylic acid, having the structure RC(=O)NR2. The term is used as a suffix in systematic name formation to denote the -C(=O)NH2 group including its carbon atom.
CHEBI:35354
CHEBI:35355
carboxamides
CNOR3
[*]C(=O)N([*])[*]
carboxamides
primary carboxamide
CHEBI:37622
carboxamide
CHEBI:37622
A thienopyridine that has formula C16H16ClNO2S.
32968
Beilstein:8151914
ChemIDplus:113665-84-2
DrugBank:DB00758
Patent:EP281459
Patent:EP99802
Patent:US4529596
Patent:US4847265
Wikipedia:Clopidogrel
methyl (2S)-(2-chlorophenyl)(6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl)acetate
(+)-Clopidogrel
C16H16ClNO2S
COC(=O)[C@@H](N1CCc2sccc2C1)c1ccccc1Cl
InChI=1S/C16H16ClNO2S/c1-20-16(19)15(12-4-2-3-5-13(12)17)18-8-6-14-11(10-18)7-9-21-14/h2-5,7,9,15H,6,8,10H2,1H3/t15-/m0/s1
InChIKey=GKTWGGQPFAXNFI-HNNXBMFYSA-N
clopidogrel
clopidogrelum
CHEBI:37941
clopidogrel
CHEBI:37941
thienopyridines
CHEBI:37942
thienopyridine
CHEBI:37942
CHEBI:37947
benzothiazoles
CHEBI:37947
carbotricyclic compounds
CHEBI:38032
carbotricyclic compound
CHEBI:38032
Any organonitrogen compound containing a cyclic component with nitrogen and at least one other element as ring member atoms.
heterocyclic organonitrogen compounds
organonitrogen heterocyclic compounds
CHEBI:38101
organonitrogen heterocyclic compound
CHEBI:38101
Any organic heterocyclic compound containing at least one ring oxygen atom.
CiteXplore:17134300
heterocyclic organooxygen compounds
organooxygen heterocyclic compounds
oxacycles
CHEBI:38104
oxacycle
CHEBI:38104
heterocyclic organosulfur compounds
organosulfur heterocyclic compounds
CHEBI:38106
organosulfur heterocyclic compound
CHEBI:38106
organic heteropentacyclic compounds
CHEBI:38164
organic heteropentacyclic compound
CHEBI:38164
CHEBI:25429
CHEBI:38075
organic heteropolycyclic compounds
CHEBI:38166
organic heteropolycyclic compound
CHEBI:38166
monocyclic heteroarenes
CHEBI:38179
monocyclic heteroarene
CHEBI:38179
polycyclic heteroarenes
CHEBI:38180
polycyclic heteroarene
CHEBI:38180
CHEBI:38261
imidazolidines
CHEBI:38261
azabicycloalkanes
CHEBI:38295
azabicycloalkane
CHEBI:38295
cyclopentapyrroles
CHEBI:38296
cyclopentapyrrole
CHEBI:38296
CHEBI:38298
benzodioxoles
CHEBI:38298
diazolidines
CHEBI:38304
diazolidine
CHEBI:38304
cephems
CHEBI:38311
cephem
CHEBI:38311
Any organic heterocyclic compound containing a benzene ring in which two of the C-H fragments have been replaced by isolobal nitrogens (the diazine parent structure).
CHEBI:38313
diazines
CHEBI:38313
pyrimidones
CHEBI:38337
pyrimidone
CHEBI:38337
CHEBI:26949
CHEBI:38417
1,3-thiazoles
CHEBI:38418
1,3-thiazole
CHEBI:38418
phenethylamine alkaloids
CHEBI:38605
phenethylamine alkaloid
CHEBI:38605
pyrazolopyrimidines
CHEBI:38669
pyrazolopyrimidine
CHEBI:38669
A gold coordination entity that has formula C4H5AuO4S.
42547
Beilstein:4030297
ChemIDplus:4846-27-9
Gmelin:1043252
Gmelin:1288314
1,2-dicarboxyethanethiolatogold(I)
1,2-dicarboxyethylsulfanylgold
gold(1+) 1,2-dicarboxyethanethiolate
(1,2-dicarboxyethylthio)gold
C4H5AuO4S
InChI=1S/C4H6O4S.Au/c5-3(6)1-2(9)4(7)8;/h2,9H,1H2,(H,5,6)(H,7,8);/q;+1/p-1
InChIKey=XJHSMFDIQHVMCY-UHFFFAOYSA-M
OC(=O)CC(S[Au])C(O)=O
aurothiomalate
mercaptobutanedioic acid, monogold(1+) salt
CHEBI:38722
Aurothiomalate
aurothiomalic acid
CHEBI:38722
CHEBI:38830
1-benzofurans
CHEBI:38830
An alkaloid containing an indole skeleton.
CHEBI:24795
CHEBI:5901
KEGG COMPOUND:C06073
Indole alkaloid
indole alkaloids
CHEBI:38958
indole alkaloid
CHEBI:38958
dioxolanes
CHEBI:39430
dioxolane
CHEBI:39430
Any compound having a pyrimidine as part of its structure.
CHEBI:13681
CHEBI:26448
CHEBI:39447
pyrimidines
CHEBI:39447
A dihydroxy monocarboxylic acid that has formula C33H35FN2O5.
83367
CHEBI:2910
CHEBI:39538
Beilstein:8373630
ChemIDplus:134523-00-5
DrugBank:DB01076
KEGG COMPOUND:134523-00-5
KEGG COMPOUND:C06834
KEGG DRUG:D07474
PDBeChem:117
Patent:EP409281
Patent:US5273995
Wikipedia:Atorvastatin
(3R,5R)-7-[3-(anilinocarbonyl)-5-(4-fluorophenyl)-4-phenyl-2-(propan-2-yl)-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid
Atorvastatin
(R-(R*,R*))-2-(4-Fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoic acid
7-[2-(4-FLUORO-PHENYL)-5-ISOPROPYL-3-PHENYL-4-PHENYLCARBAMOYL-PYRROL-1-YL]-3,5-DIHYDROXY-HEPTANOIC ACID
Atorlip
C33H35FN2O5
CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(O)=O
InChI=1S/C33H35FN2O5/c1-21(2)31-30(33(41)35-25-11-7-4-8-12-25)29(22-9-5-3-6-10-22)32(23-13-15-24(34)16-14-23)36(31)18-17-26(37)19-27(38)20-28(39)40/h3-16,21,26-27,37-38H,17-20H2,1-2H3,(H,35,41)(H,39,40)/t26-,27-/m1/s1
InChIKey=XUKUURHRXDUEBC-KAYWLYCHSA-N
atorvastatin
atorvastatina
atorvastatine
atorvastatinum
CHEBI:39548
atorvastatin
CHEBI:39548
KEGG COMPOUND:C02019
Cyclic ketone
cyclic ketones
CHEBI:3992
cyclic ketone
CHEBI:3992
5-Methylidene-5H-dibenzo[a,d]cycloheptene in which one of the hydrogens of the methylidene group is substituted by a 2-(dimethylamino)ethyl group. A centrally acting skeletal muscle relaxant, it is used as its hydrochloride salt in the symptomatic treatment of painful muscle spasm.
21949
CHEBI:128119
Beilstein:2126383
ChEMBL:128119
ChEMBL:17725338
ChEMBL:18027916
DrugBank:DB00924
KEGG COMPOUND:303-53-7
KEGG COMPOUND:C06931
KEGG DRUG:D07758
NIST Chemistry WebBook:303-53-7
Patent:GB858187
Wikipedia:Cyclobenzaprine
3-(5H-dibenzo[a,d][7]annulen-5-ylidene)-N,N-dimethylpropan-1-amine
3-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-N,N-dimethylpropan-1-amine
Cyclobenzaprine
(3-Dibenzo[a,d]cyclohepten-5-ylidene-propyl)-dimethyl-amine
C20H21N
CN(C)CCC=C1c2ccccc2C=Cc2ccccc12
InChI=1S/C20H21N/c1-21(2)15-7-12-20-18-10-5-3-8-16(18)13-14-17-9-4-6-11-19(17)20/h3-6,8-14H,7,15H2,1-2H3
InChIKey=JURKNVYFZMSNLP-UHFFFAOYSA-N
N,N-dimethyl-5H-dibenzo(a,d)cycloheptene-Delta(5,gamma)-propylamine
ciclobenzaprina
cyclobenzaprine
cyclobenzaprinum
CHEBI:3996
cyclobenzaprine
CHEBI:3996
A bicyclic structure comprising a pyrazole ring fused to a hydroxy-substituted pyrimidine ring.
519
CHEBI:2601
CHEBI:40276
Beilstein:608611
ChemIDplus:315-30-0
CiteXplore:7602118
DrugBank:DB00437
KEGG DRUG:315-30-0
KEGG DRUG:D00224
NIST Chemistry WebBook:315-30-0
Wikipedia:Allopurinol
1H-pyrazolo[3,4-d]pyrimidin-4-ol
Allopurinol
1,5-Dihydro-4H-pyrazolo(3,4-d)pyrimidin-4-one
1,5-Dihydro-4H-pyrazolo(3,4-d)pyrimidine-4-one
1H-Pyrazolo(3,4-d)pyrimidin-4-ol
4'-Hydroxypyrazolol(3,4-d)pyrimidine
4-HPP
4-Hydroxy-1H-pyrazolo(3,4-d)pyrimidine
4-Hydroxy-3,4-pyrazolopyrimidine
4-Hydroxypyrazolo(3,4-d)pyrimidine
4-Hydroxypyrazolopyrimidine
4-Hydroxypyrazolyl(3,4-d)pyrimidine
4H-Pyrazolo(3,4-d)pyrimidin-4-one
AL-100
Allopurinolum
Alopurinol
C5H4N4O
InChI=1S/C5H4N4O/c10-5-3-1-8-9-4(3)6-2-7-5/h1-2H,(H2,6,7,8,9,10)
InChIKey=OFCNXPDARWKPPY-UHFFFAOYSA-N
Oc1ncnc2[nH]ncc12
Zyloprim (TN)
CHEBI:40279
Allopurinol
allopurinol
CHEBI:40279
A delta-lactone that has formula C24H36O5.
6472
CHEBI:40299
CHEBI:6544
ChemIDplus:3631989
ChemIDplus:75330-75-5
KEGG COMPOUND:C07074
KEGG DRUG:75330-75-5
KEGG DRUG:D00359
PDBeChem:803
Wikipedia:Lovastatin
(1S,3R,7S,8S,8aR)-8-{2-[(2R,4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl]ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl (2S)-2-methylbutanoate
LOVASTATIN
Lovastatin
(1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-(2R,4R)-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl (S)-2-methyl-butyrate
2beta,6alpha-dimethyl-8alpha-(2-methyl-1-oxobutoxy)-mevinic acid lactone
6alpha-methylcompactin
C24H36O5
InChI=1S/C24H36O5/c1-5-15(3)24(27)29-21-11-14(2)10-17-7-6-16(4)20(23(17)21)9-8-19-12-18(25)13-22(26)28-19/h6-7,10,14-16,18-21,23,25H,5,8-9,11-13H2,1-4H3/t14-,15-,16-,18+,19+,20-,21-,23-/m0/s1
InChIKey=PCZOHLXUXFIOCF-BXMDZJJMSA-N
MK-803
ML-530B
Mevacor
Mevinolin
[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC
CHEBI:40303
Lovastatin
lovastatin
CHEBI:40303
A cyclic nonribosomal peptide of eleven amino acids; an immunosuppressant drug widely used in post-allogeneic organ transplant to reduce the activity of the patient's immune system, and therefore the risk of organ rejection. Also causes reversible inhibition of immunocompetent lymphocytes in the G0- and G1-phase of the cell cycle.
3008
CHEBI:63586
Beilstein:3647785
ChemIDplus:59865-13-3
CiteXplore:11058832
CiteXplore:11069928
CiteXplore:11079273
CiteXplore:11080188
CiteXplore:11238591
CiteXplore:11256490
CiteXplore:11278005
CiteXplore:11315347
CiteXplore:11370709
CiteXplore:11406057
CiteXplore:11426833
CiteXplore:11442023
CiteXplore:11481617
CiteXplore:11493684
CiteXplore:11529914
CiteXplore:11557554
CiteXplore:11564166
CiteXplore:11676831
CiteXplore:11870366
CiteXplore:12021257
CiteXplore:12050171
CiteXplore:12603598
CiteXplore:12761440
CiteXplore:12929192
CiteXplore:12950728
CiteXplore:14521916
CiteXplore:14621732
CiteXplore:14638917
CiteXplore:14672695
CiteXplore:14682659
CiteXplore:14743390
CiteXplore:15030555
CiteXplore:15175101
CiteXplore:15210365
CiteXplore:15306697
CiteXplore:15383526
CiteXplore:15541012
CiteXplore:15613074
CiteXplore:15626898
CiteXplore:15657176
CiteXplore:1566062
CiteXplore:15711594
CiteXplore:15811524
CiteXplore:15962181
CiteXplore:16372476
CiteXplore:16404634
CiteXplore:16724420
CiteXplore:16801218
CiteXplore:16898534
CiteXplore:17032751
CiteXplore:17083576
CiteXplore:17117422
CiteXplore:17192032
CiteXplore:17220244
CiteXplore:17229932
CiteXplore:17265451
CiteXplore:17446460
CiteXplore:17603747
CiteXplore:18076075
CiteXplore:18171316
CiteXplore:18191430
CiteXplore:18217899
CiteXplore:18259730
CiteXplore:18299432
CiteXplore:18359899
CiteXplore:18583716
CiteXplore:18597363
CiteXplore:18790203
CiteXplore:18818682
CiteXplore:18931077
CiteXplore:18975184
CiteXplore:19282398
CiteXplore:19589783
DrugBank:DB00091
KEGG COMPOUND:59865-13-3
KEGG COMPOUND:C05086
KEGG DRUG:D00184
Patent:US4117118
Reaxys:3647785
Wikipedia:Ciclosporin
30-ethyl-33-[(4E)-1-hydroxy-2-methylhex-4-en-1-yl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-bis(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone
Cyclosporin A
(R-[R*,R*-(E)])-Cyclic(L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl-3-hydroxy-N,4-dimethyl-L-2-amino-6-octenoyl-L-alpha-aminobutyryl-N-methylglycyl-N-methyl-L-leucyl-L-valyl-N-methyl-L-leucyl)
1,11-cyclo[L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl-(E)-(2S,3R,4R)-2-amino-3-hydroxy-N,4-dimethyloct-6-enoyl-L-2-aminobutanoyl-N-methylglycyl-N-methyl-L-leucyl-L-valyl-N-methyl-L-leucine]
30-ethyl-33-[(4E)-1-hydroxy-2-methylhex-4-en-1-yl]-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone
Antibiotic S 7481F1
C62H111N11O12
CC[C@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C
Ciclosporin
Cyclo(L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl-((3R,4R,6E)-6,7-didehydro-3-hydroxy-N,4-dimethyl-L-2-aminooctanoyl)-L-2-aminobutanoyl-N-methylglycyl-N-methyl-L-leucyl-L-valyl-N-methylleucyl)
Cyclosporine
Gengraf
InChI=1S/C62H111N11O12/c1-25-27-28-40(15)52(75)51-56(79)65-43(26-2)58(81)67(18)33-48(74)68(19)44(29-34(3)4)55(78)66-49(38(11)12)61(84)69(20)45(30-35(5)6)54(77)63-41(16)53(76)64-42(17)57(80)70(21)46(31-36(7)8)59(82)71(22)47(32-37(9)10)60(83)72(23)50(39(13)14)62(85)73(51)24/h25,27,34-47,49-52,75H,26,28-33H2,1-24H3,(H,63,77)(H,64,76)(H,65,79)(H,66,78)/b27-25+/t40-,41+,42+,43-,44+,45-,46+,47+,49+,50-,51+,52-/m1/s1
InChIKey=PMATZTZNYRCHOR-VJRYSDSKSA-N
Neoral
Sandimmune
ciclosporin
ciclosporina
ciclosporine
ciclosporinum
CHEBI:4031
Cyclosporine
cyclosporin A
CHEBI:4031
A tertiary amino compound that has formula C26H29NO.
10324
CHEBI:41767
CHEBI:9396
Beilstein:2062020
ChemIDplus:10540-29-1
DrugBank:DB00675
KEGG COMPOUND:10540-29-1
KEGG COMPOUND:C07108
Patent:BE637389
Patent:BE678807
Patent:US4536516
Wikipedia:Tamoxifen
2-{4-[(1Z)-1,2-diphenylbut-1-en-1-yl]phenoxy}-N,N-dimethylethanamine
Tamoxifen
(Z)-2-(4-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylethanamine
(Z)-2-(para-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylamine
1-p-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-para-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
Apo-Tamox
C26H29NO
CC\C(c1ccccc1)=C(/c1ccccc1)c1ccc(OCCN(C)C)cc1
Crisafeno
Diemon
InChI=1S/C26H29NO/c1-4-25(21-11-7-5-8-12-21)26(22-13-9-6-10-14-22)23-15-17-24(18-16-23)28-20-19-27(2)3/h5-18H,4,19-20H2,1-3H3/b26-25-
InChIKey=NKANXQFJJICGDU-QPLCGJKRSA-N
tamoxifen
tamoxifene
tamoxifeno
tamoxifenum
trans-Tamoxifen
CHEBI:41774
Tamoxifen
tamoxifen
CHEBI:41774
A fluorinated steroid that has formula C22H29FO5.
3264
CHEBI:41873
CHEBI:4461
Beilstein:2066652
ChemIDplus:50-02-2
DrugBank:DB01234
KEGG DRUG:D00292
Patent:DE1113690
Patent:GB869511
Patent:US3007923
Wikipedia:Dexamethasone
9-fluoro-11beta,17,21-trihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione
Dexamethasone
1-Dehydro-16alpha-methyl-9alpha-fluorohydrocortisone
16alpha-Methyl-9alpha-fluoro-1-dehydrocortisol
9alpha-Fluoro-16alpha-methylprednisolone
C22H29FO5
Decadron
InChI=1S/C22H29FO5/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,23)17(26)10-20(16,3)22(12,28)18(27)11-24/h6-7,9,12,15-17,24,26,28H,4-5,8,10-11H2,1-3H3/t12-,15+,16+,17+,19+,20+,21+,22+/m1/s1
InChIKey=UREBDLICKHMUKA-CXSFZGCWSA-N
[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
dexametasona
dexamethasone
dexamethasonum
CHEBI:41879
Dexamethasone
dexamethasone
CHEBI:41879
Diphenylsulfone in which the hydrogen atom at the 4 position of each of the phenyl groups is substituted by an amino group. It is active against a wide range of bacteria, but is mainly employed for its actions against Mycobacterium leprae, being used as part of multidrug regimens in the treatment of all forms of leprosy.
3108
CHEBI:226356
Beilstein:788055
ChEMBL:226356
ChemIDplus:80-08-0
DrugBank:DB00250
KEGG COMPOUND:80-08-0
KEGG COMPOUND:C07666
KEGG DRUG:D00592
NIST Chemistry WebBook:80-08-0
Patent:FR829926
Wikipedia:Dapsone
4,4'-sulfonyldianiline
DAPSONE
Dapsone
1,1'-sulfonylbis(4-aminobenzene)
4,4'-Sulfonylbisbenzenamine
4,4'-dapsone
4,4'-diaminodiphenyl sulfone
4,4'-sulfonylbisaniline
4-(4-amino-benzenesulfonyl)-phenylamine
4-(4-aminophenylsulfonyl)aniline
4-(4-aminophenylsulfonyl)benzenamine
4-aminophenyl sulfone
Bis(p-aminophenyl) sulfone
C12H12N2O2S
DADPS
DDS
DIAPHENYLSULFONE
Diaphenylsulfone
InChI=1S/C12H12N2O2S/c13-9-1-5-11(6-2-9)17(15,16)12-7-3-10(14)4-8-12/h1-8H,13-14H2
InChIKey=MQJKPEGWNLWLTK-UHFFFAOYSA-N
Nc1ccc(cc1)S(=O)(=O)c1ccc(N)cc1
bis(4-aminophenyl)sulfone
dapsona
dapsone
dapsonum
p,p'-diaminodiphenyl sulfone
p,p-sulphonylbisbenzamine
p,p-sulphonylbisbenzenamine
p-aminophenyl sulfone
CHEBI:4325
Dapsone
dapsone
CHEBI:4325
An acyclic desferrioxamine that has formula C25H48N6O8.
3131
Beilstein:2514118
ChemIDplus:70-51-9
DrugBank:DB00746
KEGG COMPOUND:C06940
KEGG DRUG:D03670
Patent:BE609053
Wikipedia:Deferoxamine
N'-{5-[acetyl(hydroxy)amino]pentyl}-N-(5-{4-[(5-aminopentyl)(hydroxy)amino]-4-oxobutanamido}pentyl)-N-hydroxybutanediamide
C25H48N6O8
CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN
DFO
Deferoxamin
Deferrioxamine
Desferrioxamine
InChI=1S/C25H48N6O8/c1-21(32)29(37)18-9-3-6-16-27-22(33)12-14-25(36)31(39)20-10-4-7-17-28-23(34)11-13-24(35)30(38)19-8-2-5-15-26/h37-39H,2-20,26H2,1H3,(H,27,33)(H,28,34)
InChIKey=UBQYURCVBFRUQT-UHFFFAOYSA-N
deferoxamina
deferoxamine
deferoxaminum
deferrioxamine B
CHEBI:4356
Deferoxamine
desferrioxamine B
CHEBI:4356
A dipeptide that has formula C21H31N3O5.
29046
CHEBI:43750
Beilstein:4276619
ChemIDplus:76547-98-3
PDBeChem:LPR
Wikipedia:Lisinopril
N(2)-[(1S)-1-carboxy-3-phenylpropyl]-L-lysyl-L-proline
(S)-1-(N(2)-(1-carboxy-3-phenylpropyl)-L-lysyl)-L-proline
C21H31N3O5
InChI=1S/C21H31N3O5/c22-13-5-4-9-16(19(25)24-14-6-10-18(24)21(28)29)23-17(20(26)27)12-11-15-7-2-1-3-8-15/h1-3,7-8,16-18,23H,4-6,9-14,22H2,(H,26,27)(H,28,29)/t16-,17-,18-/m0/s1
InChIKey=RLAWWYSOJDYHDC-BZSNNMDCSA-N
NCCCC[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O
[N2-[(S)-1-CARBOXY-3-PHENYLPROPYL]-L-LYSYL-L-PROLINE
lisinopril anhydrous
CHEBI:43755
Lisinopril
lisinopril
CHEBI:43755
A pteridine that has formula C20H22N8O5.
6851
CHEBI:44183
CHEBI:6837
Beilstein:70669
ChemIDplus:59-05-2
DrugBank:DB00563
KEGG COMPOUND:59-05-2
KEGG COMPOUND:C01937
KEGG DRUG:D00142
NIST Chemistry WebBook:59-05-2
PDBeChem:MTX
Patent:US2512572
Wikipedia:Methotrexate
METHOTREXATE
Methotrexate
N-(4-{[(2,4-diaminopteridin-6-yl)methyl](methyl)amino}benzoyl)-L-glutamic acid
4-amino-10-methylfolic acid
4-amino-N(10)-methylpteroylglutamic acid
C20H22N8O5
CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(cc1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
Emtexate
InChI=1S/C20H22N8O5/c1-28(9-11-8-23-17-15(24-11)16(21)26-20(22)27-17)12-4-2-10(3-5-12)18(31)25-13(19(32)33)6-7-14(29)30/h2-5,8,13H,6-7,9H2,1H3,(H,25,31)(H,29,30)(H,32,33)(H4,21,22,23,26,27)/t13-/m0/s1
InChIKey=FBOZXECLQNJBKD-ZDUSSCGKSA-N
Ledertrexate
MTX
N-[(4-{[(2,4-diaminopteridin-6-yl)methyl](methyl)amino}phenyl)carbonyl]-L-glutamic acid
N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid
Rheumatrex
Trexall
methotrexate
methotrexatum
metotrexato
CHEBI:44185
Methotrexate
methotrexate
CHEBI:44185
An urea that has formula CH4N2O2.
5552
CHEBI:44420
CHEBI:5816
ChemIDplus:127-07-1
ChemIDplus:1741548
Gmelin:130423
KEGG COMPOUND:127-07-1
KEGG COMPOUND:C07044
PDBeChem:NHY
Wikipedia:Hydroxyurea
Hydroxyurea
N-hydroxyurea
CH4N2O2
Hydroxycarbamid
Hydroxycarbamide
Hydroxyharnstoff
InChI=1S/CH4N2O2/c2-1(4)3-5/h5H,(H3,2,3,4)
InChIKey=VSNHCAURESNICA-UHFFFAOYSA-N
N-HYDROXYUREA
N-carbamoylhydroxylamine
NC(=O)NO
carbamohydroxamic acid
carbamohydroximic acid
carbamoyl oxime
carbamyl hydroxamate
hydrea
hydroxycarbamide
oxyurea
CHEBI:44423
hydroxyurea
CHEBI:44423
A phenol resulting from the formal substitution of the hydrogen at the 2 position of 1,3-diisopropylbenzene by a hydroxy group.
8782
CHEBI:44914
CHEBI:8495
ChemIDplus:1866484
ChemIDplus:2078-54-8
DrugBank:DB00818
KEGG COMPOUND:2078-54-8
KEGG COMPOUND:C07523
KEGG DRUG:D00549
NIST Chemistry WebBook:2078-54-8
PDBeChem:PFL
Wikipedia:Propofol
2,6-bis(propan-2-yl)phenol
Propofol
2,6-BIS(1-METHYLETHYL)PHENOL
2,6-Diisopropylphenol
2,6-bis(1-methylethyl)phenol
C12H18O
CC(C)c1cccc(C(C)C)c1O
Diprivan
Disoprivan
Disoprofol
InChI=1S/C12H18O/c1-8(2)10-6-5-7-11(9(3)4)12(10)13/h5-9,13H,1-4H3
InChIKey=OLBCVFGFOZPWHH-UHFFFAOYSA-N
Rapinovet
propofol
propofolum
CHEBI:44915
Propofol
propofol
CHEBI:44915
A diether compound consisting of pentane-1,5-diol with both hydroxyls bearing 4-amidinophenyl groups.
7994
CHEBI:45077
CHEBI:7976
ChemIDplus:100-33-4
ChemIDplus:3159790
CiteXplore:11438428
CiteXplore:14603035
CiteXplore:15711592
CiteXplore:18971316
CiteXplore:19966562
CiteXplore:22046004
CiteXplore:22093811
CiteXplore:22200378
CiteXplore:22327112
DrugBank:DB00738
KEGG COMPOUND:100-33-4
KEGG COMPOUND:C07420
KEGG DRUG:D08333
PDBeChem:PNT
Patent:EP975608
Patent:GB507565
Patent:US2006235001
Patent:US2008167296
Patent:US2008214569
Patent:US2394003
Patent:US7115665
Reaxys:3159790
Wikipedia:Pentamidine
4,4'-[pentane-1,5-diylbis(oxy)]dibenzenecarboximidamide
Pentamidine
1,5-bis(4-amidinophenoxy)pentane
4,4'-(1,5-pentanediylbis(oxy))bis-benzenecarboximidamide
4,4'-(pentamethylenedioxy)dibenzamidine
4,4'-Diamidinodiphenoxypentane
C19H24N4O2
InChI=1S/C19H24N4O2/c20-18(21)14-4-8-16(9-5-14)24-12-2-1-3-13-25-17-10-6-15(7-11-17)19(22)23/h4-11H,1-3,12-13H2,(H3,20,21)(H3,22,23)
InChIKey=XDRYMKDFEDOLFX-UHFFFAOYSA-N
NC(=N)c1ccc(OCCCCCOc2ccc(cc2)C(N)=N)cc1
p,p'-(pentamethylenedioxy)dibenzamidine
pentamidine
CHEBI:45081
Pentamidine
pentamidine
CHEBI:45081
85762
CHEBI:45409
Ritonavir
ritonavir
CHEBI:45409
A tetracyclic diterpenoid isolated originally from the bark of the Pacific yew tree, Taxus brevifolia. It is a mitotic inhibitor used in cancer chemotherapy. Note that the use of the former generic name 'taxol' is now limited, as Taxol is a registered trade mark.
56946
CHEBI:45862
CHEBI:7887
ChemIDplus:33069-62-4
KEGG COMPOUND:33069-62-4
KEGG COMPOUND:C07394
KEGG DRUG:D00491
PDBeChem:TA1
Wikipedia:Paclitaxel
4alpha,10beta-bis(acetyloxy)-13alpha-[(2S,3S)-3-benzamido-2-hydroxy-3-phenylpropanoyloxy]-1,7beta-dihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate
Paclitaxel
(2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha R*,betaS*),11alpha,12alpha,12balpha))-beta-(Benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
C47H51NO14
InChI=1S/C47H51NO14/c1-25-31(60-43(56)36(52)35(28-16-10-7-11-17-28)48-41(54)29-18-12-8-13-19-29)23-47(57)40(61-42(55)30-20-14-9-15-21-30)38-45(6,32(51)22-33-46(38,24-58-33)62-27(3)50)39(53)37(59-26(2)49)34(25)44(47,4)5/h7-21,31-33,35-38,40,51-52,57H,22-24H2,1-6H3,(H,48,54)/t31-,32-,33+,35-,36+,37+,38-,40-,45+,46-,47+/m0/s1
InChIKey=RCINICONZNJXQF-MZXODVADSA-N
TAXOL
Taxol A
[H][C@]12[C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C
CHEBI:45863
Paclitaxel
paclitaxel
CHEBI:45863
A triazole that has formula C13H12F2N6O.
4450
CHEBI:46079
CHEBI:5099
Beilstein:4269710
ChemIDplus:86386-73-4
KEGG DRUG:D00322
PDBeChem:TPF
Wikipedia:Fluconazole
2-(2,4-difluorophenyl)-1,3-bis-(1H-1,2,4-triazol-1-yl)propan-2-ol
Fluconazole
2,4-difluoro-alpha,alpha-bis(1H-1,2,4-triazol-1-ylmethyl)benzyl alcohol
2-(2,4-DIFLUOROPHENYL)-1,3-DI(1H-1,2,4-TRIAZOL-1-YL)PROPAN-2-OL
Biozolene
C13H12F2N6O
Diflucan
Elazor
InChI=1S/C13H12F2N6O/c14-10-1-2-11(12(15)3-10)13(22,4-20-8-16-6-18-20)5-21-9-17-7-19-21/h1-3,6-9,22H,4-5H2
InChIKey=RFHAOTPXVQNOHP-UHFFFAOYSA-N
OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F
Triflucan
CHEBI:46081
Fluconazole
fluconazole
CHEBI:46081
The sulfonamide resulting from formal condensation of the sulfo group of 4-ethoxy-3-(5-methyl-7-propylimidazo[5,1-f][1,2,4]triazin-4(1H)-one-2-yl)benzenesulfonic acid and the secondary amino group of 4-ethylpiperazine.
306674
Beilstein:9967331
ChemIDplus:224785-90-4
CiteXplore:19949666
CiteXplore:19959201
CiteXplore:20859794
CiteXplore:20925442
CiteXplore:21209618
CiteXplore:21235726
CiteXplore:21290241
CiteXplore:21427994
CiteXplore:21496853
CiteXplore:21548209
CiteXplore:21552528
CiteXplore:21771280
CiteXplore:21883954
CiteXplore:21943935
CiteXplore:21950284
DrugBank:DB00862
KEGG DRUG:D08668
PDBeChem:VDN
Reaxys:9967331
Wikipedia:Vardenafil
2-{2-ethoxy-5-[(4-ethylpiperazin-1-yl)sulfonyl]phenyl}-5-methyl-7-propylimidazo[5,1-f][1,2,4]triazin-4(1H)-one
2-{2-ETHOXY-5-[(4-ETHYLPIPERAZIN-1-YL)SULFONYL]PHENYL}-5-METHYL-7-PROPYLIMIDAZO[5,1-F][1,2,4]TRIAZIN-4(1H)-ONE
C23H32N6O4S
CCCc1nc(C)c2n1[nH]c(nc2=O)-c1cc(ccc1OCC)S(=O)(=O)N1CCN(CC)CC1
InChI=1S/C23H32N6O4S/c1-5-8-20-24-16(4)21-23(30)25-22(26-29(20)21)18-15-17(9-10-19(18)33-7-3)34(31,32)28-13-11-27(6-2)12-14-28/h9-10,15H,5-8,11-14H2,1-4H3,(H,25,26,30)
InChIKey=SECKRCOLJRRGGV-UHFFFAOYSA-N
Levitra
CHEBI:46295
vardenafil
CHEBI:46295
An organofluorine compound that has formula C4H3FN2O2.
4492
CHEBI:2054
CHEBI:46343
Beilstein:127172
ChemIDplus:51-21-8
KEGG COMPOUND:51-21-8
KEGG COMPOUND:C07649
Wikipedia:Fluorouracil
5-Fluorouracil
5-fluoropyrimidine-2,4(1H,3H)-dione
5-fluorouracil
5-FU
5-Fluoropyrimidine-2,4-dione
C4H3FN2O2
Fc1c[nH]c(=O)[nH]c1=O
Fluorouracil
InChI=1S/C4H3FN2O2/c5-2-1-6-4(9)7-3(2)8/h1H,(H2,6,7,8,9)
InChIKey=GHASVSINZRGABV-UHFFFAOYSA-N
CHEBI:46345
5-fluorouracil
Fluorouracil
CHEBI:46345
Ganciclovir is an antiviral drug used to treat or prevent AIDS-related cytomegalovirus infections.
4678
CHEBI:5273
Beilstein:3654487
ChEMBL:10197958
ChEMBL:10377226
ChEMBL:10411487
ChEMBL:10447945
ChEMBL:10560739
ChEMBL:10691698
ChEMBL:10882370
ChEMBL:10882372
ChEMBL:10882374
ChEMBL:10882375
ChEMBL:10888336
ChEMBL:10966740
ChEMBL:10966745
ChEMBL:10999475
ChEMBL:11229780
ChEMBL:11262090
ChEMBL:11412988
ChEMBL:11454465
ChEMBL:11472207
ChEMBL:11495586
ChEMBL:11585457
ChEMBL:11677126
ChEMBL:11708924
ChEMBL:11708929
ChEMBL:11754587
ChEMBL:11814776
ChEMBL:11858989
ChEMBL:11985471
ChEMBL:12408716
ChEMBL:12459010
ChEMBL:12723951
ChEMBL:1310744
ChEMBL:1319491
ChEMBL:1323678
ChEMBL:14521407
ChEMBL:14584954
ChEMBL:14643328
ChEMBL:14643358
ChEMBL:14736238
ChEMBL:15027877
ChEMBL:15081019
ChEMBL:15481985
ChEMBL:15509173
ChEMBL:15509174
ChEMBL:15509175
ChEMBL:15509176
ChEMBL:15615545
ChEMBL:15634003
ChEMBL:15658858
ChEMBL:15658861
ChEMBL:15658873
ChEMBL:15689173
ChEMBL:15745823
ChEMBL:15801851
ChEMBL:16134946
ChEMBL:16392791
ChEMBL:16392824
ChEMBL:16420056
ChEMBL:16480257
ChEMBL:1652016
ChEMBL:16759112
ChEMBL:16814545
ChEMBL:17004726
ChEMBL:17043128
ChEMBL:17092728
ChEMBL:17161946
ChEMBL:17181158
ChEMBL:17181162
ChEMBL:17188402
ChEMBL:17239594
ChEMBL:17298047
ChEMBL:17329103
ChEMBL:17402726
ChEMBL:17434304
ChEMBL:17438061
ChEMBL:17513108
ChEMBL:17518459
ChEMBL:17539622
ChEMBL:17622128
ChEMBL:17672445
ChEMBL:17869124
ChEMBL:17948980
ChEMBL:17960926
ChEMBL:18082410
ChEMBL:1849998
ChEMBL:2157013
ChEMBL:2160539
ChEMBL:2163453
ChEMBL:2163454
ChEMBL:2165163
ChEMBL:2175356
ChEMBL:2329551
ChEMBL:2329561
ChEMBL:2391689
ChEMBL:2500527
ChEMBL:2544723
ChEMBL:2822928
ChEMBL:2826784
ChEMBL:2840500
ChEMBL:2842505
ChEMBL:2846837
ChEMBL:2848125
ChEMBL:2913300
ChEMBL:2989523
ChEMBL:2993615
ChEMBL:3009811
ChEMBL:3016263
ChEMBL:3871860
ChEMBL:465284
ChEMBL:7562929
ChEMBL:7562946
ChEMBL:7562947
ChEMBL:7752205
ChEMBL:7877148
ChEMBL:7932543
ChEMBL:8071942
ChEMBL:8176714
ChEMBL:8254613
ChEMBL:8394933
ChEMBL:8632412
ChEMBL:8709116
ChEMBL:8765514
ChEMBL:8784444
ChEMBL:8784445
ChEMBL:8941388
ChEMBL:9046339
ChEMBL:9057866
ChEMBL:9057867
ChEMBL:9057868
ChEMBL:9216836
ChEMBL:9438017
ChEMBL:9548814
ChEMBL:9575044
ChEMBL:9836613
ChEMBL:9836626
ChEMBL:9871553
ChEMBL:9925738
ChEMBL:9934470
ChEMBL:9934471
ChemIDplus:82410-32-0
DrugBank:82410-32-0
DrugBank:DB01004
KEGG COMPOUND:82410-32-0
KEGG COMPOUND:C07019
KEGG DRUG:82410-32-0
KEGG DRUG:D00333
Patent:US4355032
Wikipedia:Ganciclovir
2-amino-9-{[(1,3-dihydroxypropan-2-yl)oxy]methyl}-1,9-dihydro-6H-purin-6-one
Ganciclovir
2-(6-Amino-purin-9-ylmethoxy)-propane-1,3-diol
2-Amino-9-(2-hydroxy-1-hydroxymethyl-ethoxymethyl)-1,9-dihydro-purin-6-one
2-amino-9-((1,3-dihydroxypropan-2-yloxy)methyl)-1H-purin-6(9H)-one
2-amino-9-((1,3-dihydroxypropan-2-yloxy)methyl)-3H-purin-6(9H)-one
2-amino-9-((1,3-dihydroxypropan-2-yloxy)methyl)-9H-purin-6-ol
2-amino-9-(2-hydroxy-1-hydroxymethylethoxymethyl)-6,9-dihydro-1H-6-purinone
9-((2-Hydroxy-1-(hydroxymethyl)ethoxy)methyl)guanine
9-[(1,3-dihydroxy-2-propoxy)methyl]guanine
C9H13N5O4
GA2
InChI=1S/C9H13N5O4/c10-9-12-7-6(8(17)13-9)11-3-14(7)4-18-5(1-15)2-16/h3,5,15-16H,1-2,4H2,(H3,10,12,13,17)
InChIKey=IRSCQMHQWWYFCW-UHFFFAOYSA-N
Nc1nc2n(COC(CO)CO)cnc2c(=O)[nH]1
ganciclovir
ganciclovirum
gancyclovir
CHEBI:465284
Ganciclovir
ganciclovir
CHEBI:465284
An organic disulfide that has formula C10H20N2S4.
3554
ChemIDplus:97-77-8
KEGG COMPOUND:97-77-8
KEGG COMPOUND:C01692
KEGG DRUG:D00131
NIST Chemistry WebBook:97-77-8
Wikipedia:Disulfiram
1,1',1'',1'''-[disulfanediylbis(carbonothioylnitrilo)]tetraethane
Disulfiram
1,1'-dithiobis(N,N-diethylthioformamide)
Antabuse (TN)
C10H20N2S4
CCN(CC)C(=S)SSC(=S)N(CC)CC
InChI=1S/C10H20N2S4/c1-5-11(6-2)9(13)15-16-10(14)12(7-3)8-4/h5-8H2,1-4H3
InChIKey=AUZONCFQVSMFAP-UHFFFAOYSA-N
N,N,N',N'-tetraethylthiuram disulfide
bis(diethylthiocarbamoyl) disulfide
tetraethylthioperoxydicarbonic diamide
tetraethylthiuram disulfide
tetraethylthiuram disulphide
CHEBI:4659
Disulfiram
disulfiram
CHEBI:4659
Compounds based on a fused 1,2- or 1,3-oxazole and benzene bicyclic ring skeleton.
benzoxazoles
CHEBI:46700
benzoxazole
CHEBI:46700
Compounds in which an acyclic carbonyl group is bonded to one or two nitrogen atoms of a ring or ring system.
hidden amides
CHEBI:46754
hidden amide
CHEBI:46754
Any molecule that contains two amino-acid residues connected by peptide linkages.
CHEBI:23835
CHEBI:4634
KEGG COMPOUND:C00107
Dipeptide
C4H6N2O3R2
Dipeptid
dipeptides
CHEBI:46761
dipeptide
CHEBI:46761
Organic compounds having two ether functional groups.
diether
diethers
CHEBI:46786
diether
CHEBI:46786
N-acylpiperazines
CHEBI:46844
N-acylpiperazine
CHEBI:46844
N-alkylpiperazines
CHEBI:46845
N-alkylpiperazine
CHEBI:46845
N-arylpiperazines
CHEBI:46848
N-arylpiperazine
CHEBI:46848
indolyl carboxylic acids
CHEBI:46867
indolyl carboxylic acid
CHEBI:46867
imidazotriazines
CHEBI:46906
imidazotriazine
CHEBI:46906
imidazopyridines
CHEBI:46908
imidazopyridine
CHEBI:46908
N-sulfonylpiperazines
CHEBI:46918
N-sulfonylpiperazine
CHEBI:46918
A family of aromatic fatty amides produced as secondary metabolites by chilli peppers.
capsaicinoids
CHEBI:46931
capsaicinoid
CHEBI:46931
Compounds containing an anthracene skeleton.
CHEBI:46955
anthracenes
CHEBI:46955
tetrahydrofuranols
CHEBI:47017
tetrahydrofuranol
CHEBI:47017
monohydroxytetrahydrofurans
CHEBI:47018
monohydroxytetrahydrofuran
CHEBI:47018
A dibenzoazepine that has formula C19H24N2.
5691
CHEBI:47498
CHEBI:5881
Beilstein:256892
ChemIDplus:50-49-7
DrugBank:DB00458
Gmelin:1572523
KEGG COMPOUND:50-49-7
KEGG COMPOUND:C07049
NIST Chemistry WebBook:50-49-7
PDBeChem:IXX
Patent:US2554736
Wikipedia:Imipramine
3-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethylpropan-1-amine
Imipramine
10,11-dihydro-N,N-dimethyl-5H-dibenz[b,f]azepine-5-propanamine
3-(5H-DIBENZO[B,F]AZEPIN-5-YL)-N,N-DIMETHYLPROPAN-1-AMINE
5-[3-(dimethylamino)propyl]-10,11-dihydro-5H-dibenz[b,f]azepine
Antideprin
C19H24N2
CN(C)CCCN1c2ccccc2CCc2ccccc12
Imipramin
InChI=1S/C19H24N2/c1-20(2)14-7-15-21-18-10-5-3-8-16(18)12-13-17-9-4-6-11-19(17)21/h3-6,8-11H,7,12-15H2,1-2H3
InChIKey=BCGWQEUPMDMJNV-UHFFFAOYSA-N
Irmin
Melipramine
N-(gamma-dimethylaminopropyl)iminodibenzyl
imipramine
imipraminum
imizine
CHEBI:47499
Imipramine
imipramine
CHEBI:47499
Any carboxylic ester where the carboxylic acid component is acetic acid.
CHEBI:13244
CHEBI:13799
CHEBI:22189
CHEBI:2406
KEGG COMPOUND:C01883
Acetic ester
Acetyl ester
C2H3O2R
acetate
acetate esters
acetates
acetyl ester
acetyl esters
CHEBI:47622
acetate ester
CHEBI:47622
aminoglycosides
CHEBI:47779
aminoglycoside
CHEBI:47779
A dibenzoazepine that is 10,11-dihydro-5H-dibenzo[b,f]azepine which is substituted by chlorine at position 3 and in which the hydrogen attached to the nitrogen is replaced by a 3-(dimethylamino)propyl group. One of the more sedating tricyclic antidepressants, it is used as the hydrochloride salt for the treatment of depression as well as obsessive-compulsive disorder and phobias.
2597
CHEBI:3754
CHEBI:47359
ChemIDplus:1323477
ChemIDplus:303-49-1
CiteXplore:12007764
CiteXplore:12084414
CiteXplore:16085036
CiteXplore:17471183
CiteXplore:19810911
DrugBank:DB01242
KEGG COMPOUND:303-49-1
KEGG COMPOUND:C06918
NIST Chemistry WebBook:303-49-1
PDBeChem:CXX
Patent:CH371799
Patent:US3467650
Reaxys:1323477
Wikipedia:Clomipramine
3-(3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethylpropan-1-amine
Clomipramine
3-(3-CHLORO-5H-DIBENZO[B,F]AZEPIN-5-YL)-N,N-DIMETHYLPROPAN-1-AMINE
3-(3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethyl-1-propanamine
3-chloroimipramine
C19H23ClN2
CN(C)CCCN1c2ccccc2CCc2ccc(Cl)cc12
G 34586
InChI=1S/C19H23ClN2/c1-21(2)12-5-13-22-18-7-4-3-6-15(18)8-9-16-10-11-17(20)14-19(16)22/h3-4,6-7,10-11,14H,5,8-9,12-13H2,1-2H3
InChIKey=GDLIGKIOYRNHDA-UHFFFAOYSA-N
chlorimipramine
monochlorimipramine
CHEBI:47780
Clomipramine
clomipramine
CHEBI:47780
A dibenzoazepine that has formula C18H22N2.
3247
CHEBI:4448
CHEBI:47393
ChemIDplus:1432747
ChemIDplus:50-47-5
DrugBank:DB01151
KEGG COMPOUND:50-47-5
KEGG COMPOUND:C06943
KEGG DRUG:D07791
NIST Chemistry WebBook:50-47-5
PDBeChem:DSM
Wikipedia:Desipramine
3-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N-methylpropan-1-amine
Desipramine
3-(10,11-DIHYDRO-5H-DIBENZO[B,F]AZEPIN-5-YL)-N-METHYLPROPAN-1-AMINE
5-(gamma-methylaminopropyl)iminodibenzyl
C18H22N2
CNCCCN1c2ccccc2CCc2ccccc12
DMI
Desipramin
InChI=1S/C18H22N2/c1-19-13-6-14-20-17-9-4-2-7-15(17)11-12-16-8-3-5-10-18(16)20/h2-5,7-10,19H,6,11-14H2,1H3
InChIKey=HCYAFALTSJYZDH-UHFFFAOYSA-N
N-(3-methylaminopropyl)iminobibenzyl
demethylimipramine
desipramina
desipramine
desipraminum
desmethylimipramine
monodemethylimipramine
norimipramine
CHEBI:47781
Desipramine
desipramine
CHEBI:47781
CHEBI:13607
CHEBI:1653
CHEBI:20182
KEGG COMPOUND:C01876
3-Oxosteroid
3-oxo steroids
3-oxosteroid
3-oxosteroids
CHEBI:47788
3-oxo steroid
CHEBI:47788
dibenzoazepine
dibenzazepine
dibenzoazepines
CHEBI:47804
dibenzoazepine
CHEBI:47804
A cephalosporin bearing (1-methylpyrrolidinium-1-yl)methyl and (2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido groups at positions 3 and 7, respectively, of the cephem skeleton.
20481
CHEBI:3486
CHEBI:473919
Beilstein:7453587
ChEMBL:473919
ChEMBL:478164
CiteXplore:11084674
CiteXplore:11179650
CiteXplore:11191931
CiteXplore:11260566
CiteXplore:11280610
CiteXplore:11303846
CiteXplore:11306793
CiteXplore:11328792
CiteXplore:11431192
CiteXplore:11442796
CiteXplore:11864944
CiteXplore:11910959
CiteXplore:11964152
CiteXplore:12848746
CiteXplore:14628573
CiteXplore:14642333
CiteXplore:15303411
CiteXplore:15494381
CiteXplore:15830071
CiteXplore:15978309
CiteXplore:15980347
CiteXplore:16207962
CiteXplore:16650951
CiteXplore:16705389
CiteXplore:16930923
CiteXplore:17042189
CiteXplore:17214092
CiteXplore:17323865
CiteXplore:17448937
CiteXplore:17625777
CiteXplore:18025111
CiteXplore:18154532
CiteXplore:18651542
CiteXplore:18673128
CiteXplore:18717040
CiteXplore:19053894
CiteXplore:19304881
CiteXplore:21425867
DrugBank:DB01413
KEGG COMPOUND:88040-23-7
KEGG COMPOUND:C08111
KEGG DRUG:D02376
Patent:DE3307550
Patent:US4406899
Reaxys:7453587
Wikipedia:Cefepime
7beta-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido]-3-[(1-methylpyrrolidinium-1-yl)methyl]-3,4-didehydrocepham-4-carboxylate
Cefepime
cefepime
(6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-[(1-methylpyrrolidinium-1-yl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
C19H24N6O5S2
InChI=1S/C19H24N6O5S2/c1-25(5-3-4-6-25)7-10-8-31-17-13(16(27)24(17)14(10)18(28)29)22-15(26)12(23-30-2)11-9-32-19(20)21-11/h9,13,17H,3-8H2,1-2H3,(H3-,20,21,22,26,28,29)/b23-12-/t13-,17-/m1/s1
InChIKey=HVFLCNVBZFFHBT-ZKDACBOMSA-N
[H][C@]12SCC(C[N+]3(C)CCCC3)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\c1csc(N)n1)C([O-])=O
cefepima
cefepime
cefepimum
CHEBI:478164
cefepime
CHEBI:478164
A dicarboxylic acid monoester that is ethyl 4-phenylbutanoate in which a hydrogen alpha to the carboxy group is substituted by the amino group of L-alanyl-L-proline (S-configuration).
3827
CHEBI:116847
Beilstein:3657467
ChEMBL:10669559
ChEMBL:116847
ChemIDplus:75847-73-3
DrugBank:DB00584
KEGG COMPOUND:75847-73-3
KEGG COMPOUND:C06977
KEGG DRUG:D07892
Patent:EP12401
Patent:US4374829
Wikipedia:Enalapril
ENALAPRIL
Enalapril
N-[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]-L-alanyl-L-proline
(S)-1-(N-(1-(ethoxycarbonyl)-3-phenylpropyl)-L-alanyl)-L-proline
(S)-1-{(S)-2-[1-((S)-Ethoxycarbonyl)-3-phenyl-propylamino]-propionyl}-pyrrolidine-2-carboxylic acid
1-(N-((S)-1-carboxy-3-phenylpropyl)-L-alanyl)-L-proline 1'-ethyl ester
C20H28N2O5
CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O
InChI=1S/C20H28N2O5/c1-3-27-20(26)16(12-11-15-8-5-4-6-9-15)21-14(2)18(23)22-13-7-10-17(22)19(24)25/h4-6,8-9,14,16-17,21H,3,7,10-13H2,1-2H3,(H,24,25)/t14-,16-,17-/m0/s1
InChIKey=GBXSMTUPTTWBMN-XIRDDKMYSA-N
enalapril
enalaprila
enalaprilum
CHEBI:4784
Enalapril
enalapril
CHEBI:4784
CHEBI:27220
CHEBI:36947
urea derivatives
CHEBI:47857
ureas
CHEBI:47857
CHEBI:13600
CHEBI:1619
CHEBI:35949
KEGG COMPOUND:C01656
3-Oxo acid
3-oxo monocarboxylic acids
C3H2O3R2
CHEBI:47881
3-oxo monocarboxylic acid
CHEBI:47881
CHEBI:13604
CHEBI:1626
CHEBI:20157
KEGG COMPOUND:C00619
3-Oxo-delta4-steroid
3-oxo Delta(4)-steroids
3-oxo-Delta(4)-steroid
CHEBI:47909
3-oxo Delta(4)-steroid
CHEBI:47909
2',3'-dideoxyribonucleosides
CHEBI:47945
2',3'-dideoxyribonucleoside
CHEBI:47945
A vinca alkaloid with a norvinblastine skeleton.
39541
Beilstein:9035861
ChEMBL:480999
ChemIDplus:71486-22-1
DrugBank:71486-22-1
DrugBank:DB00361
KEGG DRUG:71486-22-1
KEGG DRUG:D08680
Patent:JP8031096
Patent:US4307100
methyl (2beta,3beta,4beta,5alpha,12beta,19alpha)-4-acetoxy-15-[(6R,8S)-4-ethyl-8-(methoxycarbonyl)-1,3,6,7,8,9-hexahydro-2,6-methanoazecino[4,3-b]indol-8-yl]-3-hydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidine-3-carboxylate
C45H54N4O8
InChI=1S/C45H54N4O8/c1-8-27-19-28-22-44(40(51)55-6,36-30(25-48(23-27)24-28)29-13-10-11-14-33(29)46-36)32-20-31-34(21-35(32)54-5)47(4)38-43(31)16-18-49-17-12-15-42(9-2,37(43)49)39(57-26(3)50)45(38,53)41(52)56-7/h10-15,19-21,28,37-39,46,53H,8-9,16-18,22-25H2,1-7H3/t28-,37-,38+,39+,42+,43+,44-,45+/m0/s1
InChIKey=GBABOYUKABKIAF-GHYRFKGUSA-N
Nor-5'-anhydrovinblastine
[H][C@]12CN(CC(CC)=C1)Cc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@]1([H])[C@@](O)([C@H](OC(C)=O)[C@]3(CC)C=CCN4CC[C@]21[C@]34[H])C(=O)OC
vinorelbina
vinorelbine
vinorelbinum
CHEBI:480999
vinorelbine
CHEBI:480999
sulfamate esters
CHEBI:48199
sulfamate ester
CHEBI:48199
Compounds of structure RSSR'.
disulfides
CHEBI:48343
disulfide
CHEBI:48343
CHEBI:48420
biphenylyltetrazole
CHEBI:48420
pyrimidine 2',3'-dideoxyribonucleosides
CHEBI:48441
pyrimidine 2',3'-dideoxyribonucleoside
CHEBI:48441
purine 2',3'-dideoxyribonucleosides
CHEBI:48442
purine 2',3'-dideoxyribonucleoside
CHEBI:48442
pyrimidinethiones
CHEBI:48546
pyrimidinethione
CHEBI:48546
hydroxypiperidines
CHEBI:48590
hydroxypiperidine
CHEBI:48590
piperidinecarboxamides
CHEBI:48592
piperidinecarboxamide
CHEBI:48592
pyranoindolizinoquinolines
CHEBI:48626
pyranoindolizinoquinoline
CHEBI:48626
benzothiazepines
CHEBI:48684
benzothiazepine
CHEBI:48684
Ethane-1,2-diamine in which one hydrogen attached to each of the nitrogens is sutstituted by a 1-hydroxybutan-2-yl group (S,S-configuration). It is a bacteriostatic antimycobacterial drug, effective against Mycobacterium tuberculosis and some other mycobacteria. It is used (as the dihydrochloride salt) in combination with other antituberculous drugs in the treatment of pulmonary and extrapulmonary tuberculosis; resistant strains of M. tuberculosis are readily produced if ethambutol is used alone.
4110
CHEBI:133410
CHEBI:659237
CHEBI:678172
Beilstein:6312870
ChEMBL:10649975
ChEMBL:10891117
ChEMBL:10966749
ChEMBL:12182855
ChEMBL:133410
ChEMBL:14695841
ChEMBL:14698152
ChEMBL:15225698
ChEMBL:16005211
ChEMBL:16759086
ChEMBL:16870429
ChEMBL:17210775
ChEMBL:17239593
ChEMBL:17276683
ChEMBL:17315960
ChEMBL:17331717
ChEMBL:17562368
ChEMBL:17851083
ChEMBL:17888665
ChEMBL:19524332
ChEMBL:19648006
ChEMBL:3934384
ChEMBL:659237
ChEMBL:678172
ChemIDplus:74-55-5
DrugBank:DB00330
KEGG COMPOUND:74-55-5
KEGG COMPOUND:C06984
KEGG DRUG:D07925
Wikipedia:Ethambutol
(2S,2'S)-2,2'-(ethane-1,2-diyldiimino)dibutan-1-ol
Ethambutol
(+)-2,2'-(ethylenediimino)di-1-butanol
(+)-N,N'-bis(1-(hydroxymethyl)propyl)ethylenediamine
(+)-S,S-ethambutol
(+)-ethambutol
(2S,7S)-2,7-diethyl-3,6-diazaoctane-1,8-diol
(S,S)-ethambutol
C10H24N2O2
CC[C@@H](CO)NCCN[C@@H](CC)CO
EMB
InChI=1S/C10H24N2O2/c1-3-9(7-13)11-5-6-12-10(4-2)8-14/h9-14H,3-8H2,1-2H3/t9-,10-/m0/s1
InChIKey=AEUTYOVWOVBAKS-UWVGGRQHSA-N
S,S-Ethambutol
etambutol
ethambutol
ethambutolum
CHEBI:4877
Ethambutol
ethambutol
CHEBI:4877
benzothiadiazoles
CHEBI:48864
benzothiadiazole
CHEBI:48864
thiadiazolidines
CHEBI:48865
thiadiazolidine
CHEBI:48865
CHEBI:48901
thiazoles
CHEBI:48901
1,2-thiazoles
isothiazoles
CHEBI:48902
1,2-thiazole
CHEBI:48902
A phosphonic acid consisting of (ethane-1,1-diyl)bis(phosphonic acid) having a hydroxy substituent at the 1-position. Inhibits formation, growth, and dissolution of hydroxyapatite crystals by chemisorption to calcium phosphate surfaces
42682
CHEBI:63588
ChemIDplus:2809-21-4
CiteXplore:10385693
CiteXplore:17157266
CiteXplore:17214981
CiteXplore:18313802
DrugBank:DB01077
KEGG COMPOUND:2809-21-4
KEGG COMPOUND:C07736
KEGG DRUG:D02373
Patent:US3159581
Reaxys:1789291
Wikipedia:Etidronate
(1-hydroxyethane-1,1-diyl)bis(phosphonic acid)
(1-Hydroxyethylene)diphosphonic acid
(1-Hydroxyethylidene)bis(phosphonic acid)
(1-Hydroxyethylidene)bisphosphonic acid
(1-Hydroxyethylidene)diphosphonic acid
(Hydroxyethylidene)diphosphonic acid
1,1,1-Ethanetriol diphosphonate
1-Hydroxy-1,1-diphosphonoethane
1-Hydroxyethane-1,1-bisphosphonic acid
1-Hydroxyethane-1,1-diphosphonate
1-Hydroxyethane-1,1-diphosphonic acid
1-Hydroxyethanediphosphonic acid
1-Hydroxyethylidene-1,1-bisphosphonate
1-Hydroxyethylidene-1,1-diphosphonic acid
Acetodiphosphonic acid
C2H8O7P2
CC(O)(P(O)(O)=O)P(O)(O)=O
EHDP
Ethane-1-hydroxy-1,1-diphosphonate
Ethane-1-hydroxy-1,1-diphosphonic acid
Etidronsaeure
HEDP
Hydroxyethanediphosphonic acid
InChI=1S/C2H8O7P2/c1-2(3,10(4,5)6)11(7,8)9/h3H,1H3,(H2,4,5,6)(H2,7,8,9)
InChIKey=DBVJJBKOTRCVKF-UHFFFAOYSA-N
Oxyethylidenediphosphonic acid
acide etidronique
acido etidronico
acidum etidronicum
ethane-1-hydroxy-1,1-bisphosphonic acid
etidronate
etidronic acid
CHEBI:4907
Etidronate
etidronic acid
CHEBI:4907
A purine 2',3'-dideoxyribonucleoside that is inosine in which the hydroxy groups at both the 2' and the 3' positions on the sugar moiety have been replaced by hydrogen.
3364
CHEBI:158219
CHEBI:39738
CHEBI:4516
CHEBI:475381
CHEBI:668806
Beilstein:3619529
ChEMBL:10386939
ChEMBL:158219
ChEMBL:1619614
ChEMBL:17046264
ChEMBL:475381
ChEMBL:490877
ChEMBL:668806
ChemIDplus:69655-05-6
CiteXplore:18549801
DrugBank:DB00900
KEGG COMPOUND:69655-05-6
KEGG COMPOUND:C06953
KEGG DRUG:D00296
PDBeChem:2DI
Patent:EP206497
Wikipedia:Didanosine
2',3'-dideoxyinosine
Didanosine
2,3-dideoxyinosine
9-((2R,5S)-5-(hydroxymethyl)-tetrahydrofuran-2-yl)-1H-purin-6(9H)-one
9-((2R,5S)-5-Hydroxymethyl-tetrahydro-furan-2-yl)-1,9-dihydro-purin-6-one
9-((2S,5R)-5-Hydroxymethyl-tetrahydro-furan-2-yl)-9H-purin-6-ol
9-[(2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1,9-dihydro-6H-purin-6-one
C10H12N4O3
DDI
InChI=1S/C10H12N4O3/c15-3-6-1-2-7(17-6)14-5-13-8-9(14)11-4-12-10(8)16/h4-7,15H,1-3H2,(H,11,12,16)/t6-,7+/m0/s1
InChIKey=BXZVVICBKDXVGW-NKWVEPMBSA-N
OC[C@@H]1CC[C@@H](O1)n1cnc2c1nc[nH]c2=O
ddI
ddIno
didanosina
didanosine
didanosinum
dideoxyinosine
CHEBI:490877
Didanosine
didanosine
CHEBI:490877
A beta-D-glucoside that has formula C29H32O13.
4179
ChemIDplus:33419-42-0
DrugBank:DB00773
KEGG COMPOUND:33419-42-0
KEGG COMPOUND:C01576
KEGG DRUG:D00125
Patent:US3524844
Wikipedia:Etoposide
(5S,5aR,8aR,9R)-9-(4-hydroxy-3,5-dimethoxyphenyl)-8-oxo-5,5a,6,8,8a,9-hexahydrofuro[3',4':6,7]naphtho[2,3-d][1,3]dioxol-5-yl 4,6-O-[(1R)-ethylidene]-beta-D-glucopyranoside
Etoposide
(-)-etoposide
4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-beta-D-glucopyranoside)
4-demethylepipodophyllotoxin beta-D-ethylideneglucoside
9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-d)-1,3-dioxol-6(5aH)-one
C29H32O13
Eposin
Etopophos
Etoposido
InChI=1S/C29H32O13/c1-11-36-9-20-27(40-11)24(31)25(32)29(41-20)42-26-14-7-17-16(38-10-39-17)6-13(14)21(22-15(26)8-37-28(22)33)12-4-18(34-2)23(30)19(5-12)35-3/h4-7,11,15,20-22,24-27,29-32H,8-10H2,1-3H3/t11-,15+,20-,21-,22+,24-,25-,26-,27-,29+/m1/s1
InChIKey=VJJPUSNTGOMMGY-MRVIYFEKSA-N
Lastet
Toposar
VP-16
Vepesid
[H][C@]12COC(=O)[C@]1([H])[C@H](c1cc(OC)c(O)c(OC)c1)c1cc3OCOc3cc1[C@H]2O[C@@H]1O[C@@H]2CO[C@@H](C)O[C@H]2[C@H](O)[C@H]1O
etoposide
etoposidum
trans-Etoposide
CHEBI:4911
Etoposide
etoposide
CHEBI:4911
A hydroxyphenylalanine that has formula C9H11NO4.
Beilstein:1462084
ChemIDplus:63-84-3
Gmelin:51382
NIST Chemistry WebBook:63-84-3
2-amino-3-(3,4-dihydroxyphenyl)propanoic acid
dopa
(+-)-3-(3,4-dihydroxyphenyl)alanine
(+-)-dopa
(R,S)-dopa
3',4'-dihydroxyphenylalanine
3-hydroxy-DL-tyrosine
3-hydroxytyrosine
C9H11NO4
DL-3,4-dopa
DL-beta-(3,4-dihydroxyphenyl)alanine
DL-dihydroxyphenylalanine
DL-dioxyphenylalanine
InChI=1S/C9H11NO4/c10-6(9(13)14)3-5-1-2-7(11)8(12)4-5/h1-2,4,6,11-12H,3,10H2,(H,13,14)
InChIKey=WTDRDQBEARUVNC-UHFFFAOYSA-N
NC(Cc1ccc(O)c(O)c1)C(O)=O
beta-(3,4-dihydroxyphenyl)-DL-alpha-alanine
dl-beta-(3,4-dihydroxyphenyl)-alpha-alanine
CHEBI:49168
dopa
CHEBI:49168
Androsta-1,4-diene-3,17-dione in which the hydrogens at position 6 are replaced by a double bond to a methylene group.a selective inhibitor of the aromatase (oestrogen synthase) system, it is used in the treatment of advanced breast cancer.
258494
ChemIDplus:107868-30-4
CiteXplore:10882163
DrugBank:DB00990
KEGG COMPOUND:107868-30-4
KEGG COMPOUND:C08162
KEGG DRUG:D00963
Wikipedia:Exemestane
6-methylideneandrosta-1,4-diene-3,17-dione
Exemestane
6-methyleneandrosta-1,4-diene-3,17-dione
C20H24O2
InChI=1S/C20H24O2/c1-12-10-14-15-4-5-18(22)20(15,3)9-7-16(14)19(2)8-6-13(21)11-17(12)19/h6,8,11,14-16H,1,4-5,7,9-10H2,2-3H3/t14-,15-,16-,19+,20-/m0/s1
InChIKey=BFYIZQONLCFLEV-DAELLWKTSA-N
[H][C@@]12CC(=C)C3=CC(=O)C=C[C@]3(C)[C@@]1([H])CC[C@]1(C)C(=O)CC[C@@]21[H]
exemestane
exemestano
exemestanum
CHEBI:4953
exemestane
CHEBI:4953
An indole-3-acetic acid that has formula C19H16ClNO4.
5781
CHEBI:49660
CHEBI:5918
Beilstein:497341
ChemIDplus:53-86-1
Gmelin:1446006
KEGG COMPOUND:53-86-1
KEGG COMPOUND:C01926
KEGG DRUG:D00141
NIST Chemistry WebBook:53-86-1
PDBeChem:IMN
Wikipedia:Indomethacin
INDOMETHACIN
Indomethacin
[1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl]acetic acid
1-(p-chlorobenzoyl)-5-methoxy-2-methylindole-3-acetic acid
C19H16ClNO4
COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(O)=O)c2c1
InChI=1S/C19H16ClNO4/c1-11-15(10-18(22)23)16-9-14(25-2)7-8-17(16)21(11)19(24)12-3-5-13(20)6-4-12/h3-9H,10H2,1-2H3,(H,22,23)
InChIKey=CGIGDMFJXJATDK-UHFFFAOYSA-N
Indocin
Indometacin
CHEBI:49662
Indomethacin
indomethacin
CHEBI:49662
A compound formally derived from ammonia by replacing one, two or three hydrogen atoms by organyl groups.
organic amino compounds
CHEBI:50047
organic amino compound
CHEBI:50047
dihydropyridine
dihydropyridines
CHEBI:50075
dihydropyridine
CHEBI:50075
A phenethylamine alkaloid that has formula C13H17N.
9639
Beilstein:2092580
N-methyl-N-(1-methyl-2-phenylethyl)prop-2-yn-1-amine
C13H17N
CC(Cc1ccccc1)N(C)CC#C
InChI=1S/C13H17N/c1-4-10-14(3)12(2)11-13-8-6-5-7-9-13/h1,5-9,12H,10-11H2,2-3H3
InChIKey=MEZLKOACVSPNER-UHFFFAOYSA-N
selegilina
selegiline
selegilinum
CHEBI:50217
Selegiline
selegiline
CHEBI:50217
A 3-oxo steroid that has formula C22H30O5.
Beilstein:7113955
11beta,17,21-trihydroxy-6-methylpregna-1,4-diene-3,20-dione
(11beta)-11,17,21-trihydroxy-6-methylpregna-1,4-diene-3,20-dione
C22H30O5
InChI=1S/C22H30O5/c1-12-8-14-15-5-7-22(27,18(26)11-23)21(15,3)10-17(25)19(14)20(2)6-4-13(24)9-16(12)20/h4,6,9,12,14-15,17,19,23,25,27H,5,7-8,10-11H2,1-3H3/t12?,14-,15-,17-,19+,20-,21-,22-/m0/s1
InChIKey=VHRSUDSXCMQTMA-UWKORSIYSA-N
[H][C@@]12CC(C)C3=CC(=O)C=C[C@]3(C)[C@@]1([H])[C@@H](O)C[C@@]1(C)[C@@]2([H])CC[C@]1(O)C(=O)CO
CHEBI:50366
6-methylprednisolone
CHEBI:50366
taxane diterpenoid
taxane diterpenoids
CHEBI:50367
taxane diterpenoid
CHEBI:50367
CHEBI:50453
desferrioxamine
CHEBI:50453
CHEBI:50454
acyclic desferrioxamine
CHEBI:50454
Any compound containing the thiocarbonyl group, C=S.
thiocarbonyl compounds
CHEBI:50492
thiocarbonyl compound
CHEBI:50492
A thiocarbonyl compound that has formula C4H6N2S.
6835
CHEBI:44168
CHEBI:6828
Beilstein:108646
ChemIDplus:60-56-0
DrugBank:DB00763
KEGG DRUG:D00401
NIST Chemistry WebBook:60-56-0
PDBeChem:MMZ
Wikipedia:Methimazole
1-methyl-1,3-dihydro-2H-imidazole-2-thione
1-METHYL-1,3-DIHYDRO-2H-IMIDAZOLE-2-THIONE
1-Methylimidazole-2(3H)-thione
C4H6N2S
Cn1cc[nH]c1=S
Danantizol
Favistan
InChI=1S/C4H6N2S/c1-6-3-2-5-4(6)7/h2-3H,1H3,(H,5,7)
InChIKey=PMRYVIKBURPHAH-UHFFFAOYSA-N
Strumazol
Tapazole
Thacapzol
USAF el-30
thiamazol
thiamazole
thiamazolum
tiamazol
CHEBI:50673
Methimazole
methimazole
CHEBI:50673
A hydroxyanthraquinone that has formula C22H28N4O6.
7005
CHEBI:43919
CHEBI:6955
Beilstein:2795126
ChemIDplus:65271-80-9
DrugBank:DB01204
KEGG COMPOUND:65271-80-9
KEGG COMPOUND:C11195
PDBeChem:MIX
Patent:DE2835661
Patent:US4197249
Wikipedia:Mitoxantrone
1,4-dihydroxy-5,8-bis({2-[(2-hydroxyethyl)amino]ethyl}amino)anthracene-9,10-dione
Mitoxantrone
1,4-DIHYDROXY-5,8-BIS({2-[(2-HYDROXYETHYL)AMINO]ETHYL}AMINO)-9,10-ANTHRACENEDIONE
C22H28N4O6
InChI=1S/C22H28N4O6/c27-11-9-23-5-7-25-13-1-2-14(26-8-6-24-10-12-28)18-17(13)21(31)19-15(29)3-4-16(30)20(19)22(18)32/h1-4,23-30H,5-12H2
InChIKey=KKZJGLLVHKMTCM-UHFFFAOYSA-N
OCCNCCNc1ccc(NCCNCCO)c2C(=O)c3c(O)ccc(O)c3C(=O)c12
mitoxantrona
mitoxantrone
mitoxantronum
CHEBI:50729
Mitoxantrone
mitoxantrone
CHEBI:50729
An alkyl sulfide that has formula C35H36ClNO3S.
88249
CHEBI:49756
CHEBI:6992
Beilstein:7896575
ChemIDplus:158966-92-8
DrugBank:DB00471
KEGG COMPOUND:158966-92-8
KEGG COMPOUND:C07482
PDBeChem:MTK
Patent:EP1886997
Wikipedia:Montelukast
MONTELUKAST
Montelukast
{1-[({(1R)-1-{3-[(E)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl}-3-[2-(2-hydroxypropan-2-yl)phenyl]propyl}sulfanyl)methyl]cyclopropyl}acetic acid
(R-(E))-1-(((1-(3-(2-(7-Chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropaneacetic acid
1-[[[(1 R)-1-[3-[(1E)-2-(7-chloro-2-quinolinyl)ethenyl] phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]sulfanyl]methyl]cyclopropaneacetic acid
C35H36ClNO3S
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC1)CC(O)=O)c1cccc(\C=C\c2ccc3ccc(Cl)cc3n2)c1
InChI=1S/C35H36ClNO3S/c1-34(2,40)30-9-4-3-7-25(30)13-17-32(41-23-35(18-19-35)22-33(38)39)27-8-5-6-24(20-27)10-15-29-16-12-26-11-14-28(36)21-31(26)37-29/h3-12,14-16,20-21,32,40H,13,17-19,22-23H2,1-2H3,(H,38,39)/b15-10+/t32-/m1/s1
InChIKey=UCHDWCPVSPXUMX-TZIWLTJVSA-N
montelukast
CHEBI:50730
montelukast
CHEBI:50730
A steroid which is substituted with one or more fluorine atoms in any position.
CHEBI:50830
fluorinated steroid
CHEBI:50830
A natural or synthetic analogue of the hormones secreted by the adrenal gland.
corticoides
corticosteroides
corticosteroids
CHEBI:50858
corticosteroid
CHEBI:50858
Any molecular entity that contains carbon.
CHEBI:25700
CHEBI:33244
organic compounds
organic entity
organic molecular entities
CHEBI:50860
organic molecular entity
CHEBI:50860
CHEBI:50990
thiazolidenediones
CHEBI:50990
A compound formally derived from ammonia by replacing one hydrogen atom by an organyl group.
primary amino compounds
CHEBI:50994
primary amino compound
CHEBI:50994
A compound formally derived from ammonia by replacing two hydrogen atoms by organyl groups.
secondary amino compounds
CHEBI:50995
secondary amino compound
CHEBI:50995
A compound formally derived from ammonia by replacing three hydrogen atoms by organyl groups.
tertiary amino compounds
CHEBI:50996
tertiary amino compound
CHEBI:50996
An organofluorine compound that has formula C4H4FN3O.
4451
ChemIDplus:2022-85-7
KEGG DRUG:2022-85-7
KEGG DRUG:D00323
Wikipedia:Flucytosine
4-amino-5-fluoropyrimidin-2(1H)-one
Flucytosine
5-FC
5-Fluorocystosine
5-Fluorocytosine
Ancobon (TN)
C4H4FN3O
InChI=1S/C4H4FN3O/c5-2-1-7-4(9)8-3(2)6/h1H,(H3,6,7,8,9)
InChIKey=XRECTZIEBJDKEO-UHFFFAOYSA-N
Nc1nc(=O)[nH]cc1F
CHEBI:5100
Flucytosine
flucytosine
CHEBI:5100
CHEBI:25556
CHEBI:7594
KEGG COMPOUND:C06061
Nitrogenous compounds
nitrogen compounds
nitrogen molecular entities
CHEBI:51143
nitrogen molecular entity
CHEBI:51143
A benzenoid aromatic compound that has formula C17H18F3NO.
4493
Beilstein:39914106
ChemIDplus:54910-89-3
DrugBank:DB00472
KEGG DRUG:54910-89-3
KEGG DRUG:D00326
Patent:DE2500110
Patent:US4314081
Wikipedia:Fluoxetine
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine
(+-)-N-methyl-3-phenyl-3-((alpha,alpha,alpha-trifluoro-p-tolyl)oxy)propylamine
(+-)-N-methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine
C17H18F3NO
CNCCC(Oc1ccc(cc1)C(F)(F)F)c1ccccc1
InChI=1S/C17H18F3NO/c1-21-12-11-16(13-5-3-2-4-6-13)22-15-9-7-14(8-10-15)17(18,19)20/h2-10,16,21H,11-12H2,1H3
InChIKey=RTHCYVBBDHJXIQ-UHFFFAOYSA-N
Prozac
fluoxetina
fluoxetine
fluoxetinum
CHEBI:5118
Fluoxetine
fluoxetine
CHEBI:5118
Gmelin:101110
NIST Chemistry WebBook:14913-33-8
diamminedichloridoplatinum
diamminedichloridoplatinum(II)
diamminedichloroplatinum
diamminedichloroplatinum(II)
Cl2H6N2Pt
diammine(dichloro)platinum
diammineplatinum dichloride
CHEBI:51214
diamminedichloroplatinum
CHEBI:51214
Polycyclic aromatic hydrocarbons consisting of fused benzene rings in a rectilinear arrangement and their substitution derivatives.
CHEBI:51269
acenes
CHEBI:51269
Quinones containing an acene fused ring system.
acenoquinone
acenoquinones
CHEBI:51285
acenoquinone
CHEBI:51285
Compounds containing an adamantane skeleton.
CHEBI:51339
adamantanes
CHEBI:51339
A 5-methoxyvalerophenone O-(2-aminoethyl)oxime that has formula C15H21F3N2O2.
42355
Beilstein:5583954
ChemIDplus:54739-18-3
DrugBank:DB00176
KEGG COMPOUND:54739-18-3
KEGG COMPOUND:C07571
Patent:NL7503310
Patent:US4085225
Wikipedia:Fluvoxamine
(1E)-5-methoxy-1-[4-(trifluoromethyl)phenyl]pentan-1-one O-(2-aminoethyl)oxime
Fluvoxamine
C15H21F3N2O2
COCCCC\C(c1ccc(cc1)C(F)(F)F)=N/OCCN
InChI=1S/C15H21F3N2O2/c1-21-10-3-2-4-14(20-22-11-9-19)12-5-7-13(8-6-12)15(16,17)18/h5-8H,2-4,9-11,19H2,1H3/b20-14+
InChIKey=CJOFXWAVKWHTFT-XSFVSMFZSA-N
fluvoxamina
fluvoxamine
fluvoxaminum
CHEBI:5138
Fluvoxamine
fluvoxamine
CHEBI:5138
Cyclopropane and its derivatives formed by substitution.
CHEBI:51454
cyclopropanes
CHEBI:51454
Compounds based on a fused 1,2-oxazole and benzene bicyclic ring skeleton, with the O atom positioned adjacent to one of the positions of ring fusion.
CHEBI:51545
1,2-benzoxazoles
CHEBI:51545
Compounds based on a fused 1,2-oxazole and benzene bicyclic ring skeleton.
benzisoxazoles
CHEBI:51549
benzisoxazole
CHEBI:51549
Compounds containing a mono-unsaturated furan ring skeleton.
dihydrofurans
CHEBI:51659
dihydrofuran
CHEBI:51659
An alpha,beta-unsaturated ketone of general formula R(1)R(2)C=CR(3)-C(=O)R(4) (R(4) =/= H) in which the C=O function is conjugated to a C=C double bond at the alpha,beta position.
C3OR4
[*]\C([*])=C(\[*])C([*])=O
enones
CHEBI:51689
enone
CHEBI:51689
A ketone of general formula R(1)R(2)C=CR(3)-C(=O)R(4) (R(4) =/= H) or R(1)C#C-C(=O)R(2) (R(2) =/= H) in which the ketonic C=O function is conjugated to an unsaturated C-C bond at the alpha,beta position.
alpha,beta-unsaturated ketones
CHEBI:51721
alpha,beta-unsaturated ketone
CHEBI:51721
organic polycyclic compounds
CHEBI:51958
organic polycyclic compound
CHEBI:51958
organic tricyclic compounds
CHEBI:51959
organic tricyclic compound
CHEBI:51959
A terpenoid having a C20 tetracyclic skeleton.
tetracyclic diterpenoids
CHEBI:52557
tetracyclic diterpenoid
CHEBI:52557
Any organic heterotricyclic compound based on a skeleton comprised of an oxazine ring fused onto a quinoline system.
oxazinoquinolines
CHEBI:53665
oxazinoquinoline
CHEBI:53665
Compounds containing an ifosfamide skeleton.
isosfamides
CHEBI:55369
ifosfamides
CHEBI:55369
An imidazolidine containing one or more oxo groups.
imidazolidinones
CHEBI:55370
imidazolidinone
CHEBI:55370
Oxazoles in which the N and O atoms are adjacent.
CHEBI:46813
isoxazoles
1,2-oxazoles
CHEBI:55373
isoxazoles
CHEBI:55373
A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4; and an N-linked p-fluorobutyrophenone moiety.
5093
Beilstein:331267
ChemIDplus:52-86-8
CiteXplore:7602118
DrugBank:DB00502
KEGG COMPOUND:52-86-8
KEGG COMPOUND:C01814
KEGG DRUG:D00136
NIST Chemistry WebBook:52-86-8
Patent:BE577977
Patent:GB895309
Patent:US3438991
Wikipedia:Haloperidol
4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-1-(4-fluorophenyl)butan-1-one
1-(3-p-fluorobenzoylpropyl)-4-p-chlorophenyl-4-hydroxypiperidine
4'-fluoro-4-(4-(p-chlorophenyl)-4-hydroxypiperidinyl)butyrophenone
4'-fluoro-4-(4-hydroxy-4-(4'-chlorophenyl)piperidino)butyrophenone
4-(4-(para-chlorophenyl)-4-hydroxypiperidino)-4'-fluorobutyrophenone
4-[4-(4-chlorophenyl)-4-hydroxy-1-piperidyl]-1-(4-fluorophenyl)-butan-1-one
C21H23ClFNO2
Haldol
InChI=1S/C21H23ClFNO2/c22-18-7-5-17(6-8-18)21(26)11-14-24(15-12-21)13-1-2-20(25)16-3-9-19(23)10-4-16/h3-10,26H,1-2,11-15H2
InChIKey=LNEPOXFFQSENCJ-UHFFFAOYSA-N
OC1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)c1ccc(Cl)cc1
gamma-(4-(p-chlorophenyl)-4-hydroxpiperidino)-p-fluorbutyrophenone
haloperidol
haloperidolum
CHEBI:5613
Haloperidol
haloperidol
CHEBI:5613
2'-Deoxyadenosine in which the hydrogen at position 2 on the purine ring has been substituted by chlorine. It inhibits the synthesis and repair of DNA, particularly in lymphocytes and monocytes, and is used as an antimetabolite antineoplastic drug for the treatment of lymphoid malignancies including hairy-cell leukaemia and chronic lymphocytic leukaemia.
44157
CHEBI:31407
CHEBI:568373
Beilstein:624220
ChEMBL:17526755
ChEMBL:18570408
ChEMBL:567361
ChEMBL:568373
ChemIDplus:4291-63-8
DrugBank:DB00242
KEGG DRUG:4291-63-8
KEGG DRUG:D01370
Patent:EP173059
Patent:US4760137
Wikipedia:Cladribine
2-chloro-2'-deoxyadenosine
Cladribine
(2R,3S,5R)-5-(6-amino-2-chloropurin-9-yl)-2-(hydroxymethyl)oxolan-3-ol
2-CdA
2-chloro-2'-deoxy-beta-adenosine
2-chloro-6-amino-9-(2-deoxy-beta-D-erythro-pentofuranosyl)purine
2-chloro-deoxyadenosine
2-chlorodeoxyadenosine
2ClAdo
C10H12ClN5O3
CldAdo
InChI=1S/C10H12ClN5O3/c11-10-14-8(12)7-9(15-10)16(3-13-7)6-1-4(18)5(2-17)19-6/h3-6,17-18H,1-2H2,(H2,12,14,15)/t4-,5+,6+/m0/s1
InChIKey=PTOAARAWEBMLNO-KVQBGUIXSA-N
Nc1nc(Cl)nc2n(cnc12)[C@H]1C[C@H](O)[C@@H](CO)O1
cladribina
cladribine
cladribinum
CHEBI:567361
Cladribine
cladribine
CHEBI:567361
A cyclic compound having as ring members atoms of at least two different elements.
Heterocyclic compound
compuesto heterociclico
compuestos heterociclicos
heterocycle
heterocyclic compounds
CHEBI:5686
heterocyclic compound
CHEBI:5686
A nitrogen mustard alkylating agent used in the treatment of cancer
5657
CHEBI:219640
Beilstein:611835
ChEMBL:219640
ChemIDplus:3778-73-2
DrugBank:DB01181
KEGG COMPOUND:3778-73-2
KEGG COMPOUND:C07047
KEGG DRUG:D00343
Wikipedia:Ifosfamide
N,3-bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide
C7H15Cl2N2O2P
ClCCNP1(=O)OCCCN1CCCl
InChI=1S/C7H15Cl2N2O2P/c8-2-4-10-14(12)11(6-3-9)5-1-7-13-14/h1-7H2,(H,10,12)
InChIKey=HOMGKSMUEGBAAB-UHFFFAOYSA-N
Iphosphamide
Isofosfamide
Isophosphamide
ifosfamida
ifosfamide
ifosfamidum
isosfamide
CHEBI:5864
Ifosfamide
ifosfamide
CHEBI:5864
A compound having the structure RR'C(OR'')(OR''') (R'', R''' =/= H) and thus diethers of geminal diols. Originally, the term was confined by IUPAC to derivatives of aldehydes (R = H), but it now applies equally to derivatives of ketones (neither R nor R' = H ). Mixed acetals have R'' and R''' groups which differ.
acetals
CHEBI:59769
acetal
CHEBI:59769
An acetal of formula R2C(OR)2 (R =/= H) derived from a ketone by replacement of the oxo group by two hydrocarbyloxy groups. The class name 'ketals', once abandoned by IUPAC, has been reinstated as a subclass of acetals.
ketals
CHEBI:59777
ketal
CHEBI:59777
A ketal in the molecule of which the ketal carbon and one or both oxygen atoms thereon are members of a ring.
cyclic ketals
CHEBI:59779
cyclic ketal
CHEBI:59779
The trihydrate form of docetaxel. It is used for the treatment of breast, ovarian, and non-small cell lung cancer, and with prednisone or prednisolone in hormone-refractory metastatic prostate cancer.
72962
Beilstein:10054412
ChemIDplus:148408-66-6
DrugBank:DB01248
KEGG DRUG:148408-66-6
KEGG DRUG:D02165
Patent:EP253738
Patent:US4814470
4-(acetyloxy)-13alpha-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7beta,10beta-trihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate--water (1/3)
C43H59NO17
InChI=1S/C43H53NO14.3H2O/c1-22-26(55-37(51)32(48)30(24-15-11-9-12-16-24)44-38(52)58-39(3,4)5)20-43(53)35(56-36(50)25-17-13-10-14-18-25)33-41(8,34(49)31(47)29(22)40(43,6)7)27(46)19-28-42(33,21-54-28)57-23(2)45;;;/h9-18,26-28,30-33,35,46-48,53H,19-21H2,1-8H3,(H,44,52);3*1H2/t26-,27-,28+,30-,31+,32+,33-,35-,41+,42-,43+;;;/m0.../s1
InChIKey=XCDIRYDKECHIPE-QHEQPUDQSA-N
N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel trihydrate
N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol trihydrate
O.O.O.[H][C@@]1(C[C@@]2(O)[C@@H](OC(=O)c3ccccc3)[C@]3([H])[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](O)C(=C1C)C2(C)C)OC(C)=O)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c1ccccc1
docetaxel
CHEBI:59809
docetaxel
docetaxel trihydrate
CHEBI:59809
A chemical substance is a portion of matter of constant composition, composed of molecular entities of the same type or of different types.
Chemische Substanz
CHEBI:59999
chemical substance
CHEBI:59999
A mixture is a chemical substance composed of multiple molecules, at least two of which are of a different kind.
Mischung
CHEBI:60004
mixture
CHEBI:60004
A nucleoside having a purine base covalently bonded to a deoxyribose.
purine deoxyribonucleosides
CHEBI:60173
purine deoxyribonucleoside
CHEBI:60173
A carbohydrazide obtained by formal condensation between pyridine-4-carboxylic acid and hydrazine.
6038
Beilstein:119374
ChemIDplus:54-85-3
CiteXplore:18220565
CiteXplore:19183459
CiteXplore:445303
Gmelin:82804
KEGG COMPOUND:54-85-3
KEGG COMPOUND:C07054
NIST Chemistry WebBook:54-85-3
Reaxys:119374
Wikipedia:Isoniazid
pyridine-4-carbohydrazide
4-pyridinecarbohydrazide
C6H7N3O
InChI=1S/C6H7N3O/c7-9-6(10)5-1-3-8-4-2-5/h1-4H,7H2,(H,9,10)
InChIKey=QRXWMOHMRWLFEY-UHFFFAOYSA-N
Isoniazid
Isonicotinsaeurehydrazid
NNC(=O)c1ccncc1
isonicotinic acid hydrazide
isonicotinic hydrazide
isonicotinohydrazide
isonicotinoylhydrazide
pyridine-4-carboxylic acid hydrazide
CHEBI:6030
isoniazid
isoniazide
CHEBI:6030
A pyridinemonocarboxylic acid that has formula C6H5NO2.
Beilstein:109599
ChemIDplus:55-22-1
Gmelin:68876
KEGG COMPOUND:55-22-1
KEGG COMPOUND:C07446
NIST Chemistry WebBook:55-22-1
Wikipedia:Isonicotinic_Acid
Isonicotinic acid
isonicotinic acid
pyridine-4-carboxylic acid
4-carboxypyridine
4-pyridinecarboxylic acid
C6H5NO2
InChI=1S/C6H5NO2/c8-6(9)5-1-3-7-4-2-5/h1-4H,(H,8,9)
InChIKey=TWBYWOBDOCUKOW-UHFFFAOYSA-N
OC(=O)c1ccncc1
gamma-picolinic acid
gamma-pyridinecarboxylic acid
p-pyridinecarboxylic acid
CHEBI:6032
isonicotinic acid
CHEBI:6032
A dioxolane that has formula C35H38Cl2N8O4.
28031
ChemIDplus:84625-61-6
KEGG DRUG:84625-61-6
KEGG DRUG:D00350
Wikipedia:Itraconazole
2-(butan-2-yl)-4-{4-[4-(4-{[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazin-1-yl]phenyl}-2,4-dihydro-3H-1,2,4-triazol-3-one
Itraconazole
C35H38Cl2N8O4
CCC(C)n1ncn(-c2ccc(cc2)N2CCN(CC2)c2ccc(OC[C@H]3CO[C@@](Cn4cncn4)(O3)c3ccc(Cl)cc3Cl)cc2)c1=O
InChI=1S/C35H38Cl2N8O4/c1-3-25(2)45-34(46)44(24-40-45)29-7-5-27(6-8-29)41-14-16-42(17-15-41)28-9-11-30(12-10-28)47-19-31-20-48-35(49-31,21-43-23-38-22-39-43)32-13-4-26(36)18-33(32)37/h4-13,18,22-25,31H,3,14-17,19-21H2,1-2H3/t25?,31-,35-/m0/s1
InChIKey=VHVPQPYKVGDNFY-ZPGVKDDISA-N
Itrizole (TN)
Oriconazole
Sporanox (TN)
CHEBI:6076
Itraconazole
itraconazole
CHEBI:6076
An analogue of a nucleoside, being an N-glycosyl compound in which the nitrogen-containing moiety is a modified nucleotide base. They are commonly used as antiviral products to prevent viral replication in infected cells.
nucleoside analogues
CHEBI:60783
nucleoside analogue
CHEBI:60783
The piperidinecarboxamide obtained by the formal condensation of N-propylpipecolic acid and 2,6-dimethylaniline.
35780
Reaxys:253266
N-(2,6-dimethylphenyl)-1-propylpiperidine-2-carboxamide
(+-)-ropivacaine
1-propyl-2',6'-dimethyl-2-piperidylcarboxyanilide
1-propyl-2',6'-pipecoloxylidide
C17H26N2O
CCCN1CCCCC1C(=O)Nc1c(C)cccc1C
DL-ropivacaine
InChI=1S/C17H26N2O/c1-4-11-19-12-6-5-10-15(19)17(20)18-16-13(2)8-7-9-14(16)3/h7-9,15H,4-6,10-12H2,1-3H3,(H,18,20)
InChIKey=ZKMNUMMKYBVTFN-UHFFFAOYSA-N
N-n-propylpipecolic acid-2,6-xylidide
rac-ropivacaine
racemic ropivacaine
CHEBI:60802
ropivacaine
CHEBI:60802
A racemate is an equimolar mixture of a pair of enantiomers.
melange racemique
racemic mixture
CHEBI:60911
racemate
CHEBI:60911
A mixture composed of two or more diastereoisomers (stereoisomers not related as mirror images).
diastereomeric mixture
CHEBI:60915
diastereoisomeric mixture
CHEBI:60915
A glucoside in which the anomeric carbon of the glycosidic bond is in a beta configuration
beta-glucosides
CHEBI:60980
beta-glucoside
CHEBI:60980
A hydrate that is the monohydrate form of tacrolimus.
42316
ChemIDplus:109581-93-3
DrugBank:DB00864
KEGG DRUG:109581-93-3
KEGG DRUG:D00107
Reaxys:6265275
(3S,4R,5S,8R,9E,12S,14S,15R,16S,18R,19R,26aS)-5,19-dihydroxy-3-{(1E)-1-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]prop-1-en-2-yl}-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(prop-2-en-1-yl)-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-3H-15,19-epoxypyrido[2,1-c][1,4]oxazacyclotricosine-1,7,20,21(4H,23H)-tetrone--water (1/1)
(-)-(3S,4R,5S,8R,9E,12S,14S,15R,16S,18R,19R,26aS)-5,19-dihydroxy-3-{(1E)-1-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]prop-1-en-2-yl}-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(prop-2-en-1-yl)-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-3H-15,19-epoxypyrido[2,1-c][1,4]oxazacyclotricosine-1,7,20,21(4H,23H)-tetrone monohydrate
C44H71NO13
InChI=1S/C44H69NO12.H2O/c1-10-13-31-19-25(2)18-26(3)20-37(54-8)40-38(55-9)22-28(5)44(52,57-40)41(49)42(50)45-17-12-11-14-32(45)43(51)56-39(29(6)34(47)24-35(31)48)27(4)21-30-15-16-33(46)36(23-30)53-7;/h10,19,21,26,28-34,36-40,46-47,52H,1,11-18,20,22-24H2,2-9H3;1H2/b25-19+,27-21+;/t26-,28+,29+,30-,31+,32-,33+,34-,36+,37-,38-,39+,40+,44+;/m0./s1
InChIKey=NWJQLQGQZSIBAF-MLAUYUEBSA-N
O.CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@H]([C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC)[C@H](C[C@H]2C)OC
Prograf
Protopic
tacrolimus
tacrolimus monohydrate
tsukubaenolide hydrate
CHEBI:61057
Tacrolimus
tacrolimus hydrate
CHEBI:61057
Any compound that has a nucleobase as a part.
nucleobase-containing compound
nucleobase-containing compounds
nucleobase-containing molecular entities
CHEBI:61120
nucleobase-containing molecular entity
CHEBI:61120
A steroid compound with a structure based on a 21-carbon (pregnane) skeleton.
CHEBI:61313
C21-steroid
CHEBI:61313
Any hydroxy carboxylic acid which contains a hydroxy group located beta- to the carboxylic acid group.
3-hydroxy carboxylic acids
beta-hydroxy carboxylic acid
beta-hydroxy carboxylic acids
CHEBI:61355
3-hydroxy carboxylic acid
CHEBI:61355
A carbohydrate derivative arising formally from the elimination of water from a glycosidic hydroxy group and an H atom bound to an oxygen, carbon, nitrogen or sulfur atom of a separate entity.
glycosyl compounds
CHEBI:63161
glycosyl compound
CHEBI:63161
Any organooxygen compound derived from a carbohydrate by replacement of one or more hydroxy group(s) by an amino group, a thiol group or similar heteroatomic groups. The term also includes derivatives of these compounds.
carbohydrate derivatives
derivatised carbohydrate
derivatised carbohydrates
derivatized carbohydrate
derivatized carbohydrates
CHEBI:63299
carbohydrate derivative
CHEBI:63299
A carbohydrate derivative that is formally obtained from a monosaccharide.
monosaccharide derivatives
CHEBI:63367
monosaccharide derivative
CHEBI:63367
A monosaccharide derivative that is formally obtained from a hexose.
hexose derivatives
CHEBI:63385
hexose derivative
CHEBI:63385
A hexose derivative that is formally obtained from a ketohexose.
ketohexose derivatives
CHEBI:63391
ketohexose derivative
CHEBI:63391
A 1-ribosyltriazole that is the 1-ribofuranosyl derivative of 1,2,4-triazole-3-carboxamide. An inhibitor of HCV polymerase.
9344
CHEBI:8840
ChemIDplus:36791-04-5
ChemIDplus:892462
CiteXplore:21827730
CiteXplore:22052088
CiteXplore:22052220
CiteXplore:22156853
CiteXplore:22158703
CiteXplore:22212566
CiteXplore:22212568
CiteXplore:22212569
CiteXplore:22212572
CiteXplore:22212576
CiteXplore:22212579
CiteXplore:22220723
CiteXplore:22239498
CiteXplore:22239511
DrugBank:DB00811
KEGG DRUG:36791-04-5
KEGG DRUG:D00423
Reaxys:892462
Wikipedia:Ribavirin
1-(beta-D-ribofuranosyl)-1H-1,2,4-triazole-3-carboxamide
1-beta-D-Ribofuranosyl-1,2,4-triazole-3-carboxamide
1-beta-D-Ribofuranosyl-1H-1,2,4-triazole-3-carboxamide
C8H12N4O5
InChI=1S/C8H12N4O5/c9-6(16)7-10-2-12(11-7)8-5(15)4(14)3(1-13)17-8/h2-5,8,13-15H,1H2,(H2,9,16)/t3-,4-,5-,8-/m1/s1
InChIKey=IWUCXVSUMQZMFG-AFCXAGJDSA-N
NC(=O)c1ncn(n1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
RBV
ribavirin
ribavirina
ribavirine
ribavirinum
CHEBI:63580
Ribavirin
ribavirin
CHEBI:63580
A nucleoside analogue obtained by formal dehydration across positions 2 and 3 of thymidine. An inhibitor of HIV-1 reverse transcriptase
59763
CHEBI:9253
ChemIDplus:3056-17-5
DrugBank:DB00649
KEGG COMPOUND:3056-17-5
KEGG COMPOUND:C07312
KEGG DRUG:D00445
Patent:EP334368
Patent:US5130421
Reaxys:618327
Wikipedia:Stavudine
1-[(2R,5S)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]-5-methylpyrimidine-2,4(1H,3H)-dione
Stavudine
1-(2,3-Dideoxy-beta-D-glycero-pent-2-enofuranosyl)thymine
2',3'-Didehydro-3'-deoxythimidine
3'-Deoxy-2'-thymidinene
C10H12N2O4
Cc1cn([C@@H]2O[C@H](CO)C=C2)c(=O)[nH]c1=O
InChI=1S/C10H12N2O4/c1-6-4-12(10(15)11-9(6)14)8-3-2-7(5-13)16-8/h2-4,7-8,13H,5H2,1H3,(H,11,14,15)/t7-,8+/m0/s1
InChIKey=XNKLLVCARDGLGL-JGVFFNPUSA-N
STV
Sanilvudine
d4T
estavudina
stavudine
stavudinum
CHEBI:63581
Stavudine
stavudine
CHEBI:63581
An N-glycosyl compound that consists of any triazole having a glycosyl residue attached at position 1.
1-glycosyltriazoles
CHEBI:63593
1-glycosyltriazole
CHEBI:63593
CHEBI:63594
1-ribosyltriazole
CHEBI:63594
An optically active form of ofloxacin having (S)-configuration; an inhibitor of bacterial topoisomerase IV and DNA gyrase
82122
CHEBI:6440
ChemIDplus:100986-85-4
CiteXplore:21075586
CiteXplore:21965436
CiteXplore:21974858
CiteXplore:22088660
CiteXplore:22221614
DrugBank:DB01137
HMDB:HMDB01929
KEGG COMPOUND:100986-85-4
KEGG COMPOUND:C07660
KEGG DRUG:D08120
Reaxys:5385660
Wikipedia:Levofloxacin
(3S)-9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid
(-)-Ofloxacin
(3S)-(-)-9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid
(S)-(-)-9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzooxazine-6-carboxylic acid
(S)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid
(S)-Ofloxacin
C18H20FN3O4
C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c2n1cc(C(O)=O)c3=O
InChI=1S/C18H20FN3O4/c1-10-9-26-17-14-11(16(23)12(18(24)25)8-22(10)14)7-13(19)15(17)21-5-3-20(2)4-6-21/h7-8,10H,3-6,9H2,1-2H3,(H,24,25)/t10-/m0/s1
InChIKey=GSDSWSVVBLHKDQ-JTQLQIEISA-N
L-Ofloxacin
Ofloxacin S-(-)-form
levofloxacin
levofloxacine
levofloxacino
levofloxacinum
CHEBI:63598
Levofloxacin
levofloxacin
CHEBI:63598
A racemate composed of (+)-(11R,2'S)- and (-)-(11S,2'R)-enantiomers of mefloquine. An antimalarial agent which acts as a blood schizonticide; its mechanism of action is unknown.
6694
CHEBI:6718
ChemIDplus:53230-10-7
CiteXplore:21118921
CiteXplore:21853223
CiteXplore:21861987
CiteXplore:22006004
CiteXplore:22217970
CiteXplore:22223333
CiteXplore:22232280
CiteXplore:22233563
CiteXplore:22236373
CiteXplore:22245668
CiteXplore:22246492
DrugBank:DB00358
KEGG COMPOUND:53230-10-7
KEGG COMPOUND:C07633
KEGG DRUG:D04895
Reaxys:5306591
Wikipedia:Mefloquine
rac--(R)-[2,8-bis(trifluoromethyl)quinolin-4-yl][(2S)-piperidin-2-yl]methanol
Racemic mefloquine
[(R*,S*)-2,8-bis(trifluoromethyl)quinolin-4-yl]-(2-piperidyl)methanol
[DL-erythro-alpha-2-Piperidyl-2,8-bis(trifluoromethyl)]-4-quinolinemethanol
mefloquina
mefloquine
mefloquinum
CHEBI:63609
Mefloquine
mefloquine
CHEBI:63609
A diastereoisomeric mixture composed of approximately equal amounts of a double racemate of four of the sixteen possible diastereoisomers of methyl (13E)-11,16-dihydroxy-16-methyl-9-oxoprost-13-en-1-oate that is racemic prostaglandin E1 which is lacking the hydroxy group at position 15, but which has an additional hydroxy group at position 16. It is a synthetic prostaglandin E1 analogue, used in the treatment of gastric and duodenal ulcers. A weak abortifacient, it is also used for cervical ripening prior to surgical termination of pregnancy. The (11R,16S)-diastereoisomer is the pharmacologically active form.
42331
CHEBI:6952
ChemIDplus:59122-46-2
CiteXplore:10945193
CiteXplore:10949752
CiteXplore:11136959
CiteXplore:1417145
CiteXplore:18690850
CiteXplore:19740175
CiteXplore:2109814
CiteXplore:3080288
DrugBank:DB00929
KEGG DRUG:59122-46-2
KEGG DRUG:D00419
Patent:BE827127
Patent:US3965143
Reaxys:4155643
Wikipedia:Misoprostol
(+-)-methyl (1R,2R,3R)-3-hydroxy-2-((E)-(4RS)-4-hydroxy-4-methyl-1-octenyl)-5-oxocyclopentaneheptanoate
(11-alpha,13E)-(+-)-11,16-dihydroxy-16-methyl-9-oxoprost-13-en-1-oic acid methyl ester
Arthrotec
Cytotec
Methyl (+-)-11-alpha,16-dihydroxy-16-methyl-9-oxoprost-13-en-1-oate
misoprostol
misoprostolum
CHEBI:63610
Misoprostol
misoprostol
CHEBI:63610
A quinolone that consits of 4-oxo-1,4-dihydroquinoline-3-carboxylic acid bearing a cyclopropyl substituent at position 1, a fluoro substitiuent at position 6, a (4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl group at position 7 and a methoxy substituent at position 8. A member of the fluoroquinolone class of antibacterial agents.
139462
CHEBI:7007
ChemIDplus:151096-09-2
DrugBank:DB00218
KEGG COMPOUND:C07663
KEGG DRUG:D08237
Patent:EP550903
Reaxys:8365827
Wikipedia:Moxifloxacin
1-cyclopropyl-6-fluoro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
Moxifloxacin
1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-((4aS,7aS)-octahydro-6H-pyrrolo(3,4-b)pyridin-6-yl)-4-oxo-3-quinolinecarboxylic acid
C21H24FN3O4
InChI=1S/C21H24FN3O4/c1-29-20-17-13(19(26)14(21(27)28)9-25(17)12-4-5-12)7-15(22)18(20)24-8-11-3-2-6-23-16(11)10-24/h7,9,11-12,16,23H,2-6,8,10H2,1H3,(H,27,28)/t11-,16+/m0/s1
InChIKey=FABPRXSRWADJSP-MEDUHNTESA-N
[H][C@@]12CCCN[C@]1([H])CN(C2)c1c(F)cc2c(c1OC)n(cc(C(O)=O)c2=O)C1CC1
moxifloxacin
CHEBI:63611
moxifloxacin
CHEBI:63611
A diamine that is ergoline in which the beta-hydrogen at position 8 is replaced by a (methylthio)methyl group and the hydrogen attached to the piperidine nitrogen (position 6) is replaced by a propyl group. A dopamine D2 receptor agonist which also has D1 and D2 agonist properties, it is used as the mesylate salt in the management of Parkinson's disease, although it was withdrawn from the U.S. and Canadian markets in 2007 due to an increased risk of cardiac valve dysfunction.
8047
CHEBI:8020
ChemIDplus:66104-22-1
CiteXplore:11852289
CiteXplore:15180134
CiteXplore:16845152
CiteXplore:18071034
CiteXplore:2012117
DrugBank:DB01186
KEGG COMPOUND:66104-22-1
KEGG COMPOUND:C07425
KEGG DRUG:D08339
Patent:US4166182
Reaxys:5091461
Wikipedia:Pergolide
(8beta)-8-[(methylsulfanyl)methyl]-6-propylergoline
C19H26N2S
InChI=1S/C19H26N2S/c1-3-7-21-11-13(12-22-2)8-16-15-5-4-6-17-19(15)14(10-20-17)9-18(16)21/h4-6,10,13,16,18,20H,3,7-9,11-12H2,1-2H3/t13-,16-,18-/m1/s1
InChIKey=YEHCICAEULNIGD-MZMPZRCHSA-N
[H][C@@]12Cc3c[nH]c4cccc(c34)[C@@]1([H])C[C@@H](CSC)CN2CCC
pergolida
pergolide
pergolidum
CHEBI:63617
Pergolide
pergolide
CHEBI:63617
A carboxylic ester resulting from the formal condensation or (S)-2-methylbutyric acid with the hydroxy group adjacent to the ring junction of (3R,5R)-7-[(1S,2S,6S,8S,8aR)-6,8-dihydroxy-2-methyl-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid. Derived from microbial transformation of mevastatin, pravastatin is a reversible inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA). The sodium salt is used for lowering cholesterol and preventing cardiovascular disease. It is one of the lower potency statins, but has the advantage of fewer side effects compared with lovastatin and simvastatin.
42463
CHEBI:8360
ChemIDplus:81093-37-0
CiteXplore:21749370
CiteXplore:21851379
DrugBank:DB00175
HMDB:HMDB05022
KEGG COMPOUND:81093-37-0
KEGG COMPOUND:C01844
KEGG DRUG:D08410
Reaxys:4825538
Wikipedia:Pravastatin
(3R,5R)-3,5-dihydroxy-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-{[(2S)-2-methylbutanoyl]oxy}-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]heptanoic acid
(+)-(3R,5R)-3,5-dihydroxy-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-{[(S)-2-methylbutyryl]oxy}-1,2,6,7,8,8a-hexahydro-1-naphthyl]heptanoic acid
C23H36O7
InChI=1S/C23H36O7/c1-4-13(2)23(29)30-20-11-17(25)9-15-6-5-14(3)19(22(15)20)8-7-16(24)10-18(26)12-21(27)28/h5-6,9,13-14,16-20,22,24-26H,4,7-8,10-12H2,1-3H3,(H,27,28)/t13-,14-,16+,17+,18+,19-,20-,22-/m0/s1
InChIKey=TUZYXOIXSAXUGO-PZAWKZKUSA-N
[H][C@]12[C@H](C[C@H](O)C=C1C=C[C@H](C)[C@@H]2CC[C@@H](O)C[C@@H](O)CC(O)=O)OC(=O)[C@@H](C)CC
pravastatin
pravastatin acid
pravastatina
pravastatine
pravastatinum
CHEBI:63618
Pravastatin
pravastatin
CHEBI:63618
A ketone that is 3-(propylamino)propane-1,2-diol in which the hydrogen of the primary hydroxy group is replaced by a 2-(3-phenylpropanoyl)phenyl group. It is a class 1C antiarrhythmic drug with local anesthetic effects, and is used as the hydrochloride salt in the management of supraventricular and ventricular arrhythmias.
8754
CHEBI:8465
ChemIDplus:54063-53-5
CiteXplore:8777484
DrugBank:DB01182
KEGG COMPOUND:54063-53-5
KEGG COMPOUND:C07381
KEGG DRUG:D08435
Patent:DE2001431
Reaxys:2175182
Wikipedia:Propafenone
1-{2-[2-hydroxy-3-(propylamino)propoxy]phenyl}-3-phenylpropan-1-one
1-(2-(2-hydroxy-3-(propylamino)propoxy)phenyl)-3-phenyl-1-propanone
2-(2'-hydroxy-3'-propylaminopropoxy)-omega-phenylpropiophenone
C21H27NO3
CCCNCC(O)COc1ccccc1C(=O)CCc1ccccc1
InChI=1S/C21H27NO3/c1-2-14-22-15-18(23)16-25-21-11-7-6-10-19(21)20(24)13-12-17-8-4-3-5-9-17/h3-11,18,22-23H,2,12-16H2,1H3
InChIKey=JWHAUXFOSRPERK-UHFFFAOYSA-N
propafenona
propafenone
propafenonum
CHEBI:63619
Propafenone
propafenone
CHEBI:63619
A sulfonamide that is N-phenylmethanesulfonamide in which the phenyl group is sustituted at position 4 by a 1-hydroxy-2-(isopropylamino)ethyl group. It has both beta-adrenoreceptor blocking (Vaughan Williams Class II) and cardiac action potential duration prolongation (Vaughan Williams Class III) antiarrhythmic properties. It is used (usually as the hydrochloride salt) for the management of ventricular and supraventricular arrhythmias.
9947
CHEBI:9206
ChemIDplus:3930-20-9
CiteXplore:20562595
CiteXplore:21553267
CiteXplore:21854895
DrugBank:DB00489
KEGG COMPOUND:3930-20-9
KEGG COMPOUND:C07309
KEGG DRUG:D08525
Reaxys:2380820
Wikipedia:Sotalol
N-{4-[1-hydroxy-2-(propan-2-ylamino)ethyl]phenyl}methanesulfonamide
Sotalol
4'-(1-hydroxy-2-(isopropylamino)ethyl)methane sulfonanilide
C12H20N2O3S
CC(C)NCC(O)c1ccc(NS(C)(=O)=O)cc1
InChI=1S/C12H20N2O3S/c1-9(2)13-8-12(15)10-4-6-11(7-5-10)14-18(3,16)17/h4-7,9,12-15H,8H2,1-3H3
InChIKey=ZBMZVLHSJCTVON-UHFFFAOYSA-N
beta-cardone
sotalol
sotalolum
CHEBI:63622
Sotalol
sotalol
CHEBI:63622
1H-imidazole substituted at C-1 by a (2-ethylsulfonyl)ethyl group, at C-2 by a methyl group and at C-5 by a nitro group. It is used as an antiprotozoal, antibacterial agent.
10612
CHEBI:32227
CiteXplore:5458368
DrugBank:DB00911
KEGG DRUG:D01426
Patent:US3376311
Reaxys:618182
Wikipedia:Tinidazole
1-[2-(ethylsulfonyl)ethyl]-2-methyl-5-nitro-1H-imidazole
C8H13N3O4S
CCS(=O)(=O)CCn1c(C)ncc1[N+]([O-])=O
InChI=1S/C8H13N3O4S/c1-3-16(14,15)5-4-10-7(2)9-6-8(10)11(12)13/h6H,3-5H2,1-2H3
InChIKey=HJLSLZFTEKNLFI-UHFFFAOYSA-N
timidazole
CHEBI:63627
Tinidazole
tinidazole
CHEBI:63627
A pyridine-2-sulfonamide substituted at C-5 by a trifluoromethyl group and at the sulfonamide nitrogen by a dihydropyrone-containing m-tolyl substituent. It is an HIV-1 protease inhibitor.
190548
ChemIDplus:174484-41-4
CiteXplore:17620375
CiteXplore:20368406
CiteXplore:21041916
CiteXplore:21571982
CiteXplore:21576452
CiteXplore:21825300
CiteXplore:21871444
CiteXplore:22007990
CiteXplore:22096044
CiteXplore:22258921
DrugBank:DB00932
KEGG DRUG:D08605
Reaxys:7698323
N-(3-{(1R)-1-[(6R)-4-hydroxy-2-oxo-6-(2-phenylethyl)-6-propyl-5,6-dihydro-2H-pyran-3-yl]propyl}phenyl)-5-(trifluoromethyl)pyridine-2-sulfonamide
3'-((1R)-1-((6R)-5,6-Dihydro-4-hydroxy-2-oxo-6-phenethyl-6-propyl-2H-pyran-3-yl)propyl)-5-(trifluoromethyl)-2-pyridinesulfonanilide
C31H33F3N2O5S
CCC[C@@]1(CCc2ccccc2)CC(O)=C([C@H](CC)c2cccc(NS(=O)(=O)c3ccc(cn3)C(F)(F)F)c2)C(=O)O1
InChI=1S/C31H33F3N2O5S/c1-3-16-30(17-15-21-9-6-5-7-10-21)19-26(37)28(29(38)41-30)25(4-2)22-11-8-12-24(18-22)36-42(39,40)27-14-13-23(20-35-27)31(32,33)34/h5-14,18,20,25,36-37H,3-4,15-17,19H2,1-2H3/t25-,30-/m1/s1
InChIKey=SUJUHGSWHZTSEU-FYBSXPHGSA-N
tipranavir
CHEBI:63628
tipranavir
CHEBI:63628
2,1,3-Benzothiadiazole substituted at C-4 by a Delta(1)-imidazolin-2-ylamino group and at C-4 by a chloro group. It is an agonist at alpha2-adrenergic receptor sites.
57258
CHEBI:9608
ChemIDplus:51322-75-9
ChemIDplus:618691
CiteXplore:21317414
CiteXplore:21733633
CiteXplore:21982341
CiteXplore:22196407
CiteXplore:22223284
DrugBank:DB00697
KEGG COMPOUND:51322-75-9
KEGG COMPOUND:C07452
KEGG DRUG:D08611
Patent:US3843668
Reaxys:618691
Wikipedia:Tizanidine
5-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-2,1,3-benzothiadiazol-4-amine
Tizanidine
5-Chloro-4-(2-imidazolin-2-ylamino)-2,1,3-benzothiadiazole
C9H8ClN5S
Clc1ccc2nsnc2c1NC1=NCCN1
InChI=1S/C9H8ClN5S/c10-5-1-2-6-8(15-16-14-6)7(5)13-9-11-3-4-12-9/h1-2H,3-4H2,(H2,11,12,13)
InChIKey=XFYDIVBRZNQMJC-UHFFFAOYSA-N
tizanidina
tizanidine
tizanidinum
CHEBI:63629
tizanidine
CHEBI:63629
A hexose derivative that is 2,3:4,5-di-O-isopropylidene-beta-D-fructopyranose in which the hydroxy group has been converted to the corresponding sulfamate ester. It blocks voltage-dependent sodium channels and is used as an antiepileptic and for the prevention of migraine.
38404
CHEBI:9633
ChemIDplus:97240-79-4
CiteXplore:22233396
CiteXplore:22249827
DrugBank:DB00273
KEGG COMPOUND:97240-79-4
KEGG COMPOUND:C07502
KEGG DRUG:D00537
Patent:US4513006
Reaxys:5988957
Wikipedia:Topiramate
Topiramate
2,3:4,5-bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate
2,3:4,5-di-O-isopropylidene-beta-D-fructopyranose sulfamate
C12H21NO8S
CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1
InChI=1S/C12H21NO8S/c1-10(2)18-7-5-16-12(6-17-22(13,14)15)9(8(7)19-10)20-11(3,4)21-12/h7-9H,5-6H2,1-4H3,(H2,13,14,15)/t7-,8-,9+,12+/m1/s1
InChIKey=KJADKKWYZYXHBB-XBWDGYHZSA-N
McN-4853
RWJ-17021
TPM
Topamax
tipiramate
tipiramato
topiramate
topiramato
topiramatum
CHEBI:63631
topiramate
CHEBI:63631
A pyranoindolizinoquinoline used as an antineoplastic agent. It is a derivative of camptothecin and works by binding to the topoisomerase I-DNA complex and preventing religation of these 328 single strand breaks.
57308
CHEBI:9634
ChemIDplus:123948-87-8
CiteXplore:20574789
CiteXplore:21255983
CiteXplore:21352915
CiteXplore:21910214
CiteXplore:22028494
CiteXplore:22075006
CiteXplore:22136714
CiteXplore:22190039
DrugBank:DB01030
KEGG COMPOUND:123948-87-8
KEGG COMPOUND:C11158
KEGG DRUG:D08618
Patent:EP321122
Reaxys:4279441
Wikipedia:Topotecan
(4S)-10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione
Topotecan
9-[(dimethylamino)methyl]-10-hydroxy-(4S)-camptothecin
C23H23N3O5
CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O
InChI=1S/C23H23N3O5/c1-4-23(30)16-8-18-20-12(9-26(18)21(28)15(16)11-31-22(23)29)7-13-14(10-25(2)3)19(27)6-5-17(13)24-20/h5-8,27,30H,4,9-11H2,1-3H3/t23-/m0/s1
InChIKey=UCFGDBYHRUNTLO-QHCPKHFHSA-N
topotecan
topotecane
topotecanum
CHEBI:63632
Topotecan
topotecan
CHEBI:63632
Any organic heterobicyclic compound containing ortho-fused pyrrolidine and piperidine rings.
CHEBI:63697
pyrrolidinopiperidine
CHEBI:63697
A sulfoxide that has formula C16H14F3N3O2S.
17128
Beilstein:4333393
ChemIDplus:103577-45-3
KEGG DRUG:D00355
Patent:EP174726
Patent:US4628098
Wikipedia:Lansoprazole
2-({[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methyl}sulfinyl)-1H-benzimidazole
AG 1749
Bamalite
C16H14F3N3O2S
Cc1c(OCC(F)(F)F)ccnc1CS(=O)c1nc2ccccc2[nH]1
InChI=1S/C16H14F3N3O2S/c1-10-13(20-7-6-14(10)24-9-16(17,18)19)8-25(23)15-21-11-4-2-3-5-12(11)22-15/h2-7H,8-9H2,1H3,(H,21,22)
InChIKey=MJIHNNLFOKEZEW-UHFFFAOYSA-N
Lanzol
Lanzopral
Lanzul
Limpidex
Monolitum
Ogastro
Opiren
Prevacid
lansoprazol
lansoprazolum
CHEBI:6375
lansoprazole
CHEBI:6375
An isoxazole that has formula C12H9F3N2O2.
27169
Beilstein:4323174
ChemIDplus:75706-12-6
KEGG COMPOUND:75706-12-6
KEGG COMPOUND:C07905
KEGG DRUG:D00749
Wikipedia:Leflunomide
5-methyl-N-[4-(trifluoromethyl)phenyl]-1,2-oxazole-4-carboxamide
Leflunomide
5-Methyl-N-(4-(trifluoromethyl)phenyl)-4-isoxazolecarboxamide
5-Methylisoxazole-4-carboxylic acid (4-trifluoromethyl)anilide
Arava (TN)
C12H9F3N2O2
Cc1oncc1C(=O)Nc1ccc(cc1)C(F)(F)F
InChI=1S/C12H9F3N2O2/c1-7-10(6-16-19-7)11(18)17-9-4-2-8(3-5-9)12(13,14)15/h2-6H,1H3,(H,17,18)
InChIKey=VHOGYURTWQBHIL-UHFFFAOYSA-N
alpha,alpha,alpha-Trifluoro-5-methyl-4-isoxazolecarboxy-p-toluidide
CHEBI:6402
leflunomide
CHEBI:6402
An oligopeptide comprising pyroglutamyl, histidyl, tryptophyl, seryl, tyrosyl, D-leucyl, leucyl, arginyl, and N-ethylprolinamide residues joined in sequence. It is a synthetic nonapeptide analogue of gonadotropin-releasing hormone, and is used as a subcutaneous hydrogel implant (particularly as the acetate salt) for the treatment of prostate cancer and for the suppression of gonadal sex hormone production in children with central precocious puberty.
42375
ChemIDplus:53714-56-0
DrugBank:DB00007
KEGG COMPOUND:53714-56-0
KEGG COMPOUND:C07612
KEGG DRUG:D08113
Patent:DE2446005
Patent:US4005063
Reaxys:741818
5-oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-D-leucyl-L-leucyl-L-arginyl-N-ethyl-L-prolinamide
(D-Leu(6),des-Gly-NH2(10),Pro-ethylamide(9))-gonadotropin-releasing hormone
C59H84N16O12
CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1
InChI=1S/C59H84N16O12/c1-6-63-57(86)48-14-10-22-75(48)58(87)41(13-9-21-64-59(60)61)68-51(80)42(23-32(2)3)69-52(81)43(24-33(4)5)70-53(82)44(25-34-15-17-37(77)18-16-34)71-56(85)47(30-76)74-54(83)45(26-35-28-65-39-12-8-7-11-38(35)39)72-55(84)46(27-36-29-62-31-66-36)73-50(79)40-19-20-49(78)67-40/h7-8,11-12,15-18,28-29,31-33,40-48,65,76-77H,6,9-10,13-14,19-27,30H2,1-5H3,(H,62,66)(H,63,86)(H,67,78)(H,68,80)(H,69,81)(H,70,82)(H,71,85)(H,72,84)(H,73,79)(H,74,83)(H4,60,61,64)/t40-,41-,42-,43+,44-,45-,46-,47-,48-/m0/s1
InChIKey=GFIJNRVAKGFPGQ-LIJARHBVSA-N
L-pyroglutamyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-D-leucyl-L-leucyl-L-arginyl-L-proline ethylamide
Leuprorelin
leuprorelina
leuproreline
leuprorelinum
pGlu-His-Trp-Ser-Tyr-D-Leu-Leu-Arg-Pro-NHC2H5
pGlu-His-Trp-Ser-Tyr-D-Leu-Leu-Arg-Pro-NHEt
CHEBI:6427
Leuprolide
leuprolide
CHEBI:6427
CHEBI:64459
biaryl
CHEBI:64459
A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
52175
Beilstein:4770867
ChemIDplus:114798-26-4
CiteXplore:15703421
DrugBank:DB00678
KEGG COMPOUND:114798-26-4
KEGG COMPOUND:C07072
KEGG DRUG:D08146
Patent:EP253310
Patent:US5138069
Reaxys:4770867
Wikipedia:Losartan
(2-butyl-4-chloro-1-{[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl}-1H-imidazol-5-yl)methanol
Losartan
(2-butyl-4-chloro-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-imidazol-5-yl)methanol
2-n-butyl-4-chloro-5-hydroxymethyl-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole
C22H23ClN6O
CCCCc1nc(Cl)c(CO)n1Cc1ccc(cc1)-c1ccccc1-c1nnn[nH]1
InChI=1S/C22H23ClN6O/c1-2-3-8-20-24-21(23)19(14-30)29(20)13-15-9-11-16(12-10-15)17-6-4-5-7-18(17)22-25-27-28-26-22/h4-7,9-12,30H,2-3,8,13-14H2,1H3,(H,25,26,27,28)
InChIKey=PSIFNNKUMBGKDQ-UHFFFAOYSA-N
losartan
CHEBI:6541
Losartan
losartan
CHEBI:6541
A 17alpha-hydroxy steroid that has formula C22H30O3.
6703
Beilstein:3164843
ChemIDplus:3562-63-8
DrugBank:DB00351
KEGG COMPOUND:C07120
KEGG DRUG:D08167
17-hydroxypregna-4,6-diene-3,20-dione
Megestrol
17-Hydroxy-6-methylpregna-4,6-diene-3,20-dione
C22H30O3
InChI=1S/C21H28O3/c1-13(22)21(24)11-8-18-16-5-4-14-12-15(23)6-9-19(14,2)17(16)7-10-20(18,21)3/h4-5,12,16-18,24H,6-11H2,1-3H3/t16-,17+,18+,19+,20+,21+/m1/s1
InChIKey=JBVNBBXAMBZTMQ-CEGNMAFCSA-N
[H][C@]12CC[C@@]3(C)[C@@]([H])(CC[C@]3(O)C(C)=O)[C@]1([H])C=CC1=CC(=O)CC[C@]21C
megestrol
megestrolum
CHEBI:6722
Megestrol
megestrol
CHEBI:6722
An aromatic amine comprising salicylic acid having an amino group at the 5-position.
52582
Beilstein:2090421
DrugBank:DB00244
KEGG DRUG:D00377
Wikipedia:Mesalamine
5-amino-2-hydroxybenzoic acid
3-carboxy-4-hydroxyaniline
5-ASA
5-Aminosalicylic acid
Asacol
Asacolitin
C7H7NO3
Canasa
Claversal
Fisalamine
Iialda
InChI=1S/C7H7NO3/c8-4-1-2-6(9)5(3-4)7(10)11/h1-3,9H,8H2,(H,10,11)
InChIKey=KBOPZPXVLCULAV-UHFFFAOYSA-N
Lixacol
Mesalazina
Mesalazine
Mesalazinum
Mesasal
Nc1ccc(O)c(c1)C(O)=O
Pentasa
Rowasa
Salofalk
m-Aminosalicylic acid
mesalazine
p-Aminosalicylsaeure
CHEBI:6775
mesalamine
CHEBI:6775
A guanidine that has formula C4H11N5.
6809
ChemIDplus:657-24-9
KEGG COMPOUND:657-24-9
KEGG COMPOUND:C07151
Wikipedia:Metformin
Metformin
N,N-dimethylimidodicarbonimidic diamide
1,1-Dimethylbiguanide
C4H11N5
CN(C)C(=N)NC(N)=N
InChI=1S/C4H11N5/c1-9(2)4(7)8-3(5)6/h1-2H3,(H5,5,6,7,8)
InChIKey=XZWYZXLIPXDOLR-UHFFFAOYSA-N
CHEBI:6801
Metformin
metformin
CHEBI:6801
A 6-methylprednisolone that has formula C22H30O5.
6902
Beilstein:2340300
ChemIDplus:83-43-2
DrugBank:DB00959
KEGG DRUG:D00407
NIST Chemistry WebBook:83-43-2
Patent:US2897218
Patent:US3053832
Wikipedia:Methylprednisolone
11beta,17,21-trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione
(6alpha,11beta)-11,17,21-trihydroxy-6-methylpregna-1,4-diene-3,20-dione
1-dehydro-6alpha-methylhydrocortisone
6alpha-methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione
C22H30O5
Delta(1)-6alpha-methylhydrocortisone
InChI=1S/C22H30O5/c1-12-8-14-15-5-7-22(27,18(26)11-23)21(15,3)10-17(25)19(14)20(2)6-4-13(24)9-16(12)20/h4,6,9,12,14-15,17,19,23,25,27H,5,7-8,10-11H2,1-3H3/t12-,14-,15-,17-,19+,20-,21-,22-/m0/s1
InChIKey=VHRSUDSXCMQTMA-PJHHCJLFSA-N
Medrate
Medrol
Medrone
Methylprednisolon
Solomet
Urbason
[H][C@@]12C[C@H](C)C3=CC(=O)C=C[C@]3(C)[C@@]1([H])[C@@H](O)C[C@@]1(C)[C@@]2([H])CC[C@]1(O)C(=O)CO
methylprednisolone
methylprednisolonum
metilprednisolona
CHEBI:6888
6alpha-methylprednisolone
Methylprednisolone
CHEBI:6888
Imidazole substituted at C-1, -2 and -5 with 2-hydroxyethyl, nitro and methyl groups respectively.
6922
CHEBI:63636
Beilstein:611683
ChemIDplus:443-48-1
CiteXplore:11906111
CiteXplore:14702395
CiteXplore:15739364
CiteXplore:16901452
CiteXplore:18397330
CiteXplore:19485831
CiteXplore:22226009
CiteXplore:22252819
DrugBank:DB00916
KEGG DRUG:D00409
NIST Chemistry WebBook:443-48-1
Patent:US2944061
Reaxys:611683
Wikipedia:Metronidazole
2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethanol
1-(beta-Ethylol)-2-methyl-5-nitro-3-azapyrrole
Arilin
C6H9N3O3
Cc1ncc(n1CCO)[N+]([O-])=O
Clont
Efloran
Elyzol
Entizol
Flagyl
Fossyol
InChI=1S/C6H9N3O3/c1-5-7-4-6(9(11)12)8(5)2-3-10/h4,10H,2-3H2,1H3
InChIKey=VAOCPAMSLUNLGC-UHFFFAOYSA-N
Klion
Klont
Metrocream
Metrogel
Metrogel-Vaginal
Metrolyl
Metrotop
Nalox
Nidagel
Noritate
Novonidazol
Protostat
Trichex
Trichopol
Tricowas B
Trikacide
Trikozol
Vagilen
Vagimid
Vertisal
Zadstat
metronidazole
CHEBI:6909
Metronidazole
metronidazole
CHEBI:6909
7454
CHEBI:7591
Nitrofurantoin
nitrofurantoin
CHEBI:7591
A tricyclic antidepressant that has formula C19H21N.
7531
ChemIDplus:2216786
ChemIDplus:72-69-5
KEGG COMPOUND:72-69-5
KEGG COMPOUND:C07274
NIST Chemistry WebBook:72-69-5
Wikipedia:Nortriptyline
3-(10,11-dihydro-5H-dibenzo[a,d][7]annulen-5-ylidene)-N-methylpropan-1-amine
Nortriptyline
10,11-dihydro-N-methyl-5H-dibenzo[a,d]cycloheptene-Delta(5,gamma)-propylamine
3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine
Ateben
Avantyl
Aventyl
C19H21N
CNCCC=C1c2ccccc2CCc2ccccc12
InChI=1S/C19H21N/c1-20-14-6-11-19-17-9-4-2-7-15(17)12-13-16-8-3-5-10-18(16)19/h2-5,7-11,20H,6,12-14H2,1H3
InChIKey=PHVGLTMQBUFIQQ-UHFFFAOYSA-N
Noritren
Psychostyl
Sensaval
demethylamitriptyline
desmethylamitriptyline
CHEBI:7640
Nortriptyline
nortriptyline
CHEBI:7640
A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.
7623
CHEBI:100146
ChEMBL:100146
CiteXplore:11710934
DrugBank:DB01165
KEGG COMPOUND:82419-36-1
KEGG COMPOUND:C07321
KEGG DRUG:D00453
Wikipedia:Ofloxacin
9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid
8-Fluoro-3-methyl-9-(4-methyl-piperazin-1-yl)-6-oxo-2,3-dihydro-6H-1-oxa-3a-aza-phenalene-5-carboxylic acid
C18H20FN3O4
CC1COc2c(N3CCN(C)CC3)c(F)cc3c2n1cc(C(O)=O)c3=O
InChI=1S/C18H20FN3O4/c1-10-9-26-17-14-11(16(23)12(18(24)25)8-22(10)14)7-13(19)15(17)21-5-3-20(2)4-6-21/h7-8,10H,3-6,9H2,1-2H3,(H,24,25)
InChIKey=GSDSWSVVBLHKDQ-UHFFFAOYSA-N
OFLX
ofloxacin
CHEBI:7731
Ofloxacin
ofloxacin
CHEBI:7731
A sulfoxide having 3-methoxybenzimidazol-3-yl and 4-methoxy-3,5-dimethylpyridin-2-ylmethyl groups attached to the sulfur.
7646
Beilstein:3628192
ChemIDplus:73590-58-6
CiteXplore:11060758
CiteXplore:11208500
CiteXplore:11210716
CiteXplore:11304936
CiteXplore:11321383
CiteXplore:11395292
CiteXplore:11404722
CiteXplore:11459434
CiteXplore:11568514
CiteXplore:11700946
CiteXplore:11774962
CiteXplore:11807212
CiteXplore:11851112
CiteXplore:11903739
CiteXplore:11962536
CiteXplore:12072663
CiteXplore:12135028
CiteXplore:12235248
CiteXplore:12495367
CiteXplore:12683615
CiteXplore:13680386
CiteXplore:14616415
CiteXplore:14708212
CiteXplore:14725575
CiteXplore:15004262
CiteXplore:15125696
CiteXplore:15586641
CiteXplore:15598025
CiteXplore:15684503
CiteXplore:15707461
CiteXplore:15774534
CiteXplore:16080278
CiteXplore:16129922
CiteXplore:16259581
CiteXplore:16276979
CiteXplore:16380990
CiteXplore:16386527
CiteXplore:16397810
CiteXplore:16440530
CiteXplore:16998872
CiteXplore:17049542
CiteXplore:17384694
CiteXplore:17532167
CiteXplore:18294333
CiteXplore:18366242
CiteXplore:18416943
CiteXplore:18448060
CiteXplore:18498918
CiteXplore:18520598
CiteXplore:18571645
CiteXplore:18616070
CiteXplore:18793272
CiteXplore:18818790
CiteXplore:19150046
CiteXplore:19166730
CiteXplore:19176055
CiteXplore:19236757
CiteXplore:19327607
CiteXplore:19383986
CiteXplore:19434360
CiteXplore:19470853
CiteXplore:19517893
CiteXplore:19746659
CiteXplore:19796313
CiteXplore:19801857
CiteXplore:19937171
DrugBank:DB00338
KEGG COMPOUND:C07324
KEGG DRUG:D00455
Patent:EP5129
Patent:US4255431
Patent:US5693818
Reaxys:3628192
Wikipedia:Omeprazole
5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole
5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole
Antra
Audazol
Belmazol
C17H19N3O3S
COc1ccc2[nH]c(nc2c1)S(=O)Cc1ncc(C)c(OC)c1C
Ceprandal
Danlox
Desec
Elgam
Emeproton
Gasec
Gastrimut
InChI=1S/C17H19N3O3S/c1-10-8-18-15(11(2)16(10)23-4)9-24(21)17-19-13-6-5-12(22-3)7-14(13)20-17/h5-8H,9H2,1-4H3,(H,19,20)
InChIKey=SUBDBMMJDZJVOS-UHFFFAOYSA-N
Indurgan
Inhibitron
Losec
OMEP
OMP
OMZ
Olit
Omapren
Omebeta
Prazidec
Procelac
Sanamidol
Ulceral
Ulcesep
Ultop
omeprazol
omeprazole
omeprazolum
CHEBI:7772
Omeprazole
omeprazole
CHEBI:7772
A benzimidazole that has formula C16H15F2N3O4S.
40790
Beilstein:5361474
ChemIDplus:102625-70-7
DrugBank:DB00213
KEGG COMPOUND:C11806
KEGG DRUG:D05353
Patent:EP166287
Patent:US4758579
Wikipedia:Pantoprazole
5-(difluoromethoxy)-2-{[(3,4-dimethoxypyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole
C16H15F2N3O4S
COc1ccnc(CS(=O)c2nc3cc(OC(F)F)ccc3[nH]2)c1OC
InChI=1S/C16H15F2N3O4S/c1-23-13-5-6-19-12(14(13)24-2)8-26(22)16-20-10-4-3-9(25-15(17)18)7-11(10)21-16/h3-7,15H,8H2,1-2H3,(H,20,21)
InChIKey=IQPSEEYGBUAQFF-UHFFFAOYSA-N
pantoprazol
pantoprazole
pantoprazolum
CHEBI:7915
pantoprazole
CHEBI:7915
A benzodioxole that consists of piperidine bearing 1,3-benzodioxol-5-yloxy)methyl and 4-fluorophenyl substituents at positions 3 and 4 respectively; the (3S,4R)-diastereomer. Highly potent and selective 5-HT uptake inhibitor that binds with high affinity to the serotonin transporter (Ki = 0.05 nM). Ki values are 1.1, 350 and 1100 nM for inhibition of [3H]-5-HT, [3H]-l-NA and [3H]-DA uptake respectively. Displays minimal affinity for alpha1-, alpha2- or beta-adrenoceptors, 5-HT2A, 5-HT1A, D2 or H1 receptors at concentrations below 1000 nM, however displays weak affinity for muscarinic ACh receptors (Ki = 42 nM). Antidepressant and anxiolytic in vivo.
32937
Beilstein:7467879
ChemIDplus:61869-08-7
CiteXplore:11009210
CiteXplore:11169163
CiteXplore:11271409
CiteXplore:11281965
CiteXplore:11324355
CiteXplore:11360029
CiteXplore:11513198
CiteXplore:11563413
CiteXplore:11565622
CiteXplore:11819027
CiteXplore:11893234
CiteXplore:11910269
CiteXplore:12027788
CiteXplore:12088162
CiteXplore:12369443
CiteXplore:12421645
CiteXplore:12818234
CiteXplore:12820211
CiteXplore:12906023
CiteXplore:12920419
CiteXplore:14516531
CiteXplore:14521492
CiteXplore:14566196
CiteXplore:14566200
CiteXplore:14619895
CiteXplore:14624192
CiteXplore:14673053
CiteXplore:14689334
CiteXplore:14978354
CiteXplore:15048901
CiteXplore:15199661
CiteXplore:15241233
CiteXplore:15264994
CiteXplore:15374134
CiteXplore:15376524
CiteXplore:15544025
CiteXplore:15613191
CiteXplore:15845695
CiteXplore:15853570
CiteXplore:15903129
CiteXplore:15963219
CiteXplore:15992089
CiteXplore:16395417
CiteXplore:16397315
CiteXplore:16426087
CiteXplore:16765127
CiteXplore:16822276
CiteXplore:16913391
CiteXplore:17122538
CiteXplore:17162096
CiteXplore:17219219
CiteXplore:17286545
CiteXplore:17452166
CiteXplore:17559097
CiteXplore:17612590
CiteXplore:17652957
CiteXplore:17874333
CiteXplore:18273418
CiteXplore:18345955
CiteXplore:18808757
CiteXplore:18983224
CiteXplore:19687003
CiteXplore:19851065
CiteXplore:21404089
CiteXplore:21452176
CiteXplore:21739267
CiteXplore:21908494
CiteXplore:21909633
CiteXplore:21922171
CiteXplore:21939725
CiteXplore:22153922
CiteXplore:22198456
CiteXplore:22212003
CiteXplore:22240860
CiteXplore:22263916
CiteXplore:22283559
CiteXplore:22353759
CiteXplore:22377745
DrugBank:DB00715
KEGG COMPOUND:61869-08-7
KEGG COMPOUND:C07415
KEGG DRUG:D02362
Reaxys:7467879
Wikipedia:Paroxetine
(3S,4R)-3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine
Paroxetine
(-)-(3S,4R)-4-(p-fluorophenyl)-3-((3,4-(methylenedioxy)phenoxy)methyl)piperidine
(3S-trans)-3-((1,3-benzodioxol-5-yloxy)methyl)-4-(4-fluorophenyl)piperidine
C19H20FNO3
InChI=1S/C19H20FNO3/c20-15-3-1-13(2-4-15)17-7-8-21-10-14(17)11-22-16-5-6-18-19(9-16)24-12-23-18/h1-6,9,14,17,21H,7-8,10-12H2/t14-,17-/m0/s1
InChIKey=AHOUBRCZNHFOSL-YOEHRIQHSA-N
[H][C@]1(CCNC[C@H]1COc1ccc2OCOc2c1)c1ccc(F)cc1
paroxetina
paroxetinum
CHEBI:7936
Paroxetine
paroxetine
CHEBI:7936
A imidazolidine-2,4-dione that consists of hydantoin bearing two phenyl substituents at position 5.
8183
CHEBI:100921
Beilstein:384532
ChEMBL:100921
ChemIDplus:57-41-0
CiteXplore:7602118
DrugBank:DB00252
KEGG COMPOUND:57-41-0
KEGG COMPOUND:C07443
KEGG DRUG:D00512
Wikipedia:Phenytoin
5,5-diphenylimidazolidine-2,4-dione
5,5-Diphenyl-imidazolidine-2,4-dione
5,5-diphenylimidazolidine-2,4-dione
5,5-diphenyltetrahydro-1H-2,4-imidazoledione
C15H12N2O2
DILANTIN
InChI=1S/C15H12N2O2/c18-13-15(17-14(19)16-13,11-7-3-1-4-8-11)12-9-5-2-6-10-12/h1-10H,(H2,16,17,18,19)
InChIKey=CXOFVDLJLONNDW-UHFFFAOYSA-N
O=C1NC(=O)C(N1)(c1ccccc1)c1ccccc1
PHENTYTOIN
CHEBI:8107
Phenytoin
phenytoin
CHEBI:8107
A thiazolidenedione that has formula C19H20N2O3S.
33738
Beilstein:3595485
ChemIDplus:111025-46-8
DrugBank:DB01132
KEGG COMPOUND:111025-46-8
KEGG COMPOUND:C07675
Patent:EP193256
Patent:US4687777
Wikipedia:Pioglitazone
5-{4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl}-1,3-thiazolidine-2,4-dione
Pioglitazone
(+-)-5-((4-(2-(5-ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-thiazolidinedione
C19H20N2O3S
CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1
InChI=1S/C19H20N2O3S/c1-2-13-3-6-15(20-12-13)9-10-24-16-7-4-14(5-8-16)11-17-18(22)21-19(23)25-17/h3-8,12,17H,2,9-11H2,1H3,(H,21,22,23)
InChIKey=HYAFETHFCAUJAY-UHFFFAOYSA-N
pioglitazona
pioglitazone
pioglitazonum
CHEBI:8228
pioglitazone
CHEBI:8228
A member of the class of benzothiazoles that is 4,5,6,7-tetrahydro-1,3-benzothiazole in which the hydrogens at the 2 and 6-pro-S-positions are substituted by amino and propylamino groups, respectively.
746741
Beilstein:6479326
ChemIDplus:104632-26-0
DrugBank:DB00413
KEGG DRUG:D05575
Patent:EP186087
Patent:US4886812
Wikipedia:Pramipexole
(6S)-N(6)-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine
(-)-Pramipexole
2,6-Benzothiazolediamine, 4,5,6,7-tetrahydro-N(sup 6)-propyl-, (S)-
C10H17N3S
CCCN[C@H]1CCc2nc(N)sc2C1
InChI=1S/C10H17N3S/c1-2-5-12-7-3-4-8-9(6-7)14-10(11)13-8/h7,12H,2-6H2,1H3,(H2,11,13)/t7-/m0/s1
InChIKey=FASDKYOPVNHBLU-ZETCQYMHSA-N
pramipexol
pramipexole
pramipexolum
CHEBI:8356
Pramipexole
pramipexole
CHEBI:8356
A 21-hydroxy steroid that has formula C21H28O5.
8638
ChemIDplus:1354103
ChemIDplus:50-24-8
KEGG COMPOUND:50-24-8
KEGG COMPOUND:C07369
Wikipedia:Prednisolone
11beta,17,21-trihydroxypregna-1,4-diene-3,20-dione
Prednisolone
(11beta)-11,17,21-trihydroxypregna-1,4-diene-3,20-dione
1,4-pregnadiene-11beta,17alpha,21-triol-3,20-dione
1,4-pregnadiene-3,20-dione-11beta,17alpha,21-triol
3,20-dioxo-11beta,17alpha,21-trihydroxy-1,4-pregnadiene
C21H28O5
Delta(1)-dehydrocortisol
Delta(1)-dehydrohydrocortisone
Delta(1)-hydrocortisone
InChI=1S/C21H28O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h5,7,9,14-16,18,22,24,26H,3-4,6,8,10-11H2,1-2H3/t14-,15-,16-,18+,19-,20-,21-/m0/s1
InChIKey=OIGNJSKKLXVSLS-VWUMJDOOSA-N
[H][C@@]12CCC3=CC(=O)C=C[C@]3(C)[C@@]1([H])[C@@H](O)C[C@@]1(C)[C@@]2([H])CC[C@]1(O)C(=O)CO
hydroretrocortine
metacortandralone
CHEBI:8378
prednisolone
CHEBI:8378
A pyrimidinethione consisting of uracil in which the 2-oxo group is substituted by a thio group and the hydrogen at position 6 is substituted by a propyl group.
8794
Beilstein:130039
ChemIDplus:51-52-5
CiteXplore:11005705
CiteXplore:11036881
CiteXplore:11350963
CiteXplore:11401533
CiteXplore:12135875
CiteXplore:12922945
CiteXplore:14692727
CiteXplore:14745920
CiteXplore:16380675
CiteXplore:16498810
CiteXplore:16880639
CiteXplore:17365943
CiteXplore:17497002
CiteXplore:17878268
CiteXplore:18055877
CiteXplore:18710353
CiteXplore:19530273
CiteXplore:19578601
CiteXplore:20166204
CiteXplore:21749382
CiteXplore:6387489
DrugBank:DB00550
Gmelin:1998546
KEGG COMPOUND:51-52-5
KEGG COMPOUND:C07569
KEGG DRUG:D00562
NIST Chemistry WebBook:51-52-5
Reaxys:130039
Wikipedia:Propylthiouracil
6-propyl-2-sulfanylidene-2,3-dihydropyrimidin-4(1H)-one
6-propyl-2-thiouracil
2,3-dihydro-6-propyl-2-thioxo-4(1H)-pyrimidinone
2-Mercapto-6-propyl-4-pyrimidone
2-Mercapto-6-propylpyrimid-4-one
2-Thio-4-oxo-6-propyl-1,3-pyrimidine
2-Thio-6-propyl-1,3-pyrimidin-4-one
4-Propyl-2-thiouracil
4-propyl-2-thiouracil
6-Propyl-2-thio-2,4(1H,3H)pyrimidinedione
6-Propylthiouracil
6-Thio-4-propyluracil
6-propyl-2-thioxo-2,3-dihydropyrimidin-4(1H)-one
C7H10N2OS
CCCc1cc(=O)[nH]c(=S)[nH]1
InChI=1S/C7H10N2OS/c1-2-3-5-4-6(10)9-7(11)8-5/h4H,2-3H2,1H3,(H2,8,9,10,11)
InChIKey=KNAHARQHSZJURB-UHFFFAOYSA-N
Propylthiouracil
propiltiouracilo
propylthiouracil
propylthiouracile
propylthiouracilum
CHEBI:8502
6-propyl-2-thiouracil
Propylthiouracil
CHEBI:8502
A tricyclic antidepressant that has formula C19H21N.
8886
ChemIDplus:2217411
ChemIDplus:438-60-8
KEGG COMPOUND:438-60-8
KEGG COMPOUND:C07408
NIST Chemistry WebBook:438-60-8
Wikipedia:Protriptyline
3-(5H-dibenzo[a,d][7]annulen-5-yl)-N-methylpropan-1-amine
Protriptyline
3-(5H-dibenzo[a,d]cyclohepten-5-yl)-N-methyl-1-propanamine
5-(3-methylaminopropyl)-5H-dibenzo[a,d]cycloheptene
7-(3-methylaminopropyl)-1,2:5,6-dibenzocycloheptatriene
C19H21N
CNCCCC1c2ccccc2C=Cc2ccccc12
InChI=1S/C19H21N/c1-20-14-6-11-19-17-9-4-2-7-15(17)12-13-16-8-3-5-10-18(16)19/h2-5,7-10,12-13,19-20H,6,11,14H2,1H3
InChIKey=BWPIARFWQZKAIA-UHFFFAOYSA-N
N-methyl-5H-dibenzo[a,d]cycloheptene-5-propanamine
N-methyl-5H-dibenzo[a,d]cycloheptene-5-propylamine
amimetilina
CHEBI:8597
Protriptyline
protriptyline
CHEBI:8597
A sulfoxide that has formula C18H21N3O3S.
114979
Beilstein:8159014
ChemIDplus:117976-89-3
DrugBank:DB01129
KEGG COMPOUND:117976-89-3
KEGG COMPOUND:C07864
Wikipedia:Rabeprazole
2-({[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methyl}sulfinyl)-1H-benzimidazole
Rabeprazole
C18H21N3O3S
COCCCOc1ccnc(CS(=O)c2nc3ccccc3[nH]2)c1C
Clofezone
InChI=1S/C18H21N3O3S/c1-13-16(19-9-8-17(13)24-11-5-10-23-2)12-25(22)18-20-14-6-3-4-7-15(14)21-18/h3-4,6-9H,5,10-12H2,1-2H3,(H,20,21)
InChIKey=YREYEVIYCVEVJK-UHFFFAOYSA-N
rabeprazole
CHEBI:8768
rabeprazole
CHEBI:8768
A cyclopentapyrrole that has formula C23H32N2O5.
35296
Beilstein:4214464
ChemIDplus:87333-19-5
KEGG DRUG:87333-19-5
KEGG DRUG:D00421
Wikipedia:Ramipril
(2S,3aS,6aS)-1-[(2S)-2-{[(1S)-1-ethoxycarbonyl-3-phenylpropyl]amino}propanoyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid
Ramipril
(2S-(1(R*(R*)),2alpha,3abeta,6abeta))-1-(2-((1-(Ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydrocyclopenta(b)pyrrole-2-carboxylic acid.
Altace (TN)
C23H32N2O5
InChI=1S/C23H32N2O5/c1-3-30-23(29)18(13-12-16-8-5-4-6-9-16)24-15(2)21(26)25-19-11-7-10-17(19)14-20(25)22(27)28/h4-6,8-9,15,17-20,24H,3,7,10-14H2,1-2H3,(H,27,28)/t15-,17-,18-,19-,20-/m0/s1
InChIKey=HDACQVRGBOVJII-JBDAPHQKSA-N
Tritace
[H][C@@]12CCC[C@]1([H])N([C@@H](C2)C(O)=O)C(=O)[C@H](C)N[C@@H](CCc1ccccc1)C(=O)OCC
CHEBI:8774
Ramipril
ramipril
CHEBI:8774
An indolone that has formula C16H24N2O.
72302
Beilstein:6062222
ChemIDplus:91374-21-9
DrugBank:DB00268
KEGG COMPOUND:C07564
Patent:US4452808
Wikipedia:Ropinirole
4-[2-(dipropylamino)ethyl]-1,3-dihydro-2H-indol-2-one
Ropinirole
C16H24N2O
CCCN(CCC)CCc1cccc2NC(=O)Cc12
InChI=1S/C16H24N2O/c1-3-9-18(10-4-2)11-8-13-6-5-7-15-14(13)12-16(19)17-15/h5-7H,3-4,8-12H2,1-2H3,(H,17,19)
InChIKey=UHSKFQJFRQCDBE-UHFFFAOYSA-N
ropinirol
ropinirole
ropinirolum
CHEBI:8888
ropinirole
CHEBI:8888
A fatty acid ester comprising a dihydroxyheptanoic acid unit condensed into a lactone; a partially reduced naphthalene structure; and a 2,2-dimethylbutyric acyl substituent at C17. It is used as a cholesterol-lowering and anti-cardiovascular disease drug.
36567
CHEBI:45577
Beilstein:4768037
ChemIDplus:79902-63-9
DrugBank:DB00641
KEGG DRUG:79902-63-9
KEGG DRUG:D00434
Patent:EP33538
Patent:US4444784
Wikipedia:Simvastatin
(1S,3R,7S,8S,8aR)-8-{2-[(2R,4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl]ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl 2,2-dimethylbutanoate
Simvastatin
2,2-dimethylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8aR)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one
C25H38O5
InChI=1S/C25H38O5/c1-6-25(4,5)24(28)30-21-12-15(2)11-17-8-7-16(3)20(23(17)21)10-9-19-13-18(26)14-22(27)29-19/h7-8,11,15-16,18-21,23,26H,6,9-10,12-14H2,1-5H3/t15-,16-,18+,19+,20-,21-,23-/m0/s1
InChIKey=RYMZZMVNJRMUDD-HGQWONQESA-N
MK-733
Simvastatina
Simvastatine
Simvastatinum
Zocor
[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)C(C)(C)CC
simvastatin
CHEBI:9150
Simvastatin
simvastatin
CHEBI:9150
An azobenzene consisting of diphenyldiazene having a carboxy substituent at the 4-position, a hydroxy substituent at the 3-position and a 2-pyridylaminosulphonyl substituent at the 4'-position.
9524
CHEBI:101223
Beilstein:356241
Beilstein:8132868
ChemIDplus:599-79-1
CiteXplore:2434548
DrugBank:DB00795
Gmelin:2666050
KEGG COMPOUND:599-79-1
KEGG COMPOUND:C07316
KEGG DRUG:D00448
Patent:US2396145
Reaxys:8132868
2-hydroxy-5-{[4-(pyridin-2-ylsulfamoyl)phenyl]diazenyl}benzoic acid
Sulfasalazine
2-Hydroxy-5-((4-((2-pyridinylamino)sulfonyl)phenyl)azo)benzoic acid
2-Hydroxy-5-[4-(pyridin-2-ylsulfamoyl)-phenylazo]-benzoic acid
4-(Pyridyl-2-amidosulfonyl)-3'-carboxy-4'-hydroxyazobenzene
5-((p-(2-Pyridylsulfamoyl)phenyl)azo)salicylic acid
5-(4-(2-Pyridylsulfamoyl)phenylazo)-2-hydroxybenzoic acid
5-(p-(2-Pyridylsulfamyl)phenylazo)salicylic acid
Azulfidine
C18H14N4O5S
InChI=1S/C18H14N4O5S/c23-16-9-6-13(11-15(16)18(24)25)21-20-12-4-7-14(8-5-12)28(26,27)22-17-3-1-2-10-19-17/h1-11,23H,(H,19,22)(H,24,25)/b21-20+
InChIKey=NCEXYHBECQHGNR-QZQOTICOSA-N
OC(=O)c1cc(ccc1O)\N=N\c1ccc(cc1)S(=O)(=O)Nc1ccccn1
Salazosulfapiridina
Salazosulfapyridine
Salazosulfapyridinum
Salicylazosulfapyridine
Sulfasalazina
Sulfasalazinum
sulfasalazine
CHEBI:9334
Sulfasalazine
sulfasalazine
CHEBI:9334
A thienopyridine that has formula C14H14ClNS.
10594
ChemIDplus:55142-85-3
DrugBank:DB00208
KEGG COMPOUND:C07140
Patent:DE2404308
Patent:US4051141
Patent:US4127580
Wikipedia:Ticlopidine
5-(2-chlorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine
C14H14ClNS
Clc1ccccc1CN1CCc2sccc2C1
InChI=1S/C14H14ClNS/c15-13-4-2-1-3-11(13)9-16-7-5-14-12(10-16)6-8-17-14/h1-4,6,8H,5,7,9-10H2
InChIKey=PHWBOXQYWZNQIN-UHFFFAOYSA-N
ticlopidina
ticlopidine
ticlopidinum
CHEBI:9588
Ticlopidine
ticlopidine
CHEBI:9588
10759
CHEBI:9667
Triamcinolone
CHEBI:9667
A dibenzoazepine that has formula C20H26N2.
10834
ChemIDplus:1321466
ChemIDplus:739-71-9
KEGG DRUG:D00394
NIST Chemistry WebBook:739-71-9
Wikipedia:Trimipramine
3-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N,2-trimethylpropan-1-amine
Trimipramine
10,11-dihydro-N,N,beta-trimethyl-5H-dibenz[b,f]azepine-5-propanamine
5-(gamma-dimethylamino-beta-methylpropyl)-10,11-dihydro-5H-dibenzo[b,f]azepine
5-[3-(dimethylamino)-2-methylpropyl]-10,11-dihydro-5H-dibenz[b,f]azepine
C20H26N2
CC(CN(C)C)CN1c2ccccc2CCc2ccccc12
InChI=1S/C20H26N2/c1-16(14-21(2)3)15-22-19-10-6-4-8-17(19)12-13-18-9-5-7-11-20(18)22/h4-11,16H,12-15H2,1-3H3
InChIKey=ZSCDBOWYZJWBIY-UHFFFAOYSA-N
RP-7162
Sapilent
Trimeprimine
beta-methylimipramine
trimeproprimine
CHEBI:9738
Trimipramine
trimipramine
CHEBI:9738
A cyclohexanol that has formula C17H27NO2.
39786
Beilstein:4234848
ChemIDplus:93413-69-5
DrugBank:DB00285
KEGG COMPOUND:93413-69-5
KEGG COMPOUND:C07187
Wikipedia:Venlafaxine
1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexanol
Venlafaxine
C17H27NO2
COc1ccc(cc1)C(CN(C)C)C1(O)CCCCC1
Elafax
InChI=1S/C17H27NO2/c1-18(2)13-16(17(19)11-5-4-6-12-17)14-7-9-15(20-3)10-8-14/h7-10,16,19H,4-6,11-13H2,1-3H3
InChIKey=PNVNVHUZROJLTJ-UHFFFAOYSA-N
venlafaxina
venlafaxine
venlafaxinum
CHEBI:9943
venlafaxine
CHEBI:9943
A material entity of anatomical origin (part of or deriving from an organism) that has as its parts a maximally connected cell compartment surrounded by a plasma membrane.
CALOHA:TS-2035
FMA:68646
GO:0005623
KUPO:0000002
VHOG:0001533
WBbt:0004017
XAO:0003012
cell
CL:0000000
The definition of cell is intended to represent all cells, and thus a cell is defined as a material entity and not an anatomical structure, which implies that it is part of an organism (or the entirety of one).
cell
CL:0000000
A cell that is found in a natural setting, which includes multicellular organism cells 'in vivo' (i.e. part of an organism), and unicellular organisms 'in environment' (i.e. part of a natural environment).
CARO:0000013
cell in vivo
cell
CL:0000003
To accommodate unicellular organisms better, 'cell in vivo' has been re-labeled 'native cell' to better represent its intended meaning - that is, that it is a cell in the context of a multicellular organism or in a natural environment. 'Native' is intended to contrast with 'in vitro', which refers to cells or other biological entities that have been intentionally placed in a controlled, non-natural setting for the purpose of study or manipulation. (MAH 1.12.12).
native cell
CL:0000003
neuronal receptor cell (sensu Animalia)
cell
CL:0000006
neuronal receptor cell
CL:0000006
A cell that will develop into a neuron often after a migration phase.
BTO:0000930
FBbt:00005146
FMA:70563
cell
CL:0000031
neuroblast
CL:0000031
A relatively undifferentiated cell that retains the ability to divide and proliferate throughout life to provide progenitor cells that can differentiate into specialized cells.
CALOHA:TS-2086
FMA:63368
cell
CL:0000034
stem cell
CL:0000034
Neural stem cell is characterized as an undifferentiated cell that originates from the neuroectoderm and has the capacity both to perpetually self-renew without differentiating and to generate multiple types of lineage-restricted progenitors.
BTO:0002881
CALOHA:TS-2360
FMA:86684
NSC
neural stem cell
cell
CL:0000047
neuronal stem cell
CL:0000047
A stem cell that can give rise to multiple lineages of cells.
FMA:84789
multi-fate stem cell
multifate stem cell
multipotent cell
multipotent stem cell
cell
CL:0000048
multi fate stem cell
CL:0000048
A stem cell from which all cells of the body can form.
FMA:84790
totipotential stem cell
cell
CL:0000052
totipotent stem cell
CL:0000052
A precursor cell with a limited number of potential fates.
BTO:0000125
FMA:84782
blast cell
cell
CL:0000055
define using PATO mulit-potent or oligopotent?
non-terminally differentiated cell
CL:0000055
Any neuron having a sensory function; an afferent neuron conveying sensory impulses.
BTO:0001037
FBbt:00005124
FMA:84649
WBbt:0005759
cell
CL:0000101
sensory neuron
CL:0000101
Ectoderm destined to be nervous tissue.
neurectoderm cell
cell
CL:0000133
neurectodermal cell
CL:0000133
A pigment cell is a cell that contains pigment granules.
VHOG:0001678
chromatocyte
chromatophore
cell
CL:0000147
pigment cell
CL:0000147
pigment cell
cell
CL:0000149
visual pigment cell
CL:0000149
cell
CL:0000197
receptor cell
CL:0000197
A cell specialized to detect and transduce light.
BTO:0001060
CALOHA:TS-0868
FBbt:00004211
FMA:86740
cell
CL:0000210
photoreceptor cell
CL:0000210
A cell whose function is determined by the generation or the reception of an electric signal.
cell
CL:0000211
electrically active cell
CL:0000211
A cell of the outer of the three germ layers of the embryo.
FMA:72549
ectoderm cell
cell
CL:0000221
ectodermal cell
CL:0000221
cell
CL:0000255
eukaryotic cell
CL:0000255
A cell that is specialised to accumulate a particular substance(s).
cell
CL:0000325
stuff accumulating cell
CL:0000325
A cell of the outer layer of a blastula that gives rise to the ectoderm after gastrulation.
cell
CL:0000352
epiblast cell
CL:0000352
A cell whose function is determined by its response to an electric signal.
cell
CL:0000393
electrically responsive cell
CL:0000393
A cell that initiates an electrical signal and passes that signal to another cell.
cell
CL:0000404
electrically signaling cell
CL:0000404
A neuron which conveys sensory information centrally from the periphery.
FMA:87653
input neuron
cell
CL:0000526
afferent neuron
CL:0000526
The basic cellular unit of nervous tissue. Each neuron consists of a body, an axon, and dendrites. Their purpose is to receive, conduct, and transmit impulses in the nervous system.
BTO:0000938
CALOHA:TS-0683
FBbt:00005106
FMA:54527
VHOG:0001483
WBbt:0003679
nerve cell
cell
CL:0000540
These cells are also reportedly CD4-negative and CD200-positive. They are also capable of producing CD40L and IFN-gamma.
neuron
CL:0000540
cell
CL:0000548
animal cell
CL:0000548
A stem cell that can give rise to cell types of the body other than those of the germ-line.
CALOHA:TS-2086
FMA:63368
cell
CL:0000723
somatic stem cell
CL:0000723
A cell that is part of the nervous system.
tmeehan
2010-09-15T01:34:57Z
CALOHA:TS-2040
FMA:70333
cell
CL:0002319
neural cell
CL:0002319
A cell of the embryo.
tmeehan
2010-09-15T03:39:21Z
CALOHA:TS-0263
FMA:82840
FMA:82841
WBbt:0007028
cell
CL:0002321
embryonic cell
CL:0002321
A cell of an organism that does not pass on its genetic material to the organism's offspring (i.e. a non-germ line cell).
tmeehan
2010-09-24T09:44:42Z
BTO:0001268
FMA:72300
WBbt:0008378
cell
CL:0002371
somatic cell
CL:0002371
DRON:00000001
the role of a material entity to prevent, diagnose, treat, or study disease and/or its effects
William Hogan
William Hogan
clinical drug role
DRON:00000005
a material entity (1) containing at least one scattered molecular aggregate as part (the active ingredient) and (2) that is the bearer of a clinical drug role
William Hogan
William Hogan
drug product
DRON:00010174
5296
Altretamine
DRON:00010402
194000
capecitabine
DRON:00010449
221072
Cerivastatin sodium
NDF-RT: N0000022124
RxNORM: RXNORM/221072
DRON:00010568
83816
Delavirdine
NDF-RT: N0000022056
RxNORM: RXNORM/83816
DRON:00010978
28872
lomefloxacin
DRON:00011221
32385
olsalazine
DRON:00011289
7975
Penicillamine
DRON:00011432
8702
Procarbazine
DRON:00011589
3446
Succimer
DRON:00011676
72937
tolcapone
DRON:00011680
10636
Tolmetin
DRON:00012123
41127
fluvastatin
DRON:00012887
191831
infliximab
NDF-RT: N0000148580
RxNORM: RXNORM/191831
DRON:00012978
14851
Vigabatrin
DRON:00012980
70223
Aldesleukin
DRON:00012990
10362
Teniposide
DRON:00012997
196102
basiliximab
NDF-RT: N0000148568
RxNORM: RXNORM/196102
DRON:00013025
224905
trastuzumab
DRON:00013028
190376
linezolid
DRON:00013030
18330
arsenic trioxide
DRON:00013042
121191
rituximab
DRON:00013467
1227
Auranofin
DRON:00013468
16818
Acitretin
DRON:00013476
35302
Sirolimus
DRON:00013638
2105
Carmustine
DRON:00013678
44281
cevimeline
NDF-RT: N0000148658
RxNORM: RXNORM/44281
DRON:00013752
236646
Insulin, Protamine Zinc, Human
DRON:00013763
231049
eletriptan
NDF-RT: N0000148791
RxNORM: RXNORM/231049
DRON:00013779
68149
mycophenolate mofetil
DRON:00013784
233272
bexarotene
DRON:00013809
3363
Zalcitabine
DRON:00013975
85248
alosetron
DRON:00014193
139896
enfuvirtide
NDF-RT: N0000148793
RxNORM: RXNORM/139896
DRON:00014194
135775
zolmitriptan
DRON:00014197
138099
gemifloxacin
NDF-RT: N0000148804
RxNORM: RXNORM/138099
DRON:00014250
22299
Daptomycin
NDF-RT: N0000148828
RxNORM: RXNORM/22299
DRON:00014262
68446
pemetrexed
DRON:00014428
8698
Probenecid
DRON:00014630
2346
Chlorambucil
NDF-RT: N0000147072
RxNORM: RXNORM/2346
DRON:00015719
232158
rofecoxib
DRON:00015855
10179
Sulfamethizole
DRON:00015922
10432
Thalidomide
DRON:00015990
6916
Metolazone
DRON:00016171
83395
Saquinavir
DRON:00016203
4441
Flecainide
DRON:00016418
50975
histrelin
DRON:00016437
134748
rasagiline
DRON:00016731
228476
gatifloxacin
DRON:00016762
8120
Phenazopyridine
DRON:00016899
183379
rivastigmine
DRON:00016933
5966
Iopamidol
DRON:00016952
253453
peginterferon alfa-2b
DRON:00017214
38782
Triptorelin
DRON:00017540
24698
fludarabine
DRON:00017693
195085
efavirenz
DRON:00017760
187832
pregabalin
DRON:00017772
68244
Lamivudine
DRON:00017827
6719
Memantine
DRON:00017960
25480
gabapentin
DRON:00018005
53654
Nevirapine
DRON:00018093
214525
doxorubicin liposome
NDF-RT: N0000147829
RxNORM: RXNORM/3639
DRON:00018173
41126
fluticasone
DRON:00018221
136411
sildenafil
DRON:00018348
279645
almotriptan
NDF-RT: N0000148709
RxNORM: RXNORM/279645
DRON:00018583
278567
valdecoxib
DRON:00018677
402316
Miglustat
DRON:00018681
343047
Atazanavir
NDF-RT: N0000022320
RxNORM: RXNORM/343047
DRON:00018683
358258
bortezomib
DRON:00018685
358263
tadalafil
DRON:00018691
358255
aprepitant
NDF-RT: N0000148809
RxNORM: RXNORM/358255
DRON:00018693
282388
imatinib
DRON:00018756
337525
erlotinib
NDF-RT: N0000148872
RxNORM: RXNORM/337525
DRON:00018768
461016
Eszopiclone
NDF-RT: N0000023088
RxNORM: RXNORM/461016
DRON:00018834
495881
sorafenib
DRON:00018841
342369
lenalidomide
NDF-RT: N0000171749
RxNORM: RXNORM/342369
DRON:00018842
274771
nelarabine
DRON:00018864
618425
Nalidixate
DRON:00018901
475342
dasatinib
NDF-RT: N0000176043
RxNORM: RXNORM/475342
DRON:00018916
282446
posaconazole
DRON:00018974
620216
maraviroc
NDF-RT: N0000176115
RxNORM: RXNORM/620216
DRON:00018981
337523
ixabepilone
NDF-RT: N0000176119
RxNORM: RXNORM/337523
DRON:00018985
662281
nilotinib
DRON:00018993
475969
etravirine
NDF-RT: N0000176133
RxNORM: RXNORM/475969
DRON:00019003
754763
Fosaprepitant dimeglumine
NDF-RT: N0000176136
RxNORM: RXNORM/754763
DRON:00019225
819300
golimumab
NDF-RT: N0000178413
RxNORM: RXNORM/819300
DRON:00019228
709271
certolizumab pegol
DRON:00019457
275891
valganciclovir
DRON:00019501
877015
levoleucovorin
NDF-RT: N0000177954
RxNORM: RXNORM/877015
DRON:00019582
474128
telbivudine
DRON:00019607
612865
tocilizumab
DRON:00019850
968804
Cytarabine liposome
NDF-RT: N0000146419
RxNORM: RXNORM/3041
DRON:00019892
996051
cabazitaxel
NDF-RT: N0000181529
RxNORM: RXNORM/996051
DRON:00020017
1044584
tesamorelin
DRON:00020018
1045453
eribulin
NDF-RT: N0000182260
RxNORM: RXNORM/1045453
DRON:00020050
1094833
ipilimumab
NDF-RT: N0000182641
RxNORM: RXNORM/1094833
DRON:00020131
1147220
Vemurafenib
DRON:00020139
1148495
crizotinib
NDF-RT: N0000183253
RxNORM: RXNORM/1148495
DRON:00020212
1291301
avanafil
DRON:00020261
1302966
carfilzomib
DRON:00020281
276237
emtricitabine
DRON:00020282
300195
tenofovir disoproxil
DRON:00020307
1310520
teriflunomide
DRON:00020323
non-activating competitive beta-adrenergic receptor binding disposition
DRON:00020324
function-inhibiting hydrogen/potassium adenosine triphosphatase enzyme (H+/K+ ATPase) binding disposition
DRON:00020325
function-inhibiting L-type voltage-gated calcium channel binding disposition
DRON:00020336
96819
Triamcinolone Oral Tablet
NDF-RT: N0000145980
RxNORM: RXNORM/10759
DRON:00020337
103217
Dexamethasone Ophthalmic Ointment
NDF-RT: N0000146273
RxNORM: RXNORM/3264
DRON:00020345
108133
Hydrocortisone Ophthalmic Ointment
DRON:00020394
239053
Colchicine / Probenecid Oral Tablet
NDF-RT: N0000145804
RxNORM: RXNORM/2683
DRON:00020444
361834
fluticasone Inhalant Powder
DRON:00020458
370496
Carmustine Injectable Solution
NDF-RT: N0000146473
RxNORM: RXNORM/2105
DRON:00020493
370533
Acitretin Oral Capsule
NDF-RT: N0000148524
RxNORM: RXNORM/16818
DRON:00020504
370547
Allopurinol Oral Tablet
NDF-RT: N0000146247
RxNORM: RXNORM/519
DRON:00020516
370559
Amantadine Oral Tablet
NDF-RT: N0000147697
RxNORM: RXNORM/620
DRON:00020523
370568
Amiodarone Oral Tablet
NDF-RT: N0000146406
NDF-RT: N0000147701
RxNORM: RXNORM/203114
RxNORM: RXNORM/703
DRON:00020525
370570
Amitriptyline Oral Tablet
NDF-RT: N0000023131
RxNORM: RXNORM/203168
DRON:00020528
370573
Amlodipine Oral Tablet
NDF-RT: N0000148333
RxNORM: RXNORM/17767
DRON:00020539
370588
anastrozole Oral Tablet
NDF-RT: N0000148427
RxNORM: RXNORM/84857
DRON:00020557
370611
Aspirin Oral Tablet
DRON:00020565
370621
atorvastatin Oral Tablet
NDF-RT: N0000022046
RxNORM: RXNORM/83367
DRON:00020601
370657
hydroxyurea Oral Tablet
NDF-RT: N0000146101
RxNORM: RXNORM/5552
DRON:00020620
370679
Imipramine Oral Tablet
NDF-RT: N0000146215
NDF-RT: N0000147875
RxNORM: RXNORM/150816
RxNORM: RXNORM/5691
DRON:00020621
370680
Imipramine Oral Capsule
NDF-RT: N0000146216
RxNORM: RXNORM/91118
DRON:00020625
370686
Indomethacin Oral Suspension
NDF-RT: N0000146243
RxNORM: RXNORM/5781
DRON:00020635
370700
Iopamidol Injectable Solution
NDF-RT: N0000146122
RxNORM: RXNORM/5966
DRON:00020645
370716
isoniazid Oral Tablet
NDF-RT: N0000145890
RxNORM: RXNORM/6038
DRON:00020653
370725
Itraconazole Oral Capsule
NDF-RT: N0000148264
RxNORM: RXNORM/28031
DRON:00020736
370819
Altretamine Oral Tablet
NDF-RT: N0000147673
RxNORM: RXNORM/5296
DRON:00020868
370967
Auranofin Oral Tablet
NDF-RT: N0000146358
RxNORM: RXNORM/1227
DRON:00020955
371065
Betaxolol Oral Tablet
NDF-RT: N0000147726
RxNORM: RXNORM/1520
DRON:00020960
371070
bicalutamide Oral Tablet
NDF-RT: N0000148428
RxNORM: RXNORM/83008
DRON:00021014
371127
Bromocriptine Oral Capsule
DRON:00021046
371164
Buspirone Oral Tablet
DRON:00021059
371181
Caffeine Oral Tablet
DRON:00021113
371250
capecitabine Oral Tablet
NDF-RT: N0000148555
RxNORM: RXNORM/996051
DRON:00021114
371251
Capsaicin Topical Solution
NDF-RT: N0000147626
RxNORM: RXNORM/1992
DRON:00021345
371523
Ciprofloxacin Oral Capsule
NDF-RT: N0000147503
RxNORM: RXNORM/2551
DRON:00021347
371525
Ciprofloxacin Oral Tablet
NDF-RT: N0000147502
RxNORM: RXNORM/81981
DRON:00021386
371572
Clomipramine Oral Capsule
NDF-RT: N0000147779
RxNORM: RXNORM/2597
DRON:00021423
371613
Codeine Oral Tablet
DRON:00021462
371661
cyclobenzaprine Oral Tablet
NDF-RT: N0000147791
RxNORM: RXNORM/21949
DRON:00021467
371666
Cyclosporine Oral Capsule
NDF-RT: N0000147064
RxNORM: RXNORM/3008
DRON:00021489
371689
Dapsone Oral Tablet
NDF-RT: N0000147467
RxNORM: RXNORM/3108
DRON:00021503
371709
Desipramine Oral Tablet
NDF-RT: N0000147800
RxNORM: RXNORM/3247
DRON:00021599
371819
Didanosine Chewable Tablet
NDF-RT: N0000148104
RxNORM: RXNORM/3364
DRON:00021629
371856
Diltiazem Oral Tablet
NDF-RT: N0000147814
RxNORM: RXNORM/3443
DRON:00021698
371940
Disulfiram Oral Tablet
NDF-RT: N0000146816
RxNORM: RXNORM/3554
DRON:00021749
372003
efavirenz Oral Capsule
NDF-RT: N0000148587
RxNORM: RXNORM/195085
DRON:00021753
372007
Enalapril Oral Tablet
DRON:00021832
372091
Ethambutol Oral Tablet
NDF-RT: N0000146263
NDF-RT: N0000147838
RxNORM: RXNORM/142435
RxNORM: RXNORM/4110
DRON:00021860
372120
Etidronate Oral Tablet
NDF-RT: N0000147844
RxNORM: RXNORM/42682
DRON:00021872
372132
Etoposide Oral Capsule
NDF-RT: N0000146478
RxNORM: RXNORM/4179
DRON:00021897
372160
Fentanyl Injectable Solution
NDF-RT: N0000147049
RxNORM: RXNORM/4337
DRON:00021934
372208
Fluconazole Oral Capsule
NDF-RT: N0000147613
RxNORM: RXNORM/4450
DRON:00021937
372211
Flucytosine Oral Capsule
NDF-RT: N0000146153
RxNORM: RXNORM/4451
DRON:00021951
372227
Fluorouracil Oral Capsule
NDF-RT: N0000146166
RxNORM: RXNORM/4492
DRON:00021955
372231
Fluoxetine Oral Capsule
DRON:00021976
372255
fluvastatin Oral Capsule
NDF-RT: N0000021914
RxNORM: RXNORM/41127
DRON:00021977
372256
Fluvoxamine Oral Tablet
NDF-RT: N0000148386
RxNORM: RXNORM/203143
DRON:00021999
372292
Ganciclovir Oral Capsule
NDF-RT: N0000147855
RxNORM: RXNORM/4678
DRON:00022009
372302
Gentamicin Sulfate (USP) Injectable Solution
DRON:00022073
372376
Haloperidol Oral Solution
NDF-RT: N0000146461
RxNORM: RXNORM/5093
DRON:00022231
372563
Lamivudine Oral Tablet
NDF-RT: N0000148418
RxNORM: RXNORM/68244
DRON:00022238
372570
leflunomide Oral Tablet
NDF-RT: N0000148586
RxNORM: RXNORM/27169
DRON:00022244
372576
Leuprolide Injectable Solution
DRON:00022253
372586
Levodopa Oral Tablet
DRON:00022254
372588
Levofloxacin Oral Tablet
NDF-RT: N0000148474
RxNORM: RXNORM/82122
DRON:00022275
372614
Lisinopril Oral Tablet
NDF-RT: N0000147537
RxNORM: RXNORM/29046
DRON:00022291
372630
lomefloxacin Oral Tablet
NDF-RT: N0000148144
NDF-RT: N0000148250
RxNORM: RXNORM/235762
RxNORM: RXNORM/28872
DRON:00022309
372651
Losartan Oral Tablet
NDF-RT: N0000148401
NDF-RT: N0000148405
RxNORM: RXNORM/203160
RxNORM: RXNORM/52175
DRON:00022310
372652
Lovastatin Oral Tablet
NDF-RT: N0000147602
RxNORM: RXNORM/6472
DRON:00022383
372745
Mefloquine Oral Tablet
NDF-RT: N0000147900
RxNORM: RXNORM/6694
DRON:00022385
372747
Megestrol Oral Suspension
NDF-RT: N0000020211
RxNORM: RXNORM/6703
DRON:00022395
372757
Memantine Oral Tablet
DRON:00022419
372783
mesalamine Extended Release Capsule
NDF-RT: N0000147614
RxNORM: RXNORM/52582
DRON:00022437
372803
Metformin Oral Tablet
DRON:00022460
372827
Methimazole Oral Tablet
NDF-RT: N0000145822
RxNORM: RXNORM/6835
DRON:00022468
372835
Methotrexate Injectable Solution
NDF-RT: N0000147916
RxNORM: RXNORM/6851
DRON:00022495
372863
Methylprednisolone Topical Ointment
NDF-RT: N0000146409
RxNORM: RXNORM/52582
DRON:00022497
372866
Methylprednisolone Injectable Suspension
NDF-RT: N0000146411
RxNORM: RXNORM/155323
DRON:00022517
372888
Metolazone Oral Tablet
NDF-RT: N0000146498
RxNORM: RXNORM/6916
DRON:00022521
372893
Metronidazole Oral Suspension
NDF-RT: N0000146194
RxNORM: RXNORM/6922
DRON:00022568
372941
Misoprostol Oral Tablet
NDF-RT: N0000147506
RxNORM: RXNORM/42331
DRON:00022663
373046
Nevirapine Oral Tablet
NDF-RT: N0000148461
RxNORM: RXNORM/53654
DRON:00022714
373101
Nitrofurantoin Oral Tablet
NDF-RT: N0000147151
RxNORM: RXNORM/7454
DRON:00022733
373120
Norfloxacin Oral Tablet
NDF-RT: N0000147623
RxNORM: RXNORM/7517
DRON:00022739
373126
Nortriptyline Oral Tablet
NDF-RT: N0000147946
RxNORM: RXNORM/7531
DRON:00022754
373141
Ofloxacin Oral Tablet
NDF-RT: N0000147667
RxNORM: RXNORM/7623
DRON:00022757
373144
olsalazine Oral Tablet
NDF-RT: N0000147671
RxNORM: RXNORM/104123
DRON:00022828
373222
pantoprazole Enteric Coated Tablet
NDF-RT: N0000148654
RxNORM: RXNORM/40790
DRON:00022859
373258
Penicillamine Oral Tablet
NDF-RT: N0000146290
RxNORM: RXNORM/7975
DRON:00022864
373263
Penicillin G Oral Solution
DRON:00022867
373266
Penicillin V Oral Tablet
NDF-RT: N0000145824
RxNORM: RXNORM/203195
DRON:00022889
373291
Pergolide Oral Tablet
NDF-RT: N0000147968
RxNORM: RXNORM/8047
DRON:00022898
373303
Phenazopyridine Oral Tablet
DRON:00023012
373432
Phenytoin Oral Tablet
NDF-RT: N0000146211
RxNORM: RXNORM/8183
DRON:00023118
373560
Pravastatin Oral Tablet
NDF-RT: N0000148255
RxNORM: RXNORM/42463
DRON:00023136
373578
prednisolone Oral Tablet
DRON:00023158
373602
Procarbazine Oral Capsule
DRON:00023184
373637
Propafenone Oral Tablet
DRON:00023204
373658
Propylthiouracil Oral Tablet
NDF-RT: N0000145820
RxNORM: RXNORM/8794
DRON:00023210
373665
Protriptyline Oral Tablet
NDF-RT: N0000148003
RxNORM: RXNORM/8886
DRON:00023278
373749
Ramipril Oral Tablet
NDF-RT: N0000147662
RxNORM: RXNORM/35296
DRON:00023302
373774
Ribavirin Oral Tablet
DRON:00023323
373797
rivastigmine Oral Capsule
NDF-RT: N0000148665
RxNORM: RXNORM/183379
DRON:00023325
373800
ropinirole Oral Tablet
NDF-RT: N0000022086
RxNORM: RXNORM/72302
DRON:00023363
373842
Selegiline Oral Tablet
NDF-RT: N0000148014
RxNORM: RXNORM/9639
DRON:00023379
373871
sildenafil Oral Tablet
NDF-RT: N0000022115
RxNORM: RXNORM/136411
DRON:00023396
373888
Simvastatin Oral Tablet
NDF-RT: N0000148200
RxNORM: RXNORM/36567
DRON:00023427
373937
Sotalol Oral Tablet
NDF-RT: N0000148322
NDF-RT: N0000148334
RxNORM: RXNORM/7008
RxNORM: RXNORM/9947
DRON:00023447
373959
Stavudine Oral Capsule
NDF-RT: N0000148369
RxNORM: RXNORM/59763
DRON:00023452
373964
Succimer Oral Capsule
NDF-RT: N0000147417
RxNORM: RXNORM/3446
DRON:00023469
373981
Sulfamethizole Oral Tablet
NDF-RT: N0000146815
DRON:00023479
373991
Sulfasalazine Oral Tablet
NDF-RT: N0000146249
RxNORM: RXNORM/9524
DRON:00023497
374012
Sumatriptan Oral Tablet
DRON:00023504
374020
Tamoxifen Oral Tablet
NDF-RT: N0000148024
RxNORM: RXNORM/10324
DRON:00023599
374131
Ticlopidine Oral Tablet
NDF-RT: N0000148235
RxNORM: RXNORM/10594
DRON:00023605
374138
Tinidazole Oral Tablet
NDF-RT: N0000148851
RxNORM: RXNORM/10612
DRON:00023612
374146
tizanidine Oral Tablet
NDF-RT: N0000148492
RxNORM: RXNORM/57258
DRON:00023613
374147
Tobramycin Injectable Solution
DRON:00023619
374153
tolcapone Oral Tablet
NDF-RT: N0000148551
RxNORM: RXNORM/72937
DRON:00023623
374157
Tolmetin Oral Tablet
NDF-RT: N0000148037
RxNORM: RXNORM/10636
DRON:00023632
374166
topiramate Oral Tablet
NDF-RT: N0000148493
RxNORM: RXNORM/38404
DRON:00023704
374239
Trimipramine Oral Tablet
NDF-RT: N0000148047
RxNORM: RXNORM/10834
DRON:00023742
374285
venlafaxine Oral Tablet
NDF-RT: N0000021906
RxNORM: RXNORM/39786
DRON:00023748
374291
Vigabatrin Oral Tablet
NDF-RT: N0000171807
RxNORM: RXNORM/14851
DRON:00023781
374330
zafirlukast Oral Tablet
NDF-RT: N0000148457
RxNORM: RXNORM/114970
DRON:00023783
374332
Zidovudine Oral Tablet
NDF-RT: N0000147622
RxNORM: RXNORM/11413
DRON:00023808
374363
zolmitriptan Oral Tablet
NDF-RT: N0000148550
RxNORM: RXNORM/135775
DRON:00023809
374364
zolpidem Oral Tablet
NDF-RT: N0000021601
RxNORM: RXNORM/39993
DRON:00023989
374583
clopidogrel Oral Tablet
DRON:00024008
374606
pioglitazone Oral Tablet
DRON:00024010
374609
zaleplon Oral Capsule
NDF-RT: N0000148625
RxNORM: RXNORM/74667
DRON:00024020
374619
moxifloxacin Oral Tablet
NDF-RT: N0000148632
RxNORM: RXNORM/139462
DRON:00024022
374621
gatifloxacin Oral Tablet
DRON:00024027
374626
linezolid Oral Tablet
NDF-RT: N0000148664
RxNORM: RXNORM/190376
DRON:00024045
374649
ziprasidone Oral Capsule
NDF-RT: N0000148690
RxNORM: RXNORM/115698
DRON:00024052
374656
valganciclovir Oral Tablet
NDF-RT: N0000148704
RxNORM: RXNORM/275891
DRON:00024062
374667
mycophenolate mofetil Oral Tablet
DRON:00024071
374678
peginterferon alfa-2b Injectable Solution
NDF-RT: N0000148697
RxNORM: RXNORM/253453
DRON:00024356
375061
exemestane Oral Tablet
NDF-RT: N0000148637
RxNORM: RXNORM/258494
DRON:00024436
375173
Mitoxantrone Injectable Solution
NDF-RT: N0000147641
NDF-RT: N0000147929
RxNORM: RXNORM/203129
RxNORM: RXNORM/7005
DRON:00024462
375205
Pentamidine Injectable Solution
NDF-RT: N0000147966
RxNORM: RXNORM/7994
DRON:00024497
375256
rabeprazole Enteric Coated Tablet
DRON:00024567
375369
zonisamide Oral Tablet
NDF-RT: N0000148668
RxNORM: RXNORM/39998
DRON:00024830
375794
cefepime Injectable Solution
NDF-RT: N0000022054
RxNORM: RXNORM/20481
DRON:00025223
376337
Aurothiomalate Injectable Solution
NDF-RT: N0000146340
RxNORM: RXNORM/4981
DRON:00025255
376374
Deferoxamine Injectable Solution
NDF-RT: N0000147797
RxNORM: RXNORM/3131
DRON:00025297
376431
rofecoxib Oral Tablet
NDF-RT: N0000148611
RxNORM: RXNORM/232158
DRON:00025299
376433
Cisplatin Injectable Solution
NDF-RT: N0000146476
RxNORM: RXNORM/2555
DRON:00025587
376842
Foscarnet Injectable Solution
NDF-RT: N0000148246
RxNORM: RXNORM/33562
DRON:00025622
376887
gemcitabine Injectable Solution
NDF-RT: N0000022036
RxNORM: RXNORM/12574
DRON:00025623
376888
docetaxel Injectable Solution
NDF-RT: N0000148441
RxNORM: RXNORM/72962
DRON:00025748
377091
Aldesleukin Injectable Solution
NDF-RT: N0000148066
RxNORM: RXNORM/70223
DRON:00025763
377111
Paclitaxel Injectable Solution
NDF-RT: N0000148314
RxNORM: RXNORM/56946
DRON:00025774
377125
vinorelbine Injectable Solution
NDF-RT: N0000021986
RxNORM: RXNORM/39541
DRON:00025777
377128
Ifosfamide Injectable Solution
NDF-RT: N0000147596
RxNORM: RXNORM/5657
DRON:00025779
377130
Teniposide Injectable Solution
NDF-RT: N0000148273
RxNORM: RXNORM/10362
DRON:00025810
377175
Cladribine Injectable Solution
NDF-RT: N0000148293
RxNORM: RXNORM/44157
DRON:00025837
377209
oxaliplatin Injectable Solution
NDF-RT: N0000148774
RxNORM: RXNORM/32592
DRON:00025843
377216
trastuzumab Injectable Solution
NDF-RT: N0000148593
RxNORM: RXNORM/224905
DRON:00025863
377259
rituximab Injectable Solution
NDF-RT: N0000148560
RxNORM: RXNORM/121191
DRON:00026059
377483
Propofol Injectable Suspension
NDF-RT: N0000147620
RxNORM: RXNORM/8782
DRON:00026584
378079
bexarotene Topical Gel
NDF-RT: N0000148643
RxNORM: RXNORM/233272
DRON:00026599
378099
gabapentin Oral Tablet
NDF-RT: N0000148345
RxNORM: RXNORM/25480
DRON:00026665
378233
Bupropion Oral Tablet
NDF-RT: N0000147738
RxNORM: RXNORM/42347
DRON:00026688
378277
Sirolimus Oral Tablet
DRON:00026716
378318
ropivacaine Injectable Solution
NDF-RT: N0000022060
RxNORM: RXNORM/35780
DRON:00026729
378363
Carboplatin Injectable Solution
NDF-RT: N0000147598
RxNORM: RXNORM/40048
DRON:00026857
378634
histrelin Injectable Solution
NDF-RT: N0000176176
RxNORM: RXNORM/50975
DRON:00026889
378682
montelukast Oral Tablet
NDF-RT: N0000022122
RxNORM: RXNORM/88249
DRON:00026893
378686
valdecoxib Oral Tablet
NDF-RT: N0000148721
RxNORM: RXNORM/278567
DRON:00026894
378688
vardenafil Oral Tablet
NDF-RT: N0000148820
RxNORM: RXNORM/306674
DRON:00026895
378691
voriconazole Oral Tablet
NDF-RT: N0000148767
RxNORM: RXNORM/121243
DRON:00027059
378925
Paroxetine Oral Tablet
NDF-RT: N0000148335
RxNORM: RXNORM/32937
DRON:00027119
379009
Insulin, Protamine Zinc, Human Injectable Suspension
DRON:00027215
379127
Zalcitabine Oral Tablet
NDF-RT: N0000021287
RxNORM: RXNORM/3363
DRON:00027279
379232
Triptorelin Injectable Suspension
NDF-RT: N0000148818
RxNORM: RXNORM/38782
DRON:00027809
393413
fludarabine Oral Tablet
NDF-RT: N0000148119
NDF-RT: N0000148244
RxNORM: RXNORM/24698
RxNORM: RXNORM/25102
DRON:00027818
393435
Omeprazole Oral Tablet
NDF-RT: N0000147569
RxNORM: RXNORM/7646
DRON:00027823
393446
fluticasone Nasal Suspension
NDF-RT: N0000148245
RxNORM: RXNORM/41126
DRON:00027865
402347
Miglustat Oral Capsule
NDF-RT: N0000148822
RxNORM: RXNORM/402316
DRON:00027879
402394
bortezomib Injectable Solution
NDF-RT: N0000148811
RxNORM: RXNORM/358258
DRON:00027893
402452
tadalafil Oral Tablet
NDF-RT: N0000148829
RxNORM: RXNORM/358263
DRON:00027964
406050
imatinib Oral Tablet
NDF-RT: N0000148698
RxNORM: RXNORM/282388
DRON:00027976
406178
pemetrexed Injectable Solution
NDF-RT: N0000148831
RxNORM: RXNORM/68446
DRON:00028026
435471
butalbital Oral Tablet
DRON:00029994
451875
Tacrolimus Oral Tablet
NDF-RT: N0000148372
RxNORM: RXNORM/42316
DRON:00030017
451949
Streptomycin Oral Capsule
NDF-RT: N0000148018
RxNORM: RXNORM/10109
DRON:00030051
452059
Thalidomide Oral Tablet
NDF-RT: N0000148588
RxNORM: RXNORM/10432
DRON:00030338
483437
pregabalin Oral Capsule
NDF-RT: N0000023107
RxNORM: RXNORM/187832
DRON:00030385
485467
Saquinavir Oral Tablet
NDF-RT: N0000148419
RxNORM: RXNORM/83395
DRON:00030435
498897
Flecainide Oral Tablet
NDF-RT: N0000147848
RxNORM: RXNORM/4441
DRON:00030440
498905
Nitrofurantoin Oral Capsule
NDF-RT: N0000147151
NDF-RT: N0000163521
RxNORM: RXNORM/221129
RxNORM: RXNORM/7454
DRON:00030635
577211
tipranavir Oral Capsule
NDF-RT: N0000023100
RxNORM: RXNORM/190548
DRON:00030779
596836
lansoprazole Oral Capsule
NDF-RT: N0000148407
RxNORM: RXNORM/17128
DRON:00030794
597746
sorafenib Oral Tablet
NDF-RT: N0000171742
RxNORM: RXNORM/495881
DRON:00030815
603565
nelarabine Injectable Solution
NDF-RT: N0000171753
RxNORM: RXNORM/274771
DRON:00030845
608327
rasagiline Oral Tablet
NDF-RT: N0000171790
RxNORM: RXNORM/134748
DRON:00030932
618427
Nalidixate Oral Tablet
DRON:00031159
632025
tenofovir disoproxil Oral Tablet
NDF-RT: N0000148716
RxNORM: RXNORM/117466
DRON:00031282
639882
emtricitabine Oral Tablet
NDF-RT: N0000148813
RxNORM: RXNORM/276237
DRON:00031401
665018
posaconazole Oral Suspension
DRON:00031408
665121
telbivudine Oral Tablet
NDF-RT: N0000176071
RxNORM: RXNORM/474128
DRON:00031691
727885
Triamcinolone Prefilled Syringe
DRON:00031753
745021
Pramipexole Oral Tablet
NDF-RT: N0000022076
RxNORM: RXNORM/746741
DRON:00031780
746605
nilotinib Oral Capsule
NDF-RT: N0000176124
RxNORM: RXNORM/662281
DRON:00031783
746765
fluticasone Dry Powder Inhaler
DRON:00031788
747192
Topotecan Oral Capsule
NDF-RT: N0000022037
RxNORM: RXNORM/57308
DRON:00032163
795080
certolizumab pegol Injectable Solution
DRON:00032559
849596
certolizumab pegol Prefilled Syringe
NDF-RT: N0000178499
RxNORM: RXNORM/709271
DRON:00033048
895759
tocilizumab Injectable Solution
DRON:00033154
900574
Ritonavir Oral Tablet
NDF-RT: N0000148436
RxNORM: RXNORM/85762
DRON:00033639
1044586
tesamorelin Injectable Solution
NDF-RT: N0000182253
RxNORM: RXNORM/1044584
DRON:00033939
1147222
Vemurafenib Oral Tablet
NDF-RT: N0000183250
RxNORM: RXNORM/1147220
DRON:00034152
1291305
avanafil Oral Tablet
RxNORM: RXNORM/1291301
DRON:00034236
1302969
carfilzomib Injectable Solution
NDF-RT: N0000185509
RxNORM: RXNORM/1302966
DRON:00034279
1310524
teriflunomide Oral Tablet
NDF-RT: N0000185727
RxNORM: RXNORM/1310520
DRON:00034441
102692
penicillin G benzathine 115 MG/ML Oral Solution
NDF-RT: N0000145827
RxNORM: RXNORM/7982
DRON:00046544
314167
Procarbazine 50 MG Oral Capsule
DRON:00046801
317573
pioglitazone 15 MG Oral Tablet
DRON:00053744
545835
Leuprolide Acetate 5 MG/ML Injectable Solution
NDF-RT: N0000147256
RxNORM: RXNORM/203217
DRON:00057777
833449
0.1 ML Triamcinolone Acetonide 80 MG/ML Prefilled Syringe
DRON:00059074
858804
Enalapril Maleate 2.5 MG Oral Tablet
NDF-RT: N0000146304
RxNORM: RXNORM/203123
DRON:00061555
966903
Insulin, Protamine Zinc, Human 40 UNT/ML Injectable Suspension
DRON:00072660
207588
Procarbazine 50 MG Oral Capsule [Matulane]
NDF-RT: N0000147991
RxNORM: RXNORM/8702
DRON:00075444
261266
pioglitazone 15 MG Oral Tablet [Actos]
DRON:00080145
835559
0.1 ML Triamcinolone Acetonide 80 MG/ML Prefilled Syringe [Trivaris]
DRON:00082933
966907
Insulin, Protamine Zinc, Human 40 UNT/ML Injectable Suspension [ProZinc]
NDF-RT: N0000147876
RxNORM: RXNORM/5856
Any process that stops, prevents, or reduces the frequency, rate or extent of transcription from an RNA polymerase II promoter.
GO:0010553
GO:0045816
down regulation of transcription from RNA polymerase II promoter
down-regulation of transcription from RNA polymerase II promoter
downregulation of transcription from RNA polymerase II promoter
inhibition of transcription from RNA polymerase II promoter
negative regulation of transcription from Pol II promoter
biological_process
down regulation of global transcription from RNA polymerase II promoter
down-regulation of global transcription from RNA polymerase II promoter
downregulation of global transcription from RNA polymerase II promoter
inhibition of global transcription from RNA polymerase II promoter
negative regulation of gene-specific transcription from RNA polymerase II promoter
negative regulation of global transcription from Pol II promoter
negative regulation of transcription from RNA polymerase II promoter, global
GO:0000122
negative regulation of transcription from RNA polymerase II promoter
GO:0000122
GO:0001838
embryonic epithelial tube formation
GO:0001841
neural tube formation
Any process that modulates the frequency, rate or extent of the cytokine mediated signaling pathway.
regulation of cytokine and chemokine mediated signaling pathway
regulation of cytokine mediated signaling pathway
regulation of cytokine mediated signalling pathway
biological_process
GO:0001959
regulation of cytokine-mediated signaling pathway
GO:0001959
Any process that stops, prevents, or reduces the frequency, rate or extent of the cytokine mediated signaling pathway.
down regulation of cytokine mediated signaling pathway
down-regulation of cytokine mediated signaling pathway
downregulation of cytokine mediated signaling pathway
negative regulation of cytokine and chemokine mediated signaling pathway
negative regulation of cytokine mediated signaling pathway
negative regulation of cytokine mediated signalling pathway
inhibition of cytokine mediated signaling pathway
biological_process
GO:0001960
negative regulation of cytokine-mediated signaling pathway
GO:0001960
GO:0002009
morphogenesis of an epithelium
GO:0003008
system process
GO:0005575
cellular_component
GO:0005623
cell
Any process that modulates the frequency, rate or extent of cellular DNA-templated transcription.
GO:0032583
GO:0045449
GO:0061019
transcriptional control
regulation of cellular transcription, DNA-dependent
regulation of transcription, DNA-dependent
biological_process
regulation of gene-specific transcription
GO:0006355
regulation of transcription, DNA-templated
GO:0006355
Any process that modulates the frequency, rate or extent of transcription from an RNA polymerase II promoter.
GO:0006358
GO:0010551
regulation of transcription from Pol II promoter
biological_process
global transcription regulation from Pol II promoter
regulation of gene-specific transcription from RNA polymerase II promoter
regulation of global transcription from Pol II promoter
regulation of transcription from RNA polymerase II promoter, global
GO:0006357
regulation of transcription from RNA polymerase II promoter
GO:0006357
GO:0007275
multicellular organismal development
GO:0007369
gastrulation
GO:0007399
nervous system development
GO:0007600
sensory perception
GO:0007601
visual perception
Any process specifically pertinent to the functioning of integrated living units: cells, tissues, organs, and organisms. A process is a collection of molecular events with a defined beginning and end.
GO:0000004
GO:0007582
Wikipedia:Biological_process
biological process
physiological process
biological_process
GO:0008150
Note that, in addition to forming the root of the biological process ontology, this term is recommended for use for the annotation of gene products whose biological process is unknown. Note that when this term is used for annotation, it indicates that no information was available about the biological process of the gene product annotated as of the date the annotation was made; the evidence code ND, no data, is used to indicate this.
biological_process
GO:0008150
Any process that modulates the frequency, rate or extent of G-protein coupled receptor protein signaling pathway activity.
regulation of G protein coupled receptor protein signaling pathway
regulation of G protein coupled receptor protein signalling pathway
regulation of G-protein coupled receptor protein signalling pathway
regulation of G-protein-coupled receptor protein signaling pathway
regulation of G-protein-coupled receptor protein signalling pathway
regulation of GPCR protein signaling pathway
regulation of GPCR protein signalling pathway
biological_process
GO:0008277
regulation of G-protein coupled receptor protein signaling pathway
GO:0008277
GO:0009314
response to radiation
GO:0009416
response to light stimulus
GO:0009581
detection of external stimulus
GO:0009582
detection of abiotic stimulus
GO:0009583
detection of light stimulus
GO:0009584
detection of visible light
GO:0009605
response to external stimulus
GO:0009628
response to abiotic stimulus
GO:0009653
anatomical structure morphogenesis
GO:0009790
embryo development
GO:0009791
post-embryonic development
GO:0009792
embryo development ending in birth or egg hatching
GO:0009888
tissue development
Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of substances.
regulation of anabolism
regulation of biosynthesis
regulation of formation
regulation of synthesis
biological_process
GO:0009889
regulation of biosynthetic process
GO:0009889
Any process that stops, prevents, or reduces the rate of the chemical reactions and pathways resulting in the formation of substances.
down regulation of biosynthetic process
down-regulation of biosynthetic process
downregulation of biosynthetic process
negative regulation of anabolism
negative regulation of biosynthesis
negative regulation of formation
negative regulation of synthesis
inhibition of biosynthetic process
biological_process
GO:0009890
negative regulation of biosynthetic process
GO:0009890
Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways within a cell or an organism.
down regulation of metabolic process
down-regulation of metabolic process
downregulation of metabolic process
negative regulation of metabolism
inhibition of metabolic process
biological_process
GO:0009892
negative regulation of metabolic process
GO:0009892
Any process that modulates the frequency, rate or extent of signal transduction.
GO:0035466
biological_process
regulation of signaling pathway
regulation of signalling pathway
GO:0009966
regulation of signal transduction
GO:0009966
Any process that activates or increases the frequency, rate or extent of signal transduction.
GO:0035468
Reactome:REACT_6227
up regulation of signal transduction
up-regulation of signal transduction
upregulation of signal transduction
activation of signal transduction
stimulation of signal transduction
biological_process
positive regulation of signaling pathway
positive regulation of signalling pathway
GO:0009967
positive regulation of signal transduction
GO:0009967
Any process that stops, prevents, or reduces the frequency, rate or extent of signal transduction.
GO:0035467
Reactome:REACT_6334
down regulation of signal transduction
down-regulation of signal transduction
downregulation of signal transduction
inhibition of signal transduction
biological_process
negative regulation of signaling pathway
negative regulation of signalling pathway
GO:0009968
negative regulation of signal transduction
GO:0009968
GO:0009987
cellular process
Any process that modulates the frequency, rate or extent of gene expression. Gene expression is the process in which a gene's coding sequence is converted into a mature gene product or products (proteins or RNA). This includes the production of an RNA transcript as well as any processing to produce a mature RNA product or an mRNA (for protein-coding genes) and the translation of that mRNA into protein. Some protein processing events may be included when they are required to form an active form of a product from an inactive precursor form.
Wikipedia:Regulation_of_gene_expression
regulation of protein expression
biological_process
regulation of gene product expression
GO:0010468
regulation of gene expression
GO:0010468
Any process that modulates the frequency, rate or extent of receptor activity. Receptor activity is when a molecule combines with an extracellular or intracellular messenger to initiate a change in cell activity.
biological_process
GO:0010469
regulation of receptor activity
GO:0010469
Any process that modulates the rate, frequency or extent of the chemical reactions and pathways resulting in the formation of a macromolecule, any molecule of high relative molecular mass, the structure of which essentially comprises the multiple repetition of units derived, actually or conceptually, from molecules of low relative molecular mass.
biological_process
GO:0010556
regulation of macromolecule biosynthetic process
GO:0010556
Any process that decreases the rate, frequency or extent of the chemical reactions and pathways resulting in the formation of a macromolecule, any molecule of high relative molecular mass, the structure of which essentially comprises the multiple repetition of units derived, actually or conceptually, from molecules of low relative molecular mass.
biological_process
GO:0010558
negative regulation of macromolecule biosynthetic process
GO:0010558
Any process that decreases the frequency, rate or extent of the chemical reactions and pathways involving macromolecules, any molecule of high relative molecular mass, the structure of which essentially comprises the multiple repetition of units derived, actually or conceptually, from molecules of low relative molecular mass.
biological_process
GO:0010605
negative regulation of macromolecule metabolic process
GO:0010605
Any process that decreases the frequency, rate or extent of gene expression. Gene expression is the process in which a gene's coding sequence is converted into a mature gene product or products (proteins or RNA). This includes the production of an RNA transcript as well as any processing to produce a mature RNA product or an mRNA (for protein-coding genes) and the translation of that mRNA into protein. Some protein processing events may be included when they are required to form an active form of a product from an inactive precursor form.
biological_process
GO:0010629
negative regulation of gene expression
GO:0010629
Any process that modulates the frequency, rate or extent of cell communication. Cell communication is the process that mediates interactions between a cell and its surroundings. Encompasses interactions such as signaling or attachment between one cell and another cell, between a cell and an extracellular matrix, or between a cell and any other aspect of its environment.
biological_process
GO:0010646
regulation of cell communication
GO:0010646
Any process that increases the frequency, rate or extent of cell communication. Cell communication is the process that mediates interactions between a cell and its surroundings. Encompasses interactions such as signaling or attachment between one cell and another cell, between a cell and an extracellular matrix, or between a cell and any other aspect of its environment.
biological_process
GO:0010647
positive regulation of cell communication
GO:0010647
Any process that decreases the frequency, rate or extent of cell communication. Cell communication is the process that mediates interactions between a cell and its surroundings. Encompasses interactions such as signaling or attachment between one cell and another cell, between a cell and an extracellular matrix, or between a cell and any other aspect of its environment.
biological_process
GO:0010648
negative regulation of cell communication
GO:0010648
Any process that decreases the rate or extent of the tumor necrosis factor-mediated signaling pathway. The tumor necrosis factor-mediated signaling pathway is the series of molecular signals generated as a consequence of tumor necrosis factor binding to a cell surface receptor.
negative regulation of TNF signaling
negative regulation of TNF-mediated signaling pathway
negative regulation of tumor necrosis factor-mediated signalling pathway
biological_process
GO:0010804
negative regulation of tumor necrosis factor-mediated signaling pathway
GO:0010804
Any process that modulates the frequency, rate or extent of the regulated release of dopamine.
biological_process
GO:0014059
regulation of dopamine secretion
GO:0014059
GO:0016265
death
GO:0016331
morphogenesis of embryonic epithelium
Any process that modulates the frequency, rate or extent of the chemical reactions and pathways involving lipids.
regulation of lipid metabolism
biological_process
GO:0019216
regulation of lipid metabolic process
GO:0019216
Any cellular process that modulates the frequency, rate or extent of the chemical reactions and pathways involving nucleobases, nucleosides, nucleotides and nucleic acids.
regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolism
biological_process
regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolic process
GO:0019219
regulation of nucleobase-containing compound metabolic process
GO:0019219
Any process that modulates the frequency, rate or extent of the chemical reactions and pathways within a cell or an organism.
regulation of metabolism
biological_process
GO:0019222
regulation of metabolic process
GO:0019222
GO:0021915
neural tube development
Any process that modulates the frequency, rate or extent of a signaling process.
2010-02-16T09:30:50Z
biological_process
regulation of signaling process
regulation of signalling process
GO:0023051
regulation of signaling
GO:0023051
Any process that activates, maintains or increases the frequency, rate or extent of a signaling process.
2010-02-16T09:30:50Z
positive regulation of signalling process
biological_process
positive regulation of signaling process
GO:0023056
positive regulation of signaling
GO:0023056
Any process that stops, prevents, or reduces the frequency, rate or extent of a signaling process.
2010-02-16T09:30:50Z
biological_process
negative regulation of signaling process
negative regulation of signalling process
GO:0023057
negative regulation of signaling
GO:0023057
GO:0031012
extracellular matrix
Any process that modulates the frequency, rate or extent of the chemical reactions and pathways by which individual cells transform chemical substances.
regulation of cellular metabolism
biological_process
GO:0031323
regulation of cellular metabolic process
GO:0031323
Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways by which individual cells transform chemical substances.
down regulation of cellular metabolic process
down-regulation of cellular metabolic process
downregulation of cellular metabolic process
negative regulation of cellular metabolism
inhibition of cellular metabolic process
biological_process
GO:0031324
negative regulation of cellular metabolic process
GO:0031324
Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of substances, carried out by individual cells.
regulation of cellular anabolism
regulation of cellular biosynthesis
regulation of cellular formation
regulation of cellular synthesis
biological_process
GO:0031326
regulation of cellular biosynthetic process
GO:0031326
Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of substances, carried out by individual cells.
down regulation of cellular biosynthetic process
down-regulation of cellular biosynthetic process
downregulation of cellular biosynthetic process
negative regulation of cellular anabolism
negative regulation of cellular biosynthesis
negative regulation of cellular formation
negative regulation of cellular synthesis
inhibition of cellular biosynthetic process
biological_process
GO:0031327
negative regulation of cellular biosynthetic process
GO:0031327
Any process that modulates the frequency, rate or extent of dopaminergic synaptic transmission, the process of communication from a neuron to another neuron across a synapse using the neurotransmitter dopamine.
biological_process
GO:0032225
regulation of synaptic transmission, dopaminergic
GO:0032225
Any process that stops, prevents, or reduces the frequency, rate or extent of dopaminergic synaptic transmission, the process of communication from a neuron to another neuron across a synapse using the neurotransmitter dopamine.
down regulation of synaptic transmission, dopaminergic
down-regulation of synaptic transmission, dopaminergic
downregulation of synaptic transmission, dopaminergic
inhibition of synaptic transmission, dopaminergic
biological_process
GO:0032227
negative regulation of synaptic transmission, dopaminergic
GO:0032227
GO:0032501
multicellular organismal process
GO:0032502
developmental process
Any process that stops or reduces the rate of ATP hydrolysis by an ATPase.
down regulation of ATPase activity
down-regulation of ATPase activity
downregulation of ATPase activity
negative regulation of adenosinetriphosphatase activity
inhibition of ATPase activity
biological_process
GO:0032780
negative regulation of ATPase activity
GO:0032780
Any process that modulates the frequency, rate or extent of any process in which a cell, a substance, or a cellular entity is transported to, or maintained in, a specific location.
regulation of localisation
biological_process
GO:0032879
regulation of localization
GO:0032879
Any process that modulates the frequency, rate or extent of the activity of any intracellular steroid hormone receptor signaling pathway.
regulation of steroid hormone receptor signaling pathway
regulation of steroid hormone receptor signalling pathway
biological_process
GO:0033143
regulation of intracellular steroid hormone receptor signaling pathway
GO:0033143
Any process that stops, prevents, or reduces the frequency, rate or extent of the activity of any intracellular steroid hormone receptor signaling pathway.
negative regulation of steroid hormone receptor signaling pathway
negative regulation of steroid hormone receptor signalling pathway
biological_process
GO:0033144
negative regulation of intracellular steroid hormone receptor signaling pathway
GO:0033144
Any process that stops, prevents, or reduces the frequency, rate or extent of the regulated release of dopamine.
down regulation of dopamine secretion
down-regulation of dopamine secretion
downregulation of dopamine secretion
inhibition of dopamine secretion
biological_process
GO:0033602
negative regulation of dopamine secretion
GO:0033602
Any process that stops, prevents, or reduces the frequency, rate or extent of the regulated release of a catecholamine.
down regulation of catecholamine secretion
down-regulation of catecholamine secretion
downregulation of catecholamine secretion
inhibition of catecholamine secretion
biological_process
GO:0033604
negative regulation of catecholamine secretion
GO:0033604
Any process that modulates the frequency, rate or extent of the chemical reactions and pathways involving amides.
regulation of amide metabolism
biological_process
GO:0034248
regulation of cellular amide metabolic process
GO:0034248
Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways involving amides.
negative regulation of amide metabolism
biological_process
GO:0034249
negative regulation of cellular amide metabolic process
GO:0034249
GO:0035148
tube formation
GO:0035239
tube morphogenesis
GO:0035295
tube development
GO:0040016
embryonic cleavage
GO:0043009
chordate embryonic development
Any process that stops or reduces the activity of an enzyme.
down regulation of enzyme activity
down-regulation of enzyme activity
downregulation of enzyme activity
negative regulation of enzyme activity
inhibition of enzyme activity
biological_process
GO:0043086
negative regulation of catalytic activity
GO:0043086
Any process that modulates the frequency, rate or extent of the directed movement of charged atoms or small charged molecules into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.
biological_process
GO:0043269
regulation of ion transport
GO:0043269
Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of charged atoms or small charged molecules into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.
down regulation of ion transport
down-regulation of ion transport
downregulation of ion transport
inhibition of ion transport
biological_process
GO:0043271
negative regulation of ion transport
GO:0043271
Any process that stops, prevents, or reduces the frequency, rate or extent of the activity of a transcription factor, any factor involved in the initiation or regulation of transcription.
negative regulation of transcription factor activity
down regulation of transcription factor activity
down-regulation of transcription factor activity
downregulation of transcription factor activity
inhibition of transcription factor activity
biological_process
GO:0043433
negative regulation of sequence-specific DNA binding transcription factor activity
GO:0043433
Any process that modulates the rate of ATP hydrolysis by an ATPase.
regulation of adenosinetriphosphatase activity
biological_process
GO:0043462
regulation of ATPase activity
GO:0043462
Any process that modulates the frequency, rate or extent of the directed movement of anions, atoms or small molecules with a net negative charge into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.
biological_process
GO:0044070
regulation of anion transport
GO:0044070
Any process that stops or reduces the rate or extent of a molecular function, an elemental biological activity occurring at the molecular level, such as catalysis or binding.
jane
2009-04-21T04:07:27Z
biological_process
GO:0044092
negative regulation of molecular function
GO:0044092
GO:0044699
single-organism process
GO:0044707
single-multicellular organism process
GO:0044763
single-organism cellular process
GO:0044767
single-organism developmental process
Any process that activates or increases the frequency, rate or extent of G-protein coupled receptor protein signaling pathway activity.
positive regulation of G protein coupled receptor protein signaling pathway
positive regulation of G protein coupled receptor protein signalling pathway
positive regulation of G-protein coupled receptor protein signalling pathway
positive regulation of G-protein-coupled receptor protein signaling pathway
positive regulation of G-protein-coupled receptor protein signalling pathway
positive regulation of GPCR protein signaling pathway
positive regulation of GPCR protein signalling pathway
up regulation of G-protein coupled receptor protein signaling pathway
up-regulation of G-protein coupled receptor protein signaling pathway
upregulation of G-protein coupled receptor protein signaling pathway
activation of G-protein coupled receptor protein signaling pathway
stimulation of G-protein coupled receptor protein signaling pathway
biological_process
GO:0045745
positive regulation of G-protein coupled receptor protein signaling pathway
GO:0045745
Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways involving lipids.
down regulation of lipid metabolic process
down-regulation of lipid metabolic process
downregulation of lipid metabolic process
negative regulation of lipid metabolism
inhibition of lipid metabolic process
biological_process
GO:0045833
negative regulation of lipid metabolic process
GO:0045833
Any process that stops, prevents, or reduces the frequency, rate or extent of cellular DNA-templated transcription.
GO:0016481
GO:0032582
GO:0061021
down regulation of transcription, DNA-dependent
down-regulation of transcription, DNA-dependent
downregulation of transcription, DNA-dependent
negative regulation of cellular transcription, DNA-dependent
negative regulation of transcription, DNA-dependent
inhibition of transcription, DNA-dependent
biological_process
down regulation of gene-specific transcription
down-regulation of gene-specific transcription
downregulation of gene-specific transcription
inhibition of gene-specific transcription
negative regulation of gene-specific transcription
transcription repressor activity
GO:0045892
negative regulation of transcription, DNA-templated
GO:0045892
Any cellular process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways involving nucleobases, nucleosides, nucleotides and nucleic acids.
down regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolic process
down-regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolic process
downregulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolic process
negative regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolism
inhibition of nucleobase, nucleoside, nucleotide and nucleic acid metabolic process
biological_process
negative regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolic process
GO:0045934
negative regulation of nucleobase-containing compound metabolic process
GO:0045934
Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of glucosylceramide.
down regulation of glucosylceramide biosynthetic process
down-regulation of glucosylceramide biosynthetic process
downregulation of glucosylceramide biosynthetic process
negative regulation of glucosylceramide anabolism
negative regulation of glucosylceramide biosynthesis
negative regulation of glucosylceramide formation
negative regulation of glucosylceramide synthesis
inhibition of glucosylceramide biosynthetic process
biological_process
GO:0046318
negative regulation of glucosylceramide biosynthetic process
GO:0046318
Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of lipids.
regulation of lipid anabolism
regulation of lipid biosynthesis
regulation of lipid formation
regulation of lipid synthesis
regulation of lipogenesis
biological_process
GO:0046890
regulation of lipid biosynthetic process
GO:0046890
GO:0048513
organ development
Any process that activates or increases the frequency, rate or extent of a biological process. Biological processes are regulated by many means; examples include the control of gene expression, protein modification or interaction with a protein or substrate molecule.
GO:0043119
positive regulation of physiological process
up regulation of biological process
up-regulation of biological process
upregulation of biological process
activation of biological process
stimulation of biological process
biological_process
GO:0048518
positive regulation of biological process
GO:0048518
Any process that stops, prevents, or reduces the frequency, rate or extent of a biological process. Biological processes are regulated by many means; examples include the control of gene expression, protein modification or interaction with a protein or substrate molecule.
GO:0043118
down regulation of biological process
down-regulation of biological process
downregulation of biological process
negative regulation of physiological process
inhibition of biological process
biological_process
GO:0048519
negative regulation of biological process
GO:0048519
Any process that activates or increases the frequency, rate or extent of a cellular process, any of those that are carried out at the cellular level, but are not necessarily restricted to a single cell. For example, cell communication occurs among more than one cell, but occurs at the cellular level.
GO:0051242
positive regulation of cellular physiological process
up regulation of cellular process
up-regulation of cellular process
upregulation of cellular process
activation of cellular process
stimulation of cellular process
biological_process
GO:0048522
positive regulation of cellular process
GO:0048522
Any process that stops, prevents, or reduces the frequency, rate or extent of a cellular process, any of those that are carried out at the cellular level, but are not necessarily restricted to a single cell. For example, cell communication occurs among more than one cell, but occurs at the cellular level.
GO:0051243
down regulation of cellular process
down-regulation of cellular process
downregulation of cellular process
negative regulation of cellular physiological process
inhibition of cellular process
biological_process
GO:0048523
negative regulation of cellular process
GO:0048523
Any process that modulates the frequency, rate or extent of a response to a stimulus. Response to stimulus is a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus.
biological_process
GO:0048583
Note that this term is in the subset of terms that should not be used for direct gene product annotation. Instead, select a child term or, if no appropriate child term exists, please request a new term. Direct annotations to this term may be amended during annotation QC.
regulation of response to stimulus
GO:0048583
Any process that activates, maintains or increases the rate of a response to a stimulus. Response to stimulus is a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus.
up regulation of response to stimulus
up-regulation of response to stimulus
upregulation of response to stimulus
activation of response to stimulus
stimulation of response to stimulus
biological_process
GO:0048584
Note that this term is in the subset of terms that should not be used for direct gene product annotation. Instead, select a child term or, if no appropriate child term exists, please request a new term. Direct annotations to this term may be amended during annotation QC.
positive regulation of response to stimulus
GO:0048584
Any process that stops, prevents, or reduces the frequency, rate or extent of a response to a stimulus. Response to stimulus is a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus.
down regulation of response to stimulus
down-regulation of response to stimulus
downregulation of response to stimulus
inhibition of response to stimulus
biological_process
GO:0048585
Note that this term is in the subset of terms that should not be used for direct gene product annotation. Instead, select a child term or, if no appropriate child term exists, please request a new term. Direct annotations to this term may be amended during annotation QC.
negative regulation of response to stimulus
GO:0048585
GO:0048598
embryonic morphogenesis
GO:0048646
anatomical structure formation involved in morphogenesis
GO:0048729
tissue morphogenesis
GO:0048731
system development
GO:0048856
anatomical structure development
Any process that modulates the frequency, rate or extent of the regulated release of catecholamines.
biological_process
GO:0050433
regulation of catecholamine secretion
GO:0050433
Any process that modulates the frequency, rate or extent of a biological process. Biological processes are regulated by many means; examples include the control of gene expression, protein modification or interaction with a protein or substrate molecule.
GO:0050791
regulation of physiological process
biological_process
GO:0050789
regulation of biological process
GO:0050789
Any process that modulates the activity of an enzyme.
regulation of enzyme activity
biological_process
GO:0050790
regulation of catalytic activity
GO:0050790
Any process that modulates the frequency, rate or extent of a cellular process, any of those that are carried out at the cellular level, but are not necessarily restricted to a single cell. For example, cell communication occurs among more than one cell, but occurs at the cellular level.
GO:0051244
regulation of cellular physiological process
biological_process
GO:0050794
regulation of cellular process
GO:0050794
Any process that modulates the frequency or rate of synaptic transmission, the process of communication from a neuron to a target (neuron, muscle, or secretory cell) across a synapse.
biological_process
GO:0050804
regulation of synaptic transmission
GO:0050804
Any process that stops, prevents, or reduces the frequency, rate or extent of synaptic transmission, the process of communication from a neuron to a target (neuron, muscle, or secretory cell) across a synapse.
down regulation of synaptic transmission
down-regulation of synaptic transmission
downregulation of synaptic transmission
inhibition of synaptic transmission
biological_process
GO:0050805
negative regulation of synaptic transmission
GO:0050805
GO:0050877
neurological system process
GO:0050896
response to stimulus
GO:0050906
detection of stimulus involved in sensory perception
GO:0050953
sensory perception of light stimulus
Any process that modulates the frequency, rate or extent of the controlled release of a substance from a cell or a tissue.
biological_process
GO:0051046
regulation of secretion
GO:0051046
Any process that stops, prevents, or reduces the frequency, rate or extent of the controlled release of a substance from a cell or a tissue.
down regulation of secretion
down-regulation of secretion
downregulation of secretion
inhibition of secretion
biological_process
GO:0051048
negative regulation of secretion
GO:0051048
Any process that modulates the frequency, rate or extent of the directed movement of substances (such as macromolecules, small molecules, ions) into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.
biological_process
GO:0051049
regulation of transport
GO:0051049
Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of substances (such as macromolecules, small molecules, ions) into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.
down regulation of transport
down-regulation of transport
downregulation of transport
inhibition of transport
biological_process
GO:0051051
negative regulation of transport
GO:0051051
Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of lipids.
down regulation of lipid biosynthetic process
down-regulation of lipid biosynthetic process
downregulation of lipid biosynthetic process
negative regulation of lipid anabolism
negative regulation of lipid biosynthesis
negative regulation of lipid formation
negative regulation of lipid synthesis
negative regulation of lipogenesis
inhibition of lipid biosynthetic process
biological_process
GO:0051055
negative regulation of lipid biosynthetic process
GO:0051055
Any process that modulates the frequency, rate or extent of the activity of a transcription factor, any factor involved in the initiation or regulation of transcription.
regulation of transcription factor activity
Reactome:REACT_104536
Reactome:REACT_107559
Reactome:REACT_109535
Reactome:REACT_110257
Reactome:REACT_110693
Reactome:REACT_21326
Reactome:REACT_82719
Reactome:REACT_83365
Reactome:REACT_90659
Reactome:REACT_92725
Reactome:REACT_96476
Reactome:REACT_99415
biological_process
GO:0051090
regulation of sequence-specific DNA binding transcription factor activity
GO:0051090
Any process that modulates the frequency, rate or extent of the chemical reactions and pathways involving nitrogen or nitrogenous compounds.
regulation of nitrogen metabolic process
regulation of nitrogen metabolism
biological_process
GO:0051171
regulation of nitrogen compound metabolic process
GO:0051171
Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways involving nitrogen or nitrogenous compounds.
down regulation of nitrogen metabolic process
down-regulation of nitrogen metabolic process
downregulation of nitrogen metabolic process
negative regulation of nitrogen metabolic process
negative regulation of nitrogen metabolism
inhibition of nitrogen metabolic process
biological_process
GO:0051172
negative regulation of nitrogen compound metabolic process
GO:0051172
Any process that modulates the frequency, rate or extent of the chemical reactions and pathways involving RNA.
regulation of RNA metabolism
biological_process
GO:0051252
regulation of RNA metabolic process
GO:0051252
Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways involving RNA.
down regulation of RNA metabolic process
down-regulation of RNA metabolic process
downregulation of RNA metabolic process
negative regulation of RNA metabolism
inhibition of RNA metabolic process
biological_process
GO:0051253
negative regulation of RNA metabolic process
GO:0051253
GO:0051301
cell division
Any process that modulates the frequency, rate or extent of hydrolase activity, the catalysis of the hydrolysis of various bonds, e.g. C-O, C-N, C-C, phosphoric anhydride bonds, etc. Hydrolase is the systematic name for any enzyme of EC class 3.
hydrolase regulator
biological_process
GO:0051336
regulation of hydrolase activity
GO:0051336
Any process that modulates the frequency, rate or extent of oxidoreductase activity, the catalysis of an oxidation-reduction (redox) reaction, a reversible chemical reaction in which the oxidation state of an atom or atoms within a molecule is altered. One substrate acts as a hydrogen or electron donor and becomes oxidized, while the other acts as hydrogen or electron acceptor and becomes reduced.
oxidoreductase regulator
biological_process
GO:0051341
regulation of oxidoreductase activity
GO:0051341
Any process that stops or reduces the rate of cyclic nucleotide phosphodiesterase activity, the catalysis of the reaction: nucleotide 3',5'-cyclic phosphate + H2O = nucleotide 5'-phosphate.
3',5' cyclic nucleotide phosphodiesterase inhibitor
down regulation of cyclic nucleotide phosphodiesterase activity
down-regulation of cyclic nucleotide phosphodiesterase activity
downregulation of cyclic nucleotide phosphodiesterase activity
negative regulation of 3',5' cyclic nucleotide phosphodiesterase activity
negative regulation of cyclic nucleotide phosphodiesterase activity
3',5'-cyclic-AMP phosphodiesterase inhibitor
cAMP phosphodiesterase inhibitor
inhibition of cyclic nucleotide phosphodiesterase activity
negative regulation of 3',5'-cyclic-AMP phosphodiesterase activity
negative regulation of cAMP phosphodiesterase activity
negative regulation of cGMP phosphodiesterase activity
biological_process
phosphodiesterase inhibitor
GO:0051344
negative regulation of cyclic-nucleotide phosphodiesterase activity
GO:0051344
Any process that stops or reduces the rate of hydrolase activity, the catalysis of the hydrolysis of various bonds.
down regulation of hydrolase activity
down-regulation of hydrolase activity
downregulation of hydrolase activity
hydrolase inhibitor
inhibition of hydrolase activity
biological_process
GO:0051346
negative regulation of hydrolase activity
GO:0051346
Any process that stops or reduces the rate of oxidoreductase activity, the catalysis of an oxidation-reduction (redox) reaction, a reversible chemical reaction in which the oxidation state of an atom or atoms within a molecule is altered.
down regulation of oxidoreductase activity
down-regulation of oxidoreductase activity
downregulation of oxidoreductase activity
oxidoreductase inhibitor
inhibition of oxidoreductase activity
biological_process
GO:0051354
negative regulation of oxidoreductase activity
GO:0051354
Any process that modulates the frequency, rate or extent of the directed movement of a neurotransmitter into a neuron or glial cell.
regulation of neurotransmitter import
regulation of neurotransmitter reuptake
biological_process
GO:0051580
regulation of neurotransmitter uptake
GO:0051580
Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of a neurotransmitter into a neuron or glial cell.
down regulation of neurotransmitter uptake
down-regulation of neurotransmitter uptake
downregulation of neurotransmitter uptake
negative regulation of neurotransmitter import
biological_process
GO:0051581
negative regulation of neurotransmitter uptake
GO:0051581
Any process that modulates the frequency, rate or extent of the directed movement of the catecholamine neurotransmitter dopamine into a cell.
regulation of dopamine import involved in synaptic transmission
biological_process
GO:0051584
regulation of dopamine uptake involved in synaptic transmission
GO:0051584
Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of dopamine into a presynaptic neuron or glial cell.
down regulation of dopamine uptake involved in synaptic transmission
down-regulation of dopamine uptake involved in synaptic transmission
downregulation of dopamine uptake involved in synaptic transmission
negative regulation of dopamine import involved in synaptic transmission
biological_process
GO:0051585
negative regulation of dopamine uptake involved in synaptic transmission
GO:0051585
Any process that modulates the frequency, rate or extent of the directed movement of a neurotransmitter into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.
biological_process
GO:0051588
regulation of neurotransmitter transport
GO:0051588
Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of a neurotransmitter into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.
down regulation of neurotransmitter transport
down-regulation of neurotransmitter transport
downregulation of neurotransmitter transport
inhibition of neurotransmitter transport
biological_process
GO:0051589
negative regulation of neurotransmitter transport
GO:0051589
GO:0051606
detection of stimulus
Any process that modulates the frequency, rate or extent of the directed movement of the monoamine neurotransmitter serotonin into a cell.
regulation of 5-HT uptake
regulation of 5-hydroxytryptamine uptake
regulation of 5HT uptake
regulation of serotonin import
biological_process
GO:0051611
regulation of serotonin uptake
GO:0051611
Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of serotonin into a cell.
down regulation of serotonin uptake
down-regulation of serotonin uptake
downregulation of serotonin uptake
negative regulation of 5-HT uptake
negative regulation of 5-hydroxytryptamine uptake
negative regulation of 5HT uptake
negative regulation of serotonin import
biological_process
GO:0051612
negative regulation of serotonin uptake
GO:0051612
Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of norepinephrine into a cell.
down regulation of norepinephrine uptake
down-regulation of norepinephrine uptake
downregulation of norepinephrine uptake
negative regulation of levarterenol uptake
negative regulation of noradrenaline uptake
negative regulation of norepinephrine import
biological_process
GO:0051622
negative regulation of norepinephrine uptake
GO:0051622
Any process that prevents the activation of the directed movement of norepinephrine into a cell.
inhibition of levarterenol uptake
inhibition of noradrenaline uptake
inhibition of norepinephrine import
biological_process
GO:0051624
inhibition of norepinephrine uptake
GO:0051624
Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of calcium ions into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.
down regulation of calcium ion transport
down-regulation of calcium ion transport
downregulation of calcium ion transport
negative regulation of calcium transport
inhibition of calcium ion transport
biological_process
GO:0051926
negative regulation of calcium ion transport
GO:0051926
Any process that modulates the frequency, rate or extent of the directed movement of catecholamine neurotransmitters into a neuron or glial cell.
regulation of catecholamine uptake during transmission of nerve impulse
regulation of catecholamine neurotransmitter reuptake
regulation of catecholamine neurotransmitter uptake
biological_process
GO:0051940
regulation of catecholamine uptake involved in synaptic transmission
GO:0051940
Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of catecholamine neurotransmitters into a neuron or glial cell.
negative regulation of catecholamine uptake during transmission of nerve impulse
down regulation of catecholamine uptake during transmission of nerve impulse
down-regulation of catecholamine uptake during transmission of nerve impulse
downregulation of catecholamine uptake during transmission of nerve impulse
negative regulation of catecholamine neurotransmitter reuptake
negative regulation of catecholamine neurotransmitter uptake
inhibition of catecholamine uptake during transmission of nerve impulse
biological_process
GO:0051945
negative regulation of catecholamine uptake involved in synaptic transmission
GO:0051945
Any process that modulates the frequency, rate or extent of the directed movement of amines into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.
biological_process
GO:0051952
regulation of amine transport
GO:0051952
Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of amines into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.
down regulation of amine transport
down-regulation of amine transport
downregulation of amine transport
inhibition of amine transport
biological_process
GO:0051953
negative regulation of amine transport
GO:0051953
Any process that modulates the frequency, rate or extent of the chemical reactions and pathways involving macromolecules, any molecule of high relative molecular mass, the structure of which essentially comprises the multiple repetition of units derived, actually or conceptually, from molecules of low relative molecular mass.
biological_process
GO:0060255
regulation of macromolecule metabolic process
GO:0060255
Any process that modulates the frequency, rate or extent of a process in which a cell, a substance, or a cellular entity is transported to, or maintained in a specific location within or in the membrane of a cell.
regulation of cellular localisation
biological_process
GO:0060341
regulation of cellular localization
GO:0060341
GO:0060429
epithelium development
GO:0060562
epithelial tube morphogenesis
Any process that modulates the rate, frequency, or extent of a response to cytokine stimulus.
dph
2009-06-22T02:56:12Z
biological_process
GO:0060759
regulation of response to cytokine stimulus
GO:0060759
Any process that decreases the rate, frequency, or extent of a response to cytokine stimulus.
dph
2009-06-22T02:59:57Z
biological_process
GO:0060761
negative regulation of response to cytokine stimulus
GO:0060761
Any process that modulates the rate, frequency, or extent of the androgen receptor signaling pathway.
dph
2009-07-06T11:07:38Z
regulation of androgen receptor signalling pathway
biological_process
GO:0060765
regulation of androgen receptor signaling pathway
GO:0060765
Any process that decreases the rate, frequency, or extent of the androgen receptor signaling pathway.
dph
2009-07-06T11:09:36Z
negative regulation of androgen receptor signalling pathway
biological_process
GO:0060766
negative regulation of androgen receptor signaling pathway
GO:0060766
Any process that modulates a measurable attribute of any biological process, quality or function.
regulation
biological_process
GO:0065007
biological regulation
GO:0065007
Any process that modulates the frequency, rate or extent of a molecular function, an elemental biological activity occurring at the molecular level, such as catalysis or binding.
regulation of a molecular function
biological_process
GO:0065009
regulation of molecular function
GO:0065009
GO:0072175
epithelial tube formation
Any process that modulates the frequency, rate or extent of the chemical reactions and pathways within a cell or an organism involving those compounds formed as a part of the normal anabolic and catabolic processes. These processes take place in most, if not all, cells of the organism.
donghui
2009-04-22T04:30:52Z
biological_process
GO:0080090
regulation of primary metabolic process
GO:0080090
Any process that modulates the rate, frequency or extent of sphingolipid biosynthesis. Sphingolipid biosynthesis is the chemical reactions and pathways resulting in the formation of sphingolipids, any of a class of lipids containing the long-chain amine diol sphingosine or a closely related base (a sphingoid).
tanyaberardini
2009-12-08T03:25:49Z
biological_process
GO:0090153
regulation of sphingolipid biosynthetic process
GO:0090153
Any process that decreases the rate, frequency or extent of sphingolipid biosynthesis. Sphingolipid biosynthesis is the chemical reactions and pathways resulting in the formation of sphingolipids, any of a class of lipids containing the long-chain amine diol sphingosine or a closely related base (a sphingoid).
tanyaberardini
2009-12-08T03:33:39Z
biological_process
GO:0090155
negative regulation of sphingolipid biosynthetic process
GO:0090155
Any process that stops, prevents or reduces the frequency, rate or extent of a ceramide biosynthetic process.
dph
2012-01-25T03:18:07Z
down regulation of ceramide anabolism
down regulation of ceramide biosynthesis
down regulation of ceramide formation
down regulation of ceramide synthesis
down-regulation of ceramide anabolism
down-regulation of ceramide biosynthesis
down-regulation of ceramide formation
down-regulation of ceramide synthesis
downregulation of ceramide anabolism
downregulation of ceramide biosynthesis
downregulation of ceramide formation
downregulation of ceramide synthesis
inhibition of ceramide anabolism
inhibition of ceramide biosynthesis
inhibition of ceramide formation
inhibition of ceramide synthesis
negative regulation of ceramide anabolism
negative regulation of ceramide biosynthesis
negative regulation of ceramide formation
negative regulation of ceramide synthesis
biological_process
down regulation of ceramide biosynthetic process
down-regulation of ceramide biosynthetic process
downregulation of ceramide biosynthetic process
inhibition of ceramide biosynthetic process
GO:1900060
negative regulation of ceramide biosynthetic process
GO:1900060
Any process that modulates the frequency, rate or extent of cellular response to insulin stimulus.
yaf
2012-01-31T11:22:22Z
biological_process
GO:1900076
regulation of cellular response to insulin stimulus
GO:1900076
Any process that activates or increases the frequency, rate or extent of cellular response to insulin stimulus.
yaf
2012-01-31T11:24:30Z
up regulation of cellular response to insulin stimulus
up-regulation of cellular response to insulin stimulus
upregulation of cellular response to insulin stimulus
activation of cellular response to insulin stimulus
biological_process
GO:1900078
positive regulation of cellular response to insulin stimulus
GO:1900078
Any process that stops, prevents or reduces the frequency, rate or extent of RNA biosynthetic process.
jl
2014-02-05T16:32:01Z
down regulation of RNA anabolism
down regulation of RNA biosynthesis
down regulation of RNA biosynthetic process
down regulation of RNA formation
down regulation of RNA synthesis
down-regulation of RNA anabolism
down-regulation of RNA biosynthesis
down-regulation of RNA biosynthetic process
down-regulation of RNA formation
down-regulation of RNA synthesis
downregulation of RNA anabolism
downregulation of RNA biosynthesis
downregulation of RNA biosynthetic process
downregulation of RNA formation
downregulation of RNA synthesis
negative regulation of RNA anabolism
negative regulation of RNA biosynthesis
negative regulation of RNA formation
negative regulation of RNA synthesis
inhibition of RNA anabolism
inhibition of RNA biosynthesis
inhibition of RNA biosynthetic process
inhibition of RNA formation
inhibition of RNA synthesis
biological_process
GO:1902679
negative regulation of RNA biosynthetic process
GO:1902679
Any process that modulates the frequency, rate or extent of nucleic acid-templated transcription.
pr
2014-10-01T14:44:47Z
biological_process
GO:1903506
regulation of nucleic acid-templated transcription
GO:1903506
Any process that stops, prevents or reduces the frequency, rate or extent of nucleic acid-templated transcription.
pr
2014-10-01T14:44:56Z
down regulation of nucleic acid-templated transcription
down-regulation of nucleic acid-templated transcription
downregulation of nucleic acid-templated transcription
inhibition of nucleic acid-templated transcription
biological_process
GO:1903507
negative regulation of nucleic acid-templated transcription
GO:1903507
Any process that modulates the frequency, rate or extent of secretion by cell.
pm
2014-10-08T13:24:59Z
regulation of cellular secretion
biological_process
GO:1903530
regulation of secretion by cell
GO:1903530
Any process that stops, prevents or reduces the frequency, rate or extent of secretion by cell.
pm
2014-10-08T13:25:08Z
down regulation of cellular secretion
down regulation of secretion by cell
down-regulation of cellular secretion
down-regulation of secretion by cell
downregulation of cellular secretion
downregulation of secretion by cell
negative regulation of cellular secretion
inhibition of cellular secretion
inhibition of secretion by cell
biological_process
GO:1903531
negative regulation of secretion by cell
GO:1903531
Any process that stops, prevents or reduces the frequency, rate or extent of anion transport.
sl
2015-01-12T21:50:20Z
down regulation of anion transport
down-regulation of anion transport
downregulation of anion transport
inhibition of anion transport
biological_process
GO:1903792
negative regulation of anion transport
GO:1903792
Any process that modulates the frequency, rate or extent of cellular macromolecule biosynthetic process.
tanyaberardini
2010-09-15T08:55:45Z
regulation of cellular biopolymer biosynthetic process
regulation of cellular macromolecule anabolism
regulation of cellular macromolecule biosynthesis
regulation of cellular macromolecule formation
regulation of cellular macromolecule synthesis
biological_process
GO:2000112
regulation of cellular macromolecule biosynthetic process
GO:2000112
Any process that stops, prevents, or reduces the frequency, rate or extent of cellular macromolecule biosynthetic process.
tanyaberardini
2010-09-15T08:55:48Z
negative regulation of cellular biopolymer biosynthetic process
negative regulation of cellular macromolecule anabolism
negative regulation of cellular macromolecule biosynthesis
negative regulation of cellular macromolecule formation
negative regulation of cellular macromolecule synthesis
biological_process
GO:2000113
negative regulation of cellular macromolecule biosynthetic process
GO:2000113
Any process that stops, prevents or reduces the frequency, rate or extent of receptor activity.
rfoulger
2010-12-02T09:28:47Z
biological_process
GO:2000272
negative regulation of receptor activity
GO:2000272
Any process that modulates the frequency, rate or extent of a ceramide biosynthetic process.
dph
2011-01-04T02:37:12Z
regulation of ceramide anabolism
regulation of ceramide biosynthesis
regulation of ceramide formation
regulation of ceramide synthesis
biological_process
GO:2000303
regulation of ceramide biosynthetic process
GO:2000303
Any process that modulates the frequency, rate or extent of DNA topoisomerase (ATP-hydrolyzing) activity.
midori
2011-02-09T02:35:27Z
regulation of DNA gyrase activity
regulation of DNA topoisomerase IV activity
regulation of DNA topoisomerase type II activity
regulation of DNA-gyrase activity
regulation of deoxyribonucleic topoisomerase activity
regulation of topoisomerase II
regulation of type II DNA topoisomerase activity
biological_process
regulation of DNA topoisomerase (ATP-hydrolysing)
regulation of DNA topoisomerase II
regulation of deoxyribonucleate topoisomerase
regulation of topoisomerase
GO:2000371
regulation of DNA topoisomerase (ATP-hydrolyzing) activity
GO:2000371
Any process that stops, prevents or reduces the frequency, rate or extent of DNA topoisomerase (ATP-hydrolyzing) activity.
midori
2011-02-09T02:35:36Z
negative regulation of DNA gyrase activity
negative regulation of DNA topoisomerase IV activity
negative regulation of DNA topoisomerase type II activity
negative regulation of DNA-gyrase activity
negative regulation of deoxyribonucleic topoisomerase activity
negative regulation of topoisomerase II
negative regulation of type II DNA topoisomerase activity
biological_process
negative regulation of DNA topoisomerase (ATP-hydrolysing)
negative regulation of DNA topoisomerase II
negative regulation of deoxyribonucleate topoisomerase
negative regulation of topoisomerase
GO:2000372
negative regulation of DNA topoisomerase (ATP-hydrolyzing) activity
GO:2000372
Any process that activates or increases the frequency, rate or extent of opioid receptor signaling pathway.
rfoulger
2011-03-09T09:41:35Z
positive regulation of opioid receptor signalling pathway
biological_process
GO:2000476
positive regulation of opioid receptor signaling pathway
GO:2000476
Any process that modulates the frequency, rate or extent of androgen receptor activity.
yaf
2011-07-15T10:56:08Z
biological_process
GO:2000823
regulation of androgen receptor activity
GO:2000823
Any process that stops, prevents or reduces the frequency, rate or extent of androgen receptor activity.
yaf
2011-07-15T10:56:12Z
biological_process
GO:2000824
negative regulation of androgen receptor activity
GO:2000824
Any process that modulates the frequency, rate or extent of RNA biosynthetic process.
dph
2011-10-17T11:36:25Z
regulation of RNA anabolism
regulation of RNA biosynthesis
regulation of RNA formation
regulation of RNA synthesis
biological_process
GO:2001141
regulation of RNA biosynthetic process
GO:2001141
Any process that stops, prevents or reduces the frequency, rate or extent of hydroxymethylglutaryl-CoA reductase (NADPH) activity.
rfoulger
2011-11-16T11:34:17Z
biological_process
negative regulation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase activity
negative regulation of HMG-CoA reductase activity
GO:2001216
negative regulation of hydroxymethylglutaryl-CoA reductase (NADPH) activity
GO:2001216
IAO:0000027
data item
IAO:0000030
information content entity
IAO:0000078
curation status specification
The curation status of the term. The allowed values come from an enumerated list of predefined terms. See the specification of these instances for more detailed definitions of each enumerated value.
Better to represent curation as a process with parts and then relate labels to that process (in IAO meeting)
PERSON:Bill Bug
GROUP:OBI:<http://purl.obolibrary.org/obo/obi>
OBI_0000266
curation status specification
IAO:0000102
data about an ontology part is a data item about a part of an ontology, for example a term
Person:Alan Ruttenberg
data about an ontology part
NCBITaxon:2759
Eukaryota
NCBITaxon:33154
Opisthokonta
NCBITaxon:33208
Metazoa
NCBITaxon:33213
Bilateria
NCBITaxon:6072
Eumetazoa
OAE:0000001
a pathological bodily process that occurs after a medical intervention. An adverse event is likely caused by the medical intervention; however, such a causal association is not required to be an adverse event.
Melanie Courtot and YH: More work is needed on how to restrict the scope of a term to be an 'adverse event', notably regarding temporal association. When is an appropirate time interval between a medical intervention and an adverse event observed? One week, one month, one year, or a lifetime? For some well-studied medical interventions (e.g., administration of many vaccines or drugs), we probably have a general idea. For many new interventions, we don't know much. In OAE, this issue is associated with defining the 'adverse event incubation time'.
YH: An adverse event is a process that has specified output of some adverse medical outcome (e.g., symptom, sign or accident) after a medical intervention (or process) (e.g., administration of drug or vaccine). The medical intervention can be an administration of a drug, a vaccine (i.e., vaccination), or a special nutritional product (for example, dietary supplement, infant formula, medical food), surgery, or usage of a medical device.
YH: An adverse event is possibly induced by the medical intervention. It can be caused by the medical intervention, or may not be caused by the medical intervention. One ultimate goal (or the goal in clinics) of study adverse events is to assess if the adverse event outcome is due to the medical intervention.
YH: The main scope of OAE includes: (1) represent terms and relations in the area of adverse events, (2) assess possible associations between an adverse event and a medical intervention, particularly, identify any causal effect of a medical intervention to an adverse event; and (2) understand the mechanism (including molecular mechanisms) of causal adverse events.
YH: There has been discussion regarding whether the term 'side effect' is an alternative term for 'adverse event'. In AERO, the term 'AERO:adverse event' represents a subset of those adverse events for which causality has been established. In OAE, an adverse event for which causality has been established is called 'causal adverse event'.
Yongqun He
AE
adverse reaction
WEB: http://en.wikipedia.org/wiki/Adverse_event
WEB: http://www.fda.gov/Safety/MedWatch/HowToReport/ucm053087.htm
WEB: http://www.ncbi.nlm.nih.gov/pubmed/25093068
The OAE official website is: http://www.oae-ontology.org/.
adverse event
OAE:0000002
medical intervention is a planned process that has the goal of diagnosing, preventing or relieving illness or injury.
YH
WEB: http://wiki.answers.com/Q/What_is_medical_intervention
medical intervention
OAE:0000011
a medical intervention where a patient is administered with a drug
YH
drug administration
OAE:0000162
a peripheral neuropathy AE which has an outcome of sensory neuropathy that involves damage to nerves of the peripheral nervous system.
YH, AG
sensory neuropathy AE
sensory neuropathy AE
OAE:0000168
a peripheral neuropathy AE which is caused by a damage to motor neurons
AG, YH
motor neuropathy AE
OAE:0000169
A peripheral neuropathy AE which is characterized by damage to more than one nerve
AG, YH, RR
WEB: http://www.merckmanuals.com/home/brain_spinal_cord_and_nerve_disorders/peripheral_nerve_disorders/polyneuropathy.html
polyneuropathy AE
HPO: HP_0001271
MedDRA ID: 10036105
SIDER: C0152025
OAE:0000337
an neuropathy AE that results in a damage to the peripheral nervous system (PNS, outside the brain and spinal cord), the vast communication network that transmits information from the brain and the spinal cord (the central nervous system) to every other part of the body.
SS, YH
neuropathy peripheral AE
WEB: http://en.wikipedia.org/wiki/Peripheral_neuropathy
WEB: http://www.ninds.nih.gov/disorders/peripheralneuropathy/detail_peripheralneuropathy.htm
peripheral neuropathy AE
MedDRA: 10029331
OAE:0000392
a sensory neuropathy AE that shows a sensation of tingling, pricking, or numbness of a person's skin with no apparent long-term physical effect.
YH
WEB: http://en.wikipedia.org/wiki/Paraesthesia
Paresthesia is more generally known as the feeling of "pins and needles" or of a limb being "asleep" (although this is not directly related to the phenomenon of sleep). The manifestation of paresthesia may be transient or chronic.
paresthesia AE
MedDRA: 10033775
OAE:0000418
a nervous system AE that shows a damage to or disease affecting the nerves.
YH, RR
WEB: http://www.emedicinehealth.com/neuropathy/article_em.htm
WEB: http://www.medicalnewstoday.com/articles/147963.php
WEB: http://www.neuropathy.org/
neuropathy AE
HPO: HP_0007141
SIDER: C0442874
OAE:0000570
an AE that occurs in nervous system.
YH
nervous system AE
MP: MP_0003633
OAE:0000625
a peripheral neuropathy AE which has an outcome of neuritis, the local accumulation of fluid, plasma proteins, and leukocytes in the brain and/or spinal cord
neuritis AE
MP: MP_0006082
MedDRA ID: 10029240
OAE:0001215
a nervous system AE that alters the normal activity of the nervous system due to exposure to neurotoxins, causes damage to nervous tissue
SZ, SS, YH
WEB: http://en.wikipedia.org/wiki/Neurotoxicity
neurotoxicity AE
MedDRA: 10029350
OAE:0001287
a peripheral sensory neuropathy AE that results in the patient losing the ability to move or feel.
SZ, SS, YH
WEB: http://www.nlm.nih.gov/medlineplus/ency/article/000750.htm
Neuropathy can affect nerves that provide feeling (sensory neuropathy) or cause movement (motor neuropathy). It can also affect both, in which case it is called a sensorimotor neuropathy.
peripheral sensorimotor neuropathy AE
MedDRA: 10056673
OAE:0001288
a sensory neuropathy AE that has an outcome of damaged nerves outside the brain and spinal cord
SZ, SS, YH
WEB: http://medical-dictionary.thefreedictionary.com/Peripheral+sensory+neuropathy
peripheral sensory neuropathy AE
HPO: HP_0000763
MedDRA: 10034620
SIDER: C0151313
OAE:0002005
Carpal tunnel syndrome AE is a peripheral neuropathy AE that is a median entrapment neuropathy that causes paresthesia, pain, numbness, and other symptoms in the distribution of the median nerve due to its compression at the wrist in the carpal tunnel.
JX, LW, YH
median nerve neuropathy AE
WEB: http://emedicine.medscape.com/article/1141168-clinical#showall
WEB: http://en.wikipedia.org/wiki/Carpal_tunnel_syndrome
腕管综合征
carpal tunnel syndrome AE
MedDRA: 10007697
OAE:0002056
an optic neuropahty AE which shows an infarction of the optic disk which presents as painless vision loss
RR
optic ischemic neuropathy AE
WEB: http://www.geteyesmart.org/eyesmart/diseases/ischemic-optic-neuropathy/
WEB: http://www.merckmanuals.com/professional/eye_disorders/optic_nerve_disorders/ischemic_optic_neuropathy.html
ischemic optic neuropathy AE
MedDRA: 10030924
OAE:0002553
a peripheral neuropathy AE which shows an damage or abnormality to the nerves in the eyes.
RR, YH
WEB: http://www.allaboutvision.com/conditions/optic-neuritis.htm
optic neuropathy AE
MedDRA: 10061323
OAE:0002554
an optic neuropathy AE characterized by optic disc swelling, peripapillary and macular hard exudates, and vitreous cells.
RR, YH
WEB: http://www.ncbi.nlm.nih.gov/pubmed/6466175
neuroretinitis AE
MedDRA: 10060701
OAE:0002555
an optic neuropathy AE characterized by vision loss, optic disc swelling, flame hemorrhages, and cotton-wool exudates. It occurs when blood flow is interrupted to the front (anterior) part of the optic nerve (also called optic nerve head).
RR, YH
AION
WEB: http://emedicine.medscape.com/article/1216891-overview
WEB: http://www.geteyesmart.org/eyesmart/diseases/ischemic-optic-neuropathy/
anterior ischemic optic neuropathy AE
MedDRA: 10068250
OAE:0002556
a type of anterior ischemic optic neuropathy AE that presents primarily with vision loss, especially upon wakening, and sectorial disc edema.
RR, YH
WEB: http://emedicine.medscape.com/article/1216891-clinical#a0217
non-arteritic anterior ischemic optic neuropathy AE
MedDRA: 10068249
OAE:0002557
a peripheral neuropathy AE that shows a combination of axonal and demyelinating neuropathy.
RR, YH
WEB: http://www.aafp.org/afp/2010/0401/p887.html
mixed neuropathy AE
OAE:0002558
a peripheral sensory neuropathy AE that shows neuropathy in many sensory nerves at one time
RR, YH
WEB: http://www.merckmanuals.com/home/brain_spinal_cord_and_nerve_disorders/peripheral_nerve_disorders/polyneuropathy.html
sensory peripheral polyneuropathy AE
OAE:0002559
a peripheral neuropathy AE that results from the loss of the myelin sheath on peripheral nerves roughly evenly distributed on both sides of the body
RR, YH
peripheral demyelinating polyneuropathy AE
OAE:0002560
a neuropathy AE that shows nerve damage and occurs in a patient with diabetes
RR, YH
WEB: http://www.mayoclinic.org/diseases-conditions/diabetic-neuropathy/basics/definition/con-20033336
diabetic neuropathy AE
MedDRA: 10012680
OAE:0002561
a nervous system AE that is an umbrella term referring to conditions relating to the nervous system, including loss of sensation and paralysis
RR, YH
WEB: http://en.wikipedia.org/wiki/Functional_neurological_deficit
neurological deficit AE
OBI:0000011
A processual entity that realizes a plan which is the concretization of a plan specification.
planned process
OBI:0000047
processed material
Examples include gel matrices, filter paper, parafilm and buffer solutions, mass spectrometer, tissue samples
Is a material entity that is created or changed during material processing.
PERSON: Alan Ruttenberg
http://purl.obolibrary.org/obo/obi.owl
processed material
OBI:0000576
scattered molecular aggregate
scattered molecular aggregate
the sodium and chloride ions in a glass of salt water
A scattered molecular aggregate is a material entity that consists of all the molecules of a specific type that are located in some bounded region and which is part of a more massive material entity that has parts that are other such aggregates
a material entity that consists of all the molecules of a specific type that are located in some bounded region and which is part of a more massive material entity that has parts that are other such aggregates
PERSON: Alan Ruttenberg
Collective
Discussion in Karslruhe with, among others, Alan Rector, Stefan Schulz, Marijke Keet, Melanie Courtot, and Alan Ruttenberg. With inspiration from the paper Granularity, scale and collectivity: When size does and does not matter, Alan Recto, Jeremy Rogers, Thomas Bittner, Journal of Biomedical Informatics 39 (2006) 333-349
scattered molecular aggregate
OBI:0100026
organism
animal
fungus
plant
virus
A material entity that is an individual living system, such as animal, plant, bacteria or virus, that is capable of replicating or reproducing, growth and maintenance in the right environment. An organism may be unicellular or made up, like humans, of many billions of cells divided into specialized tissues and organs.
10/21/09: This is a placeholder term, that should ideally be imported from the NCBI taxonomy, but the high level hierarchy there does not suit our needs (includes plasmids and 'other organisms')
GROUP: OBI Biomaterial Branch
WEB: http://en.wikipedia.org/wiki/Organism
organism
ODNAE:0000001
a neuropathy adverse event that is associated with a drug.
YH, RR
drug-associated neuropathy AE
ODNAE:0000002
RR, YH
role in cellular and molecular interactions
ODNAE:0000003
RR, YH
drug-associated mixed neuropathy AE
ODNAE:0000004
RR, YH
drug-associated peripheral neuropathy adverse event
ODNAE:0000005
RR, YH
drug-associated motor neuropathy AE
ODNAE:0000006
RR, YH
drug-associated neuritis neuropathy AE
ODNAE:0000007
RR, YH
drug-associated optic neuropathy AE
ODNAE:0000008
RR, YH
drug-associated diabetic neuropathy AE
ODNAE:0000009
RR, YH
drug-associated neuroretinitis neuropathy AE
ODNAE:0000010
RR, YH
drug-associated polyneuropathy AE
ODNAE:0000011
RR, YH
drug-associated sensory neuropathy AE
ODNAE:0000012
RR, YH
drug-associated neurotoxicity neuropathy AE
ODNAE:0000013
RR, YH
drug-associated peripheral sensory neuropathy AE
ODNAE:0000014
RR, YH
drug-associated sensory peripheral polyneuropathy AE
ODNAE:0000015
RR, YH
drug-associated peripheral sensorimotor neuropathy AE
ODNAE:0000016
RR, YH
drug-associated peripheral demyelinating polyneuropathy AE
ODNAE:0000017
RR, YH
drug-associated anterior ischemic optic neuropathy AE
ODNAE:0000018
RR, YH
drug-associated non-arteritic anterior ischemic optic neuropathy AE
ODNAE:0000019
RR, YH
drug-associated carpal tunnel syndrome AE
ODNAE:0000020
RR, YH
drug-associated neurological deficit AE
ODNAE:0000022
RR, YH
drug-associated paresthesia AE
ODNAE:0000023
RR, AG, YH
WEB: http://www.fda.gov/downloads/Drugs/EmergencyPreparedness/BioterrorismandDrugPreparedness/UCM130802.pdf
ciprofloxacin hydrochloride (Ciloxan, Cipro, Cetraxal)-associated peripheral neuropathy AE
ODNAE:0000024
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050679s036lbl.pdf
cefepime (Maxipime)-associated neurotoxicity AE
ODNAE:0000025
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050141s231lbl.pdf
penicillin G benzathine (Bicillin L-A)-associated neuropathy AE
ODNAE:0000026
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021549s021lbl.pdf
fosaprepitant dimeglumine (Emend)-associated sensory neuropathy AE
ODNAE:0000027
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021500s019lbl.pdf
emtricitabine (Emtriva)-associated neuropathy AE
ODNAE:0000028
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021500s019lbl.pdf
emtricitabine (Emtriva)-associated peripheral neuritis AE
ODNAE:0000029
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020533s028lbl.pdf
ropivacaine (Naropin)-associated neuropathy AE
ODNAE:0000030
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/019810s095,022056s011lbl.pdf
omeprazole (Prilosec)-associated anterior ischemic optic neuropathy AE
ODNAE:0000031
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/016295s041s042lbl.pdf
hydroxyurea (Droxia, Hydrea)-associated peripheral neuropathy AE
ODNAE:0000032
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202429s000lbl.pdf
vemurafenib (Zelboraf)-associated peripheral neuropathy AE
ODNAE:0000033
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/125377s0000lbl.pdf
ipilimumab (Yervoy)-associated neuropathy AE
ODNAE:0000034
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/125289s0038lbl.pdf
golimumab (Simponi)-associated peripheral demylinating polyneuropathy AE
ODNAE:0000035
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/103949s5217s5222lbl.pdf
peginterferon alfa-2b (Peg Intron, Sylatron)-associated peripheral neuropathy AE
ODNAE:0000036
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/103772s5301lbl.pdf
infliximab (Remicade)-associated neuropathy AE
ODNAE:0000037
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/050708s036s037,050709s028s030lbl.pdf
tacrolimus (Astagraf XL, Hecoria, Prograf, Protopic)-associated neuropathy AE
ODNAE:0000038
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/050708s036s037,050709s028s030lbl.pdf
tacrolimus (Astagraf XL, Hecoria, Prograf, Protopic)-associated neurotoxicity AE
ODNAE:0000039
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022505s001s003lbl.pdf
tesamorelin (Egrifta)-associated peripheral neuropathy AE
ODNAE:0000040
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022234s000lbl.pdf
docetaxel (Taxotere, Docefrez)-associated neuropathy AE
ODNAE:0000041
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022187s008lbl.pdf
etravirine (Intelence)-associated peripheral neuropathy AE
ODNAE:0000042
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022128s007lbl.pdf
maraviroc (Selzentry)-associated peripheral neuropathy AE
ODNAE:0000043
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022108s005s006lbl.pdf
bupropion (Aplezin, Wellbutrin, Zyban, Budeprion SR, Buproban, Forfivo XL)-associated neuropathy AE
ODNAE:0000044
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022068s008s009lbl.pdf
nilotinib (Tasigna)-associated peripheral neuropathy AE
ODNAE:0000045
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022065s006lbl.pdf
ixabepilone (Ixempra)-associated peripheral neuropathy AE
ODNAE:0000046
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022011S012,022154S009lbl.pdf
telbivudine (Tyzeka)-associated peripheral neuropathy AE
ODNAE:0000047
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021986s009s010lbl.pdf
dasatinib (Sprycel)-associated neuropathy AE
ODNAE:0000048
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021923s012lbl.pdf
sorafenib (NexAVAR)-associated sensory neuropathy AE
ODNAE:0000049
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021880s023lbl.pdf
lenalidomide (Revlimid)-associated neuropathy AE
ODNAE:0000050
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021814s011lbl.pdf
tipranavir (Aptivus)-associated peripheral neuropathy AE
ODNAE:0000051
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021806s003lbl.pdf
metronidazole (Flagyl, Metrocream, Metrogel, Metrolotion, Noritate)-associated peripheral neuropathy AE
ODNAE:0000052
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021732s007s010s012lbl.pdf
histrelin (Vantas, Supprelin LA)-associated neuropathy AE
ODNAE:0000053
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021602s029s030lbl.pdf
bortezomib (Velcade)-associated peripheral neuropathy AE
ODNAE:0000054
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021588s030s031lbl.pdf
imatinib (Gleevec)-associated peripheral neuropathy AE
ODNAE:0000055
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021572s038lbl.pdf
daptomycin (Cubicin)-associated peripheral neuropathy AE
ODNAE:0000056
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021567s026lbl.pdf
atazanavir (Reyataz)-associated peripheral neurologic symptoms AE
ODNAE:0000057
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021481s020lbl.pdf
enfuvirtide (Fuzeon)-associated peripheral neuropathy AE
ODNAE:0000058
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021462s029s030s032lbl.pdf
pemetrexed (Alimta)-associated motor neuropathy AE
ODNAE:0000059
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021462s029s030s032lbl.pdf
pemetrexed (Alimta)-associated sensory neuropathy AE
ODNAE:0000060
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021400s013lbl.pdf
vardenafil (Levitra, Staxyn)-associated non-arteritic anterior ischemic optic neuropathy AE
ODNAE:0000061
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021356s041lbl.pdf
tenofovir (Viread)-associated peripheral neuropathy AE
ODNAE:0000062
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021266s035,021267s040,021630s026lbl.pdf
voriconazole (Vfend)-associated neuropathy AE
ODNAE:0000063
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021158s021lbl.pdf
gemifloxacin (Factive)-associated peripheral neuropathy AE
ODNAE:0000064
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021085s050s053,021277s046s050lbl.pdf
moxifloxacin (Avelox, Vigamox, Moxeza)-associated peripheral neuropathy AE
ODNAE:0000065
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021055s006lbl.pdf
bexarotene (Targretin)-associated neuropathy AE
ODNAE:0000066
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021041s023lbl.pdf
cytarabine (Cytosar-U, Tarabine PFS)-associated peripheral neuropathy AE
ODNAE:0000067
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021016s018lbl.pdf
eletriptan (Relpax)-associated neuropathy AE
ODNAE:0000068
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020972s040lbl.pdf
efavirenz (Sustiva)-associated neuropathy AE
ODNAE:0000069
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020905s022lbl.pdf
leflunomide (Arava)-associated peripheral neuropathy AE
ODNAE:0000070
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020896s026lbl.pdf
capecitabine (Xeloda)-associated peripheral sensory neuropathy AE
ODNAE:0000071
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020895s036lbl.pdf
sildenafil (Revatio, Viagra)-associated neuropathy AE
ODNAE:0000072
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020829s060,020830s062,021409s037lbl.pdf
montelukast (Singulair)-associated neuropathy AE
ODNAE:0000073
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020753s009s011s012lbl.pdf
exemestane (Aromasin)-associated neuropathy AE
ODNAE:0000074
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020715s025,021288s022,022437s003lbl.pdf
triptorelin (Trelstar)-associated neuropathy AE
ODNAE:0000075
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020667s025lbl.pdf
pramipexole (Mirapex)-associated neuropathy AE
ODNAE:0000076
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020659s055,022417s006lbl.pdf
ritonavir (Norvir)-associated neuropathy AE
ODNAE:0000077
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020636s039_020933s030lbl.pdf
nevirapine (Viramune)-associated paresthesia AE
ODNAE:0000078
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020634s062s064,020635s068s070,021721s029s031lbl.pdf
levofloxacin (Levaquin, Quixin, Iquix)-associated peripheral neuropathy AE
ODNAE:0000079
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020564s031,020596s030lbl.pdf
lamivudine (Epivir)-associated neuropathy AE
ODNAE:0000080
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020547s031lbl.pdf
zafirlukast (Accolate)-associated neuropathy AE
ODNAE:0000081
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020509s069lbl.pdf
gemcitabine (Gemzar)-associated neuropathy AE
ODNAE:0000082
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020505s042,020844s036lbl.pdf
topiramate (Topamax, Topiragen, Trokendi XR, Qudexy XR)-associated neuropathy AE
ODNAE:0000083
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020427s002lbl.pdf
vigabatrin (Sabril)-associated peripheral neuropathy AE
ODNAE:0000084
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020412s038,020413s030lbl.pdf
stavudine (Zerit)-associated peripheral neuropathy AE
ODNAE:0000085
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020386s056lbl.pdf
losartan (Cozaar)-associated peripheral neuropathy AE
ODNAE:0000086
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020261s042,021192s016lbl.pdf
fluvastatin (Lescol)-associated peripheral neuropathy AE
ODNAE:0000087
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020156s048lbl.pdf
desipramine (Norpramin)-associated peripheral neuropathy AE
ODNAE:0000088
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020140s002lbl.pdf
levoleucovorin (Fusilev)-associated neuropathy AE
ODNAE:0000089
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020092s017lbl.pdf
diltiazem (Dilacor, Cardizem, Cartia XT, Tiazac, Dilt-CD, Dilt-XR, Diltia XT)-associated neuropathy AE
ODNAE:0000090
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020031s058s066,020710s022s030lbl.pdf
paroxetine (Paxil, Pexeva, Brisdelle)-associated neuropathy AE
ODNAE:0000091
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019943s032,020011s039lbl.pdf
leuprolide acetate (Lupron, Eligard, Viadur)-associated peripheral neuropathy AE
ODNAE:0000092
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019901s058lbl.pdf
ramipril (Altace)-associated neuropathy AE
ODNAE:0000093
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019898s061lbl.pdf
pravastatin (Pravachol)-associated neuropathy AE
ODNAE:0000094
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019865s020lbl.pdf
sotalol (Betapace, Sorine, Sotylize)-associated peripheral neuropathy AE
ODNAE:0000095
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019821s018lbl.pdf
acitretin (Soriatane)-associated peripheral neuropathy AE
ODNAE:0000096
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019787s052lbl.pdf
amlodipine (Norvasc)-associated neuropathy peripheral AE
ODNAE:0000097
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019766s083lbl.pdf
simvastatin (Zocor)-associated peripheral neuropathy AE
ODNAE:0000098
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019763s016lbl.pdf
ifosfamide (Ifex)-associated polyneuropathy AE
ODNAE:0000099
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019735s061lbl.pdf
ofloxacin (Floxin, Ocuflox)-associated peripheral neuropathy AE
ODNAE:0000100
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019655s052,019910s039,020518s022lbl.pdf
zidovudine (Retrovir)-associated neuropathy AE
ODNAE:0000101
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019558s054lbl.pdf
lisinopril (Prinivil, Zestril)-associated peripheral neuropathy AE
ODNAE:0000102
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019537s074,020780s032lbl.pdf
ciprofloxacin (Cipro, Ciloxan, Cetraxal)-associated peripheral neuropathy AE
ODNAE:0000103
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019507s008lbl.pdf
betaxolol (Kerlone, Betoptic S)-associated neuropathy AE
ODNAE:0000104
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019384s060lbl.pdf
norfloxacin (Noroxin)-associated peripheral neuropathy AE
ODNAE:0000105
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/018972s044lbl.pdf
amiodarone (Cordarone, Pacerone)-associated peripheral neuropathy AE
ODNAE:0000106
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/018057s081lbl.pdf
cisplatin (Platinol)-associated peripheral neuropathy AE
ODNAE:0000107
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/017422s042lbl.pdf
carmustine (Bicnu, Gliadel)-associated neuroretinitis AE
ODNAE:0000108
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/016267s050lbl.pdf
deferoxamine (Desferal)-associated mixed neuropathy AE
ODNAE:0000109
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/010669s032lbl.pdf
chlorambucil (Leukeran)-associated peripheral neuropathy AE
ODNAE:0000110
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/006188s021s022lbl.pdf
propylthiouracil-associated neuropathy AE
ODNAE:0000111
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/201532lbl.pdf
eribulin (Halaven)-associated peripheral neuropathy AE
ODNAE:0000112
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/201023lbl.pdf
cabazitaxel (Jevtana)-associated peripheral neuropathy AE
ODNAE:0000113
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/125160s111lbl.pdf
certolizumab pegol (Cimzia)-associated peripheral neuropathy AE
ODNAE:0000114
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021743s14s16lbl.pdf
erlotinib (Tarceva)-associated neuropathy AE
ODNAE:0000115
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021549s017lbl.pdf
aprepitant (Emend)-associated sensory neuropathy AE
ODNAE:0000116
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021348s008lbl.pdf
miglustat (Zavesca)-associated peripheral neuropathy AE
ODNAE:0000117
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021304s008,022257s003lbl.pdf
valganciclovir (Valcyte)-associated peripheral neuropathy AE
ODNAE:0000118
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021130s022lbl.pdf
linezolid (Zyvox)-associated optic neuropathy AE
ODNAE:0000119
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020825s038,020919s025,021483s005lbl.pdf
ziprasidone (Geodon)-associated neuropathy AE
ODNAE:0000120
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020671s016s017lbl.pdf
topotecan (Hycamtin)-associated neuropathy AE
ODNAE:0000121
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020498s022lbl.pdf
bicalutamide (Casodex)-associated neuropathy AE
ODNAE:0000122
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020151s056s057lbl.pdf
venlafaxine (Effexor)-associated neuropathy AE
ODNAE:0000123
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020083s046lbl.pdf
itraconazole (Onmel, Sporanox)-associated neuropathy AE
ODNAE:0000124
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020038s033lbl.pdf
fludarabine (Fludara)-associated peripheral neuropathy AE
ODNAE:0000125
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/019908s029lbl.pdf
zolpidem (Zolpimist, Ambien, Edluar, Intermezzo)-associated neuropathy AE
ODNAE:0000126
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/012802s031lbl.pdf
triamcinolone (Aristocort, Azmacort, Cinolar, Kenalog, Nasacort, Clinacort, Triam-Forte, Triamcot, Aristospan)-associated neuropathy AE
ODNAE:0000127
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/012623s061lbl.pdf
metronidazole (Flagyl, Metrocream, Metrogel, Metrolotion, Noritate)-associated optic neuropathy AE
ODNAE:0000128
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/078810s000lbl.pdf
oxaliplatin (Eloxatin)-associated neuropathy AE
ODNAE:0000129
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/050715s028,050716s029lbl.pdf
cyclosporine (Gengraf, Neoral, Sandimmune, Restasis)-associated neuropathy AE
ODNAE:0000130
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022395lbl.pdf
capsaicin (Zostrix, Capsagel, Capsagesic HP, Capsin, Trixaicin, Pain Enz, Rid-A-Pain, Sportsmed)-associated peripheral sensory neuropathy AE
ODNAE:0000131
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021877s001lbl.pdf
nelarabine (Arranon)-associated peripheral neuropathy AE
ODNAE:0000132
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021794s006lbl.pdf
dapsone (Aczone)-associated peripheral neuropathy AE
ODNAE:0000133
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021641s002s003s004s005s007s008s010lbl.pdf
rasagiline (Azilect)-associated neuropathy AE
ODNAE:0000134
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021476s012lbl.pdf
eszopiclone (Lunesta)-associated neuropathy AE
ODNAE:0000135
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021001s010s011lbl.pdf
almotriptan (Axert)-associated neuropathy AE
ODNAE:0000136
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020702s056lbl.pdf
atorvastatin (Lipitor)-associated peripheral neuropathy AE
ODNAE:0000137
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020697s013s015lbl.pdf
tolcapone (Tasmar)-associated neuropathy AE
ODNAE:0000138
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020064s019lbl.pdf
nitrofurantoin (Furadantin)-associated peripheral neuropathy AE
ODNAE:0000139
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019715s027lbl.pdf
olsalazine sodium (Dipentum)-associated peripheral neuropathy AE
ODNAE:0000140
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019591s026s028lbl.pdf
mefloquine (Lariam)-associated sensory neuropathy AE
ODNAE:0000141
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019591s026s028lbl.pdf
mefloquine (Lariam)-associated motor neuropathy AE
ODNAE:0000142
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019268s041lbl.pdf
misoprostol (Cytotec)-associated neuropathy AE
ODNAE:0000143
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/018332s032lbl.pdf
indomethacin (Indocin, Tivorbex)-associated peripheral neuropathy AE
ODNAE:0000144
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/017831s055lbl.pdf
etidronate (Didronel)-associated peripheral neuropathy AE
ODNAE:0000145
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/007073s124lbl.pdf
sulfasalazine (Azulfidine, Sulfazine)-associated peripheral neuropathy AE
ODNAE:0000146
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050718s033lbl.pdf
doxorubicin (Doxil, Adriamycin)-associated peripheral neuropathy AE
ODNAE:0000147
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022301lbl.pdf
mesalamine (Canasa, Pentasa, Rowasa, Lialda, Apriso, Asacol HD, sfRowasa, Delzicol)-associated peripheral neuropathy AE
ODNAE:0000148
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021479s003s004lbl.pdf
selegiline (Emsam, Eldepryl, Zelapar)-associated neuropathy AE
ODNAE:0000149
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020658s018s020s021lbl.pdf
ropinirole (Requip)-associated peripheral neuropathy AE
ODNAE:0000150
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/018998s071lbl.pdf
enalapril maleate (Vasotec, Epaned)-associated peripheral neuropathy AE
ODNAE:0000151
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021777lbl.pdf
cyclobenzaprine (Flexeril, Amrix, Fexmid, FusePaq Tabradol)-associated peripheral neuropathy AE
ODNAE:0000152
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021618s003lbl.pdf
tinidazole (Tindamax)-associated neuropathy AE
ODNAE:0000153
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/020859s011lbl.pdf
zaleplon (Sonata)-associated neuropathy AE
ODNAE:0000154
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/020068s017lbl.pdf
foscarnet (Foscavir)-associated neuropathy AE
ODNAE:0000155
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019998s013lbl.pdf
succimer (Chemet)-associated sensorimotor neuropathy AE
ODNAE:0000156
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019906s34lbl.pdf
clomipramine (Anafranil)-associated neuropathy AE
ODNAE:0000157
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/018013s58lbl.pdf
nortriptyline (Aventyl, Pamelor)-associated peripheral neuropathy AE
ODNAE:0000158
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/016792s025lbl.pdf
trimipramine (Surmontil)-associated peripheral neuropathy AE
ODNAE:0000159
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021430s000,020785s031lbl.pdf
thalidomide (Thalomid)-associated peripheral neuropathy AE
ODNAE:0000160
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/020989s008lbl.pdf
cevimeline (Evoxac)-associated neuropathy AE
ODNAE:0000161
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/020397s021,021447s002lbl.pdf
tizanidine (Zanaflex)-associated neuropathy AE
ODNAE:0000162
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/020154s50,20155s39,20156s40,21183s16lbl.pdf
didanosine (Videx)-associated peripheral neuropathy AE
ODNAE:0000163
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/019661s030lbl.pdf
ganciclovir (Cytovene, Vitrasert, Zirgan)-associated neuropathy AE
ODNAE:0000164
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/017001s027lbl.pdf
flucytosine (Ancobon)-associated peripheral neuropathy AE
ODNAE:0000165
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/20013s015lbl.pdf
lomefloxacin (Maxaquin)-associated peripheral neuropathy AE
ODNAE:0000166
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021785s001,002,020828s019,020,020628s022,023lbl.pdf
saquinavir (Invirase)-associated peripheral neuropathy AE
ODNAE:0000167
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21341lbl.pdf
valdecoxib (Bextra)-associated neuropathy AE
ODNAE:0000168
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21316s010lbl.pdf
lovastatin (Altoprev, Mevacor)-associated peripheral neuropathy AE
ODNAE:0000169
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2004/20549slr016,20548slr020,20121slr030_flonase_lbl.pdf
fluticasone (Flonase, Cutivate, Flovent)-associated neuropathy AE
ODNAE:0000170
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2004/19853s012,014lbl.pdf
penicillamine (Cuprimine, Depen)-associated peripheral neuropathy AE
ODNAE:0000171
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2004/11664slr062_decadron_lbl.pdf
dexamethasone (Decadron, DexPak, Maxidex, Dekpak 13 day Taperpak, Baycadron Elixer, Ozurdex)-associated neuropathy AE
ODNAE:0000172
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2004/021052s026_021042s019lbl.pdf
This drug has been withdrawn from the US market.
rofecoxib-associated median nerve neuropathy AE
ODNAE:0000173
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/basnov010203LB.htm
basiliximab (Simulect)-associated neuropathy AE
ODNAE:0000174
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/19385slr030,031,035_permax_lbl.pdf
This drug has been withdrawn from the US market.
pergolide (Permax)-associated neuropathy AE
ODNAE:0000175
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2002/20388S014lbl.pdf
vinorelbine (Navelbine)-associated neuropathy AE
ODNAE:0000176
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2002/20199s16lbl.pdf
This drug has been discontinued from the US market.
zalcitabine-associated peripheral neuropathy AE
ODNAE:0000177
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2001/20740S19lbl.pdf
This drug has been withdrawn from the US market.
cerivastatin (Baycol)-associated peripheral neuropathy AE
ODNAE:0000178
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2001/20705S8lbl.pdf
delavirdine (Rescriptor)-associated neuropathy AE
ODNAE:0000179
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/anda/98/74-739_Amiodarone_prntlbl.pdf
amiodarone hydrochloride (Cordarone, Pacerone)-associated optic neuropathy AE
ODNAE:0000180
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/anda/2002/75184_Paclitaxel_Prntlbl.pdf
paclitaxel (Taxol, Onxol, Nov-Onxol, Paclitaxel Novaplus)-associated peripheral neuropathy AE
ODNAE:0000181
RR, AG, YH
WEB: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ff61b237-be8e-461b-8114-78c52a8ad0ae#nlm34084-4
tadalafil (Cialis, Adcirca)-associated non-arteritic anterior ischemic optic neuropathy AE
ODNAE:0000182
RR, AG, YH
WEB: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fead084a-a376-4d57-bdf0-aa7ed3655505#nlm34084-4
rivastigmine (Exelon)-associated peripheral neuropathy AE
ODNAE:0000183
RR, AG, YH
WEB: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fcb8ef8a-f770-4416-8fc5-fa01d98c8eee#nlm34084-4
mitoxantrone hydrochloride (Novantrone)-associated neurological deficit AE
ODNAE:0000184
RR, AG, YH
WEB: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f94b2ba4-024f-4068-8759-da6c8d31c546#nlm34084-4
zonisamide (Zonegran)-associated neuropathy AE
ODNAE:0000185
RR, AG, YH
WEB: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f16f9ae6-d29f-4b31-a240-c7ebb0d7d36a#nlm34084-4
sotalol hydrochloride (Betapace, Sorine, Sotylize)-associated peripheral neuropathy AE
ODNAE:0000186
RR, AG, YH
WEB: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e3105799-a4b6-f3f4-e6e2-b2b29bbdb538#nlm34084-4
propofol (Diprivan, Fresenious Propoven)-associated neuropathy AE
ODNAE:0000187
RR, AG, YH
WEB: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e2ad9d3c-b6c3-4f70-87e0-722a8ff94ccb#nlm34084-4
pentamidine (Nebupent, Pentam)-associated neuropathy AE
ODNAE:0000188
RR, AG, YH
WEB: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=de1c8271-64d8-4ea5-85e8-871faa4d7632#nlm34084-4
procarbazine 50 MG oral capsule [Matulane]-associated neuropathy AE
ODNAE:0000189
RR, AG, YH
WEB: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d6918541-6285-48ea-8255-23212f9a3ad7#nlm34084-4
penicillin V potassium (Veetids, Truxcillin VK)-associated neuropathy AE
ODNAE:0000190
RR, AG, YH
WEB: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d1dde497-1889-4424-af18-da7ca6459cf3#nlm34084-4
Imipramine pamoate (Tofranil-PM)-associated peripheral neuropathy AE
ODNAE:0000191
RR, AG, YH
WEB: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ccb4d123-7b12-4aef-8ef0-f8d68c1a6547#nlm34084-4
methylprednisolone acetate (Depo-Medrol)-associated neuropathy AE
ODNAE:0000192
RR, AG, YH
WEB: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=be27854a-a805-4300-9729-accd1b7f226f#nlm34084-4
This drug has been discontinued from the US market.
sulfamethizole-associated neuropathy AE
ODNAE:0000193
RR, AG, YH
WEB: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bac91e37-91ce-4bbf-77bc-ef5f242589f8#nlm34084-4
zolmitriptan (Zomig)-associated neuropathy AE
ODNAE:0000194
RR, AG, YH
WEB: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b2f95b0b-9de3-4c0b-a46e-a7eee6428b4b#nlm34084-4
ethambutol (Myambutol)-associated peripheral neuritis AE
ODNAE:0000195
RR, AG, YH
WEB: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b2f95b0b-9de3-4c0b-a46e-a7eee6428b4b#nlm34084-4
ethambutol hydrochloride (Myambutol)-associated optic neuropathy AE
ODNAE:0000196
RR, AG, YH
WEB: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b172773b-3905-4a1c-ad95-bab4b6126563#nlm34084-4
rituximab (Rituxan)-associated peripheral sensory neuropathy AE
ODNAE:0000197
RR, AG, YH
WEB: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=acd53964-52dc-4534-b20f-14a7561b8a6c#nlm34084-4
amitriptyline hydrochloride (Elavil, Vanatrip)-associated peripheral neuropathy AE
ODNAE:0000198
RR, AG, YH
WEB: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=aa2e353f-860b-4d10-9a62-aad1c533b8aa#nlm34084-4
gabapentin (Gabarone, Neurontin, Gralise, FusePaq Fanatrex)-associated neuropathy AE
ODNAE:0000199
RR, AG, YH
WEB: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a6c72634-4613-4d21-bc9a-09dad17eb137#nlm34084-4
tolmetin (Tolectin)-associated optic neuropathy AE
ODNAE:0000200
RR, AG, YH
WEB: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=65b28775-ee59-88cf-e4d8-372c6c79ad14#nlm34084-4
megestrol (Megace)-associated neuropathy AE
ODNAE:0000201
RR, AG, YH
WEB: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=60185c88-ecfd-46f9-adb9-b97c6b00a553#nlm34084-4
pregabalin (Lyrica)-associated neuropathy AE
ODNAE:0000202
RR, AG, YH
WEB: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=55311747-710c-43c4-821d-76323ff2520e#nlm34084-4
imipramine (Tofranil, Tofranil-PM)-associated peripheral neuropathy AE
ODNAE:0000203
RR, AG, YH
WEB: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=532f0c6c-cd76-44d1-27b7-581cee86bc34#nlm34084-4
methylprednisolone (Medrol, Methylpred-DP)-associated neuropathy AE
ODNAE:0000204
RR, AG, YH
WEB: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4d80812c-dfc1-456c-9368-697267630c2c#nlm34084-4
fluvoxamine maleate (Luvox)-associated neuropathy AE
ODNAE:0000205
RR, AG, YH
WEB: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4d0f0f1a-31af-40fa-9c64-e90891fa6ce4#nlm34084-4
mitoxantrone (Novantrone)-associated neuropathy AE
ODNAE:0000206
RR, AG, YH
WEB: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4b4edc09-bbfd-471f-ac16-6118937a6e7e#nlm34084-4
pantoprazole (Protonix)-associated neuropathy AE
ODNAE:0000207
RR, AG, YH
WEB: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4a4c577d-9267-40eb-9ed9-09ceb6377026#nlm34084-4
phenytoin (Dilantin, Phenytek)-associated sensory peripheral polyneuropathy AE
ODNAE:0000208
RR, AG, YH
WEB: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=492dbdb2-077e-4064-bff3-372d6af0a7a2#nlm34084-4
trastuzumab (Herceptin)-associated motor neuropathy AE
ODNAE:0000209
RR, AG, YH
WEB: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=492dbdb2-077e-4064-bff3-372d6af0a7a2#nlm34084-4
trastuzumab (Herceptin)-associated sensory neuropathy AE
ODNAE:0000210
RR, AG, YH
WEB: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3f60ac2e-031a-48fa-ab47-4e3aec49cb83#nlm34084-4
losartan potassium (Cozaar)-associated peripheral neuropathy AE
ODNAE:0000211
RR, AG, YH
WEB: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=34868f95-78d0-4089-8cbd-bec1cb730eda#nlm34084-4
metolazone (Mykrox, Zaroxolyn)-associated neuropathy AE
ODNAE:0000212
RR, AG, YH
WEB: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=27cfe684-7d11-4f37-9c8b-b2bdd6b5348e#nlm34084-4
haloperidol (Haldol)-associated neurotoxicity AE
ODNAE:0000213
RR, AG, YH
WEB: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=173018f5-fd76-4480-90f8-4b7efe328444#nlm34084-4
lomefloxacin hydrochloride (Maxaquin)-associated peripheral neuropathy AE
ODNAE:0000214
RR, AG, YH
WEB: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=13d85420-75e2-46e7-93eb-dcd10675cd03#nlm34084-4
ticlopidine (Ticlid)-associated peripheral neuropathy AE
ODNAE:0000215
RR, AG, YH
WEB: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=12850de3-c97c-42c1-b8d3-55dc6fd05750#nlm34084-4
disulfiram (Antabuse)-associated peripheral neuropathy AE
ODNAE:0000216
RR, AG, YH
WEB: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=013433a1-c27c-4712-a03b-0949b2969fbb#nlm34084-4
nitrofurantoin macrocrystals (Macrodantin)-associated peripheral neuropathy AE
ODNAE:0000217
RR, AG, YH
WEB: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=013433a1-c27c-4712-a03b-0949b2969fbb#nlm34084-4
nitrofurantoin, monohydrate (Macrobid)-associated peripheral neuropathy AE
ODNAE:0000218
RR, AG, YH
WEB: http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=f694c617-3383-416c-91b6-b94fda371204&type=display
fluconazole (Diflucan)-associated paresthesia AE
ODNAE:0000219
RR, AG, YH
WEB: http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=f1ffd18c-9f6b-4479-94b9-6890bc730ecc&type=display
fludarabine phosphate-associated peripheral neuropathy AE
ODNAE:0000220
RR, AG, YH
WEB: http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=90b94524-f913-48b3-3771-7b2fcffd888a&type=display
fentanyl (Actiq, Duragesic, Subsys, Fentora, Abstral)-associated neuropathy AE
ODNAE:0000221
RR, AG, YH
WEB: http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8dbc0e47-8df9-4484-903b-70fdd26f7998&type=display
insulin, protamine zinc, human 40 UNT/ML injectable suspension [ProZinc]-associated diabetic neuropathy AE
ODNAE:0000222
RR, AG, YH
WEB: http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8379f1db-4255-4285-abd3-8ecdcaf03372&type=display
fluorouracil (Carac, Efudex, Fluoroplex, Adrucil)-associated neurotoxicity AE
ODNAE:0000223
RR, AG, YH
WEB: http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=806736d3-215a-4df5-8187-97f2161e5a53&type=display
carboplatin (Paraplatin)-associated peripheral neuropathy AE
ODNAE:0000224
RR, AG, YH
WEB: http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=77795c31-1cdf-4a20-b4a1-cd15f5b310f1&type=display
isoniazid (Nydrazid)-associated peripheral neuropathy AE
ODNAE:0000225
RR, AG, YH
WEB: http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=6cf2e15a-6286-41f7-aa7d-3968d735c864&type=display
methotrexate (Rheumatrex, Trexall, Otrexup, Rasuvo)-associated neurotoxicity AE
ODNAE:0000226
RR, AG, YH
WEB: http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=2f7d5e7f-79aa-4f3a-b9a6-758d9f3ce74d&type=display
imipramine hydrochloride (Tofranil)-associated peripheral neuropathy AE
ODNAE:0000227
RR, AG, YH
WEB: http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=063fa789-4570-4715-c3bd-1bad0449fb26&type=display
tamoxifen (Nolvadex, Soltamox)-associated neurotoxicity AE
ODNAE:0000228
RR, AG, YH
WEB: http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee1583ac-c308-4beb-b602-9ecac4977026#section-6
colchicine (Colcrys, Mitigare)-associated sensory motor neuropathy AE
ODNAE:0000229
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202570s003lbl.pdf
crizotinib (Xalkori)-associated neuropathy AE
ODNAE:0000230
RR, AG, YH
WEB: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=73cd79c1-6bab-4d7b-ae8b-0176efbaf5b9#nlm34084-4
allopurinol (Zyloprim, Aloprim)-associated peripheral neuropathy AE
ODNAE:0000231
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/103293s5130lbl.pdf
aldesleukin (Proleukin)-associated neuropathy AE
ODNAE:0000232
RR, AG, YH
WEB: http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8456a8db-a7f6-4bc0-86be-e9c8c374140b&type=display
altretamine (Hexalen)-associated peripheral neuropathy AE
ODNAE:0000233
RR, AG, YH
WEB: http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fc78c074-3ca8-4e29-9c18-8fab97558fc2&type=display
amantadine (Symmetrel)-associated paresthesia AE
ODNAE:0000234
RR, AG, YH
WEB: http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=03586c40-eb32-45c5-beb7-6762a6b78790&type=display
anastrozole (Arimidex)-associated paresthesia AE
ODNAE:0000235
RR, AG, YH
WEB: http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=05c34ddf-a0f7-4267-83f5-d02be3defc37&type=display
auranofin (Ridaura)-associated peripheral neuropathy AE
ODNAE:0000236
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202276s001lbl.pdf
avanafil (Stendra)-associated non-arteritic anterior ischemic optic neuropathy AE
ODNAE:0000237
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202714lbl.pdf
carfilzomib (Kyprolis)-associated peripheral neuropathy AE
ODNAE:0000238
RR, AG, YH
WEB: http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a2592a9b-bca6-4a5a-89c2-855a0634d5fe&type=display
cladribine (Leustatin)-associated peripheral sensory neuropathy AE
ODNAE:0000239
RR, AG, YH
WEB: http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a2592a9b-bca6-4a5a-89c2-855a0634d5fe&type=display
cladribine (Leustatin)-associated motor neuropathy AE
ODNAE:0000240
RR, AG, YH
WEB: http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a2592a9b-bca6-4a5a-89c2-855a0634d5fe&type=display
cladribine (Leustatin)-associated polyneuropathy AE
ODNAE:0000241
RR, AG, YH
WEB: http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=e28c05f0-081f-406d-8bfb-9160a6908307&type=display
etoposide (Vepesid, Etopophos)-associated peripheral neurotoxicity AE
ODNAE:0000242
RR, AG, YH
WEB: http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fa68b35e-9f50-408b-9e70-e84cecf3fd6e&type=display
flecainide (Tambocor)-associated neuropathy AE
ODNAE:0000243
RR, AG, YH
WEB: http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a29045b5-ba4f-407a-a0fd-3ef7e1ce64ee&type=display
gold sodium thiomalate (Myochrysine)-associated peripheral neuropathy AE
ODNAE:0000244
RR, AG, YH
WEB: http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=416ab996-a2e8-4fe1-a9c9-f10b86df3bb5&type=display
iopamidol (Isovue)-associated paresthesia AE
ODNAE:0000245
RR, AG, YH
WEB: http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=924c5a35-4804-4e14-a2fc-2b84d186d257&type=display
lansoprazole (Prevacid)-associated paresthesia AE
ODNAE:0000246
RR, AG, YH
WEB: http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=dc92f45f-8d27-4dcb-b72d-6b8b04c6f0ce&type=display
methimazole (Tapazole)-associated paresthesia AE
ODNAE:0000247
RR, AG, YH
WEB: http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=700abc58-9362-4ef5-9d7a-dd3c4d364d0a&type=display
protriptyline (Vivactil)-associated peripheral neuropathy AE
ODNAE:0000248
RR, AG, YH
WEB: http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=abd1f64e-4283-4370-aae8-3666316aa36e&type=display
streptomycin-associated paresthesia AE
ODNAE:0000249
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020119s010s011lbl.pdf
teniposide (Vumon)-associated neurotoxicity AE
ODNAE:0000250
RR, AG, YH
WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202992s000lbl.pdf
teriflunomide (Aubagio)-associated peripheral neuropathy AE
OGMS:0000060
Albert Goldfain
creation date: 2009-06-23T11:53:49Z
bodily process
OGMS:0000061
A bodily process that is clinically abnormal.
Albert Goldfain
http://ontology.buffalo.edu/medo/Disease_and_Diagnosis.pdf
creation date: 2009-06-23T11:54:29Z
pathological bodily process
A time quality inhering in a bearer by virtue of how long the bearer has existed.
PATO:0000011
age
PATO:0000011
A quality in which events occur in sequence.
PATO:0000165
time
PATO:0000165
A quality of a physical entity that exists through action of continuants at the physical level of organisation in relation to other entities.
PATO:0002079
Wikipedia:Physical_property
relational physical quality
PATO:0001018
physical quality
PATO:0001018
A quality which inheres in a continuant.
PATO:0001237
PATO:0001238
snap:Quality
monadic quality of a continuant
multiply inhering quality of a physical entity
quality of a continuant
quality of a single physical entity
quality of an object
quality of continuant
monadic quality of an object
monadic quality of continuant
PATO:0001241
Relational qualities are qualities that hold between multiple entities. Normal (monadic) qualities such as the shape of a eyeball exist purely as a quality of that eyeball. A relational quality such as sensitivity to light is a quality of that eyeball (and connecting nervous system) as it relates to incoming light waves/particles.
physical object quality
PATO:0001241
PATO:0001992
cellularity
PATO:0001993
multicellular
PATO:0001995
organismal quality
A major division of the nervous system that contains nerves which connect the central nervous system (CNS) with sensory organs, other organs, muscles, blood vessels and glands.
Nervous structures including ganglia outside of the central nervous system. Kimmel et al, 1995.[TAO]
Part of nervous system in which nerves extend throughout the body outside of the brain and spinal cord.[AAO]
The peripheral nervous system (PNS) is the part of the nervous system connected to the CNS which contains cranial nerves III - XII, spinal, peripheral and autonomic nerves. (CUMBO)
(...) specific vertebrate traits within the chordate phylum such as skeletal tissues, PNS, and spectacular head and brain development, are linked to the NC (neural crest) and its derivatives.[well established][VHOG]
AAO:0000429
BAMS:PNS
BILA:0000081
BTO:0001028
CALOHA:TS-0808
EFO:0000891
EHDAA2:0001445
EHDAA:2893
EMAPA:16665
EMAPA:18370
EV:0100335
FBbt:00005098
FMA:9903
GAID:715
MA:0000218
MAT:0000338
MESH:A08.800
MIAA:0000338
TAO:0000142
UMLS:C0206417
UMLS:C1305921
VHOG:0000399
XAO:0000178
ZFA:0000142
http://braininfo.rprc.washington.edu/centraldirectory.aspx?ID=247
uberon
PNS
lateral part of the basal amygdalar nucleus
lateral part of the basolateral nucleus
nucleus amygdalae basalis, pars lateralis
nucleus amygdaloideus basalis, pars lateralis magnocellularis
nucleus basalis lateralis amygdalae
pars peripherica; systema nervosum periphericum
UBERON:0000010
peripheral nervous system
UBERON:0000010
An organ that is capable of detection of chemical stimulus involved in sensory perception of smell.
AEO:0000094
BSA:0000121
BTO:0000202
CALOHA:TS-2043
EHDAA2:0001824
EHDAA:500
EMAPA:16192
EMAPA:35955
FBbt:00005155
GAID:63
HAO:0000930
MA:0000017
MESH:A09
UMLS:C0935626
VHOG:0001407
WBbt:0006929
organ of sense organ system
organ of sensory organ system
organ of sensory system
sense organ system organ
sensory organ
sensory organ system organ
sensory system organ
sensillum
uberon
Sinnesorgan
sensor
UBERON:0000020
sense organ
UBERON:0000020
Material anatomical entity that has inherent 3D shape and is generated by coordinated expression of the organism's own genome.
AAO:0010825
AEO:0000003
BILA:0000003
CARO:0000003
EHDAA2:0003003
EMAPA:0
FBbt:00007001
FMA:67135
GAID:781
HAO:0000003
MA:0003000
MESH:A13
TAO:0000037
TGMA:0001823
VHOG:0001759
WBbt:0000100
XAO:0003000
ZFA:0000037
biological structure
uberon
UBERON:0000061
anatomical structure
UBERON:0000061
Anatomical structure that performs a specific function or group of functions [WP].
Organs are commonly observed as visibly distinct structures, but may also exist as loosely associated clusters of cells that work together to perform a specific function or functions.
CARO does not include a generic 'organ' class, only simple and compound organ
EFO:0000634
EMAPA:35949
ENVO:01000162
FMA:67498
MA:0003001
OpenCyc:Mx4rv5XMb5wpEbGdrcN5Y29ycA
OpenCyc:Mx4rwP3iWpwpEbGdrcN5Y29ycA
UMLS:C0178784
WBbt:0003760
uberon
anatomical unit
body organ
element
UBERON:0000062
organ
UBERON:0000062
The stage of development at which the animal is fully formed, including immaturity and maturity. Includes both sexually immature stage, and adult stage.
adult stage
BTO:0001043
BilaDO:0000004
EFO:0001272
FBdv:00005369
WBls:0000041
XtroDO:0000084
fully formed animal stage
juvenile-adult stage
uberon
UBERON:0000066
fully formed stage
UBERON:0000066
A stage that is part of the embryo stage.
embryonic stage part
uberon
UBERON:0000067
embryo stage part
UBERON:0000067
A life cycle stage that starts with fertilization and ends with the fully formed embryo.
BilaDO:0000002
EV:0300001
FBdv:00005289
HsapDv:0000002
MmusDv:0000002
OGES:000000
OGES:000022
WBls:0000003
WBls:0000092
WBls:0000102
XAO:1000012
embryonic stage
uberon
embryogenesis
UBERON:0000068
embryo stage
UBERON:0000068
End of the life of an organism.
ncit:Death is an outcome
XAO:0000437
XtroDO:0000085
uberon
death
UBERON:0000071
death stage
UBERON:0000071
stage succeeding embryo, including mature structure
In birds, the postnatal stage begins when the beak penetrates the shell (i.e., external pipping) (Brown et al. 1997)
BilaDO:0000003
OGES:000010
OGES:000014
OGES:000024
WBls:0000022
WBls:0000093
WBls:0000103
postembryonic stage
post-hatching stage
uberon
postembryonic
UBERON:0000092
post-embryonic stage
UBERON:0000092
An entire span of an organism's life, commencing with the zygote stage and ending in the death of the organism.
FBdv:00000000
HsapDv:0000001
MmusDv:0000001
OGES:000011
life
lifespan
uberon
UBERON:0000104
life cycle
UBERON:0000104
A spatiotemporal region encompassing some part of the life cycle of an organism.
we map the ZFS unknown stage here as it is logically equivalent to saying *some* life cycle stage
BILS:0000105
EFO:0000399
FBdv:00007012
HsapDv:0000000
MmusDv:0000000
OlatDv:0000010
PdumDv:0000090
WBls:0000002
XAO:1000000
ZFS:0000000
ZFS:0100000
developmental stage
stage
uberon
UBERON:0000105
life cycle stage
UBERON:0000105
A stage at which the organism is a single cell produced by means of sexual reproduction.
As in all metazoans, eumetazoan development begins with a fertilized egg, or zygote.[well established][VHOG]
BILS:0000106
BilaDO:0000005
EFO:0001322
EHDAA:27
EMAPA:16033
FBdv:00005288
PdumDv:0000100
VHOG:0000745
XAO:1000001
ZFS:0000001
1-cell stage
fertilized egg stage
one cell stage
uberon
fertilized egg stage
one-cell stage
zygote
zygotum
UBERON:0000106
zygote stage
UBERON:0000106
The first few specialized divisions of an activated animal egg; Stage consisting of division of cells in the early embryo. The zygotes of many species undergo rapid cell cycles with no significant growth, producing a cluster of cells the same size as the original zygote. The different cells derived from cleavage are called blastomeres and form a compact mass called the morula. Cleavage ends with the formation of the blastula.
BILS:0000107
BilaDO:0000006
EFO:0001290
FBdv:00000054
MESH:A16.254.270
MmusDv:0000004
OGES:000015
OGES:000020
PdumDv:0000200
XAO:1000004
ZFS:0000046
uberon
UBERON:0000107
cleavage stage
UBERON:0000107
An early stage of embryonic development in animals. It is produced by cleavage of a fertilized ovum and consists of a spherical layer of around 128 cells surrounding a central fluid-filled cavity called the blastocoel. The blastula follows the morula and precedes the gastrula in the developmental sequence.
consider adding a preceding stage 'morula stage' as part of cleavage
BILS:0000108
BilaDO:0000007
EFO:0001282
HsapDv:0000006
MmusDv:0000007
OGES:000003
OGES:000016
OGES:000021
OpenCyc:Mx4rEetFnKP2EdqAAAACs4vPlg
WBls:0000005
XAO:1000003
ZFS:0000045
uberon
UBERON:0000108
blastula stage
UBERON:0000108
A stage defined by complex and coordinated series of cellular movements that occurs at the end of cleavage during embryonic development of most animals. The details of gastrulation vary from species to species, but usually result in the formation of the three primary germ layers, ectoderm, mesoderm and endoderm.
BILS:0000109
BilaDO:0000008
EFO:0001296
FBdv:00005317
HsapDv:0000010
MmusDv:0000013
OGES:000004
OGES:000019
WBls:0000010
XAO:1000005
ZFS:0000047
uberon
blastocystis trilaminaris stage
trilaminar blastocyst stage
trilaminar blastoderm stage
trilaminar disk stage
trilaminar germ stage
trilaminar stage
UBERON:0000109
gastrula stage
UBERON:0000109
Staged defined by the formation of a tube from the flat layer of ectodermal cells known as the neural plate. This will give rise to the central nervous system.
BILS:0000110
BilaDO:0000009
HsapDv:0000012
MmusDv:0000017
XAO:1000006
uberon
UBERON:0000110
neurula stage
UBERON:0000110
A stage at which the ectoderm, endoderm, and mesoderm develop into the internal organs of the organism.
BILS:0000111
BilaDO:0000010
HsapDv:0000015
MmusDv:0000018
OGES:000005
OGES:000032
uberon
segmentation stage
UBERON:0000111
organogenesis stage
UBERON:0000111
Organism at the blastula stage - an early stage of embryonic development in animals. It is produced by cleavage of a fertilized ovum and consists of a spherical layer of around 128 cells surrounding a central fluid-filled cavity called the blastocoel. The blastula follows the morula and precedes the gastrula in the developmental sequence.
TODO - check relationship with epiblast. Note in FMA this is not a subclass of embryo, but in uberon embryo is the whole organism from zygote onwards and thus includes the blastula
UBERON:0007011
BILA:0000059
BTO:0000128
GAID:1294
MESH:A16.254.270.274
OGEM:000006
OpenCyc:Mx4rEetFnKP2EdqAAAACs4vPlg
blastula embryo
uberon
blastosphere
UBERON:0000307
blastula
UBERON:0000307
Anatomical entity that has mass.
AAO:0010264
AEO:0000006
BILA:0000006
CARO:0000006
EHDAA2:0003006
FBbt:00007016
FMA:67165
HAO:0000006
TAO:0001836
TGMA:0001826
VHOG:0001721
uberon
UBERON:0000465
material anatomical entity
UBERON:0000465
Anatomical entity that has no mass.
AAO:0010265
AEO:0000007
BILA:0000007
CARO:0000007
EHDAA2:0003007
FBbt:00007015
FMA:67112
HAO:0000007
TAO:0001835
TGMA:0001827
VHOG:0001727
immaterial physical anatomical entity
uberon
UBERON:0000466
immaterial anatomical entity
UBERON:0000466
Anatomical group that is has as its parts distinct anatomical structures interconnected by anatomical structures at a lower level of granularity[CARO]. A group of organs that work together to perform a certain task [Wikipedia].
system
AAO:0000007
AEO:0000011
BILA:0000011
BSA:0000049
CALOHA:TS-2088
CARO:0000011
EHDAA2:0003011
EHDAA:392
EMAPA:16103
EV:0100000
FBbt:00004856
FMA:7149
HAO:0000011
MA:0000003
OpenCyc:Mx4rCWM0QCtDEdyAAADggVbxzQ
TAO:0001439
TGMA:0001831
UMLS:C0460002
VHOG:0001725
WBbt:0005746
WBbt:0005763
XAO:0003002
ZFA:0001439
galen:AnatomicalSystem
body system
organ system
uberon
UBERON:0000467
anatomical system
UBERON:0000467
Anatomical structure that is an individual member of a species and consists of more than one cell.
TODO - split body and mc organism? body continues after death stage
organismal
AAO:0010026
AEO:0000191
BILA:0000012
BSA:0000038
BTO:0000042
CARO:0000012
EFO:0002906
EHDAA2:0003103
EHDAA2:0003191
EHDAA:1
EHDAA:9178
EMAPA:25765
EV:0100016
FBbt:00000001
FMA:256135
HAO:0000012
TADS:0000001
TAO:0001094
TGMA:0001832
VHOG:0000671
WBbt:0007833
XAO:0003004
ZFA:0001094
galen:Organism
organism
whole organism
animal
uberon
Koerper
body
whole body
UBERON:0000468
multi-cellular organism
UBERON:0000468
Anatomical group that has its parts adjacent to one another.
AAO:0010009
AEO:0000041
BILA:0000041
CARO:0000041
EHDAA2:0003041
FBbt:00007277
FMA:49443
HAO:0000041
TADS:0000605
TAO:0001478
TGMA:0001842
VHOG:0001737
XAO:0003160
ZFA:0001478
uberon
UBERON:0000477
anatomical cluster
UBERON:0000477
Multicellular anatomical structure that consists of many cells of one or a few types, arranged in an extracellular matrix such that their long-range organisation is at least partly a repetition of their short-range organisation.
changed label and definition to reflect CARO2
AAO:0000607
AAO:0010054
AEO:0000043
BILA:0000043
CALOHA:TS-2090
CARO:0000043
EHDAA2:0003043
EMAPA:35868
FBbt:00007003
FMA:9637
HAO:0000043
MA:0003002
MESH:A10
TAO:0001477
TGMA:0001844
UMLS:C0040300
VHOG:0001757
WBbt:0005729
XAO:0003040
ZFA:0001477
galen:Tissue
portion of tissue
tissue portion
simple tissue
uberon
UBERON:0000479
tissue
UBERON:0000479
Anatomical structure consisting of at least two non-overlapping organs, multi-tissue aggregates or portion of tissues or cells of different types that does not constitute an organism, organ, multi-tissue aggregate, or portion of tissue.
AAO:0010008
AEO:0000054
BILA:0000054
CARO:0000054
EHDAA2:0003054
HAO:0000054
TAO:0001512
TGMA:0001846
VHOG:0001724
XAO:0003001
ZFA:0001512
uberon
UBERON:0000480
anatomical group
UBERON:0000480
Anatomical entity that comprises the organism in the early stages of growth and differentiation that are characterized by cleavage, the laying down of fundamental tissues, and the formation of primitive organs and organ systems. For example, for mammals, the process would begin with zygote formation and end with birth. For insects, the process would begin at zygote formation and end with larval hatching. For plant zygotic embryos, this would be from zygote formation to the end of seed dormancy. For plant vegetative embryos, this would be from the initial determination of the cell or group of cells to form an embryo until the point when the embryo becomes independent of the parent plant.
embryonic
AAO:0011035
AEO:0000169
BILA:0000056
BSA:0000039
BTO:0000379
CALOHA:TS-0229
EFO:0001367
EHDAA2:0000002
EHDAA2_RETIRED:0003236
EHDAA:38
EMAPA:16039
FBbt:00000052
FMA:69068
GAID:963
MAT:0000226
MESH:A16.254
MIAA:0000019
OGEM:000001
OpenCyc:Mx4rwP1ceZwpEbGdrcN5Y29ycA
UMLS:C0013935
VHOG:0001766
XAO:0000113
ZFA:0000103
embryonic organism
uberon
developing organism
developmental tissue
UBERON:0000922
Obsoleted in ZFA. Note that embryo is not classified as an embryonic structure - an embryonic structure is only the parts of an embryo
embryo
UBERON:0000922
A layer of cells produced during the process of gastrulation during the early development of the animal embryo, which is distinct from other such layers of cells, as an early step of cell differentiation. The three types of germ layers are the endoderm, ectoderm, and mesoderm.
The Bilateria are triploblastic (with true endoderm, mesoderm, and ectoderm) (...).[well established][VHOG]
embryonic tissue
AAO:0000480
BILA:0000035
BTO:0000556
FBbt:00000110
FMA:69069
GAID:1303
MESH:A16.254.425
TAO:0001122
UMLS:C0920502
UMLS:C1708239
VHOG:0001223
XAO:0003011
ZFA:0001122
germinal layer
primary germ layer
uberon
embryonic germ layer
embryonic germ layers
UBERON:0000923
Classically the germ layers are ectoderm, mesoderm and endoderm. Alternatively: primary = ectoderm, endoderm; secondary=mesoderm; tertiary=dorsal mesoderm, NC[UBERONREF:0000002]
germ layer
UBERON:0000923
Primary germ layer that is the outer of the embryo's three germ layers and gives rise to epidermis and neural tissue.
Primary germ layer that is the outer of the embryonic germ layers and gives rise to epidermis and neural tissue.[AAO]
The Bilateria are triploblastic (with true endoderm, mesoderm, and ectoderm) (...).[well established][VHOG]
ectodermal
AAO:0000137
BILA:0000036
BTO:0000315
CALOHA:TS-0216
EFO:0000414
EHDAA2:0000428
EMAPA:16069
EV:0100003
FBbt:00000111
FMA:69070
GAID:1304
MAT:0000155
MAT:0000173
MESH:A16.254.425.273
MIAA:0000173
TAO:0000016
UMLS:C0013574
VHOG:0000153
XAO:0000001
ZFA:0000016
embryonic ectoderm
uberon
UBERON:0000924
ectoderm
UBERON:0000924
An organ that detects light.
This class encompasses a variety of light-detecting structures from different phyla with no implication of homology, from the compound insect eye to the vertebrate camera-type eye (distinct classes are provided for each)
ocular
optic
Note that whilst this is classified as an organ, it is in fact more of a unit composed of different structures: in Drosophila, it includes the interommatidial bristle as a part; we consider here the vertebrate eye to include the eyeball/eye proper as a part, with the eye having as parts (when present): eyelids, conjuctiva,
BILA:0000017
BTO:0000439
CALOHA:TS-0309
EFO:0000827
EV:0100336
FBbt:00005162
GAID:69
MAT:0000140
MESH:A01.456.505.420
MIAA:0000140
OpenCyc:Mx4rvViTvpwpEbGdrcN5Y29ycA
uberon
light-detecting organ
visual apparatus
UBERON:0000970
eye
UBERON:0000970
The nervous system is an organ system containing predominantly neuron and glial cells. In bilaterally symmetrical organism, it is arranged in a network of tree-like structures connected to a central body. The main functions of the nervous system are to regulate and control body functions, and to receive sensory input, process this information, and generate behavior [CUMBO].
A regulatory system of the body that consists of neurons and neuroglial cells. The nervous system is divided into two parts, the central nervous system (CNS) and the peripheral nervous system (PNS). (Source: BioGlossary, www.Biology-Text.com)[TAO]
Anatomical system consisting of nerve bodies and nerve fibers which regulate the response of the body to external and internal stimuli.[AAO]
relationship type change: differentiates_from ectoderm (AAO:0000137) CHANGED TO: develops_from ectoderm (UBERON:0000924)[AAO]
Nervous systems evolved in the ancestor of Eumetazoa.[well established][VHOG]
nervous
neural
AAO:0000324
BILA:0000079
BTO:0001484
CALOHA:TS-1313
EFO:0000802
EHDAA2:0001246
EHDAA:826
EMAPA:16469
EV:0100162
FBbt:00005093
FMA:7157
GAID:466
MA:0000016
MAT:0000026
MESH:A08
MIAA:0000026
OpenCyc:Mx4rvViT_pwpEbGdrcN5Y29ycA
TAO:0000396
UMLS:C0027763
VHOG:0000402
WBbt:0005735
XAO:0000177
ZFA:0000396
nerve net
uberon
Nervensystem
systema nervosum
UBERON:0001016
nervous system
UBERON:0001016
The central nervous system is the core nervous system that serves an integrating and coordinating function. In vertebrates it consists of the brain, spinal cord and spinal nerves. In those invertebrates with a central nervous system it typically consists of a brain, cerebral ganglia and a nerve cord[GO].
Part of the nervous system which includes the brain and spinal cord.[AAO]
The brain and spinal cord. Kimmel et al, 1995.[TAO]
The central nervous system (CNS) is the part of the nervous system which includes the brain, spinal cord, and nerve cell layer of the retina (CUMBO).
(...) at some stage of its development, every chordate exhibits five uniquely derived characters or synapomorphies of the group: (...) (4) a single, tubular nerve cord that is located dorsal to the notochord (...) (reference 1); The neural tube is destined to differentiate into the brain and spinal cord (the central nervous system) (reference 2); Taken together, our data make a very strong case that the complex molecular mediolateral architecture of the developing trunk CNS (central nervous system), as shared between Platynereis and vertebrates, was already present in their last common ancestor, Urbilateria. The concept of bilaterian nervous system centralization implies that neuron types concentrate on one side of the trunk, as is the case in vertebrates and many invertebrates including Platynereis, where they segregate and become spatially organized (as opposed to a diffuse nerve net). Our data reveal that a large part of the spatial organization of the annelid and vertebrate CNS was already present in their last common ancestor, which implies that Urbilateria had already possessed a CNS (reference 3).[well established][VHOG]
AAO:0000090
BAMS:CNS
BILA:0000080
BTO:0000227
CALOHA:TS-0150
EFO:0000908
EHDAA2:0000225
EHDAA:828
EMAPA:16470
EMAPA:16754
EV:0100163
FBbt:00005094
FMA:55675
GAID:570
MA:0000167
MAT:0000457
MESH:A08.186
OpenCyc:Mx4rvzYt3pwpEbGdrcN5Y29ycA
TAO:0000012
UMLS:C0927232
VHOG:0000293
XAO:0000215
ZFA:0000012
http://braininfo.rprc.washington.edu/centraldirectory.aspx?ID=246
CNS
neuraxis
systema nervosum centrale
cerebrospinal axis
uberon
basal nucleus of the amygdala
basolateral nucleus of amygdala
basolateral nucleus of the amygdala
nucleus amygdalae basalis
nucleus amygdaloideus basalis
nucleus amygdaloideus basolateralis
nucleus basalis amygdalae
UBERON:0001017
central nervous system
UBERON:0001017
Anatomical system that overlaps the nervous system and is responsible for receiving and processing sensory information.
An early step in the evolution of neural crest, therefore, may have been the origin of a specific dorsal neural cell population contributing to sensory processing; this would predate the divergence of the amphioxus and vertebrate lineages.[well established][VHOG]
note the distinct between entire sensory system and individual system. this reconciles is_a and part_of distinctions between ssAOs
AAO:0000555
BAMS:SEN
BILA:0000099
EFO:0000805
EHDAA2:0003094
EMAPA:16192
FBbt:00005827
FMA:75259
MA:0002442
MAT:0000031
MIAA:0000031
TAO:0000282
VHOG:0001674
XAO:0003194
ZFA:0000282
organa sensuum
sense organ subsystem
sense organs
sense organs set
sensory subsystem
sensory systems
uberon
organa sensuum
sensory organ system
set of sense organs
UBERON:0001032
sensory system
UBERON:0001032
Biological entity that is either an individual member of a biological species or constitutes the structural organization of an individual member of a biological species.
AAO:0010841
AEO:0000000
BILA:0000000
CARO:0000000
EHDAA2:0002229
FBbt:10000000
FBbt_root:00000000
FMA:62955
HAO:0000000
MA:0000001
TAO:0100000
TGMA:0001822
UMLS:C1515976
XAO:0000000
ZFA:0100000
uberon
UBERON:0001062
anatomical entity
UBERON:0001062
Anatomical structure that is part of an embryo.
Anatomical structure that is part of the embryo and is comprised of portions of tissue or cells.[AAO]
Anatomical structure that is part of the embryo and is comprised of portions of tissue or cells.[TAO]
Anatomical structure that is part of the embryo and is comprised of portions of tissue or cells.[VSAO]
in FMA embryo is_a embryonic structure
AAO:0000138
BILA:0000034
BTO:0000174
CALOHA:TS-2110
EFO:0000461
FBbt:00004208
FMA:69067
GAID:407
MESH:A16
RETIRED_EHDAA2:0003169
TAO:0001105
UMLS:C0013948
VSAO:0000178
XAO:0003042
ZFA:0001105
developing embryonic structure
embryonic anatomical structure
uberon
developing structure
embryonale Struktur
UBERON:0002050
embryonic structure
UBERON:0002050
The sensory system subserving the sense of vision.
This class was created automatically from a combination of ontologies
The sensory system used for sight.[AAO]
UBERON:0007036
AAO:0000632
BILA:0000140
FMA:7191
MA:0002444
OpenCyc:Mx4rvViCtpwpEbGdrcN5Y29ycA
TAO:0001127
UMLS:C0587900
XAO:0003198
ZFA:0001127
photosensory system
visual organ system
uberon
UBERON:0002104
visual system
UBERON:0002104
Sensory system responsible for the perception of spatial orientation and auditory stimuli.
The sensory system used for balance and hearing.[AAO]
AAO:0000631
FMA:78500
TAO:0001138
XAO:0003195
ZFA:0001138
auditory organ system
vestibuloauditory system
uberon
auditory system
auditory/vestibular system
vestibuloauditory system
UBERON:0002105
vestibulo-auditory system
UBERON:0002105
In amniote animal embryology, the epiblast is a tissue type derived either from the inner cell mass in mammals or the blastodisc in birds and reptiles. It lies above the hypoblast. In mammalian embryogenesis, the columnar cells of the epiblast are adjacent to the trophoblast, while the cuboidal cells of the hypoblast are closer to the blastocoele. The epiblast, whilst referred to as the primary ectoderm, differentiates to form all three layers of the trilaminar germ disc in a process called gastrulation[WP]. The outer of the two layers of the blastoderm that form during gastrulation, corresponding to primitive ectoderm during gastrulation and to the definitive ectoderm after gastrulation[ZFA]
MP says - tissue that gives rise to the ectoderm, endoderm and mesoderm of the embryo proper. In HOG, epiblast is part of primitive streak/blastpore, which is inconsistent with the MP definition of primitive streak as a ridge of the epiblast. Note that these terms, epiblast and hypoblast, are also used to describe layers of the avian embryonic blastoderm, but the layers so-named seem to be altogether different in these two kinds of vertebrate embryos(CVS). Consider obsoleting this as a grouping class
In pregastrula zebrafish embryos, the epiblast is an inverted cup of cells that sits on top of a large yolk cell. (...) In amniote embryos (mammals and birds), gastrulation initiates in an epithelial layer called the epiblast. Cells in the epiblast undergo an epithelial to mesenchymal transition (EMT), migrate through the primitive streak (PS), and incorporate in the middle (mesoderm) or outer (endoderm) layer. The presumptive definitive endoderm (DE) cells invade and displace an outer layer of extraembryonic tissue cells, the hypoblast in chick and the visceral endoderm (VE) in mouse, which form supporting structures such as the yolk sac.[uncertain][VHOG]
BTO:0004593
MAT:0000067
MIAA:0000067
VHOG:0000243
epiblast
uberon
blastocyst
ectoblast
epiblastus
primitive ectoderm
UBERON:0002532
epiblast (generic)
UBERON:0002532
An anatomical structure that develops (entirely or partially) from the ectoderm.
uberon
UBERON:0004121
Grouping term for query purposes
ectoderm-derived structure
UBERON:0004121
Sum of all sensory systems in an organism.
note the distinct between entire sensory system and individual system. this reconciles is_a and part_of distinctions between ssAOs
FMA:78499
sense organ system
uberon
UBERON:0004456
entire sense organ system
UBERON:0004456
A portion of tissue that is part of an embryo.
CALOHA:TS-2100
portion of embryonic tissue
uberon
developing tissue
UBERON:0005291
embryonic tissue
UBERON:0005291
AEO:0000125
CALOHA:TS-2122
EHDAA2:0003125
FBbt:00007006
MIAA:0000019
uberon
developing structure
developmental structure
developmental tissue
UBERON:0005423
developing anatomical structure
UBERON:0005423
AAO:0000479
TAO:0001116
ZFA:0001116
presumptive structures
uberon
UBERON:0006598
presumptive structure
UBERON:0006598
Presumptive structure of the blastula that will develop into ectoderm.
AAO:0000470
EFO:0003466
TAO:0001376
XAO:0004132
ZFA:0001376
uberon
presumptive epidermis
UBERON:0006601
presumptive ectoderm
UBERON:0006601
Non-material anatomical entity of two dimensions, that is demarcated by anatomical lines or points on the external or internal surfaces of anatomical structures.
AAO:0010270
BILA:0000010
CARO:0000010
EHDAA2:0003192
FMA:24137
ID:0000000
UMLS:C1515977
ZFA:0005594
uberon
UBERON:0006984
anatomical surface
UBERON:0006984
Organism at the cleavage stage.
BILA:0000058
uberon
UBERON:0007010
cleaving embryo
UBERON:0007010
An anatomical structure that has more than one cell as a part.
CARO:0010000
FBbt:00100313
multicellular structure
uberon
UBERON:0010000
multicellular anatomical structure
UBERON:0010000
uberon
UBERON:0010316
germ layer / neural crest
UBERON:0010316
Anatomical structure, which consists of a specific set of the members of (predominantly) one organ or organ part subclass interconnected by zones of continuity or body substances; is demarcated from other subdivisions of the same organ system by one or more zones of continuity or anatomical lines; together with other subdivisions of the same organ system, it constitutes an organ system. Examples: rib cage, facial skeleton, portal system, central nervous system, upper respiratory tract, muscle group of back.
FBbt:00007330
FMA:67509
uberon
UBERON:0011216
organ system subdivision
UBERON:0011216
Primordium that develops into the central nervous system
UBERON:3000469
future CNS
presumptive central nervous system
uberon
UBERON:0016879
future central nervous system
UBERON:0016879
Primordium that develops into the nervous system
UBERON:3000477
AAO:0000477
presumptive nervous system
uberon
UBERON:0016880
future nervous system
UBERON:0016880
example to be eventually removed
Class has all its metadata, but is either not guaranteed to be in its final location in the asserted IS_A hierarchy or refers to another class that is not complete.
metadata complete
term created to ease viewing/sort terms for development purpose, and will not be included in a release
organizational term
Class has undergone final review, is ready for use, and will be included in the next release. Any class lacking "ready_for_release" should be considered likely to change place in hierarchy, have its definition refined, or be obsoleted in the next release. Those classes deemed "ready_for_release" will also derived from a chain of ancestor classes that are also "ready_for_release."
ready for release
Class is being worked on; however, the metadata (including definition) are not complete or sufficiently clear to the branch editors.
metadata incomplete
Nothing done yet beyond assigning a unique class ID and proposing a preferred term.
uncurated
All definitions, placement in the asserted IS_A hierarchy and required minimal metadata are complete. The class is awaiting a final review by someone other than the definition editor.
pending final vetting
Terms with this status should eventually replaced with a term from another ontology.
Alan Ruttenberg
group:OBI
to be replaced with external ontology term
A term that is metadata complete, has been reviewed, and problems have been identified that require discussion before release. Such a term requires editor note(s) to identify the outstanding issues.
Alan Ruttenberg
group:OBI
requires discussion
axiom holds for all times
Vision Release; 1.0.13
C264
Display_Name
C134
MeSH_DUI
C287
MeSH_Name
C10490107818172
NUI
C818
RxNorm_CUI
C136
Synonym
C140
UMLS_CUI
AHC0
1
BFO:0000051
uberon
has_part
has_part
has part
has_part
bearer-of_st
bearerOfAt
b bearer_of c at t =Def. c s-depends_on b at t & b is an independent continuant that is not a spatial region. (axiom label in BFO2 Reference: [053-004])
Alan Ruttenberg: This is a binary version of a ternary time-indexed, instance level, relation. The BFO reading of the binary relation 'bearer of at some time@en' is: exists t, exists_at(x,t) & exists_at(y,t) & 'bearer of@en'(x,y,t)
BFO2 Reference: independent continuant that is not a spatial region
BFO2 Reference: specifically dependent continuant
bearer of
bearer_of
http://purl.obolibrary.org/obo/omrse.owl
(iff (bearerOfAt a b t) (and (specificallyDependsOnAt b a t) (IndependentContinuant a) (not (SpatialRegion a)) (existsAt b t))) // axiom label in BFO2 CLIF: [053-004]
bearer of at some time
is bearer of
is_bearer_of
realized-in
realizedIn
[copied from inverse property 'realizes'] to say that b realizes c at t is to assert that there is some material entity d & b is a process which has participant d at t & c is a disposition or role of which d is bearer_of at t& the type instantiated by b is correlated with the type instantiated by c. (axiom label in BFO2 Reference: [059-003])
if a realizable entity b is realized in a process p, then p stands in the has_participant relation to the bearer of b. (axiom label in BFO2 Reference: [106-002])
(forall (x y z t) (if (and (RealizableEntity x) (Process y) (realizesAt y x t) (bearerOfAt z x t)) (hasParticipantAt y z t))) // axiom label in BFO2 CLIF: [106-002]
realized in
has participant
has_participant
has participant
X preceded_by Y iff: end(Y) before_or_simultaneous_with start(X)
preceded by
preceded_by
proceeds
starts_after
BFO:0000062
is preceded by
takes place after
uberon
preceded_by
preceded_by
X preceded_by Y iff: end(Y) before_or_simultaneous_with start(X)
is preceded by
preceded by
preceded_by
BFO:0000063
uberon
precedes
precedes
precedes
precedes
occurs-in
occursIn
b occurs_in c =def b is a process and c is a material entity or immaterial entity& there exists a spatiotemporal region r and b occupies_spatiotemporal_region r.& forall(t) if b exists_at t then c exists_at t & there exist spatial regions s and s’ where & b spatially_projects_onto s at t& c is occupies_spatial_region s’ at t& s is a proper_continuant_part_of s’ at t [XXX-001
BFO:0000066
occurs_in
occurs in
occurs in
has-q_st
has quality at some time
a 'occurs in' relation that is applied at the adverse event setting and indicates where an adverse event occurs in.
Yongqun He
adverse event occurs in
RO:0000086
uberon
has_quality
has_quality
has quality
has quality
this person has role this investigator role (more colloquially: this person has this role of investigator)
a relation between an independent continuant (the bearer) and a role, in which the role specifically depends on the bearer for its existence
A bearer can have many roles, and its roles can exist for different periods of time, but none of its roles can exist when the bearer does not exist. A role need not be realized at all the times that the role exists.
has_role
has role
The relationship between a material entity and the boundary (2D immaterial entity) that delimits it.
RO:0002002
uberon
has_boundary
has_boundary
has boundary
has boundary
Relation between occurrents, shares start and end boundaries.
RO:0002082
coincides_with
is_equal_to
uberon
simultaneous_with
simultaneous_with
simultaneous_with
simultaneous_with
X immediately_preceded_by Y iff: end(X) simultaneous_with start(Y)
A non-transitive temporal relation in which one process immediately precedes another process, such that there is no interval of time between the two processes[SIO:000251].
RO:0002087
directly preceded by
is directly preceded by
is immediately preceded by
starts_at_end_of
uberon
immediately_preceded_by
immediately_preceded_by
immediately_preceded_by
immediately_preceded_by
S only_in_taxon T iff: S SubClassOf in_taxon only T
x only in taxon y if and only if x is in taxon y, and there is no other organism z such that y!=z a and x is in taxon z.
RO:0002160
uberon
only_in_taxon
only_in_taxon
only in taxon
only_in_taxon
x is in taxon y if an only if y is an organism, and the relationship between x and y is one of: part of (reflexive), developmentally preceded by, derives from, secreted by, expressed.
RO:0002162
uberon
in_taxon
in_taxon
in taxon
A relation between a material entity (such as a cell) and a process, in which the material entity has the ability to carry out the process.
RO:0002215
uberon
capable_of
capable_of
capable of
capable_of
c stands in this relationship to p if and only if there exists some p' such that c is capable_of p', and p' is part_of p.
RO:0002216
uberon
capable_of_part_of
capable_of_part_of
capable of part of
capable_of_part_of
Relation between occurrents, shares a start boundary with.
inverse of starts with
RO:0002223
uberon
starts
starts
starts
starts
Relation between occurrents, shares an end boundary with.
inverse of ends with
RO:0002229
finishes
uberon
ends
ends
ends
ends
x has the potential to develop into y iff x develops into y or if x is capable of developing into y
x has the potential to develop into y iff x develops into y or if x is capable of developing into y
RO:0002387
uberon
has_potential_to_develop_into
has_potential_to_develop_into
has potential to develop into
has potential to develop into
x composed_primarily_of y if and only if more than half of the mass of x is made from y or units of the same type as y.
x composed_primarily_of y iff: more than half of the mass of x is made from parts of y
UBREL:0000002
RO:0002473
uberon
composed_primarily_of
composed_primarily_of
composed primarily of
composed_primarily_of
Relation between continuant and occurrent, such that c comes into existence at the start of p.
c existence starts during s iff start_of(c) = start_of(s)
RO:0002489
uberon
existence_starts_with
existence_starts_with
existence starts with
Relation between continuant c and occurrent s, such that every instance of c ceases to exist during some s, if it does not die prematurely.
BFO:0000069
RO:0002492
ceases_to_exist_during
uberon
existence_ends_during
existence_ends_during
existence ends during
Relation between continuant and occurrent, such that c ceases to exist at the end of p.
RO:0002493
uberon
existence_ends_with
existence_ends_with
existence ends with
x immediate transformation of y iff x immediately succeeds y temporally at a time boundary t, and all of the matter present in x at t is present in y at t, and all the matter in y at t is present in x at t
RO:0002495
direct_transformation_of
immediately transforms from
uberon
immediate_transformation_of
immediate_transformation_of
immediate transformation of
RO:0002496
uberon
existence_starts_during_or_after
existence_starts_during_or_after
existence starts during or after
RO:0002497
uberon
existence_ends_during_or_before
existence_ends_during_or_before
existence ends during or before
Product version
Guoqian Jiang
Jane Bane
Junguk Hur
Yu Lin
Abra Guo
Rebecca Racz
Yongqun "Oliver" He (YH)
2016-05-16
ODNAE is an extension of OAE with a focus on drug-associated neuropathy adverse events.
OWL-DL
An ontology for the annotation of the adverse event domain.
ODNAE: Ontology of Drug Neuropathy Adverse Events
Vision Release; 1.0.13
uberon
existence_starts_and_ends_during
existence starts and ends during
http://purl.org/obo/owl/relationship
OBO_REL:0000007
relationship
has_proper_part
has_proper_part